{"0eb0709167c38890dad1f603a5d0be1799842143": [["IntroductionThe American College of Cardiology/American Heart Association and the European Association for Cardiothoracic Surgery guidelines recommend the use of volatile anesthetics (VAs) in cardiovascular surgery [1, 2] .", [["cardiovascular", "ANATOMY", 192, 206], ["Cardiothoracic Surgery", "TREATMENT", 107, 129], ["volatile anesthetics", "TREATMENT", 162, 182], ["cardiovascular surgery", "TREATMENT", 192, 214], ["Heart", "ANATOMY", 56, 61]]], ["VAs, such as desflurane and sevoflurane, protect myocardial cells via multiple mechanisms [3] [4] [5] [6] [7] [8] .", [["myocardial cells", "ANATOMY", 49, 65], ["VAs", "DISEASE", 0, 3], ["desflurane", "CHEMICAL", 13, 23], ["sevoflurane", "CHEMICAL", 28, 39], ["desflurane", "CHEMICAL", 13, 23], ["sevoflurane", "CHEMICAL", 28, 39], ["VAs", "SIMPLE_CHEMICAL", 0, 3], ["desflurane", "SIMPLE_CHEMICAL", 13, 23], ["sevoflurane", "SIMPLE_CHEMICAL", 28, 39], ["myocardial cells", "CELL", 49, 65], ["[3] [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 90, 113], ["myocardial cells", "CELL_TYPE", 49, 65], ["VAs", "TREATMENT", 0, 3], ["desflurane", "TREATMENT", 13, 23], ["sevoflurane", "TREATMENT", 28, 39]]], ["Therefore, their application during cardiopulmonary bypass (CPB) may improve prognosis compared with that of total intravenous anesthesia (TIVA).", [["cardiopulmonary", "ANATOMY", 36, 51], ["intravenous", "ANATOMY", 115, 126], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 115, 126], ["cardiopulmonary bypass", "TREATMENT", 36, 58], ["CPB", "TREATMENT", 60, 63], ["total intravenous anesthesia", "TREATMENT", 109, 137], ["bypass", "OBSERVATION", 52, 58]]], ["However, the MYRIAD study disproved the hypothesis that VAs improve clinical outcomes in patients undergoing coronary artery bypass graft compared to TIVA based on the mortality rate in the two groups 1 year after surgery [9] .", [["coronary artery", "ANATOMY", 109, 124], ["patients", "ORGANISM", 89, 97], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 109, 124], ["patients", "SPECIES", 89, 97], ["the MYRIAD study", "TEST", 9, 25], ["coronary artery bypass graft", "TREATMENT", 109, 137], ["TIVA", "TREATMENT", 150, 154], ["the mortality rate", "TEST", 164, 182], ["surgery", "TREATMENT", 214, 221], ["coronary artery", "ANATOMY", 109, 124], ["bypass graft", "OBSERVATION", 125, 137]]], ["Although the authors did not use a strict protocol, they argued that their trial was pragmatic and realistic.", [["a strict protocol", "TREATMENT", 33, 50]]], ["Indeed, the difficulties of Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s0054 0-020-02844 -1) contains supplementary material, which is available to authorized users.Introductionconducting large-scale studies under a strict protocol have been recognized, but Zaugg et al. [10] pointed out that the administration protocol determines the success or failure of the study and should be set with stricter criteria in critical studies that verify the protective effect of VAs.", [["Electronic supplementary material", "TREATMENT", 28, 61], ["a strict protocol", "TREATMENT", 266, 283], ["the administration protocol", "TREATMENT", 345, 372], ["the study", "TEST", 410, 419], ["critical studies", "TEST", 464, 480]]], ["Therefore, there is an ample scope for determining the usefulness of VA in CPB, and, hence, the findings of the MYRIAD study must be challenged by strict protocols comparing VA to TIVA in the future.IntroductionBesides the administration protocol, we believe that the performance of the oxygenator can also dramatically affect the results, a point that was not addressed in the MYRIAD study.", [["TIVA", "CHEMICAL", 180, 184], ["VA in CPB", "TREATMENT", 69, 78], ["the MYRIAD study", "TEST", 108, 124], ["TIVA", "TREATMENT", 180, 184], ["the administration protocol", "TREATMENT", 219, 246], ["the oxygenator", "TREATMENT", 283, 297], ["the MYRIAD study", "TEST", 374, 390]]], ["Microporous polypropylene (PP) is often used as the material in the hollow fiber membranes (HFM) of CPB circuit oxygenators.", [["hollow fiber membranes", "ANATOMY", 68, 90], ["HFM", "ANATOMY", 92, 95], ["polypropylene", "CHEMICAL", 12, 25], ["PP", "CHEMICAL", 27, 29], ["polypropylene", "CHEMICAL", 12, 25], ["PP", "SIMPLE_CHEMICAL", 27, 29], ["fiber membranes", "CELLULAR_COMPONENT", 75, 90], ["Microporous polypropylene (PP)", "TREATMENT", 0, 30], ["the hollow fiber membranes", "TREATMENT", 64, 90], ["CPB circuit oxygenators", "TREATMENT", 100, 123], ["polypropylene", "OBSERVATION", 12, 25]]], ["Currently, many manufacturers have introduced PP HFM oxygenators with a biocompatible coating to reduce the adsorption and denaturation of blood cells and plasma proteins, contact reaction of blood with foreign matters, and changes in blood cell components by smoothing the membrane surface.", [["blood cells", "ANATOMY", 139, 150], ["plasma", "ANATOMY", 155, 161], ["blood", "ANATOMY", 192, 197], ["blood cell", "ANATOMY", 235, 245], ["membrane surface", "ANATOMY", 274, 290], ["blood cells", "CELL", 139, 150], ["plasma", "ORGANISM_SUBSTANCE", 155, 161], ["blood", "ORGANISM_SUBSTANCE", 192, 197], ["blood cell", "CELL", 235, 245], ["membrane surface", "CELLULAR_COMPONENT", 274, 290], ["blood cells", "CELL_TYPE", 139, 150], ["plasma proteins", "PROTEIN", 155, 170], ["PP HFM oxygenators", "TREATMENT", 46, 64], ["a biocompatible coating", "TREATMENT", 70, 93], ["the adsorption", "PROBLEM", 104, 118], ["denaturation of blood cells", "PROBLEM", 123, 150], ["plasma proteins", "TEST", 155, 170], ["foreign matters", "PROBLEM", 203, 218], ["changes in blood cell components", "PROBLEM", 224, 256], ["foreign matters", "OBSERVATION", 203, 218], ["blood cell", "OBSERVATION", 235, 245], ["membrane", "OBSERVATION_MODIFIER", 274, 282], ["surface", "OBSERVATION_MODIFIER", 283, 290]]], ["Despite the aforementioned benefits, we believe that these coatings may affect the pharmacokinetics of VA, leading to over-or under-dosage.", [["VA", "SIMPLE_CHEMICAL", 103, 105]]], ["The effects, including pharmacokinetic effects, of these membranes on isoflurane properties during CPB [11, 12] have been studied, but only a few have considered desflurane or sevoflurane, which are frequently used in CPB general anesthesia [13] .IntroductionWe hypothesized that the blood levels of VAs differed with the use of four different oxygenators.", [["membranes", "ANATOMY", 57, 66], ["blood", "ANATOMY", 284, 289], ["isoflurane", "CHEMICAL", 70, 80], ["desflurane", "CHEMICAL", 162, 172], ["sevoflurane", "CHEMICAL", 176, 187], ["isoflurane", "CHEMICAL", 70, 80], ["desflurane", "CHEMICAL", 162, 172], ["sevoflurane", "CHEMICAL", 176, 187], ["membranes", "CELLULAR_COMPONENT", 57, 66], ["isoflurane", "SIMPLE_CHEMICAL", 70, 80], ["desflurane", "SIMPLE_CHEMICAL", 162, 172], ["sevoflurane", "SIMPLE_CHEMICAL", 176, 187], ["blood", "ORGANISM_SUBSTANCE", 284, 289], ["VAs", "SIMPLE_CHEMICAL", 300, 303], ["isoflurane properties", "TREATMENT", 70, 91], ["CPB", "TREATMENT", 99, 102], ["desflurane", "TREATMENT", 162, 172], ["sevoflurane", "TREATMENT", 176, 187], ["CPB general anesthesia", "TREATMENT", 218, 240], ["the blood levels", "TEST", 280, 296], ["four different oxygenators", "TREATMENT", 329, 355]]], ["In the present study, we aimed to measure the blood concentrations of desflurane and sevoflurane in patients managed with PP HFM oxygenators from four different manufacturers during CPB.Patients and study designThis prospective pilot study was registered with the University Hospital Medical Information Network (UMIN ID: UMIN000033710, Principal investigator: Takahiro Tamura, Date of registration: November 1, 2018) and approved by the Institutional Review Board of the Nagoya University Hospital (IRB #2018-0329), Nagoya, Japan, where this study was conducted.", [["blood", "ANATOMY", 46, 51], ["desflurane", "CHEMICAL", 70, 80], ["sevoflurane", "CHEMICAL", 85, 96], ["desflurane", "CHEMICAL", 70, 80], ["sevoflurane", "CHEMICAL", 85, 96], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["desflurane", "SIMPLE_CHEMICAL", 70, 80], ["sevoflurane", "SIMPLE_CHEMICAL", 85, 96], ["patients", "ORGANISM", 100, 108], ["Patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 100, 108], ["Patients", "SPECIES", 186, 194], ["desflurane", "TREATMENT", 70, 80], ["sevoflurane", "TREATMENT", 85, 96], ["PP HFM oxygenators", "TREATMENT", 122, 140], ["CPB", "TREATMENT", 182, 185], ["This prospective pilot study", "TEST", 211, 239], ["this study", "TEST", 538, 548]]], ["Patients aged 20-90 years who were scheduled for elective cardiac or aortic surgery with CPB between January and August 2019 were recruited.", [["cardiac", "ANATOMY", 58, 65], ["aortic", "ANATOMY", 69, 75], ["Patients", "ORGANISM", 0, 8], ["cardiac", "ORGAN", 58, 65], ["aortic", "MULTI-TISSUE_STRUCTURE", 69, 75], ["Patients", "SPECIES", 0, 8], ["elective cardiac", "TREATMENT", 49, 65], ["aortic surgery", "TREATMENT", 69, 83], ["CPB", "TREATMENT", 89, 92], ["cardiac", "ANATOMY", 58, 65], ["aortic", "ANATOMY", 69, 75], ["surgery", "OBSERVATION", 76, 83]]], ["Patients with contraindications for VA use, such as those with malignant hyperthermia and significant renal or hepatic impairment, were excluded.", [["renal", "ANATOMY", 102, 107], ["hepatic", "ANATOMY", 111, 118], ["hyperthermia", "DISEASE", 73, 85], ["renal or hepatic impairment", "DISEASE", 102, 129], ["Patients", "ORGANISM", 0, 8], ["renal", "ORGAN", 102, 107], ["hepatic", "ORGAN", 111, 118], ["Patients", "SPECIES", 0, 8], ["VA use", "TREATMENT", 36, 42], ["malignant hyperthermia", "PROBLEM", 63, 85], ["significant renal or hepatic impairment", "PROBLEM", 90, 129], ["malignant", "OBSERVATION_MODIFIER", 63, 72], ["hyperthermia", "OBSERVATION", 73, 85], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["renal", "ANATOMY", 102, 107], ["hepatic", "ANATOMY", 111, 118], ["impairment", "OBSERVATION", 119, 129]]], ["After obtaining written informed consent from the patients, they were randomly assigned via computer-generated simple randomization into one of two VA groups, desflurane or sevoflurane, and, then, into one of four oxygenator groups within each VA group, defined as follows: TE (CAPIOX manufactured by Terumo Co. Ltd., Tokyo, Japan) [14] , LI (INSPIRE by LivaNova Japan K.K., Tokyo, Japan) [15] , ME (Fusion by Medtronic Japan Co. Ltd., Tokyo, Japan) [16] , and SE (EXELUNG by Senko Medical Instrument Mfg.", [["desflurane", "CHEMICAL", 159, 169], ["sevoflurane", "CHEMICAL", 173, 184], ["SE", "DISEASE", 461, 463], ["desflurane", "CHEMICAL", 159, 169], ["sevoflurane", "CHEMICAL", 173, 184], ["patients", "ORGANISM", 50, 58], ["desflurane", "SIMPLE_CHEMICAL", 159, 169], ["sevoflurane", "SIMPLE_CHEMICAL", 173, 184], ["patients", "SPECIES", 50, 58], ["desflurane", "TREATMENT", 159, 169], ["sevoflurane", "TREATMENT", 173, 184]]], ["These four manufacturers supply approximately 80% of the PP HFM oxygenators used in Japan.", [["the PP HFM oxygenators", "TREATMENT", 53, 75], ["PP HFM oxygenators", "OBSERVATION", 57, 75]]], ["Assigning of patients was performed by dedicated study personnel in a separate environment, and the patients were randomly assigned to one of the four parallel groups in a 1:1:1:1 ratio (n = 3).", [["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 100, 108]]], ["Additionally, in each VA group, three patients were randomly selected and redundantly allocated to the human lung (HL) group (for control blood concentration of VA without an oxygenator before surgical intervention with mechanical ventilation).", [["lung", "ANATOMY", 109, 113], ["blood", "ANATOMY", 138, 143], ["patients", "ORGANISM", 38, 46], ["human", "ORGANISM", 103, 108], ["lung", "ORGAN", 109, 113], ["HL", "CANCER", 115, 117], ["blood", "ORGANISM_SUBSTANCE", 138, 143], ["patients", "SPECIES", 38, 46], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["an oxygenator", "TREATMENT", 172, 185], ["surgical intervention", "TREATMENT", 193, 214], ["mechanical ventilation", "TREATMENT", 220, 242], ["lung", "ANATOMY", 109, 113]]], ["Only the CPB operator was aware of the patient's allocated oxygenator, but was blinded to the trial participants, anesthesiologists, sample collectors, and sample analysts.", [["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["participants", "SPECIES", 100, 112], ["oxygenator", "TREATMENT", 59, 69], ["sample collectors", "TEST", 133, 150]]], ["The anesthesiologists, sample collectors, and sample analysts were aware of the patients' allocated VA.Patients and study designThe primary outcome of the study was the 20-min arterial blood concentration of desflurane or sevoflurane after administration into each type of oxygenator during CPB.", [["arterial", "ANATOMY", 176, 184], ["blood", "ANATOMY", 185, 190], ["desflurane", "CHEMICAL", 208, 218], ["sevoflurane", "CHEMICAL", 222, 233], ["desflurane", "CHEMICAL", 208, 218], ["sevoflurane", "CHEMICAL", 222, 233], ["patients", "ORGANISM", 80, 88], ["Patients", "ORGANISM", 103, 111], ["arterial", "MULTI-TISSUE_STRUCTURE", 176, 184], ["blood", "ORGANISM_SUBSTANCE", 185, 190], ["desflurane", "SIMPLE_CHEMICAL", 208, 218], ["sevoflurane", "SIMPLE_CHEMICAL", 222, 233], ["patients", "SPECIES", 80, 88], ["Patients", "SPECIES", 103, 111], ["the study", "TEST", 151, 160], ["desflurane", "TREATMENT", 208, 218], ["sevoflurane", "TREATMENT", 222, 233], ["oxygenator during CPB", "TREATMENT", 273, 294]]], ["Secondary outcomes included oxygenator-related complications, such as plasma leaks or fissure.", [["plasma", "ANATOMY", 70, 76], ["plasma", "ORGANISM_SUBSTANCE", 70, 76], ["related complications", "PROBLEM", 39, 60], ["plasma leaks or fissure", "PROBLEM", 70, 93], ["leaks", "OBSERVATION", 77, 82], ["fissure", "OBSERVATION_MODIFIER", 86, 93]]], ["In addition, membrane fibers in each oxygenator were assessed using scanning electron microscopy (SEM) before and after VA exposure to determine VA exposure-related changes in membrane surface properties.General anesthesia procedureNon-invasive arterial blood pressure monitor, electrocardiography, pulse oximetry, electroencephalography monitor, regional oximetry monitor for the brain, and radial artery cannula for blood pressure monitoring and sampling were employed in all patients.", [["membrane fibers", "ANATOMY", 13, 28], ["membrane surface", "ANATOMY", 176, 192], ["arterial", "ANATOMY", 245, 253], ["blood", "ANATOMY", 254, 259], ["brain", "ANATOMY", 381, 386], ["radial artery", "ANATOMY", 392, 405], ["blood", "ANATOMY", 418, 423], ["membrane fibers", "CELLULAR_COMPONENT", 13, 28], ["membrane surface", "CELLULAR_COMPONENT", 176, 192], ["arterial", "MULTI-TISSUE_STRUCTURE", 245, 253], ["blood", "ORGANISM_SUBSTANCE", 254, 259], ["brain", "ORGAN", 381, 386], ["radial artery cannula", "MULTI-TISSUE_STRUCTURE", 392, 413], ["blood", "ORGANISM_SUBSTANCE", 418, 423], ["patients", "ORGANISM", 478, 486], ["patients", "SPECIES", 478, 486], ["membrane fibers in each oxygenator", "TREATMENT", 13, 47], ["scanning electron microscopy", "TEST", 68, 96], ["VA exposure", "PROBLEM", 145, 156], ["changes in membrane surface properties", "PROBLEM", 165, 203], ["General anesthesia procedure", "TREATMENT", 204, 232], ["Non-invasive arterial blood pressure monitor", "TEST", 232, 276], ["electrocardiography", "TEST", 278, 297], ["pulse oximetry", "TEST", 299, 313], ["electroencephalography monitor", "TEST", 315, 345], ["regional oximetry monitor", "TEST", 347, 372], ["radial artery cannula", "TREATMENT", 392, 413], ["blood pressure monitoring", "TEST", 418, 443], ["membrane surface", "OBSERVATION", 176, 192], ["anesthesia", "OBSERVATION", 212, 222], ["brain", "ANATOMY", 381, 386], ["radial artery", "ANATOMY", 392, 405]]], ["Intravenous (IV) fentanyl and IV midazolam were administered to induce general anesthesia.", [["fentanyl", "CHEMICAL", 17, 25], ["midazolam", "CHEMICAL", 33, 42], ["fentanyl", "CHEMICAL", 17, 25], ["midazolam", "CHEMICAL", 33, 42], ["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["fentanyl", "SIMPLE_CHEMICAL", 17, 25], ["IV", "SIMPLE_CHEMICAL", 30, 32], ["midazolam", "SIMPLE_CHEMICAL", 33, 42], ["Intravenous (IV) fentanyl", "TREATMENT", 0, 25], ["IV midazolam", "TREATMENT", 30, 42], ["general anesthesia", "TREATMENT", 71, 89]]], ["Remifentanil and rocuronium were used to facilitate tracheal intubation.", [["tracheal", "ANATOMY", 52, 60], ["Remifentanil", "CHEMICAL", 0, 12], ["rocuronium", "CHEMICAL", 17, 27], ["Remifentanil", "CHEMICAL", 0, 12], ["rocuronium", "CHEMICAL", 17, 27], ["Remifentanil", "SIMPLE_CHEMICAL", 0, 12], ["rocuronium", "SIMPLE_CHEMICAL", 17, 27], ["tracheal", "MULTI-TISSUE_STRUCTURE", 52, 60], ["Remifentanil", "TREATMENT", 0, 12], ["rocuronium", "TREATMENT", 17, 27], ["tracheal intubation", "TREATMENT", 52, 71], ["tracheal", "ANATOMY", 52, 60], ["intubation", "OBSERVATION", 61, 71]]], ["General anesthesia was maintained using air and oxygen at 3.0 l/min of total flow, 6.0 vol% desflurane or 1.7 vol% sevoflurane, and remifentanil (0.1-0.25 \u03bcg/kg/min).", [["oxygen", "CHEMICAL", 48, 54], ["desflurane", "CHEMICAL", 92, 102], ["sevoflurane", "CHEMICAL", 115, 126], ["remifentanil", "CHEMICAL", 132, 144], ["oxygen", "CHEMICAL", 48, 54], ["desflurane", "CHEMICAL", 92, 102], ["sevoflurane", "CHEMICAL", 115, 126], ["remifentanil", "CHEMICAL", 132, 144], ["oxygen", "SIMPLE_CHEMICAL", 48, 54], ["desflurane", "SIMPLE_CHEMICAL", 92, 102], ["sevoflurane", "SIMPLE_CHEMICAL", 115, 126], ["remifentanil", "SIMPLE_CHEMICAL", 132, 144], ["General anesthesia", "TREATMENT", 0, 18], ["air and oxygen", "TREATMENT", 40, 54], ["total flow", "TREATMENT", 71, 81], ["desflurane", "TREATMENT", 92, 102], ["sevoflurane", "TREATMENT", 115, 126], ["remifentanil", "TREATMENT", 132, 144], ["anesthesia", "OBSERVATION", 8, 18]]], ["Bolus doses of fentanyl (up to 20 \u03bcg/kg) and rocuronium were supplemented as required.", [["fentanyl", "CHEMICAL", 15, 23], ["rocuronium", "CHEMICAL", 45, 55], ["fentanyl", "CHEMICAL", 15, 23], ["rocuronium", "CHEMICAL", 45, 55], ["fentanyl", "SIMPLE_CHEMICAL", 15, 23], ["rocuronium", "SIMPLE_CHEMICAL", 45, 55], ["fentanyl", "TREATMENT", 15, 23], ["rocuronium", "TREATMENT", 45, 55]]], ["Porcine heparin (300 U/ kg) and additional heparin bolus (50 U/kg) were injected to maintain an activated clotting time of at least 450 s.General anesthesia procedureThe CDI-500 monitoring system (Terumo Co., Ltd.) was used for blood parameter monitoring during CPB (S5, LivaNova Japan K.K.).", [["blood", "ANATOMY", 228, 233], ["heparin", "CHEMICAL", 8, 15], ["heparin", "CHEMICAL", 43, 50], ["Porcine", "ORGANISM", 0, 7], ["heparin", "SIMPLE_CHEMICAL", 8, 15], ["heparin", "SIMPLE_CHEMICAL", 43, 50], ["blood", "ORGANISM_SUBSTANCE", 228, 233], ["Porcine", "SPECIES", 0, 7], ["Porcine heparin", "TREATMENT", 0, 15], ["additional heparin bolus", "TREATMENT", 32, 56], ["General anesthesia procedure", "TREATMENT", 138, 166], ["The CDI", "TEST", 166, 173], ["blood parameter monitoring", "TEST", 228, 254], ["CPB", "TREATMENT", 262, 265], ["clotting", "OBSERVATION", 106, 114]]], ["The circuit was primed with a balanced crystalloid solution.", [["The circuit", "TREATMENT", 0, 11], ["a balanced crystalloid solution", "TREATMENT", 28, 59]]], ["The non-pulsatile pump was maintained at a flow rate of 2.6 l/min/m 2 \u00b1 10%.", [["The non-pulsatile pump", "TREATMENT", 0, 22], ["a flow rate", "TEST", 41, 52], ["non-pulsatile pump", "OBSERVATION", 4, 22]]], ["Alpha-stat blood gas management was used for acid-base control.", [["blood", "ANATOMY", 11, 16], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["Alpha", "TEST", 0, 5], ["stat blood gas management", "TREATMENT", 6, 31], ["acid-base control", "TREATMENT", 45, 62]]], ["After aortic cross-clamping and administration of the cold cardioplegic solution, a stable level of perfusion pressure in mild hypothermia (arterial and rectal temperature, 32-33 \u00b0C) was obtained.", [["aortic", "ANATOMY", 6, 12], ["arterial", "ANATOMY", 140, 148], ["rectal", "ANATOMY", 153, 159], ["hypothermia", "DISEASE", 127, 138], ["aortic", "MULTI-TISSUE_STRUCTURE", 6, 12], ["arterial", "MULTI-TISSUE_STRUCTURE", 140, 148], ["rectal", "ORGAN", 153, 159], ["aortic cross-clamping", "TREATMENT", 6, 27], ["the cold cardioplegic solution", "TREATMENT", 50, 80], ["perfusion pressure", "TEST", 100, 118], ["mild hypothermia", "PROBLEM", 122, 138], ["arterial", "TEST", 140, 148], ["rectal temperature", "TEST", 153, 171], ["aortic", "ANATOMY", 6, 12], ["cross-clamping", "OBSERVATION", 13, 27], ["stable", "OBSERVATION_MODIFIER", 84, 90], ["perfusion pressure", "OBSERVATION", 100, 118], ["mild", "OBSERVATION_MODIFIER", 122, 126], ["hypothermia", "OBSERVATION", 127, 138], ["arterial", "ANATOMY", 140, 148], ["rectal", "ANATOMY", 153, 159]]], ["When reaching the target flow rate, ventilation was stopped, and the delivery of 6.0 vol% desflurane or 1.7 vol% sevoflurane was started through a vaporizer (D-Vaper 3000, Dr\u00e4ger Medical Japan Ltd., Tokyo, Japan) from the oxygenator's gas supply line with a constant gas mixture of oxygen and air (F I O 2 50-60%) at 0.5-3.0 l/min.", [["desflurane", "CHEMICAL", 90, 100], ["sevoflurane", "CHEMICAL", 113, 124], ["oxygen", "CHEMICAL", 282, 288], ["desflurane", "CHEMICAL", 90, 100], ["sevoflurane", "CHEMICAL", 113, 124], ["oxygen", "CHEMICAL", 282, 288], ["desflurane", "SIMPLE_CHEMICAL", 90, 100], ["sevoflurane", "SIMPLE_CHEMICAL", 113, 124], ["oxygen", "SIMPLE_CHEMICAL", 282, 288], ["ventilation", "TREATMENT", 36, 47], ["the delivery of 6.0 vol% desflurane", "TREATMENT", 65, 100], ["sevoflurane", "TREATMENT", 113, 124], ["a vaporizer (D-Vaper", "TREATMENT", 145, 165], ["the oxygenator's gas supply line", "TREATMENT", 218, 250], ["a constant gas mixture of oxygen", "TREATMENT", 256, 288]]], ["The gas was regulated based on the CDI-500 and atrial blood gas readings.General anesthesia procedureVentilation and inotropic drug support were started before commencing CPB, and the patients were admitted to the intensive care unit with intubation.", [["atrial blood", "ANATOMY", 47, 59], ["atrial", "MULTI-TISSUE_STRUCTURE", 47, 53], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 184, 192], ["The gas", "TEST", 0, 7], ["the CDI", "TEST", 31, 38], ["atrial blood gas readings", "TEST", 47, 72], ["General anesthesia procedure", "TREATMENT", 73, 101], ["Ventilation", "TREATMENT", 101, 112], ["inotropic drug support", "TREATMENT", 117, 139], ["CPB", "TREATMENT", 171, 174], ["intubation", "TREATMENT", 239, 249], ["anesthesia", "OBSERVATION", 81, 91]]], ["The following parameters were subject to the discretion of the individual anesthesiologist: intraoperative ventilator settings other than the vaporizer concentration setting of desflurane or sevoflurane, F I O 2 , total gas flow rate (l/min), fluid infusion volume, anesthesia dosage other than VA, and choice of vasopressor (dopamine, dobutamine, or noradrenaline).", [["fluid", "ANATOMY", 243, 248], ["desflurane", "CHEMICAL", 177, 187], ["sevoflurane", "CHEMICAL", 191, 202], ["dopamine", "CHEMICAL", 326, 334], ["dobutamine", "CHEMICAL", 336, 346], ["noradrenaline", "CHEMICAL", 351, 364], ["desflurane", "CHEMICAL", 177, 187], ["sevoflurane", "CHEMICAL", 191, 202], ["F I O 2", "CHEMICAL", 204, 211], ["dopamine", "CHEMICAL", 326, 334], ["dobutamine", "CHEMICAL", 336, 346], ["noradrenaline", "CHEMICAL", 351, 364], ["desflurane", "SIMPLE_CHEMICAL", 177, 187], ["sevoflurane", "SIMPLE_CHEMICAL", 191, 202], ["dopamine", "SIMPLE_CHEMICAL", 326, 334], ["dobutamine", "SIMPLE_CHEMICAL", 336, 346], ["noradrenaline", "SIMPLE_CHEMICAL", 351, 364], ["intraoperative ventilator settings", "TREATMENT", 92, 126], ["the vaporizer concentration", "TREATMENT", 138, 165], ["desflurane", "TREATMENT", 177, 187], ["sevoflurane", "TREATMENT", 191, 202], ["total gas flow rate", "TEST", 214, 233], ["fluid infusion volume", "TREATMENT", 243, 264], ["anesthesia dosage", "TREATMENT", 266, 283], ["vasopressor (dopamine", "TREATMENT", 313, 334], ["dobutamine", "TREATMENT", 336, 346], ["noradrenaline", "TREATMENT", 351, 364]]], ["Protamine (3 mg/kg) was administered to neutralize the effects of heparin.", [["Protamine", "CHEMICAL", 0, 9], ["heparin", "CHEMICAL", 66, 73], ["Protamine", "CHEMICAL", 0, 9], ["Protamine", "SIMPLE_CHEMICAL", 0, 9], ["heparin", "SIMPLE_CHEMICAL", 66, 73], ["Protamine", "TREATMENT", 0, 9], ["heparin", "TREATMENT", 66, 73]]], ["We used an intraoperative cell salvage device in all cases, and red blood cell concentrates were transfused to maintain a hemoglobin level > 8 mg/dl during CPB.", [["cell", "ANATOMY", 26, 30], ["red blood cell", "ANATOMY", 64, 78], ["cell", "CELL", 26, 30], ["red blood cell", "CELL", 64, 78], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 122, 132], ["red blood cell concentrates", "CELL_TYPE", 64, 91], ["hemoglobin", "PROTEIN", 122, 132], ["an intraoperative cell salvage device", "TREATMENT", 8, 45], ["red blood cell concentrates", "TREATMENT", 64, 91], ["a hemoglobin level", "TEST", 120, 138], ["CPB", "TREATMENT", 156, 159], ["intraoperative cell salvage", "OBSERVATION", 11, 38]]], ["Coagulation function was monitored by TEG 6 s (Haemonetics Japan GK, Tokyo, Japan), and fresh frozen plasma or platelet concentrate was administered where needed.General anesthesia procedureThe anesthetic gas concentration in each oxygenator was monitored using the anesthesia machine (Perseus A500, Dr\u00e4ger Medical Japan Ltd).", [["plasma", "ANATOMY", 101, 107], ["platelet", "ANATOMY", 111, 119], ["plasma", "ORGANISM_SUBSTANCE", 101, 107], ["platelet", "CELL", 111, 119], ["Coagulation function", "TEST", 0, 20], ["TEG", "TEST", 38, 41], ["fresh frozen plasma", "TREATMENT", 88, 107], ["platelet concentrate", "TREATMENT", 111, 131], ["General anesthesia procedure", "TREATMENT", 162, 190], ["The anesthetic gas concentration", "TREATMENT", 190, 222], ["each oxygenator", "TREATMENT", 226, 241], ["the anesthesia machine", "TREATMENT", 262, 284], ["anesthesia", "OBSERVATION", 170, 180]]], ["A drainage system was used to decrease VA leakage during CPB [18, 19] .", [["A drainage system", "TREATMENT", 0, 17], ["VA leakage during CPB", "TREATMENT", 39, 60], ["drainage", "OBSERVATION", 2, 10], ["leakage", "OBSERVATION_MODIFIER", 42, 49]]], ["Gas sampling was performed at the gas inlet of the oxygenator and an outlet port of our VA drainage system where the gas was aspirated at a flow rate of 200 ml/min.", [["Gas sampling", "TEST", 0, 12], ["the oxygenator", "TREATMENT", 47, 61], ["an outlet port", "TREATMENT", 66, 80], ["our VA drainage system", "TREATMENT", 84, 106], ["the gas", "TEST", 113, 120], ["outlet port", "OBSERVATION", 69, 80], ["gas", "OBSERVATION", 117, 120]]], ["The gas analysis monitor was calibrated just prior to starting the study and was adjusted to zero every time before initiating a measurement according to the manufacturer's instruction.Blood sample collectionThree blood samples were collected in each group via a radial artery cannula system with a closed circuit for blood sampling (Tru Wave with VAMP system, Edwards Lifesciences Co., Ltd., Irvine, CA).", [["Blood sample", "ANATOMY", 185, 197], ["blood samples", "ANATOMY", 214, 227], ["radial artery", "ANATOMY", 263, 276], ["blood", "ANATOMY", 318, 323], ["Blood", "ORGANISM_SUBSTANCE", 185, 190], ["blood samples", "ORGANISM_SUBSTANCE", 214, 227], ["radial artery", "MULTI-TISSUE_STRUCTURE", 263, 276], ["blood", "ORGANISM_SUBSTANCE", 318, 323], ["The gas analysis monitor", "TEST", 0, 24], ["the study", "TEST", 63, 72], ["a measurement", "TEST", 127, 140], ["Blood sample collection", "TEST", 185, 208], ["Three blood samples", "TEST", 208, 227], ["a radial artery cannula system", "TREATMENT", 261, 291], ["a closed circuit", "TREATMENT", 297, 313], ["blood sampling", "TEST", 318, 332], ["radial artery", "ANATOMY", 263, 276], ["closed", "OBSERVATION", 299, 305]]], ["To measure desflurane and sevoflurane blood concentrations, blood samples (0.5 ml) were collected in a vial sealed with a rubber cap and aluminum crimp seal containing saline (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan).", [["blood", "ANATOMY", 38, 43], ["blood samples", "ANATOMY", 60, 73], ["desflurane", "CHEMICAL", 11, 21], ["sevoflurane", "CHEMICAL", 26, 37], ["aluminum", "CHEMICAL", 137, 145], ["desflurane", "CHEMICAL", 11, 21], ["sevoflurane", "CHEMICAL", 26, 37], ["aluminum", "CHEMICAL", 137, 145], ["desflurane", "SIMPLE_CHEMICAL", 11, 21], ["sevoflurane", "SIMPLE_CHEMICAL", 26, 37], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["blood samples", "ORGANISM_SUBSTANCE", 60, 73], ["saline", "SIMPLE_CHEMICAL", 168, 174], ["desflurane", "TREATMENT", 11, 21], ["sevoflurane blood concentrations", "TREATMENT", 26, 58], ["blood samples", "TEST", 60, 73], ["a rubber cap", "TREATMENT", 120, 132], ["aluminum crimp seal containing saline", "TREATMENT", 137, 174], ["rubber cap", "OBSERVATION", 122, 132], ["crimp seal", "OBSERVATION", 146, 156]]], ["The HL sampling for both anesthetics was undertaken 20 min after starting the delivery of 6.0 vol% desflurane or 1.7 vol% sevoflurane with tracheal intubation and 3.0 l/min total gas flow.", [["tracheal", "ANATOMY", 139, 147], ["desflurane", "CHEMICAL", 99, 109], ["sevoflurane", "CHEMICAL", 122, 133], ["desflurane", "CHEMICAL", 99, 109], ["sevoflurane", "CHEMICAL", 122, 133], ["desflurane", "SIMPLE_CHEMICAL", 99, 109], ["sevoflurane", "SIMPLE_CHEMICAL", 122, 133], ["tracheal", "ORGAN", 139, 147], ["The HL sampling", "TREATMENT", 0, 15], ["both anesthetics", "TREATMENT", 20, 36], ["the delivery of 6.0 vol% desflurane", "TREATMENT", 74, 109], ["1.7 vol% sevoflurane", "TREATMENT", 113, 133], ["tracheal intubation", "TREATMENT", 139, 158], ["tracheal", "ANATOMY", 139, 147], ["intubation", "OBSERVATION", 148, 158], ["gas flow", "OBSERVATION", 179, 187]]], ["To measure the blood concentration of both VAs via oxygenator, blood samples were collected at 20 min after starting the delivery of 6.0 vol% desflurane or 1.7 vol% sevoflurane to the oxygenator with a constant gas mixture of oxygen and air (F I O 2 50-60%) at 0.5-3.0 l/min.", [["blood", "ANATOMY", 15, 20], ["blood samples", "ANATOMY", 63, 76], ["desflurane", "CHEMICAL", 142, 152], ["sevoflurane", "CHEMICAL", 165, 176], ["oxygen", "CHEMICAL", 226, 232], ["desflurane", "CHEMICAL", 142, 152], ["sevoflurane", "CHEMICAL", 165, 176], ["oxygen", "CHEMICAL", 226, 232], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["VAs", "SIMPLE_CHEMICAL", 43, 46], ["blood samples", "ORGANISM_SUBSTANCE", 63, 76], ["desflurane", "SIMPLE_CHEMICAL", 142, 152], ["sevoflurane", "SIMPLE_CHEMICAL", 165, 176], ["oxygen", "SIMPLE_CHEMICAL", 226, 232], ["the blood concentration", "TEST", 11, 34], ["blood samples", "TEST", 63, 76], ["the delivery of 6.0 vol% desflurane", "TREATMENT", 117, 152], ["vol% sevoflurane", "TREATMENT", 160, 176], ["the oxygenator", "TREATMENT", 180, 194], ["a constant gas mixture of oxygen", "TREATMENT", 200, 232]]], ["Based on the drug package insert information, it was predicted that the serum concentration of VAs would be sufficiently parallel at 20 min after their delivery to the patient was started.", [["serum", "ANATOMY", 72, 77], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["VAs", "SIMPLE_CHEMICAL", 95, 98], ["patient", "ORGANISM", 168, 175], ["patient", "SPECIES", 168, 175], ["the drug package insert information", "TREATMENT", 9, 44], ["the serum concentration of VAs", "TREATMENT", 68, 98]]], ["Blood samples were also obtained 40 min after starting the delivery of 1.7 vol% sevoflurane through the oxygenators to investigate changes with time.", [["Blood samples", "ANATOMY", 0, 13], ["sevoflurane", "CHEMICAL", 80, 91], ["sevoflurane", "CHEMICAL", 80, 91], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["sevoflurane", "SIMPLE_CHEMICAL", 80, 91], ["Blood samples", "TEST", 0, 13], ["the delivery of 1.7 vol% sevoflurane", "TREATMENT", 55, 91], ["the oxygenators", "TREATMENT", 100, 115]]], ["Several conditions, such as fresh gas flow rate and body temperature at the time of sampling, were transferred from the electronic medical chart.Gas chromatographyDesflurane, the standard, was obtained from Baxter Limited (Tokyo, Japan), and isoprene, the internal standard, was purchased from Sigma-Aldrich (St. Louis, MO).", [["body", "ANATOMY", 52, 56], ["Desflurane", "CHEMICAL", 163, 173], ["isoprene", "CHEMICAL", 242, 250], ["Desflurane", "CHEMICAL", 163, 173], ["isoprene", "CHEMICAL", 242, 250], ["body", "ORGANISM_SUBDIVISION", 52, 56], ["Desflurane", "SIMPLE_CHEMICAL", 163, 173], ["isoprene", "SIMPLE_CHEMICAL", 242, 250], ["Sigma-Aldrich", "ORGANISM", 294, 307], ["St. Louis, MO", "ORGANISM", 309, 322], ["Several conditions", "PROBLEM", 0, 18], ["fresh gas flow rate", "TEST", 28, 47], ["body temperature", "PROBLEM", 52, 68], ["Gas chromatography", "TEST", 145, 163], ["Desflurane", "TREATMENT", 163, 173]]], ["All other chemicals, including sevoflurane for standard and its internal standard, isoflurane, were purchased from Fujifilm Wako Pure Chemical Industries, Ltd.", [["sevoflurane", "CHEMICAL", 31, 42], ["isoflurane", "CHEMICAL", 83, 93], ["sevoflurane", "CHEMICAL", 31, 42], ["isoflurane", "CHEMICAL", 83, 93], ["sevoflurane", "SIMPLE_CHEMICAL", 31, 42], ["isoflurane", "SIMPLE_CHEMICAL", 83, 93], ["sevoflurane", "TREATMENT", 31, 42], ["isoflurane", "TREATMENT", 83, 93], ["Chemical Industries", "OBSERVATION", 134, 153]]], ["(Osaka, Japan).Gas chromatographyGas chromatography-tandem mass spectrometry (GC-MS/MS) for desflurane blood concentration was performed on a Shimadzu GCMS-TQ8030 triple quadrupole mass spectrometer (Shimadzu Corp., Kyoto, Japan) with fused-silica capillary column Rtx-5MS (30 m \u00d7 0.25 mm internal diameter (i.d.), 0.25 \u03bcm film thickness, Restek Corp., Bellefonte, PA).", [["blood", "ANATOMY", 103, 108], ["desflurane", "CHEMICAL", 92, 102], ["Rtx-5MS", "CHEMICAL", 265, 272], ["desflurane", "CHEMICAL", 92, 102], ["silica", "CHEMICAL", 241, 247], ["desflurane", "SIMPLE_CHEMICAL", 92, 102], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["Gas chromatography", "TEST", 15, 33], ["Gas chromatography", "TEST", 33, 51], ["tandem mass spectrometry", "TEST", 52, 76], ["GC", "TEST", 78, 80], ["MS", "TEST", 84, 86], ["desflurane blood concentration", "TEST", 92, 122], ["a Shimadzu GCMS", "TEST", 140, 155], ["triple quadrupole mass spectrometer", "TREATMENT", 163, 198], ["fused-silica capillary column Rtx", "TREATMENT", 235, 268], ["silica", "ANATOMY_MODIFIER", 241, 247], ["capillary column", "ANATOMY", 248, 264]]], ["Helium was chosen as the carrier gas at a flow rate of 1 ml/min.", [["Helium", "CHEMICAL", 0, 6], ["Helium", "CHEMICAL", 0, 6], ["Helium", "TREATMENT", 0, 6], ["the carrier gas", "TEST", 21, 36], ["a flow rate", "TEST", 40, 51]]], ["The column oven temperature program was as follows: initial temperature of 35 \u00b0C held for 2 min, followed by a 10 \u00b0C/min linear ramp to a final temperature of 110 \u00b0C, with a final hold for 2 min (total run time, 11.5 min).", [["initial temperature", "TEST", 52, 71], ["column", "OBSERVATION_MODIFIER", 4, 10]]], ["The inlet temperature was set at 150 \u00b0C, and the gas sample (500 \u03bcl) was injected manually using a gas tight syringe after sample vial incubation for 15 min at 40 \u00b0C. MS detector parameters were as follows: interface temperature, 250 \u00b0C; ion source temperature, 230 \u00b0C. An electron impact (EI) ionization mode with an ionization energy of 70 eV was used.", [["sample", "ANATOMY", 53, 59], ["electron", "SIMPLE_CHEMICAL", 273, 281], ["The inlet temperature", "TEST", 0, 21], ["the gas sample", "TEST", 45, 59], ["a gas tight syringe", "TREATMENT", 97, 116], ["sample vial incubation", "TREATMENT", 123, 145], ["MS detector parameters", "TEST", 167, 189], ["interface temperature", "TEST", 207, 228], ["ion source temperature", "TEST", 238, 260], ["An electron impact (EI) ionization mode", "TREATMENT", 270, 309], ["an ionization energy", "TREATMENT", 315, 335], ["inlet", "OBSERVATION_MODIFIER", 4, 9]]], ["The analysis was performed in the selected ion monitoring (SIM) mode.", [["The analysis", "TEST", 0, 12]]], ["In the SIM mode, we selected the ions of mass-to-charge ratio (m/z) 51 for desflurane and m/z 67 for isoprene.", [["desflurane", "CHEMICAL", 75, 85], ["isoprene", "CHEMICAL", 101, 109], ["desflurane", "CHEMICAL", 75, 85], ["isoprene", "CHEMICAL", 101, 109], ["desflurane", "SIMPLE_CHEMICAL", 75, 85], ["isoprene", "SIMPLE_CHEMICAL", 101, 109], ["mass", "TEST", 41, 45], ["desflurane", "TREATMENT", 75, 85], ["isoprene", "TREATMENT", 101, 109], ["mass", "OBSERVATION", 41, 45]]], ["Data acquisition, processing, analyte identification, and quantification were conducted using LabSolutions Insight\u2122 software (ver.", [["Data acquisition", "TEST", 0, 16], ["analyte identification", "TEST", 30, 52]]], ["4.20, Shimadzu Corp.).Gas chromatographyThe headspace analysis for sevoflurane blood concentration was performed on a Shimadzu GC-2014AF/SPL 100 V (Shimadzu Corp.) with a flame ionization detector equipped with a capillary column SUPELCOWAX 10 (30 m \u00d7 0.25 mm i.d., 0.25 \u03bcm film thickness; Sigma-Aldrich).", [["blood", "ANATOMY", 79, 84], ["sevoflurane", "CHEMICAL", 67, 78], ["sevoflurane", "CHEMICAL", 67, 78], ["sevoflurane", "SIMPLE_CHEMICAL", 67, 78], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["Gas chromatography", "TEST", 22, 40], ["The headspace analysis", "TEST", 40, 62], ["sevoflurane blood concentration", "TEST", 67, 98], ["a Shimadzu GC", "TEST", 116, 129], ["a flame ionization detector", "TREATMENT", 169, 196], ["a capillary column SUPELCOWAX", "TREATMENT", 211, 240]]], ["The oven and detector temperatures were 60 \u00b0C and 120 \u00b0C, respectively.", [["detector temperatures", "TEST", 13, 34]]], ["The Shimadzu HS-20 LT headspace (Shimadzu Corp.) was used as an autosampler.", [["The Shimadzu HS-20 LT headspace (Shimadzu Corp.)", "TREATMENT", 0, 48], ["an autosampler", "TREATMENT", 61, 75]]], ["The inlet pressure was set at 90 kPa.", [["The inlet pressure", "TEST", 0, 18], ["inlet", "OBSERVATION_MODIFIER", 4, 9], ["pressure", "OBSERVATION_MODIFIER", 10, 18]]], ["The carrier gas (helium) flow was 36.5 ml/min.", [["The carrier gas (helium) flow", "TEST", 0, 29]]], ["Data acquisition and processing, analyte identification, and quantification were conducted using LabSolutions Insight\u2122 software (ver.", [["Data acquisition", "TEST", 0, 16], ["analyte identification", "TEST", 33, 55]]], ["Further data evaluation was performed using Microsoft Excel (Microsoft Corp., Redmond, WA).", [["Further data evaluation", "TEST", 0, 23]]], ["Desflurane and sevoflurane concentrations were calculated in \u03bcg/ml and corrected for blood sample weight.Oxygenator membrane and fiber preparationOf the oxygenators from each manufacturer, the one with the longest VA exposure time in surgeries was selected for this study.", [["blood sample", "ANATOMY", 85, 97], ["membrane", "ANATOMY", 116, 124], ["Desflurane", "CHEMICAL", 0, 10], ["sevoflurane", "CHEMICAL", 15, 26], ["Desflurane", "CHEMICAL", 0, 10], ["sevoflurane", "CHEMICAL", 15, 26], ["Desflurane", "SIMPLE_CHEMICAL", 0, 10], ["sevoflurane", "SIMPLE_CHEMICAL", 15, 26], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["Oxygenator membrane", "CELLULAR_COMPONENT", 105, 124], ["Desflurane", "TREATMENT", 0, 10], ["sevoflurane concentrations", "TEST", 15, 41], ["blood sample weight", "TEST", 85, 104], ["Oxygenator membrane", "TREATMENT", 105, 124], ["fiber preparationOf the oxygenators", "TREATMENT", 129, 164], ["surgeries", "TREATMENT", 234, 243], ["this study", "TEST", 261, 271], ["fiber preparationOf", "OBSERVATION", 129, 148], ["oxygenators", "OBSERVATION_MODIFIER", 153, 164]]], ["The shell of each oxygenator was removed.", [["The shell of each oxygenator", "TREATMENT", 0, 28], ["shell", "OBSERVATION_MODIFIER", 4, 9], ["oxygenator", "OBSERVATION_MODIFIER", 18, 28]]], ["PP HFMs were randomly selected from near the center of the membrane layer, the middle layer, or near the surface layer and taken out.", [["membrane layer", "ANATOMY", 59, 73], ["middle layer", "ANATOMY", 79, 91], ["surface layer", "ANATOMY", 105, 118], ["membrane layer", "CELLULAR_COMPONENT", 59, 73], ["PP HFMs", "TEST", 0, 7], ["center", "ANATOMY_MODIFIER", 45, 51], ["membrane", "OBSERVATION_MODIFIER", 59, 67], ["layer", "OBSERVATION_MODIFIER", 68, 73], ["middle", "OBSERVATION_MODIFIER", 79, 85], ["layer", "OBSERVATION_MODIFIER", 86, 91], ["surface", "OBSERVATION_MODIFIER", 105, 112], ["layer", "OBSERVATION_MODIFIER", 113, 118]]], ["Membranes from unused oxygenators were prepared as controls.Scanning electron microscopy settingsThe de-cellularized and dried fibers were cut lengthwise to observe the microstructure of the inner surface.", [["Membranes", "ANATOMY", 0, 9], ["fibers", "ANATOMY", 127, 133], ["inner surface", "ANATOMY", 191, 204], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["inner surface", "CELLULAR_COMPONENT", 191, 204], ["unused oxygenators", "TREATMENT", 15, 33], ["Scanning electron microscopy settings", "TEST", 60, 97], ["The de-cellularized and dried fibers", "TREATMENT", 97, 133], ["unused oxygenators", "OBSERVATION", 15, 33], ["dried", "OBSERVATION_MODIFIER", 121, 126], ["fibers", "OBSERVATION_MODIFIER", 127, 133], ["microstructure", "OBSERVATION_MODIFIER", 169, 183], ["inner", "ANATOMY_MODIFIER", 191, 196], ["surface", "ANATOMY_MODIFIER", 197, 204]]], ["The cut fibers were fixed on the sample stage with a carbon tape to observe the inner surface.", [["fibers", "ANATOMY", 8, 14], ["inner surface", "ANATOMY", 80, 93], ["carbon", "CHEMICAL", 53, 59], ["inner surface", "CELLULAR_COMPONENT", 80, 93], ["The cut fibers", "TREATMENT", 0, 14], ["a carbon tape", "TREATMENT", 51, 64], ["inner", "ANATOMY_MODIFIER", 80, 85], ["surface", "ANATOMY_MODIFIER", 86, 93]]], ["Then, the fibers were prepared with an osmium coating.", [["fibers", "ANATOMY", 10, 16], ["osmium", "CHEMICAL", 39, 45], ["osmium", "CHEMICAL", 39, 45], ["fibers", "CELLULAR_COMPONENT", 10, 16], ["osmium", "SIMPLE_CHEMICAL", 39, 45], ["an osmium coating", "TREATMENT", 36, 53], ["osmium coating", "OBSERVATION", 39, 53]]], ["The observation was performed using a high-resolution field emission SEM (JSM-7610F, JEOL, Tokyo, Japan).Statistical analysesThe sample size was calculated as three for each group based on the quality control of gas chromatography \u2264 15%, coefficient of variation \u2264 10%, and sample sizes and variability of blood concentration of desflurane [20] and sevoflurane [21] in drug interview forms.", [["sample", "ANATOMY", 129, 135], ["sample", "ANATOMY", 274, 280], ["blood", "ANATOMY", 306, 311], ["desflurane", "CHEMICAL", 329, 339], ["sevoflurane", "CHEMICAL", 349, 360], ["desflurane", "CHEMICAL", 329, 339], ["sevoflurane", "CHEMICAL", 349, 360], ["blood", "ORGANISM_SUBSTANCE", 306, 311], ["desflurane", "SIMPLE_CHEMICAL", 329, 339], ["sevoflurane", "SIMPLE_CHEMICAL", 349, 360], ["JSM", "TEST", 74, 77], ["Statistical analyses", "TEST", 105, 125], ["The sample size", "TEST", 125, 140], ["gas chromatography", "TEST", 212, 230], ["blood concentration of desflurane", "TREATMENT", 306, 339], ["sevoflurane", "TREATMENT", 349, 360], ["size", "OBSERVATION_MODIFIER", 136, 140]]], ["Parametric tests were used for statistical analysis, as the Levene test showed that variances were homogeneous.", [["Parametric tests", "TEST", 0, 16], ["statistical analysis", "TEST", 31, 51], ["the Levene test", "TEST", 56, 71], ["homogeneous", "OBSERVATION_MODIFIER", 99, 110]]], ["The groups were compared using oneway analysis of variance, followed by two-tailed Dunnett's or Tukey's test.", [["Tukey's test", "TEST", 96, 108]]], ["Non-parametric tests were performed using the Kruskal-Wallis or Mann-Whitney U test.", [["Non-parametric tests", "TEST", 0, 20]]], ["P values < 0.05 indicated statistical significance and all P values were two tailed.", [["P values", "TEST", 0, 8], ["all P values", "TEST", 55, 67]]], ["All data were analyzed using SPSS software, version 26 (IBM Corp., Armonk, NY).ResultsBetween January and August 2019, 24 patients were assessed for eligibility.", [["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["All data", "TEST", 0, 8], ["SPSS software", "TEST", 29, 42], ["version", "TEST", 44, 51]]], ["All 24 were eligible for recruitment and were randomly allocated: 12 to the desflurane and 12 to the sevoflurane administration groups (Fig. 1) .", [["desflurane", "CHEMICAL", 76, 86], ["sevoflurane", "CHEMICAL", 101, 112], ["desflurane", "CHEMICAL", 76, 86], ["sevoflurane", "CHEMICAL", 101, 112], ["sevoflurane", "SIMPLE_CHEMICAL", 101, 112], ["recruitment", "TREATMENT", 25, 36], ["the desflurane", "TREATMENT", 72, 86], ["the sevoflurane administration groups", "TREATMENT", 97, 134]]], ["The 12 patients in each VA group were further allocated into four groups (TE, LI, ME, and SE) of three individuals.", [["SE", "DISEASE", 90, 92], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15]]], ["In the sampling for the HL group, three patients were randomly selected in each VA administration group.", [["HL", "CANCER", 24, 26], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48]]], ["No patients withdrew from the study.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["the study", "TEST", 26, 35], ["withdrew", "OBSERVATION", 12, 20]]], ["Finally, 30 samples were collected for blood concentration measurement and analyzed.", [["samples", "ANATOMY", 12, 19], ["blood", "ANATOMY", 39, 44], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["blood concentration measurement", "TEST", 39, 70]]], ["Patient information and surgical characteristics are presented in Table 1 .ResultsThe mean (standard deviation) concentration of desflurane at 20 min after starting its delivery was 182.4 (23.2) \u03bcg/ml in the HL group (Fig. 2a) .", [["desflurane", "CHEMICAL", 129, 139], ["desflurane", "CHEMICAL", 129, 139], ["desflurane", "SIMPLE_CHEMICAL", 129, 139], ["HL", "CANCER", 208, 210], ["Patient", "SPECIES", 0, 7], ["The mean (standard deviation) concentration of desflurane", "TREATMENT", 82, 139]]], ["We did not observe any significant difference for any of the oxygenators (TE: 181.8 (24.", [["the oxygenators", "TEST", 57, 72]]], ["3) \u03bcg/ml, P = 1.000; LI: 163.3 (3.0) \u03bcg/ml, P = 0.613; ME: 155.8 (9.4) \u03bcg/ml, P = 0.353; and SE: 162.8 (28.1) \u03bcg/ ml, P = 0.595; Fig. 2a ) when compared to the HL group.", [["SE", "DISEASE", 93, 95], ["HL", "CANCER", 160, 162], ["P", "TEST", 10, 11], ["LI", "TEST", 21, 23], ["P", "TEST", 44, 45], ["ME", "TEST", 55, 57], ["P", "TEST", 78, 79], ["SE", "TEST", 93, 95], ["P", "TEST", 118, 119]]], ["For sevoflurane, the concentration at 20 min after starting its delivery was 54.0 (9.6) \u03bcg/ml in the HL group (Fig. 2b) .", [["sevoflurane", "CHEMICAL", 4, 15], ["sevoflurane", "CHEMICAL", 4, 15], ["sevoflurane", "SIMPLE_CHEMICAL", 4, 15], ["HL", "CANCER", 101, 103], ["sevoflurane", "TREATMENT", 4, 15]]], ["There was no significant difference in the results from any of the oxygenators (TE: 60.4 (5.9) \u03bcg/ml, P = 0.947; LI: 63.1 (11.3) \u03bcg/ml, P = 0.773; ME: 55.4 (5.3) \u03bcg/ml, P = 1.000; and SE: 60.5 (12.4) \u03bcg/ml, P = 0.943; Fig. 2b ) when compared to the HL group.ResultsSecondary outcomes assessed included complications related to oxygenators, such as plasma leaks, fissure, denaturation, blood clot, hypoxia, and other unexpected complications.", [["plasma", "ANATOMY", 348, 354], ["blood clot", "ANATOMY", 385, 395], ["SE", "DISEASE", 184, 186], ["blood clot", "DISEASE", 385, 395], ["hypoxia", "DISEASE", 397, 404], ["HL", "CANCER", 249, 251], ["plasma", "ORGANISM_SUBSTANCE", 348, 354], ["blood", "ORGANISM_SUBSTANCE", 385, 390], ["significant difference", "PROBLEM", 13, 35], ["the oxygenators", "TEST", 63, 78], ["TE", "TEST", 80, 82], ["P", "TEST", 102, 103], ["LI", "TEST", 113, 115], ["P", "TEST", 136, 137], ["ME", "TEST", 147, 149], ["\u03bcg", "TEST", 162, 164], ["P", "TEST", 169, 170], ["SE", "TEST", 184, 186], ["\u03bcg", "TEST", 200, 202], ["P", "TEST", 207, 208], ["Fig.", "TEST", 218, 222], ["complications", "PROBLEM", 302, 315], ["oxygenators", "TREATMENT", 327, 338], ["plasma leaks", "PROBLEM", 348, 360], ["fissure", "PROBLEM", 362, 369], ["denaturation", "PROBLEM", 371, 383], ["blood clot", "PROBLEM", 385, 395], ["hypoxia", "PROBLEM", 397, 404], ["other unexpected complications", "PROBLEM", 410, 440], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION", 25, 35], ["fissure", "OBSERVATION_MODIFIER", 362, 369], ["blood", "ANATOMY", 385, 390], ["clot", "OBSERVATION", 391, 395], ["hypoxia", "OBSERVATION", 397, 404], ["unexpected", "OBSERVATION_MODIFIER", 416, 426], ["complications", "OBSERVATION", 427, 440]]], ["No complications were observed in this study.", [["complications", "PROBLEM", 3, 16], ["this study", "TEST", 34, 44], ["complications", "OBSERVATION", 3, 16]]], ["Images were acquired for the SEM-based evaluation of fibers in each unused oxygenator HFM, except for SE, in which its unique coating hindered definite image acquisition of the fiber surface.", [["fibers", "ANATOMY", 53, 59], ["fiber surface", "ANATOMY", 177, 190], ["SE", "DISEASE", 102, 104], ["fibers", "CELL", 53, 59], ["fiber surface", "CELLULAR_COMPONENT", 177, 190], ["Images", "TEST", 0, 6], ["the SEM", "TEST", 25, 32], ["oxygenator HFM", "OBSERVATION", 75, 89], ["fiber", "OBSERVATION_MODIFIER", 177, 182], ["surface", "OBSERVATION_MODIFIER", 183, 190]]], ["It was apparent that the shape of the fiber surface differed depending on the manufacturer (Fig. 3a) .", [["fiber surface", "ANATOMY", 38, 51], ["fiber surface", "CELLULAR_COMPONENT", 38, 51], ["the fiber surface", "TREATMENT", 34, 51], ["shape", "OBSERVATION_MODIFIER", 25, 30], ["fiber surface", "OBSERVATION", 38, 51]]], ["Images of fibers were acquired after clinical use (Fig. 3b) .", [["fibers", "ANATOMY", 10, 16], ["fibers", "CELL", 10, 16], ["Images of fibers", "TEST", 0, 16]]], ["Apparent structural changes were not identified between unused and used fibers of the three oxygenators.DiscussionThe fiber coatings of the different oxygenators used in this study were poly-2-methoxyethyl acrylate coating in TE, phosphorylcholine coating in LI, sulfate and sulfonate groups-polyethylene oxide coating in ME, and polyethylene glycol-silicon-alkyl group coating in SE.", [["fibers", "ANATOMY", 72, 78], ["fiber", "ANATOMY", 118, 123], ["poly-2-methoxyethyl acrylate", "CHEMICAL", 186, 214], ["phosphorylcholine", "CHEMICAL", 230, 247], ["LI, sulfate and sulfonate", "CHEMICAL", 259, 284], ["polyethylene oxide", "CHEMICAL", 292, 310], ["polyethylene glycol-silicon-alkyl", "CHEMICAL", 330, 363], ["SE", "DISEASE", 381, 383], ["poly-2-methoxyethyl acrylate", "CHEMICAL", 186, 214], ["phosphorylcholine", "CHEMICAL", 230, 247], ["sulfate", "CHEMICAL", 263, 270], ["sulfonate", "CHEMICAL", 275, 284], ["polyethylene oxide", "CHEMICAL", 292, 310], ["polyethylene glycol", "CHEMICAL", 330, 349], ["silicon", "CHEMICAL", 350, 357], ["poly-2-methoxyethyl acrylate", "SIMPLE_CHEMICAL", 186, 214], ["TE", "SIMPLE_CHEMICAL", 226, 228], ["phosphorylcholine", "SIMPLE_CHEMICAL", 230, 247], ["LI", "SIMPLE_CHEMICAL", 259, 261], ["sulfate", "SIMPLE_CHEMICAL", 263, 270], ["sulfonate groups-polyethylene oxide", "SIMPLE_CHEMICAL", 275, 310], ["ME", "SIMPLE_CHEMICAL", 322, 324], ["polyethylene glycol-silicon-alkyl", "SIMPLE_CHEMICAL", 330, 363], ["Apparent structural changes", "PROBLEM", 0, 27], ["The fiber coatings", "TREATMENT", 114, 132], ["the different oxygenators", "TREATMENT", 136, 161], ["this study", "TEST", 170, 180], ["methoxyethyl acrylate coating in TE, phosphorylcholine coating in LI, sulfate and sulfonate groups", "TREATMENT", 193, 291], ["polyethylene oxide coating in ME", "TREATMENT", 292, 324], ["polyethylene glycol-silicon-alkyl group coating", "TREATMENT", 330, 377]]], ["They are biocompatible non-biological materials applied to the PP HFM.", [["HFM", "DISEASE", 66, 69], ["biocompatible non-biological materials", "TREATMENT", 9, 47], ["biocompatible", "OBSERVATION_MODIFIER", 9, 22]]], ["The results of this study revealed two major findings: First, at 20 min after starting VA administration, there were no significant differences between HL and the four oxygenators tested.", [["HL", "CANCER", 152, 154], ["this study", "TEST", 15, 25], ["VA administration", "TREATMENT", 87, 104], ["significant differences between HL", "PROBLEM", 120, 154], ["no", "UNCERTAINTY", 117, 119], ["significant", "OBSERVATION_MODIFIER", 120, 131]]], ["Second, no apparent changes were observed in the fiber structures of three PP HFM oxygenators after clinical use.DiscussionThe selected VA concentrations, 6 vol% desflurane [20] and 1.7 vol% sevoflurane [22, 23] , were approximately equal to one minimum alveolar concentration.", [["fiber structures", "ANATOMY", 49, 65], ["alveolar", "ANATOMY", 254, 262], ["desflurane", "CHEMICAL", 162, 172], ["sevoflurane", "CHEMICAL", 191, 202], ["desflurane", "CHEMICAL", 162, 172], ["sevoflurane", "CHEMICAL", 191, 202], ["sevoflurane", "SIMPLE_CHEMICAL", 191, 202], ["alveolar", "MULTI-TISSUE_STRUCTURE", 254, 262], ["apparent changes", "PROBLEM", 11, 27], ["PP HFM oxygenators", "TREATMENT", 75, 93], ["6 vol% desflurane", "TREATMENT", 155, 172], ["vol% sevoflurane", "TREATMENT", 186, 202], ["no apparent", "UNCERTAINTY", 8, 19], ["changes", "OBSERVATION", 20, 27], ["alveolar concentration", "OBSERVATION", 254, 276]]], ["Moreover, the selected concentrations were close to the concentrations administered in general anesthesia.", [["general anesthesia", "TREATMENT", 87, 105]]], ["In the HL group, the mean blood concentration of desflurane with 6 vol% was similar to the value described in the package insert [20] .", [["blood", "ANATOMY", 26, 31], ["desflurane", "CHEMICAL", 49, 59], ["desflurane", "CHEMICAL", 49, 59], ["HL", "CANCER", 7, 9], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["desflurane", "SIMPLE_CHEMICAL", 49, 59], ["the mean blood concentration", "TEST", 17, 45], ["desflurane", "TEST", 49, 59]]], ["No data variability between the oxygenator groups and no significant difference from the HL group were noted.", [["HL", "CANCER", 89, 91], ["data variability", "PROBLEM", 3, 19], ["the oxygenator groups", "TREATMENT", 28, 49], ["variability", "OBSERVATION_MODIFIER", 8, 19], ["no", "UNCERTAINTY", 54, 56], ["significant", "OBSERVATION_MODIFIER", 57, 68], ["difference", "OBSERVATION_MODIFIER", 69, 79]]], ["Similar results were obtained with 1.7 vol% sevoflurane after 20-min administration.", [["sevoflurane", "CHEMICAL", 44, 55], ["sevoflurane", "CHEMICAL", 44, 55], ["sevoflurane", "SIMPLE_CHEMICAL", 44, 55], ["1.7 vol% sevoflurane", "TREATMENT", 35, 55]]], ["Additionally, the 40-min blood concentration of sevoflurane was almost identical to that at 20 min (Supplemental Fig. 1) , demonstrating that the sevoflurane blood concentration is stably maintained after passage through any one of the four types of PP HFM oxygenators.", [["blood", "ANATOMY", 25, 30], ["blood", "ANATOMY", 158, 163], ["sevoflurane", "CHEMICAL", 48, 59], ["sevoflurane", "CHEMICAL", 146, 157], ["sevoflurane", "CHEMICAL", 48, 59], ["sevoflurane", "CHEMICAL", 146, 157], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["sevoflurane", "SIMPLE_CHEMICAL", 48, 59], ["sevoflurane", "SIMPLE_CHEMICAL", 146, 157], ["blood", "ORGANISM_SUBSTANCE", 158, 163], ["sevoflurane", "TREATMENT", 48, 59], ["the sevoflurane blood concentration", "TREATMENT", 142, 177], ["PP HFM oxygenators", "TREATMENT", 250, 268], ["stably", "OBSERVATION_MODIFIER", 181, 187], ["PP HFM oxygenators", "OBSERVATION", 250, 268]]], ["In the Table 1 Patients' demographic and surgical characteristics Data are expressed as means (standard deviation) or number of patients.", [["Patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 128, 136], ["Patients", "SPECIES", 15, 23], ["patients", "SPECIES", 128, 136]]], ["Twenty-four patients scheduled for elective cardiopulmonary bypass were randomly allocated to one of the two VA groups (desflurane and sevoflurane groups) and, then, randomly divided into one of the four groups (TE, LI, ME, and SE) consisted of four individuals within each VA group.", [["cardiopulmonary", "ANATOMY", 44, 59], ["desflurane", "CHEMICAL", 120, 130], ["sevoflurane", "CHEMICAL", 135, 146], ["SE", "DISEASE", 228, 230], ["desflurane", "CHEMICAL", 120, 130], ["sevoflurane", "CHEMICAL", 135, 146], ["patients", "ORGANISM", 12, 20], ["desflurane", "SIMPLE_CHEMICAL", 120, 130], ["sevoflurane", "SIMPLE_CHEMICAL", 135, 146], ["patients", "SPECIES", 12, 20], ["elective cardiopulmonary bypass", "TREATMENT", 35, 66], ["desflurane and sevoflurane groups", "TREATMENT", 120, 153], ["cardiopulmonary", "ANATOMY", 44, 59], ["bypass", "OBSERVATION", 60, 66]]], ["The same number of patients was also randomly and redundantly allocated to group HL in each VA group.", [["HL", "DISEASE", 81, 83], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27]]], ["Therefore, the patients in the HL group are not included in this previous study conducted by Nitzschke et al. using 1.8 vol% of sevoflurane and types of PP HFM oxygenator different from ours [13] , the sevoflurane blood concentration before introduction of the oxygenator was similar to our HL data.", [["blood", "ANATOMY", 214, 219], ["sevoflurane", "CHEMICAL", 128, 139], ["sevoflurane", "CHEMICAL", 202, 213], ["sevoflurane", "CHEMICAL", 128, 139], ["sevoflurane", "CHEMICAL", 202, 213], ["patients", "ORGANISM", 15, 23], ["HL", "CANCER", 31, 33], ["sevoflurane", "SIMPLE_CHEMICAL", 128, 139], ["sevoflurane", "SIMPLE_CHEMICAL", 202, 213], ["blood", "ORGANISM_SUBSTANCE", 214, 219], ["patients", "SPECIES", 15, 23], ["this previous study", "TEST", 60, 79], ["sevoflurane", "TREATMENT", 128, 139], ["PP HFM oxygenator", "TREATMENT", 153, 170], ["the sevoflurane blood concentration", "TREATMENT", 198, 233], ["the oxygenator", "TREATMENT", 257, 271], ["our HL data", "TEST", 287, 298]]], ["In addition, the blood concentrations from 17 to 32 min after introduction of the oxygenator were stable with little variation.", [["blood", "ANATOMY", 17, 22], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["the blood concentrations", "TEST", 13, 37], ["the oxygenator", "TREATMENT", 78, 92], ["stable", "OBSERVATION_MODIFIER", 98, 104], ["little variation", "OBSERVATION", 110, 126]]], ["These data emphasized that our blood sampling points defined from the package insert and their values were valid.", [["blood", "ANATOMY", 31, 36], ["blood", "ORGANISM_SUBSTANCE", 31, 36], ["our blood sampling points", "TEST", 27, 52], ["the package insert", "TREATMENT", 66, 84], ["package insert", "OBSERVATION", 70, 84]]], ["Thus, the uptake and elimination of desflurane or sevoflurane via the tested PP HFM oxygenators are equivalent.", [["desflurane", "CHEMICAL", 36, 46], ["sevoflurane", "CHEMICAL", 50, 61], ["desflurane", "CHEMICAL", 36, 46], ["sevoflurane", "CHEMICAL", 50, 61], ["desflurane", "SIMPLE_CHEMICAL", 36, 46], ["sevoflurane", "SIMPLE_CHEMICAL", 50, 61], ["the uptake", "TEST", 6, 16], ["desflurane", "TREATMENT", 36, 46], ["sevoflurane", "TREATMENT", 50, 61], ["the tested PP HFM oxygenators", "TREATMENT", 66, 95]]], ["In addition, anesthesiologists could adjust the desflurane or sevoflurane concentrations during cardiac or aortic surgeries with CPB in the same manner as in surgeries without oxygenators.DiscussionThe fiber structure of the three PP HFM oxygenators did not change with clinical use.", [["cardiac", "ANATOMY", 96, 103], ["aortic", "ANATOMY", 107, 113], ["fiber", "ANATOMY", 202, 207], ["desflurane", "CHEMICAL", 48, 58], ["sevoflurane", "CHEMICAL", 62, 73], ["desflurane", "CHEMICAL", 48, 58], ["sevoflurane", "CHEMICAL", 62, 73], ["desflurane", "SIMPLE_CHEMICAL", 48, 58], ["sevoflurane", "SIMPLE_CHEMICAL", 62, 73], ["cardiac", "ORGAN", 96, 103], ["aortic", "MULTI-TISSUE_STRUCTURE", 107, 113], ["the desflurane", "TREATMENT", 44, 58], ["sevoflurane concentrations", "TREATMENT", 62, 88], ["cardiac or aortic surgeries", "TREATMENT", 96, 123], ["CPB", "TREATMENT", 129, 132], ["oxygenators", "TREATMENT", 176, 187], ["the three PP HFM oxygenators", "TREATMENT", 221, 249], ["aortic", "ANATOMY", 107, 113], ["surgeries", "OBSERVATION", 114, 123]]], ["The light microscopy results reported by Crosbie et al. [24] confirmed no changes in the structure or integrity of the PP fibers after short-term (3 h) or long-term (1 week) exposure to liquid sevoflurane.", [["PP fibers", "ANATOMY", 119, 128], ["sevoflurane", "CHEMICAL", 193, 204], ["sevoflurane", "CHEMICAL", 193, 204], ["PP fibers", "CELLULAR_COMPONENT", 119, 128], ["sevoflurane", "SIMPLE_CHEMICAL", 193, 204], ["The light microscopy", "TEST", 0, 20], ["changes in the structure", "PROBLEM", 74, 98], ["the PP fibers", "TREATMENT", 115, 128], ["liquid sevoflurane", "TREATMENT", 186, 204], ["liquid sevoflurane", "OBSERVATION", 186, 204]]], ["We attempted light microscopy, as performed by Crosbie et al., but image acquisition was challenging even with 1000 \u00d7 magnification.", [["light microscopy", "TEST", 13, 29], ["image acquisition", "TEST", 67, 84]]], ["After cutting the coated PP membrane fiber, we were able to observe the internal structure of the HFM where VAs pass.", [["PP membrane fiber", "ANATOMY", 25, 42], ["cutting the coated PP membrane fiber", "TREATMENT", 6, 42], ["internal", "ANATOMY_MODIFIER", 72, 80], ["HFM", "ANATOMY", 98, 101]]], ["Considering that the concentrations of desflurane and sevoflurane used in clinical practice are comparable to or lower than those used in this study, the absence of oxygenator-related complications and structural changes in our experiments denotes that an oxygenator can be a safe and reliable option for use in the future.", [["desflurane", "CHEMICAL", 39, 49], ["sevoflurane", "CHEMICAL", 54, 65], ["desflurane", "CHEMICAL", 39, 49], ["sevoflurane", "CHEMICAL", 54, 65], ["desflurane", "SIMPLE_CHEMICAL", 39, 49], ["sevoflurane", "SIMPLE_CHEMICAL", 54, 65], ["desflurane", "TREATMENT", 39, 49], ["sevoflurane", "TREATMENT", 54, 65], ["this study", "TEST", 138, 148], ["related complications", "PROBLEM", 176, 197], ["structural changes", "PROBLEM", 202, 220], ["an oxygenator", "TREATMENT", 253, 266]]], ["There are no reports of spontaneous oxygenator-related complications occurring during CPB with VA.", [["spontaneous oxygenator-related complications", "PROBLEM", 24, 68], ["CPB", "TREATMENT", 86, 89], ["no reports of", "UNCERTAINTY", 10, 23], ["spontaneous", "OBSERVATION_MODIFIER", 24, 35], ["oxygenator", "OBSERVATION", 36, 46], ["complications", "OBSERVATION", 55, 68]]], ["Nonetheless, there have been multiple reports where liquid VA spillage during vaporizer filling caused the development of cracks in the polycarbonate shell and venous connector of CPB circuit components [25, 26] .", [["venous", "ANATOMY", 160, 166], ["polycarbonate", "CHEMICAL", 136, 149], ["liquid VA spillage", "PROBLEM", 52, 70], ["vaporizer filling", "TREATMENT", 78, 95], ["cracks in the polycarbonate shell", "TREATMENT", 122, 155], ["venous connector of CPB circuit components", "TREATMENT", 160, 202], ["multiple", "OBSERVATION_MODIFIER", 29, 37], ["cracks", "OBSERVATION", 122, 128], ["polycarbonate shell", "OBSERVATION", 136, 155], ["venous", "ANATOMY", 160, 166], ["connector", "ANATOMY_MODIFIER", 167, 176], ["CPB circuit", "OBSERVATION", 180, 191]]], ["In the laboratory setting, we added 10 ml of liquid desflurane or sevoflurane directly to the shell and venous blood reservoir surfaces of each oxygenator and the connector tube.", [["shell", "ANATOMY", 94, 99], ["venous blood", "ANATOMY", 104, 116], ["desflurane", "CHEMICAL", 52, 62], ["sevoflurane", "CHEMICAL", 66, 77], ["desflurane", "CHEMICAL", 52, 62], ["sevoflurane", "CHEMICAL", 66, 77], ["desflurane", "SIMPLE_CHEMICAL", 52, 62], ["sevoflurane", "SIMPLE_CHEMICAL", 66, 77], ["venous blood", "ORGANISM_SUBSTANCE", 104, 116], ["tube", "TISSUE", 173, 177], ["liquid desflurane", "TREATMENT", 45, 62], ["sevoflurane", "TREATMENT", 66, 77], ["the shell and venous blood reservoir surfaces of each oxygenator", "TREATMENT", 90, 154], ["the connector tube", "TREATMENT", 159, 177], ["shell", "ANATOMY_MODIFIER", 94, 99], ["venous", "ANATOMY", 104, 110], ["each oxygenator", "OBSERVATION", 139, 154], ["connector tube", "OBSERVATION", 163, 177]]], ["We did not observe any change in these components (data not shown), which might be due to possible improvements in the type of material used based on changes in the process of VA supplementation to vaporizer and the vaporizer placement.", [["the type of material", "PROBLEM", 115, 135], ["VA supplementation", "TREATMENT", 176, 194], ["vaporizer", "TREATMENT", 198, 207], ["the vaporizer placement", "TREATMENT", 212, 235], ["vaporizer placement", "OBSERVATION", 216, 235]]], ["Even so, liquid VA spills on peripheral devices, including the oxygenator, should be regarded with caution.DiscussionThis study had a limitation that should be addressed.", [["peripheral devices", "TREATMENT", 29, 47], ["the oxygenator", "TREATMENT", 59, 73], ["This study", "TEST", 117, 127]]], ["We were not able to homogenize the surgical intervention, operator, conditions of the HL, and patient characteristics in each group.", [["HL", "DISEASE", 86, 88], ["HL", "CANCER", 86, 88], ["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["the surgical intervention", "TREATMENT", 31, 56]]], ["Besides fresh gas flow rate and hematocrit values at the time of sampling, the amount of bleeding during surgical intervention, body temperature, and the amount of blood in the CPB reservoir could have influenced the blood concentration of VA because of the volatility of VAs.", [["body", "ANATOMY", 128, 132], ["blood", "ANATOMY", 164, 169], ["blood", "ANATOMY", 217, 222], ["bleeding", "DISEASE", 89, 97], ["body", "ORGANISM_SUBDIVISION", 128, 132], ["blood", "ORGANISM_SUBSTANCE", 164, 169], ["blood", "ORGANISM_SUBSTANCE", 217, 222], ["fresh gas flow rate", "TEST", 8, 27], ["hematocrit values", "TEST", 32, 49], ["bleeding", "PROBLEM", 89, 97], ["surgical intervention", "TREATMENT", 105, 126], ["body temperature", "TEST", 128, 144], ["the CPB reservoir", "TREATMENT", 173, 190], ["gas flow", "OBSERVATION", 14, 22], ["amount", "OBSERVATION_MODIFIER", 79, 85], ["bleeding", "OBSERVATION", 89, 97], ["amount", "OBSERVATION_MODIFIER", 154, 160]]], ["Actually, in our study, there were significant differences between the HL and LI groups in fresh gas flow rate, between the HL and TE groups in the body temperature, and between the HL and TE, and the HL and LI groups in hematocrit values at the time point of sampling for desflurane measurement.", [["body", "ANATOMY", 148, 152], ["desflurane", "CHEMICAL", 273, 283], ["desflurane", "CHEMICAL", 273, 283], ["HL", "CANCER", 71, 73], ["body", "ORGANISM_SUBDIVISION", 148, 152], ["desflurane", "SIMPLE_CHEMICAL", 273, 283], ["our study", "TEST", 13, 22], ["fresh gas flow rate", "TEST", 91, 110], ["the HL", "TREATMENT", 120, 126], ["the body temperature", "TEST", 144, 164], ["the HL", "PROBLEM", 197, 203], ["hematocrit values", "TEST", 221, 238], ["desflurane measurement", "TEST", 273, 295], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["gas flow", "OBSERVATION", 97, 105]]], ["In the sampling for sevoflurane measurement, no group difference was observed in the aforementioned three parameters (Supplemental Table 1 ).", [["sevoflurane", "CHEMICAL", 20, 31], ["sevoflurane", "CHEMICAL", 20, 31], ["sevoflurane", "SIMPLE_CHEMICAL", 20, 31], ["sevoflurane measurement", "TEST", 20, 43], ["no", "UNCERTAINTY", 45, 47]]], ["Strictly speaking, regarding sevoflurane, there was no difference between the groups in terms of factors affecting the blood levels.", [["blood", "ANATOMY", 119, 124], ["sevoflurane", "CHEMICAL", 29, 40], ["sevoflurane", "CHEMICAL", 29, 40], ["sevoflurane", "SIMPLE_CHEMICAL", 29, 40], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["sevoflurane", "TREATMENT", 29, 40], ["the blood levels", "TEST", 115, 131]]], ["Therefore, it can be stated that there was no problem with the blood concentration values.DiscussionConversely, in desflurane, there were some differences.", [["blood", "ANATOMY", 63, 68], ["desflurane", "CHEMICAL", 115, 125], ["desflurane", "CHEMICAL", 115, 125], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["desflurane", "SIMPLE_CHEMICAL", 115, 125], ["the blood concentration values", "TEST", 59, 89]]], ["Thus, it may be necessary to conduct detailed examination under the same conditions.", [["detailed examination", "TEST", 37, 57]]], ["However, our results indicated a similar mean blood concentration level and variation among all groups.", [["blood", "ANATOMY", 46, 51], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["a similar mean blood concentration level", "PROBLEM", 31, 71]]], ["We believe that our results accurately reflect the clinical settings.DiscussionIn conclusion, the blood concentrations of desflurane and sevoflurane passing through oxygenators used during CPB were similar to those in the HL control.", [["blood", "ANATOMY", 98, 103], ["desflurane", "CHEMICAL", 122, 132], ["sevoflurane", "CHEMICAL", 137, 148], ["desflurane", "CHEMICAL", 122, 132], ["sevoflurane", "CHEMICAL", 137, 148], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["desflurane", "SIMPLE_CHEMICAL", 122, 132], ["sevoflurane", "SIMPLE_CHEMICAL", 137, 148], ["desflurane", "TREATMENT", 122, 132], ["sevoflurane", "TREATMENT", 137, 148], ["oxygenators", "TREATMENT", 165, 176], ["CPB", "TREATMENT", 189, 192], ["the HL control", "TREATMENT", 218, 232]]]], "2e3f666f53a6b54e8cecfff3ca2ff01adfaf0a2c": [["pr\u00e9valence des sympt\u00f4mes autod\u00e9clar\u00e9s d'anosmie/d'hyposmie et de dysgeusie/d'ageusie.", [["pr\u00e9valence des sympt\u00f4mes autod\u00e9clar\u00e9s d'anosmie/d'hyposmie et de dysgeusie/d'ageusie", "SPECIES", 0, 84]]], ["R\u00e9sultats: Dans l'ensemble, 56 patients sur 102 (50%) d\u00e9clar\u00e9s positifs et 72 patients sur 306 (23,5%) d\u00e9clar\u00e9s n\u00e9gatifs ont poursuivi l'enqu\u00eate jusqu'au bout.", [["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 78, 86]]], ["La pr\u00e9valence de l'anosmie/l'hyposmie et de la dysgeusie/l'ageusie \u00e9tait plus \u00e9lev\u00e9e chez les patients d\u00e9clar\u00e9s positifs (odorat : 41,1% contre [c.] 4,2%, p < 0,001; go\u00fbt : 46,4% c.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["l'ageusie \u00e9tait", "TREATMENT", 57, 72]]], ["L'anosmie/l'hyposmie et la dysgeusie/l'ageusie se sont r\u00e9v\u00e9l\u00e9es des sympt\u00f4mes ind\u00e9pendants, fortement associ\u00e9s \u00e0 la positivit\u00e9 des r\u00e9sultats \u00e0 l'\u00e9gard de la COVID-19 (risque relatif approch\u00e9 rajust\u00e9 : 14,4 et 11,4 pour l'odorat et le go\u00fbt, respectivement).", [["L'anosmie/l'hyposmie", "PROBLEM", 0, 20], ["et la dysgeusie", "PROBLEM", 21, 36], ["l", "ANATOMY_MODIFIER", 10, 11]]], ["Il s'agirait l\u00e0 d'une manifestation susceptible de faciliter la pose du diagnostic clinique de la COVID-19, tout particuli\u00e8rement dans les milieux o\u00f9 la capacit\u00e9 de d\u00e9pistage est restreinte.INTRODUCTIONCoronavirus disease 2019 (COVID- 19) is an international outbreak of respiratory illness characterized by high transmission rate, particularly in individuals with no or mild symptoms.", [["respiratory", "ANATOMY", 271, 282], ["INTRODUCTIONCoronavirus disease", "DISEASE", 190, 221], ["COVID- 19", "CHEMICAL", 228, 237], ["respiratory illness", "DISEASE", 271, 290], ["la COVID", "TEST", 95, 103], ["INTRODUCTIONCoronavirus disease", "PROBLEM", 190, 221], ["COVID", "TEST", 228, 233], ["respiratory illness", "PROBLEM", 271, 290], ["high transmission rate", "PROBLEM", 308, 330], ["mild symptoms", "PROBLEM", 371, 384], ["respiratory illness", "OBSERVATION", 271, 290], ["mild", "OBSERVATION_MODIFIER", 371, 375], ["symptoms", "OBSERVATION", 376, 384]]], ["1, 2 A key step in minimizing transmission is to screen and isolate those infected with COVID-19 using specific clinical criteria.", [["COVID", "TEST", 88, 93]]], ["While several symptoms are used to screen, there is lack of data to suggest specific symptoms of COVID-19.", [["COVID", "DISEASE", 97, 102], ["COVID-19", "CHEMICAL", 97, 105], ["several symptoms", "PROBLEM", 6, 22], ["specific symptoms", "PROBLEM", 76, 93], ["COVID", "TEST", 97, 102]]], ["Anosmia/hyposmia and ageusia/dysgeusia have emerged as potential specific symptoms, as reported in recent studies from the United States and Europe.", [["Anosmia", "DISEASE", 0, 7], ["hyposmia", "DISEASE", 8, 16], ["ageusia", "DISEASE", 21, 28], ["dysgeusia", "DISEASE", 29, 38], ["Anosmia", "PROBLEM", 0, 7], ["hyposmia", "PROBLEM", 8, 16], ["ageusia", "PROBLEM", 21, 28], ["dysgeusia", "PROBLEM", 29, 38], ["potential specific symptoms", "PROBLEM", 55, 82], ["hyposmia", "OBSERVATION", 8, 16]]], ["3-5 Spinato et al. described 64.4% of altered smell or taste among Italian adults with mild symptoms and Yan et al. described 68% and 71% of anosmia and dysgeusia, respectively, in COVID-19 positive individuals with an odds ratio (OR) of 10.", [["anosmia", "DISEASE", 141, 148], ["dysgeusia", "DISEASE", 153, 162], ["smell", "ORGANISM_SUBDIVISION", 46, 51], ["altered smell or taste", "PROBLEM", 38, 60], ["mild symptoms", "PROBLEM", 87, 100], ["anosmia", "PROBLEM", 141, 148], ["dysgeusia", "PROBLEM", 153, 162], ["COVID", "TEST", 181, 186], ["an odds ratio", "TEST", 216, 229], ["mild", "OBSERVATION_MODIFIER", 87, 91]]], ["3,4 A recently published study from Quebec reported 51.5% of anosmia.", [["anosmia", "DISEASE", 61, 68], ["A recently published study", "TEST", 4, 30], ["anosmia", "PROBLEM", 61, 68]]], ["6 These reports suggest that anosmia/hyposmia and dysgeusia/anosmia have the potential to be used to specifically screen for individuals with mild symptoms.", [["anosmia", "DISEASE", 29, 36], ["hyposmia", "DISEASE", 37, 45], ["dysgeusia", "DISEASE", 50, 59], ["anosmia", "DISEASE", 60, 67], ["anosmia", "PROBLEM", 29, 36], ["hyposmia", "PROBLEM", 37, 45], ["dysgeusia", "PROBLEM", 50, 59], ["anosmia", "PROBLEM", 60, 67], ["mild symptoms", "PROBLEM", 142, 155], ["hyposmia", "OBSERVATION", 37, 45]]], ["However, there are wide variations in the reported prevalence of anosmia/hyposmia and ageusia/dysgeusia across different regions, potentially suggesting variable geographic presentations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["anosmia", "DISEASE", 65, 72], ["hyposmia", "DISEASE", 73, 81], ["ageusia", "DISEASE", 86, 93], ["dysgeusia", "DISEASE", 94, 103], ["acute respiratory syndrome coronavirus", "DISEASE", 197, 235], ["SARS-CoV-2", "ORGANISM", 239, 249], ["severe acute respiratory syndrome coronavirus", "SPECIES", 190, 235], ["SARS-CoV-2", "SPECIES", 239, 249], ["wide variations", "PROBLEM", 19, 34], ["anosmia", "PROBLEM", 65, 72], ["hyposmia", "PROBLEM", 73, 81], ["ageusia", "PROBLEM", 86, 93], ["dysgeusia", "PROBLEM", 94, 103], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 190, 235], ["SARS", "TEST", 239, 243], ["CoV", "TEST", 244, 247], ["wide", "OBSERVATION_MODIFIER", 19, 23], ["variations", "OBSERVATION_MODIFIER", 24, 34], ["anosmia", "OBSERVATION", 65, 72], ["hyposmia", "OBSERVATION", 73, 81], ["dysgeusia", "OBSERVATION", 94, 103], ["potentially suggesting", "UNCERTAINTY", 130, 152], ["variable", "OBSERVATION_MODIFIER", 153, 161], ["geographic", "OBSERVATION_MODIFIER", 162, 172], ["severe", "OBSERVATION_MODIFIER", 190, 196], ["acute", "OBSERVATION_MODIFIER", 197, 202], ["respiratory syndrome coronavirus", "OBSERVATION", 203, 235]]], ["7 Therefore, it is imperative that we further examine this potential association between loss of smell and taste and COVID-19 diagnosis in the Canadian and Ontario context.", [["loss of smell", "DISEASE", 89, 102], ["loss of smell and taste", "PROBLEM", 89, 112], ["COVID", "TEST", 117, 122]]], ["The objective was to evaluate the prevalence and association of anosmia/hyposmia and dysgeusia/ageusia in patients who underwent COVID-19 testing using self-reported measures.Study design and patient populationThe approval of this study was granted by the Research Ethics Board at Unity Health Toronto, Toronto, Ontario, through Clinical Trials Ontario (CTO ID: 2142).", [["anosmia", "DISEASE", 64, 71], ["hyposmia", "DISEASE", 72, 80], ["dysgeusia", "DISEASE", 85, 94], ["ageusia", "DISEASE", 95, 102], ["patients", "ORGANISM", 106, 114], ["patient", "ORGANISM", 192, 199], ["patients", "SPECIES", 106, 114], ["patient", "SPECIES", 192, 199], ["anosmia", "PROBLEM", 64, 71], ["hyposmia", "PROBLEM", 72, 80], ["dysgeusia", "PROBLEM", 85, 94], ["ageusia", "PROBLEM", 95, 102], ["COVID", "TEST", 129, 134], ["self-reported measures", "TREATMENT", 152, 174], ["Study design", "TEST", 175, 187], ["this study", "TEST", 226, 236], ["hyposmia", "OBSERVATION", 72, 80]]], ["We designed a cross-sectional survey of adults (over 18 years of age) who had undergone polymerase chain reaction-confirmed COVID-19 testing via nasopharyngeal swab at the COVID-19 Assessment Centre at St. Michael's Hospital, Toronto, Ontario, between March 16 and April 15, 2020.", [["nasopharyngeal swab", "ANATOMY", 145, 164], ["adults", "ORGANISM", 40, 46], ["polymerase chain reaction", "PROBLEM", 88, 113], ["COVID", "TEST", 124, 129], ["nasopharyngeal swab", "TEST", 145, 164], ["the COVID", "TEST", 168, 177], ["nasopharyngeal", "ANATOMY", 145, 159]]], ["Patients were contacted by phone for an invitation to a secure online survey, which was constructed using Snap Software, fully compliant with the Personal Health Information Protection Act, after being notified of the results of their swab.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["their swab", "TEST", 229, 239]]], ["During this period, we identified 102 unique COVID-19 positive patients and 1,243 unique negative patients.", [["patients", "ORGANISM", 63, 71], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 98, 106], ["unique COVID", "TEST", 38, 50]]], ["Due to a large number of negative patients, we randomly sampled negative patients in a 1:3 ratio.Outcome measures and data collectionBaseline characteristics were collected and included: age, gender, medical comorbidities, and smoking status.", [["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 73, 81], ["Outcome measures", "TEST", 97, 113], ["data collection", "TEST", 118, 133], ["medical comorbidities", "PROBLEM", 200, 221], ["large", "OBSERVATION_MODIFIER", 9, 14], ["negative", "OBSERVATION", 25, 33]]], ["We listed chronic rhinosinusitis and history of recent severe upper respiratory tract infection (URTI) or flu as a separate comorbidity, as these may impact baseline sense of smell.", [["upper respiratory tract", "ANATOMY", 62, 85], ["chronic rhinosinusitis", "DISEASE", 10, 32], ["upper respiratory tract infection", "DISEASE", 62, 95], ["URTI", "DISEASE", 97, 101], ["flu", "DISEASE", 106, 109], ["upper respiratory", "ORGANISM_SUBDIVISION", 62, 79], ["tract", "ORGANISM_SUBDIVISION", 80, 85], ["chronic rhinosinusitis", "PROBLEM", 10, 32], ["recent severe upper respiratory tract infection", "PROBLEM", 48, 95], ["URTI)", "PROBLEM", 97, 102], ["flu", "PROBLEM", 106, 109], ["a separate comorbidity", "PROBLEM", 113, 135], ["chronic", "OBSERVATION_MODIFIER", 10, 17], ["rhinosinusitis", "OBSERVATION", 18, 32], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["upper", "ANATOMY_MODIFIER", 62, 67], ["respiratory tract", "ANATOMY", 68, 85], ["infection", "OBSERVATION", 86, 95]]], ["COVID-19 diagnosis, symptoms, and hospitalizations were collected.", [["COVID", "TEST", 0, 5], ["symptoms", "PROBLEM", 20, 28]]], ["Smell and taste-specific questions included the presence of smell or taste loss around the onset of COVID-19-like symptoms (5 days earlier or any time after), as well as the current ability to smell.", [["taste loss", "DISEASE", 69, 79], ["Smell and taste", "PROBLEM", 0, 15], ["smell", "PROBLEM", 60, 65], ["taste loss", "PROBLEM", 69, 79], ["COVID-19-like symptoms", "PROBLEM", 100, 122]]], ["The type of taste loss was collected (sweet, salty, sour, bitter, and savoury).Statistical analysisDemographic and clinical characteristics were summarized descriptively by reporting the median and interquartile (IQR) range for continuous variables and the frequency and proportion for categorical variables.", [["taste loss", "DISEASE", 12, 22], ["sweet", "ORGANISM_SUBDIVISION", 38, 43], ["taste loss", "PROBLEM", 12, 22], ["taste loss", "OBSERVATION", 12, 22]]], ["Differences in characteristics between two comparison groups were compared using the Kruskal-Wallis test for continuous variables and Fisher's exact test for categorical variables.", [["the Kruskal-Wallis test", "TEST", 81, 104], ["Fisher's exact test", "TEST", 134, 153]]], ["Unadjusted ORs were calculated with univariable logistic regression.", [["univariable logistic regression", "PROBLEM", 36, 67]]], ["Adjusted OR was calculated using multivariable logistic regression analysis with a priori criteria.", [["multivariable logistic regression analysis", "TEST", 33, 75]]], ["To prevent over-fitting, we included the loss of smell or taste around the onset of COVID-19-like symptoms and four other covariates with a statistically significant magnitude of association of at least twofold (i.e., OR > 2.0 or OR < 0.5).RESULTSOf 102 positive patients and 306 negative patients who were contacted, 56 (50%) positive patients and 72 (23.5%) negative patients completed the survey between April 15 and May 1, 2020.", [["loss of smell", "DISEASE", 41, 54], ["patients", "ORGANISM", 263, 271], ["patients", "ORGANISM", 289, 297], ["patients", "ORGANISM", 336, 344], ["patients", "ORGANISM", 369, 377], ["patients", "SPECIES", 263, 271], ["patients", "SPECIES", 289, 297], ["patients", "SPECIES", 336, 344], ["patients", "SPECIES", 369, 377], ["the loss of smell or taste", "PROBLEM", 37, 63], ["COVID", "TEST", 84, 89], ["symptoms", "PROBLEM", 98, 106]]], ["Positive patients were younger than negative patients (38.0 IQR 31.8-47.2 v. 43.0 IQR 33.5-55.0, p < 0.05).", [["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 45, 53], ["IQR", "TEST", 60, 63], ["IQR", "TEST", 82, 85], ["p", "TEST", 97, 98]]], ["Gender, smoking status, and comorbidities relevant to smell function (head trauma, chronic rhinosinusitis, and recent URTI/flu) were wellbalanced.", [["head", "ANATOMY", 70, 74], ["head trauma", "DISEASE", 70, 81], ["chronic rhinosinusitis", "DISEASE", 83, 105], ["head", "ORGANISM_SUBDIVISION", 70, 74], ["comorbidities", "PROBLEM", 28, 41], ["smell function", "PROBLEM", 54, 68], ["head trauma", "PROBLEM", 70, 81], ["chronic rhinosinusitis", "PROBLEM", 83, 105], ["recent URTI/flu)", "PROBLEM", 111, 127], ["chronic", "OBSERVATION_MODIFIER", 83, 90], ["rhinosinusitis", "OBSERVATION", 91, 105]]], ["There was a longer time lapse between the diagnosis and the survey among the negative patients compared with the positive patients (67.6% for negative v. 30.4% for positive for more than 4 weeks since the diagnosis).RESULTSThe overall symptoms are summarized in Table 1 .", [["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 122, 130], ["the survey", "TEST", 56, 66], ["overall symptoms", "PROBLEM", 227, 243]]], ["A significantly higher proportion of positive patients reported anosmia (42.9% v. 2.8%, p < 0.001), hyposmia (12.5% v. 1.4%, p < 0.05) and dysgeusia/ageusia (57.1% v. 1.4%, p < 0.001) compared with negative patients.", [["anosmia", "DISEASE", 64, 71], ["hyposmia", "DISEASE", 100, 108], ["dysgeusia", "DISEASE", 139, 148], ["ageusia", "DISEASE", 149, 156], ["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 207, 215], ["anosmia", "TEST", 64, 71], ["v.", "TEST", 79, 81], ["p", "TEST", 88, 89], ["hyposmia", "TEST", 100, 108], ["v.", "TEST", 116, 118], ["p", "TEST", 125, 126], ["dysgeusia", "PROBLEM", 139, 148], ["ageusia", "TEST", 149, 156], ["v.", "TEST", 164, 166]]], ["In addition, cough, fever, diarrhea, and headache were more common among positive patients.", [["cough", "DISEASE", 13, 18], ["fever", "DISEASE", 20, 25], ["diarrhea", "DISEASE", 27, 35], ["headache", "DISEASE", 41, 49], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["cough", "PROBLEM", 13, 18], ["fever", "PROBLEM", 20, 25], ["diarrhea", "PROBLEM", 27, 35], ["headache", "PROBLEM", 41, 49], ["cough", "OBSERVATION", 13, 18], ["fever", "OBSERVATION", 20, 25]]], ["On the other hand, sore throat was more common among negative patients (63% v. 37%, p < 0.01).RESULTSCharacterization of anosmia/hyposmia and dysgeusia/ ageusia is summarized in Table 2 .", [["sore throat", "ANATOMY", 19, 30], ["sore throat", "DISEASE", 19, 30], ["anosmia", "DISEASE", 121, 128], ["hyposmia", "DISEASE", 129, 137], ["dysgeusia", "DISEASE", 142, 151], ["ageusia", "DISEASE", 153, 160], ["throat", "ORGANISM_SUBDIVISION", 24, 30], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["sore throat", "PROBLEM", 19, 30], ["p", "TEST", 84, 85], ["anosmia", "PROBLEM", 121, 128], ["hyposmia", "PROBLEM", 129, 137], ["dysgeusia", "PROBLEM", 142, 151], ["ageusia", "PROBLEM", 153, 160], ["sore throat", "ANATOMY", 19, 30], ["anosmia", "OBSERVATION", 121, 128], ["hyposmia", "OBSERVATION", 129, 137]]], ["When patients were inquired about their smell loss around the time of COVID-19-like symptom onset (5 days before or any time after), there was a significantly higher proportion of COVID-19-positive patients compared with the negative patients (41.1% v. 4.2%, p < 0.001).", [["smell loss", "DISEASE", 40, 50], ["patients", "ORGANISM", 5, 13], ["COVID-19", "GENE_OR_GENE_PRODUCT", 180, 188], ["patients", "ORGANISM", 198, 206], ["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 198, 206], ["patients", "SPECIES", 234, 242], ["their smell loss", "PROBLEM", 34, 50], ["COVID", "TEST", 70, 75], ["COVID", "TEST", 180, 185], ["v.", "TEST", 250, 252], ["p", "TEST", 259, 260]]], ["Of 23 positive patients with anosmia/hyposmia, 12 (52.2%) patients reported that anosmia/hyposmia was one of the early symptoms.", [["anosmia", "DISEASE", 29, 36], ["hyposmia", "DISEASE", 37, 45], ["anosmia", "DISEASE", 81, 88], ["hyposmia", "DISEASE", 89, 97], ["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 58, 66], ["anosmia", "PROBLEM", 29, 36], ["hyposmia", "PROBLEM", 37, 45], ["anosmia", "PROBLEM", 81, 88], ["hyposmia", "PROBLEM", 89, 97], ["the early symptoms", "PROBLEM", 109, 127], ["23 positive", "OBSERVATION_MODIFIER", 3, 14], ["hyposmia", "OBSERVATION", 89, 97]]], ["There was a significantly higher proportion of positive patients reporting dysgeusia/ ageusia compared with negative patients (46.4% v. 5.6%, p < 0.001).", [["dysgeusia", "DISEASE", 75, 84], ["ageusia", "DISEASE", 86, 93], ["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 117, 125], ["positive patients reporting dysgeusia", "PROBLEM", 47, 84], ["ageusia", "PROBLEM", 86, 93], ["v.", "TEST", 133, 135], ["positive", "OBSERVATION_MODIFIER", 47, 55]]], ["Twenty (35.7%) positive patients reported concomitant smell and taste loss.RESULTSOn the univariable analysis, anosmia/hyposmia and dysgeusia/ageusia were highly associated with COVID-19 positivity OR 19.7 (95% confidence interval [CI] 6.1-88.7) and OR 13.2 (95% CI 4.6-48.0), respectively (Table 3) .", [["taste loss", "DISEASE", 64, 74], ["anosmia", "DISEASE", 111, 118], ["hyposmia", "DISEASE", 119, 127], ["dysgeusia", "DISEASE", 132, 141], ["ageusia", "DISEASE", 142, 149], ["patients", "ORGANISM", 24, 32], ["taste", "ORGANISM_SUBDIVISION", 64, 69], ["COVID-19", "GENE_OR_GENE_PRODUCT", 178, 186], ["patients", "SPECIES", 24, 32], ["concomitant smell", "PROBLEM", 42, 59], ["taste loss", "PROBLEM", 64, 74], ["the univariable analysis", "TEST", 85, 109], ["anosmia", "PROBLEM", 111, 118], ["hyposmia", "PROBLEM", 119, 127], ["dysgeusia", "PROBLEM", 132, 141], ["ageusia", "PROBLEM", 142, 149], ["COVID", "TEST", 178, 183], ["CI", "TEST", 232, 234], ["CI", "TEST", 263, 265], ["concomitant", "OBSERVATION_MODIFIER", 42, 53], ["smell", "OBSERVATION", 54, 59], ["taste loss", "OBSERVATION", 64, 74], ["hyposmia", "OBSERVATION", 119, 127]]], ["Fever, cough, sore throat, and headache were included in the multivariable analysis with either anosmia/hyposmia or dysgeusia/ageusia.", [["Fever", "DISEASE", 0, 5], ["cough", "DISEASE", 7, 12], ["sore throat", "DISEASE", 14, 25], ["headache", "DISEASE", 31, 39], ["anosmia", "DISEASE", 96, 103], ["hyposmia", "DISEASE", 104, 112], ["dysgeusia", "DISEASE", 116, 125], ["ageusia", "DISEASE", 126, 133], ["Fever", "PROBLEM", 0, 5], ["cough", "PROBLEM", 7, 12], ["sore throat", "PROBLEM", 14, 25], ["headache", "PROBLEM", 31, 39], ["the multivariable analysis", "TEST", 57, 83], ["anosmia", "PROBLEM", 96, 103], ["hyposmia", "PROBLEM", 104, 112], ["dysgeusia", "PROBLEM", 116, 125], ["ageusia", "PROBLEM", 126, 133], ["cough", "OBSERVATION", 7, 12], ["sore throat", "ANATOMY", 14, 25], ["hyposmia", "OBSERVATION", 104, 112], ["dysgeusia", "OBSERVATION", 116, 125]]], ["In the multivariable models, smell loss and taste loss demonstrated high adjusted ORs with COVID-19 positivity (OR 14.4 [95% CI 4.0-70.5] and OR 11.4 [95% CI 3.6-45.3], respectively).", [["smell loss", "DISEASE", 29, 39], ["taste loss", "DISEASE", 44, 54], ["smell loss", "PROBLEM", 29, 39], ["taste loss", "PROBLEM", 44, 54], ["COVID", "TEST", 91, 96], ["CI", "TEST", 125, 127], ["OR", "TEST", 142, 144], ["CI", "TEST", 155, 157], ["smell loss", "OBSERVATION", 29, 39]]], ["Sore throat was negatively associated with COVID-19 positivity.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 43, 51], ["COVID", "PROTEIN", 43, 48], ["Sore throat", "PROBLEM", 0, 11], ["COVID", "TEST", 43, 48], ["throat", "ANATOMY", 5, 11]]], ["Other symptoms were statistically not significant.RESULTSThere were no differences between patients with and without anosmia/hyposmia in terms of age, smoking, relevant comorbidities (chronic rhinosinusitis, recent URTI/ flu, head trauma), and symptoms (rhinorrhea and nasal congestion) ( Table 4 ).", [["head", "ANATOMY", 226, 230], ["nasal", "ANATOMY", 269, 274], ["anosmia", "DISEASE", 117, 124], ["hyposmia", "DISEASE", 125, 133], ["chronic rhinosinusitis", "DISEASE", 184, 206], ["URTI/ flu", "DISEASE", 215, 224], ["head trauma", "DISEASE", 226, 237], ["rhinorrhea", "DISEASE", 254, 264], ["nasal congestion", "DISEASE", 269, 285], ["patients", "ORGANISM", 91, 99], ["head", "ORGANISM_SUBDIVISION", 226, 230], ["nasal", "ORGANISM_SUBDIVISION", 269, 274], ["patients", "SPECIES", 91, 99], ["Other symptoms", "PROBLEM", 0, 14], ["anosmia", "PROBLEM", 117, 124], ["hyposmia", "PROBLEM", 125, 133], ["relevant comorbidities", "PROBLEM", 160, 182], ["chronic rhinosinusitis", "PROBLEM", 184, 206], ["recent URTI/ flu", "PROBLEM", 208, 224], ["head trauma", "PROBLEM", 226, 237], ["symptoms", "PROBLEM", 244, 252], ["rhinorrhea", "PROBLEM", 254, 264], ["nasal congestion", "PROBLEM", 269, 285], ["no", "UNCERTAINTY", 68, 70], ["hyposmia", "OBSERVATION", 125, 133], ["chronic", "OBSERVATION_MODIFIER", 184, 191], ["rhinosinusitis", "OBSERVATION", 192, 206], ["head", "ANATOMY", 226, 230], ["nasal", "ANATOMY", 269, 274], ["congestion", "OBSERVATION", 275, 285]]], ["There were significantly more COVID-19-positive patients in the group with smell loss than the one without (88.5% v. 28.1%, p < 0.001).RESULTSAmong those with anosmia/hyposmia (n = 25, 1 did not answer), 13 (52%) patients reported their sense of smell at the time of survey to be normal.", [["smell loss", "DISEASE", 75, 85], ["anosmia", "DISEASE", 159, 166], ["hyposmia", "DISEASE", 167, 175], ["COVID-19", "GENE_OR_GENE_PRODUCT", 30, 38], ["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 213, 221], ["COVID", "TEST", 30, 35], ["smell loss", "PROBLEM", 75, 85], ["anosmia", "PROBLEM", 159, 166], ["hyposmia", "PROBLEM", 167, 175], ["hyposmia", "OBSERVATION", 167, 175], ["normal", "OBSERVATION", 280, 286]]], ["Twelve (48%) patients who had persistent smell loss were within less than 4 weeks from the diagnosis.", [["smell loss", "DISEASE", 41, 51], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["persistent smell loss", "PROBLEM", 30, 51], ["persistent", "OBSERVATION_MODIFIER", 30, 40], ["smell loss", "OBSERVATION", 41, 51]]], ["All eight patients who completed the survey more than 4 weeks after the diagnosis reported a normal sense of smell.Interpretation of findingsThis study suggests that there is a higher prevalence of self-reported chemosensory impairment in Association between COVID-19 and anosmia and dysgeusia COVID-19-positive patients compared with negative patients with early recovery of smell function in a large proportion of patients.", [["chemosensory impairment", "DISEASE", 212, 235], ["anosmia", "DISEASE", 272, 279], ["patients", "ORGANISM", 10, 18], ["COVID-19", "GENE_OR_GENE_PRODUCT", 294, 302], ["patients", "ORGANISM", 312, 320], ["patients", "ORGANISM", 344, 352], ["smell", "ORGANISM_SUBDIVISION", 376, 381], ["patients", "ORGANISM", 416, 424], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 312, 320], ["patients", "SPECIES", 344, 352], ["patients", "SPECIES", 416, 424], ["This study", "TEST", 141, 151], ["chemosensory impairment", "PROBLEM", 212, 235], ["COVID", "TEST", 259, 264], ["anosmia", "PROBLEM", 272, 279], ["dysgeusia", "TEST", 284, 293], ["COVID", "TEST", 294, 299], ["smell function", "PROBLEM", 376, 390], ["impairment", "OBSERVATION", 225, 235], ["smell function", "OBSERVATION", 376, 390]]], ["In our series, olfactory and gustatory impairments were respectively 14 times and 11 times more likely to be associated with COVID-19 positivity.", [["olfactory", "ANATOMY", 15, 24], ["gustatory", "ANATOMY", 29, 38], ["olfactory and gustatory impairments", "DISEASE", 15, 50], ["olfactory", "ORGAN", 15, 24], ["gustatory", "ORGAN", 29, 38], ["COVID-19", "GENE_OR_GENE_PRODUCT", 125, 133], ["olfactory and gustatory impairments", "PROBLEM", 15, 50], ["COVID", "TEST", 125, 130]]], ["Overall, our findings suggest that loss of smell and loss of taste have a higher chance of identifying COVID-19-positive patients among those with influenza-like symptoms seen on an ambulatory basis.", [["loss of smell", "DISEASE", 35, 48], ["influenza-like symptoms", "DISEASE", 147, 170], ["COVID-19", "GENE_OR_GENE_PRODUCT", 103, 111], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["loss of smell", "PROBLEM", 35, 48], ["loss of taste", "PROBLEM", 53, 66], ["COVID", "TEST", 103, 108], ["influenza-like symptoms", "PROBLEM", 147, 170], ["an ambulatory basis", "TEST", 179, 198], ["loss", "OBSERVATION_MODIFIER", 35, 39], ["smell", "OBSERVATION", 43, 48]]], ["The reported prevalence of olfactory dysfunction varies significantly from 5.1% in a Chinese study to 85.6% in a European study.", [["olfactory", "ANATOMY", 27, 36], ["olfactory dysfunction", "DISEASE", 27, 48], ["olfactory", "ORGAN", 27, 36], ["olfactory dysfunction", "PROBLEM", 27, 48], ["a Chinese study", "TEST", 83, 98], ["a European study", "TEST", 111, 127], ["olfactory dysfunction", "OBSERVATION", 27, 48]]], ["[3] [4] [5] [7] [8] [9] Our results are consistent with previous reports that showed a higher prevalence of self-reported smell or taste loss among COVID-19positive patients.", [["taste loss", "DISEASE", 131, 141], ["[3] [4] [5] [7] [8] [9]", "SIMPLE_CHEMICAL", 0, 23], ["taste", "ORGANISM_SUBDIVISION", 131, 136], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 165, 173], ["taste loss", "PROBLEM", 131, 141], ["COVID", "TEST", 148, 153]]], ["Interestingly, in our study, although 31 out of 56 (55.4%) of COVID-19-positive survey participants included anosmia or hyposmia as one of their overall symptoms, only 23 (41.1%) patients maintained that they lost their sense of smell around the time of COVID-19 symptom onset (5 days prior or thereafter) with a 16% rate of \"unable to recall.\"", [["anosmia", "DISEASE", 109, 116], ["hyposmia", "DISEASE", 120, 128], ["COVID-19", "GENE_OR_GENE_PRODUCT", 62, 70], ["participants", "ORGANISM", 87, 99], ["patients", "ORGANISM", 179, 187], ["participants", "SPECIES", 87, 99], ["patients", "SPECIES", 179, 187], ["our study", "TEST", 18, 27], ["COVID", "TEST", 62, 67], ["anosmia", "PROBLEM", 109, 116], ["hyposmia", "PROBLEM", 120, 128], ["their overall symptoms", "PROBLEM", 139, 161], ["COVID", "TEST", 254, 259], ["hyposmia", "OBSERVATION", 120, 128]]], ["This discrepancy likely represents recall bias, which is common in crosssectional studies.", [["likely represents", "UNCERTAINTY", 17, 34], ["recall bias", "OBSERVATION", 35, 46]]], ["Therefore, we believe that the 40% rate of smell loss around the time of COVID-19 symptom onset is a more accurate representation than the 55% overall rate.Comparison with previous studiesOur rate of anosmia/hyposmia of 41.1% is lower than the rate of 60%-85% in recently published studies with comparable study designs or 51.5% found in another Canadian study.", [["smell loss", "DISEASE", 43, 53], ["anosmia", "DISEASE", 200, 207], ["hyposmia", "DISEASE", 208, 216], ["smell loss", "PROBLEM", 43, 53], ["COVID", "TEST", 73, 78], ["previous studies", "TEST", 172, 188], ["anosmia", "PROBLEM", 200, 207], ["hyposmia", "PROBLEM", 208, 216], ["the rate", "TEST", 240, 248], ["another Canadian study", "TEST", 338, 360], ["smell loss", "OBSERVATION", 43, 53], ["hyposmia", "OBSERVATION", 208, 216]]], ["3, 4, 6, 8 There may be several explanations for this difference.", [["this difference", "PROBLEM", 49, 64], ["may be", "UNCERTAINTY", 17, 23]]], ["One consideration is the cultural difference in olfactory perception.", [["olfactory", "ANATOMY", 48, 57], ["olfactory", "ANATOMICAL_SYSTEM", 48, 57]]], ["[10] [11] [12] In fact, participants in other cultures may have different thresholds for their smell loss.", [["smell loss", "DISEASE", 95, 105], ["[10] [11] [12", "SIMPLE_CHEMICAL", 0, 13], ["participants", "SPECIES", 24, 36], ["other cultures", "TEST", 40, 54], ["their smell loss", "PROBLEM", 89, 105]]], ["Another possible explanation is the presence of mutant strains with varying pathogenicity, as evidenced from genomic studies in multiple nations.", [["mutant strains", "PROBLEM", 48, 62], ["varying pathogenicity", "PROBLEM", 68, 89], ["genomic studies", "TEST", 109, 124], ["possible explanation", "UNCERTAINTY", 8, 28], ["varying", "OBSERVATION_MODIFIER", 68, 75], ["pathogenicity", "OBSERVATION", 76, 89]]], ["[13] [14] [15] [16] These different strains may cause varying degrees of chemosensory impairment with regional discrepancy, although this has not been scientifically proven.", [["chemosensory impairment", "DISEASE", 73, 96], ["[13] [14] [15] [16]", "SIMPLE_CHEMICAL", 0, 19], ["These different strains", "PROBLEM", 20, 43], ["chemosensory impairment", "PROBLEM", 73, 96], ["regional discrepancy", "PROBLEM", 102, 122], ["varying degrees", "OBSERVATION_MODIFIER", 54, 69], ["chemosensory impairment", "OBSERVATION", 73, 96], ["regional discrepancy", "OBSERVATION", 102, 122]]], ["Therefore, it is important to collect and examine regional data to depict a representative landscape for our population.", [["regional data", "TEST", 50, 63]]], ["Lastly, we do note Association between COVID-19 and anosmia and dysgeusia that this difference could be a simple function of recall bias from cross-sectional surveys, as other studies do not report an \"unable to recall\" option, thus forcing patients to choose with an altered response rate of self-reported smell loss.", [["anosmia", "DISEASE", 52, 59], ["dysgeusia", "DISEASE", 64, 73], ["smell loss", "DISEASE", 307, 317], ["patients", "ORGANISM", 241, 249], ["smell", "ORGANISM_SUBDIVISION", 307, 312], ["patients", "SPECIES", 241, 249], ["COVID", "TEST", 39, 44], ["anosmia", "PROBLEM", 52, 59], ["dysgeusia", "PROBLEM", 64, 73], ["other studies", "TEST", 170, 183], ["smell loss", "PROBLEM", 307, 317], ["smell loss", "OBSERVATION", 307, 317]]], ["Regardless, all published studies unanimously support the inclusion of smell and taste loss as important markers of COVID-19.Clinical and research implicationsA possible mechanism of olfactory dysfunction caused by SARS-CoV-2 has been demonstrated in experimental models with inoculation of coronaviruses.", [["olfactory", "ANATOMY", 183, 192], ["taste loss", "DISEASE", 81, 91], ["olfactory dysfunction", "DISEASE", 183, 204], ["SARS", "DISEASE", 215, 219], ["smell", "ORGANISM_SUBDIVISION", 71, 76], ["olfactory", "ORGAN", 183, 192], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 215, 225], ["coronaviruses", "ORGANISM", 291, 304], ["COVID-19", "DNA", 116, 124], ["all published studies", "TEST", 12, 33], ["smell", "PROBLEM", 71, 76], ["taste loss", "PROBLEM", 81, 91], ["COVID", "TEST", 116, 121], ["olfactory dysfunction", "PROBLEM", 183, 204], ["SARS", "PROBLEM", 215, 219], ["inoculation of coronaviruses", "PROBLEM", 276, 304], ["possible mechanism of", "UNCERTAINTY", 161, 182], ["olfactory dysfunction", "OBSERVATION", 183, 204]]], ["Coronaviruses can damage the olfactory neuroepithelium via apoptosis with a subsequent reduction of mature sensory neurons and disordering of olfactory epithelium.", [["olfactory neuroepithelium", "ANATOMY", 29, 54], ["sensory neurons", "ANATOMY", 107, 122], ["olfactory epithelium", "ANATOMY", 142, 162], ["Coronaviruses", "CHEMICAL", 0, 13], ["olfactory neuroepithelium", "TISSUE", 29, 54], ["sensory neurons", "CELL", 107, 122], ["olfactory epithelium", "TISSUE", 142, 162], ["mature sensory neurons", "CELL_TYPE", 100, 122], ["Coronaviruses", "PROBLEM", 0, 13], ["the olfactory neuroepithelium", "PROBLEM", 25, 54], ["apoptosis", "PROBLEM", 59, 68], ["mature sensory neurons", "PROBLEM", 100, 122], ["disordering of olfactory epithelium", "PROBLEM", 127, 162], ["olfactory", "ANATOMY_MODIFIER", 29, 38], ["neuroepithelium", "ANATOMY_MODIFIER", 39, 54], ["apoptosis", "OBSERVATION", 59, 68], ["mature", "OBSERVATION_MODIFIER", 100, 106], ["sensory neurons", "OBSERVATION", 107, 122], ["olfactory epithelium", "OBSERVATION", 142, 162]]], ["[17] [18] [19] Another line of research suggests that the anosmia/hyposmia may result from infection of the support and perivascular cells in olfactory epithelium, via angiotensin-converting enzyme 2 receptors, which are identified as the receptors of SARS-CoV-2.", [["perivascular cells", "ANATOMY", 120, 138], ["olfactory epithelium", "ANATOMY", 142, 162], ["anosmia", "DISEASE", 58, 65], ["hyposmia", "DISEASE", 66, 74], ["infection", "DISEASE", 91, 100], ["angiotensin", "CHEMICAL", 168, 179], ["perivascular cells", "CELL", 120, 138], ["olfactory epithelium", "TISSUE", 142, 162], ["angiotensin-converting enzyme 2 receptors", "GENE_OR_GENE_PRODUCT", 168, 209], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 252, 262], ["perivascular cells", "CELL_TYPE", 120, 138], ["angiotensin-converting enzyme 2 receptors", "PROTEIN", 168, 209], ["the anosmia", "PROBLEM", 54, 65], ["hyposmia", "PROBLEM", 66, 74], ["infection", "PROBLEM", 91, 100], ["perivascular cells in olfactory epithelium", "PROBLEM", 120, 162], ["angiotensin-converting enzyme 2 receptors", "TREATMENT", 168, 209], ["CoV", "TEST", 257, 260], ["hyposmia", "OBSERVATION", 66, 74], ["infection", "OBSERVATION", 91, 100], ["perivascular cells", "OBSERVATION", 120, 138], ["olfactory epithelium", "ANATOMY", 142, 162]]], ["20, 21 Clinically, nasal inoculation of coronavirus resulted in olfactory impairment in healthy volunteers.", [["nasal", "ANATOMY", 19, 24], ["olfactory", "ANATOMY", 64, 73], ["coronavirus", "DISEASE", 40, 51], ["olfactory impairment", "DISEASE", 64, 84], ["nasal", "ORGANISM_SUBDIVISION", 19, 24], ["coronavirus", "ORGANISM", 40, 51], ["olfactory", "ORGAN", 64, 73], ["volunteers", "ORGANISM", 96, 106], ["nasal inoculation of coronavirus", "PROBLEM", 19, 51], ["olfactory impairment in healthy volunteers", "PROBLEM", 64, 106], ["nasal", "ANATOMY", 19, 24], ["coronavirus", "OBSERVATION", 40, 51], ["olfactory impairment", "OBSERVATION", 64, 84]]], ["22 Dysgeusia/ageusia is generally regarded to be secondary to loss of smell, as it may be difficult to distinguish between flavor and taste.", [["loss of smell", "DISEASE", 62, 75], ["22 Dysgeusia", "PROBLEM", 0, 12], ["ageusia", "PROBLEM", 13, 20], ["loss of smell", "PROBLEM", 62, 75], ["Dysgeusia", "OBSERVATION", 3, 12], ["ageusia", "OBSERVATION", 13, 20]]], ["In a large study investigating taste disorders unrelated to COVID-19, many reported loss of taste without any objective gustatory loss but found to have olfactory deficits alone.", [["olfactory", "ANATOMY", 153, 162], ["taste disorders", "DISEASE", 31, 46], ["loss of taste", "DISEASE", 84, 97], ["gustatory loss", "DISEASE", 120, 134], ["olfactory deficits", "DISEASE", 153, 171], ["olfactory", "ORGAN", 153, 162], ["taste disorders", "PROBLEM", 31, 46], ["COVID", "TEST", 60, 65], ["loss of taste", "PROBLEM", 84, 97], ["any objective gustatory loss", "PROBLEM", 106, 134], ["olfactory deficits", "PROBLEM", 153, 171], ["large", "OBSERVATION_MODIFIER", 5, 10], ["deficits", "OBSERVATION", 163, 171]]], ["23 While it is possible that loss of taste in COVID-19 may be a distinct mechanism, 24 the rate of taste loss in our patients likely represents subtle olfactory deficits.", [["olfactory", "ANATOMY", 151, 160], ["taste loss", "DISEASE", 99, 109], ["olfactory deficits", "DISEASE", 151, 169], ["COVID-19", "GENE_OR_GENE_PRODUCT", 46, 54], ["taste", "ORGANISM_SUBDIVISION", 99, 104], ["patients", "ORGANISM", 117, 125], ["olfactory", "ORGAN", 151, 160], ["patients", "SPECIES", 117, 125], ["loss of taste", "PROBLEM", 29, 42], ["COVID", "TEST", 46, 51], ["taste loss", "PROBLEM", 99, 109], ["subtle olfactory deficits", "PROBLEM", 144, 169], ["likely represents", "UNCERTAINTY", 126, 143], ["subtle", "OBSERVATION_MODIFIER", 144, 150], ["olfactory deficits", "OBSERVATION", 151, 169]]], ["In our series, 52% of the affected individuals reported a normal sense of smell at the time of survey with many recovering within 4 weeks.", [["individuals", "ORGANISM", 35, 46]]], ["This finding is consistent with previous reports and suggests that the damage to the olfactory function by COVID-19 may not be permanent.", [["olfactory", "ANATOMY", 85, 94], ["COVID-19", "CHEMICAL", 107, 115], ["COVID-19", "CHEMICAL", 107, 115], ["olfactory", "ORGAN", 85, 94], ["the damage", "PROBLEM", 67, 77], ["COVID", "TEST", 107, 112], ["consistent with", "UNCERTAINTY", 16, 31]]], ["4 However, this warrants further investigation with follow-up assessments of smell function.", [["smell", "ORGANISM_SUBDIVISION", 77, 82], ["further investigation", "TEST", 25, 46], ["follow-up assessments", "TEST", 52, 73]]], ["All in all, the presence of loss of smell and taste may be a distinguishable feature of COVID-19 from other viral URTIs.Clinical and research implicationsOur results have strong implications in public health measures.", [["loss of smell", "DISEASE", 28, 41], ["URTIs", "DISEASE", 114, 119], ["COVID-19", "CELL", 88, 96], ["loss of smell and taste", "PROBLEM", 28, 51], ["COVID", "TEST", 88, 93], ["other viral URTIs", "PROBLEM", 102, 119], ["loss", "OBSERVATION", 28, 32], ["smell", "OBSERVATION", 36, 41], ["viral URTIs", "OBSERVATION", 108, 119], ["strong", "OBSERVATION_MODIFIER", 171, 177]]], ["A recent study demonstrated 56% of residents to be COVID-19 positive but \"asymptomatic\" in a skilled nursing facility.", [["A recent study", "TEST", 0, 14], ["COVID", "TEST", 51, 56], ["asymptomatic", "PROBLEM", 74, 86]]], ["25 However, this study did not include the loss of smell or taste in the symptom assessment.", [["loss of smell", "DISEASE", 43, 56], ["this study", "TEST", 12, 22], ["the loss of smell or taste", "PROBLEM", 39, 65], ["the symptom assessment", "TEST", 69, 91]]], ["In a previous study from Italy and our study, both demonstrate that a significant portion of the patients complained of decreased sense of smell or taste during the early phase of their disease.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["a previous study", "TEST", 3, 19], ["our study", "TEST", 35, 44], ["decreased sense of smell or taste", "PROBLEM", 120, 153], ["their disease", "PROBLEM", 180, 193], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["portion", "OBSERVATION_MODIFIER", 82, 89], ["decreased", "OBSERVATION_MODIFIER", 120, 129], ["disease", "OBSERVATION", 186, 193]]], ["3 Hence, it would be essential to incorporate anosmia/hyposmia and dysgeusia/ageusia as part of future epidemiologic COVID-19 surveillance studies and tailor the screening criteria for COVID-19 accordingly.", [["anosmia", "DISEASE", 46, 53], ["hyposmia", "DISEASE", 54, 62], ["dysgeusia", "DISEASE", 67, 76], ["ageusia", "DISEASE", 77, 84], ["anosmia", "PROBLEM", 46, 53], ["hyposmia", "PROBLEM", 54, 62], ["dysgeusia", "PROBLEM", 67, 76], ["ageusia", "PROBLEM", 77, 84], ["epidemiologic COVID", "TEST", 103, 122], ["surveillance studies", "TEST", 126, 146], ["the screening criteria", "TEST", 158, 180], ["COVID", "TEST", 185, 190], ["hyposmia", "OBSERVATION", 54, 62]]], ["Furthermore, these symptoms can be easily assessed in the context of telemedicine and virtual care.", [["these symptoms", "PROBLEM", 13, 27], ["virtual care", "TREATMENT", 86, 98]]], ["This can, in turn, facilitate improved patient counselling for the screening of COVID-19 and help curb the spread of COVID-19 in the vulnerable population, including those in long-term care facilities and remote communities where testing may be limited.", [["COVID-19", "CHEMICAL", 117, 125], ["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["the screening", "TEST", 63, 76], ["COVID", "TEST", 80, 85], ["COVID", "TEST", 117, 122]]], ["Currently, while several provincial bodies have implemented loss of smell/taste as screening symptoms, the self-assessment tool from the Canadian Federal Government still does not incorporate these symptoms.", [["loss of smell/taste", "DISEASE", 60, 79], ["loss of smell/taste", "PROBLEM", 60, 79], ["screening symptoms", "PROBLEM", 83, 101], ["these symptoms", "PROBLEM", 192, 206]]], ["With our Ontario regional data demonstrating a high probability of COVID-19 positivity with loss of smell/ taste, there is now evidence to expand public awareness of this association and ultimately improve our public health response to this pandemic.LimitationsInterpretation of our study results is limited by recall bias, as there is a significant time lapse between diagnosis and survey administration.", [["loss of smell/ taste", "DISEASE", 92, 112], ["COVID-19", "GENE_OR_GENE_PRODUCT", 67, 75], ["COVID", "TEST", 67, 72], ["loss of smell/ taste", "PROBLEM", 92, 112], ["this pandemic", "PROBLEM", 236, 249], ["our study", "TEST", 279, 288], ["significant", "OBSERVATION_MODIFIER", 338, 349]]], ["The recent media spotlight of COVID-19 and anosmia might have resulted in elevated rates of self-reported anosmia.", [["COVID-19", "CHEMICAL", 30, 38], ["anosmia", "DISEASE", 43, 50], ["anosmia", "DISEASE", 106, 113], ["COVID", "TEST", 30, 35], ["anosmia", "PROBLEM", 43, 50], ["elevated rates", "PROBLEM", 74, 88], ["anosmia", "PROBLEM", 106, 113], ["elevated", "OBSERVATION", 74, 82]]], ["Future studies could be administered at the time of swab to avoid this bias.", [["Future studies", "TEST", 0, 14], ["swab", "TEST", 52, 56], ["this bias", "PROBLEM", 66, 75]]], ["We also acknowledge non-response bias.", [["non-response bias", "PROBLEM", 20, 37], ["non-response bias", "OBSERVATION", 20, 37]]], ["While the study results are limited by the nature of a single-institutional-based study, we collected data over a longer period of time than previous reports to improve our sampling.", [["the study", "TEST", 6, 15], ["based study", "TEST", 76, 87], ["our sampling", "TEST", 169, 181]]], ["3, 4 Furthermore, the testing criteria focused on frontline workers from at-risk settings, such as healthcare or long-term care, residents in group homes, and returning travelers.", [["the testing criteria", "TEST", 18, 38]]], ["This may reduce external validity.", [["external", "OBSERVATION_MODIFIER", 16, 24], ["validity", "OBSERVATION", 25, 33]]], ["Lastly, with ethical concerns of transmission to our research team and preservation of personal protective equipment, we are presently unable to objectively measure smell in symptomatic patients during the point of assessment.LimitationsWe acknowledge the need for large-scale epidemiologic studies to further investigate this association between smell and taste loss and COVID-19 positivity.", [["taste loss", "DISEASE", 357, 367], ["patients", "ORGANISM", 186, 194], ["taste", "ORGANISM_SUBDIVISION", 357, 362], ["COVID-19", "GENE_OR_GENE_PRODUCT", 372, 380], ["patients", "SPECIES", 186, 194], ["personal protective equipment", "TREATMENT", 87, 116], ["assessment", "TEST", 215, 225], ["large-scale epidemiologic studies", "TEST", 265, 298], ["this association between smell", "PROBLEM", 322, 352], ["taste loss", "PROBLEM", 357, 367], ["COVID", "TEST", 372, 377]]], ["Our research group currently has ongoing projects to investigate a larger regional population and to incorporate selfreported objective measures of smell using common household items.", [["a larger regional population", "PROBLEM", 65, 93]]], ["Despite the limitations, the baseline characteristics between positive and negative groups were comparable, and our data emphasize the importance of considering smell and taste as screening symptoms.CONCLUSIONOur results demonstrate that there is a higher rate of selfreported anosmia/hyposmia and concurrent dysgeusia/ ageusia among COVID-19 patients in a regional sample of Canadians in Toronto, Ontario.", [["anosmia", "DISEASE", 277, 284], ["hyposmia", "DISEASE", 285, 293], ["dysgeusia", "DISEASE", 309, 318], ["ageusia", "DISEASE", 320, 327], ["patients", "ORGANISM", 343, 351], ["patients", "SPECIES", 343, 351], ["smell and taste", "PROBLEM", 161, 176], ["selfreported anosmia", "PROBLEM", 264, 284], ["hyposmia", "PROBLEM", 285, 293], ["concurrent dysgeusia", "PROBLEM", 298, 318], ["ageusia", "PROBLEM", 320, 327], ["hyposmia", "OBSERVATION", 285, 293]]], ["Our study offers strong support for clinicians to use loss of smell and loss of taste as key symptoms for the clinical diagnosis of COVID-19, especially in settings with limited testing.Association between COVID-19 and anosmia and dysgeusiaFuture population-based studies are needed to further investigate this association.", [["loss of smell", "DISEASE", 54, 67], ["anosmia", "DISEASE", 219, 226], ["Our study", "TEST", 0, 9], ["loss of smell", "PROBLEM", 54, 67], ["loss of taste", "PROBLEM", 72, 85], ["key symptoms", "PROBLEM", 89, 101], ["COVID", "TEST", 132, 137], ["limited testing", "TEST", 170, 185], ["COVID", "TEST", 206, 211], ["anosmia", "PROBLEM", 219, 226], ["dysgeusiaFuture population", "TEST", 231, 257], ["based studies", "TEST", 258, 271]]]], "71f45bcdac8e83e02ee1d8b5eab8ce5c425f5cce": [["IntroductionDeveloping broad-range virus-neutralizing antibodies (bnAbs) requires identifying the immunological targets that are conserved among the targeted viruses and are suitable for antibody targeting.", [["neutralizing antibodies", "PROTEIN", 41, 64], ["bnAbs", "PROTEIN", 66, 71], ["broad-range virus", "TREATMENT", 23, 40], ["neutralizing antibodies (bnAbs)", "PROBLEM", 41, 72], ["the immunological targets", "PROBLEM", 94, 119], ["the targeted viruses", "PROBLEM", 145, 165], ["antibody targeting", "TREATMENT", 187, 205], ["broad", "OBSERVATION_MODIFIER", 23, 28], ["range virus", "OBSERVATION", 29, 40]]], ["Discovery of oligomannosyl moieties as targets of bnAbs against HIV-1 has stimulated substantial interest in carbohydrate moieties as vaccine candidates [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] .", [["oligomannosyl", "CHEMICAL", 13, 26], ["carbohydrate", "CHEMICAL", 109, 121], ["oligomannosyl moieties", "SIMPLE_CHEMICAL", 13, 35], ["bnAbs", "SIMPLE_CHEMICAL", 50, 55], ["HIV-1", "ORGANISM", 64, 69], ["carbohydrate moieties", "SIMPLE_CHEMICAL", 109, 130], ["[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 153, 198], ["oligomannosyl moieties", "PROTEIN", 13, 35], ["bnAbs", "PROTEIN", 50, 55], ["HIV-1", "SPECIES", 64, 69], ["HIV-1", "SPECIES", 64, 69], ["oligomannosyl moieties", "TREATMENT", 13, 35], ["bnAbs", "PROBLEM", 50, 55], ["HIV", "PROBLEM", 64, 67], ["carbohydrate moieties", "TREATMENT", 109, 130]]], ["The heavy glycosylation of the HIV envelope with oligomannoses appears to be a defense mechanism for the virus to evade host immune recognition of protein-based neutralizing epitopes.", [["HIV envelope", "ORGANISM", 31, 43], ["oligomannoses", "GENE_OR_GENE_PRODUCT", 49, 62], ["protein-based neutralizing epitopes", "PROTEIN", 147, 182], ["HIV", "SPECIES", 31, 34], ["HIV", "SPECIES", 31, 34], ["the HIV envelope", "PROBLEM", 27, 43], ["a defense mechanism", "PROBLEM", 77, 96], ["the virus", "PROBLEM", 101, 110], ["protein", "TEST", 147, 154], ["neutralizing epitopes", "TREATMENT", 161, 182], ["heavy", "OBSERVATION_MODIFIER", 4, 9], ["glycosylation", "OBSERVATION", 10, 23], ["neutralizing epitopes", "OBSERVATION", 161, 182]]], ["However, isolation of a number of glycan-dependent HIV bnAbs from HIV-infected individuals, such as 2G12, PG9/PG16, and other potent bnAbs [1, 5, 6, 10, 12, 13] , strongly suggests that the \"glycan shield\" of HIV virions may also display important targets for immunological intervention against viral infections.IntroductionLike HIV-1, virtually all human viruses decorate their virions with carbohydrate moieties.", [["HIV-infected", "DISEASE", 66, 78], ["viral infections", "DISEASE", 295, 311], ["carbohydrate", "CHEMICAL", 392, 404], ["glycan", "GENE_OR_GENE_PRODUCT", 34, 40], ["HIV bnAbs", "ORGANISM", 51, 60], ["HIV-infected individuals", "ORGANISM", 66, 90], ["2G12", "GENE_OR_GENE_PRODUCT", 100, 104], ["PG9", "GENE_OR_GENE_PRODUCT", 106, 109], ["PG16", "GENE_OR_GENE_PRODUCT", 110, 114], ["HIV virions", "ORGANISM", 209, 220], ["HIV-1", "ORGANISM", 329, 334], ["human", "ORGANISM", 350, 355], ["HIV bnAbs", "PROTEIN", 51, 60], ["2G12", "PROTEIN", 100, 104], ["PG9", "PROTEIN", 106, 109], ["HIV", "SPECIES", 51, 54], ["HIV", "SPECIES", 66, 69], ["HIV", "SPECIES", 329, 332], ["human", "SPECIES", 350, 355], ["HIV", "SPECIES", 51, 54], ["HIV", "SPECIES", 66, 69], ["HIV", "SPECIES", 209, 212], ["HIV-1", "SPECIES", 329, 334], ["human", "SPECIES", 350, 355], ["glycan-dependent HIV bnAbs", "PROBLEM", 34, 60], ["HIV", "PROBLEM", 66, 69], ["infected individuals", "PROBLEM", 70, 90], ["2G12", "TEST", 100, 104], ["other potent bnAbs", "TEST", 120, 138], ["HIV virions", "PROBLEM", 209, 220], ["immunological intervention", "TREATMENT", 260, 286], ["viral infections", "PROBLEM", 295, 311], ["carbohydrate moieties", "TREATMENT", 392, 413]]], ["Thus, the potential of viral carbohydrates as immunological targets for other viral pathogens warrants exploration.", [["carbohydrates", "CHEMICAL", 29, 42], ["viral carbohydrates", "TREATMENT", 23, 42], ["immunological targets", "TEST", 46, 67], ["other viral pathogens", "PROBLEM", 72, 93], ["exploration", "TEST", 103, 114]]], ["One intriguing question is whether human viruses of distinct phylogenetic origins, such as HIV-1 and SARS-CoV, may display conserved glycan targets that are suitable for broad virus neutralization.", [["human", "ORGANISM", 35, 40], ["HIV-1", "ORGANISM", 91, 96], ["SARS-CoV", "ORGANISM", 101, 109], ["human", "SPECIES", 35, 40], ["HIV-1", "SPECIES", 91, 96], ["human", "SPECIES", 35, 40], ["HIV-1", "SPECIES", 91, 96], ["SARS-CoV", "SPECIES", 101, 109], ["HIV", "TEST", 91, 94], ["SARS", "PROBLEM", 101, 105], ["CoV", "PROBLEM", 106, 109], ["conserved glycan targets", "PROBLEM", 123, 147], ["broad virus neutralization", "PROBLEM", 170, 196]]], ["Availability of bnAbs targeting such conserved glycans is clearly important for improving a biodefensive public health response to unexpected viral epidemics.IntroductionIn response to the 2003 SARS epidemic, our team introduced carbohydrate microarrays to study SARS-CoV-elicited anti-glycan antibodies [14] .", [["SARS", "DISEASE", 194, 198], ["carbohydrate", "CHEMICAL", 229, 241], ["bnAbs", "GENE_OR_GENE_PRODUCT", 16, 21], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 263, 271], ["bnAbs", "PROTEIN", 16, 21], ["anti-glycan antibodies", "PROTEIN", 281, 303], ["SARS-CoV", "SPECIES", 263, 271], ["bnAbs", "TREATMENT", 16, 21], ["unexpected viral epidemics", "PROBLEM", 131, 157], ["carbohydrate microarrays", "TREATMENT", 229, 253], ["study SARS", "TEST", 257, 267], ["CoV", "TEST", 268, 271], ["anti-glycan antibodies", "TEST", 281, 303], ["viral epidemics", "OBSERVATION", 142, 157]]], ["In essence, we characterized the carbohydrate-binding activity of the SARS-CoV-neutralizing antibodies elicited by immunizing horses with an inactivated SARS-CoV vaccine.", [["carbohydrate", "CHEMICAL", 33, 45], ["SARS-CoV", "ORGANISM", 70, 78], ["horses", "ORGANISM", 126, 132], ["SARS-CoV", "ORGANISM", 153, 161], ["SARS-CoV-neutralizing antibodies", "PROTEIN", 70, 102], ["SARS-CoV", "SPECIES", 70, 78], ["horses", "SPECIES", 126, 132], ["SARS-CoV", "SPECIES", 153, 161], ["the SARS", "PROBLEM", 66, 74], ["CoV", "TEST", 75, 78], ["neutralizing antibodies", "PROBLEM", 79, 102], ["immunizing horses", "PROBLEM", 115, 132], ["CoV vaccine", "TREATMENT", 158, 169]]], ["In these horse antibodies, we detected unexpected auto-antibody reactivity specific for the carbohydrate moieties of an abundant human serum glycoprotein, asialo-orosomucoid (ASOR).", [["serum", "ANATOMY", 135, 140], ["carbohydrate", "CHEMICAL", 92, 104], ["horse", "ORGANISM", 9, 14], ["human", "ORGANISM", 129, 134], ["serum", "ORGANISM_SUBSTANCE", 135, 140], ["asialo-orosomucoid", "GENE_OR_GENE_PRODUCT", 155, 173], ["ASOR", "GENE_OR_GENE_PRODUCT", 175, 179], ["horse antibodies", "PROTEIN", 9, 25], ["carbohydrate moieties", "PROTEIN", 92, 113], ["human serum glycoprotein", "PROTEIN", 129, 153], ["asialo-orosomucoid", "PROTEIN", 155, 173], ["ASOR", "PROTEIN", 175, 179], ["horse", "SPECIES", 9, 14], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["these horse antibodies", "TEST", 3, 25], ["unexpected auto-antibody reactivity", "PROBLEM", 39, 74]]], ["The targeted carbohydrates are tri-antennary type II (Gal\u03b21\u21924GlcNAc) or multi-valent type II (Tri/m-II) sugar moieties.IntroductionThe N-glycosylation pathway has potential to generate numerous cryptic N-glycans of distinct structural characteristics.", [["Tri/m-II", "CHEMICAL", 94, 102], ["carbohydrates", "CHEMICAL", 13, 26], ["sugar", "CHEMICAL", 104, 109], ["N", "CHEMICAL", 135, 136], ["N", "CHEMICAL", 202, 203], ["Gal\u03b21\u21924GlcNAc", "GENE_OR_GENE_PRODUCT", 54, 67], ["tri-antennary type II", "PROTEIN", 31, 52], ["Gal\u03b21", "PROTEIN", 54, 59], ["4GlcNAc", "PROTEIN", 60, 67], ["multi-valent type II (Tri/m-II) sugar moieties", "PROTEIN", 72, 118], ["The N-glycosylation pathway", "TREATMENT", 131, 158]]], ["The spike glycoprotein of SARS-CoV has 23 potential N-linked glycosylation sites [15] [16] [17] [18] .", [["N", "CHEMICAL", 52, 53], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 26, 34], ["[15] [16] [17] [18]", "SIMPLE_CHEMICAL", 81, 100], ["spike glycoprotein", "PROTEIN", 4, 22], ["N-linked glycosylation sites", "PROTEIN", 52, 80], ["SARS-CoV", "SPECIES", 26, 34], ["The spike glycoprotein of SARS", "PROBLEM", 0, 30], ["potential N-linked glycosylation sites", "TREATMENT", 42, 80]]], ["Ritchie et al. determined the glycan profiles of the spike protein produced by monkey Vero-E6 cells [19] .", [["Vero-E6 cells", "ANATOMY", 86, 99], ["monkey", "ORGANISM", 79, 85], ["Vero-E6 cells", "CELL", 86, 99], ["spike protein", "PROTEIN", 53, 66], ["monkey Vero-E6 cells", "CELL_LINE", 79, 99], ["monkey Vero", "SPECIES", 79, 90], ["the glycan profiles", "TEST", 26, 45], ["the spike protein", "TEST", 49, 66]]], ["Its major glycans include high-mannose (Man5-9GlcNAc2), hybrid, and bi-, tri-and tetra-antennary complex carbohydrates with and without bisecting GlcNAc and core fucose.", [["Man5-9GlcNAc2", "CHEMICAL", 40, 53], ["mannose", "CHEMICAL", 31, 38], ["carbohydrates", "CHEMICAL", 105, 118], ["GlcNAc", "CHEMICAL", 146, 152], ["fucose", "CHEMICAL", 162, 168], ["high-mannose", "SIMPLE_CHEMICAL", 26, 38], ["Man5-9GlcNAc2", "SIMPLE_CHEMICAL", 40, 53], ["bi-", "SIMPLE_CHEMICAL", 68, 71], ["tri-and tetra-antennary complex carbohydrates", "SIMPLE_CHEMICAL", 73, 118], ["GlcNAc", "GENE_OR_GENE_PRODUCT", 146, 152], ["fucose", "SIMPLE_CHEMICAL", 162, 168], ["9GlcNAc2", "PROTEIN", 45, 53], ["high-mannose (Man5-9GlcNAc2)", "TREATMENT", 26, 54], ["hybrid", "TREATMENT", 56, 62], ["bi-, tri-and tetra-antennary complex carbohydrates", "TREATMENT", 68, 118], ["bisecting GlcNAc", "TREATMENT", 136, 152], ["high", "OBSERVATION_MODIFIER", 26, 30]]], ["Interestingly, sialylation was negligible in the spike proteins produced by monkey Vero-E6 cells, which led to exposure of terminal galactoses in Tri/m-II glyco-determinants.", [["Vero-E6 cells", "ANATOMY", 83, 96], ["monkey", "ORGANISM", 76, 82], ["Vero-E6 cells", "CELL", 83, 96], ["spike proteins", "PROTEIN", 49, 63], ["monkey Vero-E6 cells", "CELL_LINE", 76, 96], ["terminal galactoses", "PROTEIN", 123, 142], ["Tri/m-II glyco-determinants", "PROTEIN", 146, 173], ["monkey Vero", "SPECIES", 76, 87], ["the spike proteins", "PROBLEM", 45, 63], ["terminal galactoses", "PROBLEM", 123, 142], ["negligible", "OBSERVATION_MODIFIER", 31, 41], ["E6 cells", "OBSERVATION", 88, 96], ["terminal galactoses", "OBSERVATION", 123, 142]]], ["Thus, induction of anti-ASOR auto-antibodies by inactivated SARS-CoV can be attributed to the fact that ASOR and the SARS-CoV spike glycoprotein commonly express the Tri/m-II cryptic glyco-determinants.", [["auto-antibodies", "DISEASE", 29, 44], ["SARS", "DISEASE", 60, 64], ["anti-ASOR", "GENE_OR_GENE_PRODUCT", 19, 28], ["SARS-CoV", "ORGANISM", 60, 68], ["ASOR", "GENE_OR_GENE_PRODUCT", 104, 108], ["SARS-CoV", "ORGANISM", 117, 125], ["anti-ASOR auto-antibodies", "PROTEIN", 19, 44], ["ASOR", "PROTEIN", 104, 108], ["SARS-CoV spike glycoprotein", "PROTEIN", 117, 144], ["Tri/m-II cryptic glyco-determinants", "PROTEIN", 166, 201], ["SARS-CoV", "SPECIES", 60, 68], ["SARS-CoV", "SPECIES", 117, 125], ["anti-ASOR auto-antibodies", "PROBLEM", 19, 44], ["inactivated SARS-CoV", "PROBLEM", 48, 68], ["ASOR", "TEST", 104, 108], ["the SARS", "PROBLEM", 113, 121], ["CoV spike glycoprotein", "PROBLEM", 122, 144]]], ["Of note, this structural glycomics study revealed that SARS-CoV also expresses the high-mannose series of carbohydrate structures as its major glycan moieties.", [["SARS", "DISEASE", 55, 59], ["mannose", "CHEMICAL", 88, 95], ["carbohydrate", "CHEMICAL", 106, 118], ["SARS-CoV", "ORGANISM", 55, 63], ["SARS-CoV", "SPECIES", 55, 63], ["this structural glycomics study", "TEST", 9, 40], ["SARS-CoV", "PROBLEM", 55, 63], ["glycan moieties", "OBSERVATION", 143, 158]]], ["Thus, despite the fact that the two viruses differ in their general glycan profiles, they commonly overexpress oligomannosyl cores of N-glycans.IntroductionA significant number of virus-neutralizing agents target oligomannosyl moieties.", [["oligomannosyl", "CHEMICAL", 111, 124], ["oligomannosyl", "CHEMICAL", 213, 226], ["N-glycans", "GENE_OR_GENE_PRODUCT", 134, 143], ["oligomannosyl moieties", "SIMPLE_CHEMICAL", 213, 235], ["N-glycans", "PROTEIN", 134, 143], ["oligomannosyl moieties", "PROTEIN", 213, 235], ["the two viruses", "PROBLEM", 28, 43], ["virus-neutralizing agents", "TREATMENT", 180, 205], ["virus", "OBSERVATION", 180, 185]]], ["Notably, these include mAb 2G12 and lectin GNA.", [["mAb 2G12", "GENE_OR_GENE_PRODUCT", 23, 31], ["lectin GNA", "GENE_OR_GENE_PRODUCT", 36, 46], ["mAb 2G12", "PROTEIN", 23, 31], ["lectin GNA", "PROTEIN", 36, 46], ["mAb 2G12", "TEST", 23, 31], ["lectin GNA", "TEST", 36, 46]]], ["However, the two probes represent distinct classes of virus-neutralizing agents.", [["virus-neutralizing agents", "TREATMENT", 54, 79], ["distinct", "OBSERVATION_MODIFIER", 34, 42], ["classes", "OBSERVATION_MODIFIER", 43, 50], ["virus", "OBSERVATION", 54, 59], ["neutralizing agents", "OBSERVATION", 60, 79]]], ["The former is \"mono-specific\" for HIV-1; the latter is \"pauci reactive\", being a potent neutralizer for several viruses, including at least HIV-1, HCMV, and SARS-CoV [20] [21] [22] [23] [24] .", [["HIV-1", "ORGANISM", 34, 39], ["HIV-1", "ORGANISM", 140, 145], ["HCMV", "ORGANISM", 147, 151], ["SARS-CoV", "ORGANISM", 157, 165], ["20] [21] [22] [23] [24]", "SIMPLE_CHEMICAL", 167, 190], ["HIV-1", "SPECIES", 34, 39], ["HIV-1", "SPECIES", 140, 145], ["HIV-1", "SPECIES", 34, 39], ["HIV-1", "SPECIES", 140, 145], ["HCMV", "SPECIES", 147, 151], ["SARS-CoV", "SPECIES", 157, 165], ["HIV", "PROBLEM", 34, 37], ["pauci reactive", "PROBLEM", 56, 70], ["a potent neutralizer", "TREATMENT", 79, 99], ["several viruses", "PROBLEM", 104, 119], ["HIV", "TEST", 140, 143], ["HCMV", "TEST", 147, 151], ["SARS-CoV", "TEST", 157, 165]]], ["Given the spectrum of anti-virus activities, GNA may serve as a model for exploration of broad-spectrum virus-neutralizing epitopes.", [["GNA", "SIMPLE_CHEMICAL", 45, 48], ["GNA", "PROTEIN", 45, 48], ["neutralizing epitopes", "PROTEIN", 110, 131], ["anti-virus activities", "PROBLEM", 22, 43], ["GNA", "PROBLEM", 45, 48], ["exploration", "TEST", 74, 85], ["broad-spectrum virus", "TREATMENT", 89, 109], ["neutralizing epitopes", "TREATMENT", 110, 131]]], ["An essential step toward this goal is to identify the natural ligands of GNA that are preserved among GNA-targeted viral pathogens, which is the focus of this study.Results and DiscussionWe reasoned that exploring glycan-binding profiles of broadly virus-neutralizing agents may provide key information to uncover the carbohydrate-based viral neutralization epitopes.", [["carbohydrate", "CHEMICAL", 318, 330], ["GNA", "GENE_OR_GENE_PRODUCT", 73, 76], ["GNA", "GENE_OR_GENE_PRODUCT", 102, 105], ["GNA", "PROTEIN", 73, 76], ["carbohydrate-based viral neutralization epitopes", "PROTEIN", 318, 366], ["GNA", "PROBLEM", 73, 76], ["targeted viral pathogens", "PROBLEM", 106, 130], ["this study", "TEST", 154, 164], ["broadly virus", "PROBLEM", 241, 254], ["neutralizing agents", "TREATMENT", 255, 274], ["the carbohydrate", "TREATMENT", 314, 330], ["viral neutralization epitopes", "TREATMENT", 337, 366], ["viral pathogens", "OBSERVATION", 115, 130], ["viral", "OBSERVATION", 337, 342], ["neutralization epitopes", "OBSERVATION", 343, 366]]], ["In the first set of the experiments, we verified that the preparations of GNA or 2G12 we utilized recognize corresponding epitopes presented by the native viral antigens.", [["GNA", "GENE_OR_GENE_PRODUCT", 74, 77], ["2G12", "GENE_OR_GENE_PRODUCT", 81, 85], ["GNA", "PROTEIN", 74, 77], ["2G12", "PROTEIN", 81, 85], ["epitopes", "PROTEIN", 122, 130], ["native viral antigens", "PROTEIN", 148, 169], ["GNA", "PROBLEM", 74, 77], ["2G12", "TREATMENT", 81, 85], ["corresponding epitopes", "PROBLEM", 108, 130], ["viral antigens", "OBSERVATION", 155, 169]]], ["Subsequently, we performed a comparative carbohydrate microarray analysis to characterize the glycan-binding profiles of 2G12 and GNA and to pinpoint specific glyco-epitopes they recognize.Detection of GNA-or 2G12-Epitopes in the Native Viral Antigen PreparationsIn Figure 1A ,B, we examined detection of GNA-and 2G12-epitopes in HIV-1 gp120 glycoproteins.", [["carbohydrate", "CHEMICAL", 41, 53], ["2G12", "GENE_OR_GENE_PRODUCT", 121, 125], ["GNA", "GENE_OR_GENE_PRODUCT", 130, 133], ["GNA", "GENE_OR_GENE_PRODUCT", 202, 205], ["GNA", "GENE_OR_GENE_PRODUCT", 305, 308], ["HIV-1", "ORGANISM", 330, 335], ["gp120", "ORGANISM", 336, 341], ["2G12", "PROTEIN", 121, 125], ["GNA", "PROTEIN", 130, 133], ["glyco-epitopes", "PROTEIN", 159, 173], ["GNA", "PROTEIN", 202, 205], ["2G12", "PROTEIN", 209, 213], ["GNA", "PROTEIN", 305, 308], ["2G12", "PROTEIN", 313, 317], ["epitopes", "PROTEIN", 318, 326], ["HIV-1 gp120 glycoproteins", "PROTEIN", 330, 355], ["HIV-1", "SPECIES", 330, 335], ["HIV-1", "SPECIES", 330, 335], ["a comparative carbohydrate microarray analysis", "TEST", 27, 73], ["2G12", "TEST", 121, 125], ["GNA", "PROBLEM", 130, 133], ["GNA", "TEST", 202, 205], ["2G12", "TEST", 209, 213], ["GNA", "TEST", 305, 308], ["2G12", "TEST", 313, 317], ["HIV", "TEST", 330, 333]]], ["To preserve the native glyco-epitopes, we produced two gp120 preparations in HEK293 cells, i.e., Bal-gp120-Man9 and Bal-gp120.", [["HEK293 cells", "ANATOMY", 77, 89], ["HEK293 cells", "CELL", 77, 89], ["Bal-gp120-Man9", "GENE_OR_GENE_PRODUCT", 97, 111], ["Bal-gp120", "GENE_OR_GENE_PRODUCT", 116, 125], ["gp120", "PROTEIN", 55, 60], ["HEK293 cells", "CELL_LINE", 77, 89], ["Bal-gp120", "PROTEIN", 97, 106], ["Bal-gp120", "PROTEIN", 116, 125], ["Bal-gp120", "TEST", 97, 106], ["Bal-gp", "TEST", 116, 122]]], ["Bal-gp120-Man9 was expressed in HEK293 cells in the presence of kifunensine (2 \u00b5g/mL), a potent \u03b1-mannosidase I inhibitor, following the previously described procedures [25, 26] .", [["HEK293 cells", "ANATOMY", 32, 44], ["kifunensine", "CHEMICAL", 64, 75], ["kifunensine", "CHEMICAL", 64, 75], ["Bal-gp120", "GENE_OR_GENE_PRODUCT", 0, 9], ["Man9", "GENE_OR_GENE_PRODUCT", 10, 14], ["HEK293 cells", "CELL", 32, 44], ["kifunensine", "SIMPLE_CHEMICAL", 64, 75], ["\u03b1-mannosidase I", "GENE_OR_GENE_PRODUCT", 96, 111], ["gp120", "PROTEIN", 4, 9], ["Man9", "PROTEIN", 10, 14], ["HEK293 cells", "CELL_LINE", 32, 44], ["Bal", "TEST", 0, 3], ["kifunensine", "TREATMENT", 64, 75], ["a potent \u03b1-mannosidase I inhibitor", "TREATMENT", 87, 121]]], ["The use of the \u03b1-mannosidase I inhibitor allows the enrichment of high-mannose type (Man9) glycoform through blocking further glycosylation processing to complex or hybrid carbohydrates.", [["mannose", "CHEMICAL", 71, 78], ["carbohydrates", "CHEMICAL", 172, 185], ["\u03b1-mannosidase I", "GENE_OR_GENE_PRODUCT", 15, 30], ["Man9) glycoform", "GENE_OR_GENE_PRODUCT", 85, 100], ["\u03b1-mannosidase I", "PROTEIN", 15, 30], ["mannose type (Man9) glycoform", "PROTEIN", 71, 100], ["the \u03b1-mannosidase I inhibitor", "TREATMENT", 11, 40], ["high-mannose type (Man9) glycoform", "TREATMENT", 66, 100], ["blocking further glycosylation processing", "TREATMENT", 109, 150], ["hybrid carbohydrates", "TREATMENT", 165, 185]]], ["Thus, Bal-gp120-Man9 was produced to resemble the native envelope spikes of HIV, which are almost entirely coated with oligomannose antigens [27] .", [["oligomannose", "CHEMICAL", 119, 131], ["Bal-gp120-Man9", "GENE_OR_GENE_PRODUCT", 6, 20], ["HIV", "ORGANISM", 76, 79], ["Bal-gp120", "PROTEIN", 6, 15], ["Man9", "PROTEIN", 16, 20], ["oligomannose antigens", "PROTEIN", 119, 140], ["HIV", "SPECIES", 76, 79], ["HIV", "SPECIES", 76, 79], ["HIV", "PROBLEM", 76, 79], ["oligomannose antigens", "PROBLEM", 119, 140]]], ["These proteins were applied on ELISA plates at 1.0 \u00b5g/mL, and the glycan staining was performed in comparison with lectins Phaseolus vulgaris-L lectin (PHA-L) and Sambucus nigra I agglutinin (SNA-I).", [["Phaseolus vulgaris", "ORGANISM", 123, 141], ["-L lectin", "GENE_OR_GENE_PRODUCT", 141, 150], ["PHA-L", "GENE_OR_GENE_PRODUCT", 152, 157], ["Sambucus nigra I agglutinin", "ORGANISM", 163, 190], ["SNA-I", "GENE_OR_GENE_PRODUCT", 192, 197], ["lectins", "PROTEIN", 115, 122], ["Phaseolus vulgaris-L lectin", "PROTEIN", 123, 150], ["PHA", "PROTEIN", 152, 155], ["L", "PROTEIN", 156, 157], ["Sambucus nigra I agglutinin", "PROTEIN", 163, 190], ["SNA", "PROTEIN", 192, 195], ["Phaseolus vulgaris", "SPECIES", 123, 141], ["Sambucus nigra", "SPECIES", 163, 177], ["Phaseolus vulgaris", "SPECIES", 123, 141], ["Sambucus nigra", "SPECIES", 163, 177], ["These proteins", "TEST", 0, 14], ["ELISA plates", "TREATMENT", 31, 43], ["the glycan staining", "TEST", 62, 81], ["lectins", "TEST", 115, 122], ["Phaseolus vulgaris", "TEST", 123, 141], ["L lectin", "TEST", 142, 150], ["PHA", "TEST", 152, 155], ["Phaseolus vulgaris", "ANATOMY", 123, 141], ["Sambucus nigra", "ANATOMY", 163, 177]]], ["With GNA and 2G12 targeting oligomannosyl epitopes, PHA-L for Tri/m-II cryptic epitopes, and SNA-I recognizing \u03b12-6-linked Neu5Ac residues, this panel of probes monitors expression of layers of cryptic glyco-epitopes as schematically shown in Figure 2A .Detection of GNA-or 2G12-Epitopes in the Native Viral Antigen PreparationsThis assay demonstrated that both Bal-gp120-Man9 ( Figure 1A ) and Bal-gp120 ( Figure 1B ) were strongly positive with GNA and 2G12.", [["Neu5Ac", "CHEMICAL", 123, 129], ["2G12", "GENE_OR_GENE_PRODUCT", 13, 17], ["PHA-L", "GENE_OR_GENE_PRODUCT", 52, 57], ["SNA-I", "GENE_OR_GENE_PRODUCT", 93, 98], ["\u03b12-6", "GENE_OR_GENE_PRODUCT", 111, 115], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 123, 129], ["GNA", "GENE_OR_GENE_PRODUCT", 267, 270], ["Bal-gp120-Man9", "GENE_OR_GENE_PRODUCT", 362, 376], ["Figure 1A", "GENE_OR_GENE_PRODUCT", 379, 388], ["Bal-gp120", "GENE_OR_GENE_PRODUCT", 395, 404], ["Figure 1B", "GENE_OR_GENE_PRODUCT", 407, 416], ["GNA", "PROTEIN", 5, 8], ["2G12", "PROTEIN", 13, 17], ["oligomannosyl epitopes", "PROTEIN", 28, 50], ["PHA-L for Tri/m-II cryptic epitopes", "PROTEIN", 52, 87], ["SNA", "PROTEIN", 93, 96], ["\u03b12", "PROTEIN", 111, 113], ["cryptic glyco-epitopes", "PROTEIN", 194, 216], ["GNA", "PROTEIN", 267, 270], ["2G12", "PROTEIN", 274, 278], ["Bal-gp120", "PROTEIN", 362, 371], ["Man9", "PROTEIN", 372, 376], ["gp120", "PROTEIN", 399, 404], ["GNA", "PROTEIN", 447, 450], ["2G12", "PROTEIN", 455, 459], ["Bal-gp120", "SPECIES", 395, 404], ["GNA", "PROBLEM", 5, 8], ["2G12 targeting oligomannosyl epitopes", "PROBLEM", 13, 50], ["PHA", "TEST", 52, 55], ["Tri/m-II cryptic epitopes", "PROBLEM", 62, 87], ["SNA", "TEST", 93, 96], ["\u03b12", "TEST", 111, 113], ["linked Neu5Ac residues", "PROBLEM", 116, 138], ["this panel", "TEST", 140, 150], ["cryptic glyco-epitopes", "PROBLEM", 194, 216], ["GNA", "TEST", 267, 270], ["2G12", "TEST", 274, 278], ["This assay", "TEST", 328, 338], ["Bal-gp120", "TEST", 362, 371], ["Bal", "TEST", 395, 398], ["Figure 1B", "TEST", 407, 416], ["GNA", "TEST", 447, 450], ["SNA", "ANATOMY", 93, 96], ["cryptic glyco-epitopes", "OBSERVATION", 194, 216]]], ["PHA-L was selectively reactive with Bal-gp120 but not with Bal-gp120-Man9.", [["PHA", "CHEMICAL", 0, 3], ["Bal-gp120-Man9", "CHEMICAL", 59, 73], ["PHA-L", "GENE_OR_GENE_PRODUCT", 0, 5], ["Bal-gp120", "GENE_OR_GENE_PRODUCT", 36, 45], ["Bal-gp120-Man9", "SIMPLE_CHEMICAL", 59, 73], ["PHA", "PROTEIN", 0, 3], ["gp120", "PROTEIN", 40, 45], ["Bal-gp120", "PROTEIN", 59, 68], ["Man9", "PROTEIN", 69, 73], ["PHA", "TEST", 0, 3], ["Bal", "TEST", 36, 39], ["L", "ANATOMY_MODIFIER", 4, 5], ["reactive", "OBSERVATION_MODIFIER", 22, 30]]], ["This PHA-L-differential staining pattern reflects the effective blockage of biosynthesis of Tri/m-II complex moieties during Bal-gp120-Man9 production as we initially planned.", [["Tri/m-II", "CHEMICAL", 92, 100], ["Bal-gp120-Man9", "CHEMICAL", 125, 139], ["Bal-gp120-Man9", "CHEMICAL", 125, 139], ["PHA", "SIMPLE_CHEMICAL", 5, 8], ["Tri/m-II", "GENE_OR_GENE_PRODUCT", 92, 100], ["Bal-gp120-Man9", "SIMPLE_CHEMICAL", 125, 139], ["PHA", "PROTEIN", 5, 8], ["Tri/m-II complex moieties", "PROTEIN", 92, 117], ["This PHA", "TEST", 0, 8], ["differential staining pattern", "PROBLEM", 11, 40], ["biosynthesis of Tri/m-II complex moieties", "PROBLEM", 76, 117], ["effective", "OBSERVATION_MODIFIER", 54, 63], ["blockage", "OBSERVATION", 64, 72]]], ["SNA-1 was negative to both glycoproteins under the same staining condition.", [["SNA-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["SNA", "PROTEIN", 0, 3], ["glycoproteins", "PROTEIN", 27, 40], ["SNA", "TEST", 0, 3]]], ["ELISA results were presented without background subtraction in A-C or with background subtraction in D and E. Lectins were applied at the concentrations (\u00b5g/mL) as specified.", [["A-C", "SIMPLE_CHEMICAL", 63, 66], ["D", "SIMPLE_CHEMICAL", 101, 102], ["ELISA results", "TEST", 0, 13], ["background subtraction", "TEST", 37, 59], ["background subtraction in D and E. Lectins", "TREATMENT", 75, 117]]], ["The ELISA data shown here are representative results of multiple assays.Detection of GNA-or 2G12-Epitopes in the Native Viral Antigen PreparationsWe further examined whether SARS-CoV expresses the native GNA-epitopes and PHA-L-epitopes.", [["PHA", "CHEMICAL", 221, 224], ["GNA", "GENE_OR_GENE_PRODUCT", 85, 88], ["SARS-CoV", "ORGANISM", 174, 182], ["PHA-L-epitopes", "SIMPLE_CHEMICAL", 221, 235], ["GNA", "PROTEIN", 85, 88], ["2G12", "PROTEIN", 92, 96], ["native GNA-epitopes", "PROTEIN", 197, 216], ["PHA", "PROTEIN", 221, 224], ["L-epitopes", "PROTEIN", 225, 235], ["SARS-CoV", "SPECIES", 174, 182], ["The ELISA data", "TEST", 0, 14], ["multiple assays", "TEST", 56, 71], ["GNA", "TEST", 85, 88], ["2G12", "TEST", 92, 96], ["Epitopes", "PROBLEM", 97, 105], ["SARS", "PROBLEM", 174, 178], ["CoV", "PROBLEM", 179, 182], ["the native GNA", "PROBLEM", 193, 207], ["epitopes", "PROBLEM", 208, 216], ["PHA", "TEST", 221, 224], ["L-epitopes", "PROBLEM", 225, 235]]], ["In Figure 1C , the ELISA plates were coated with the native SARS-CoV antigens that were expressed by Vero E6 cells.", [["Vero E6 cells", "ANATOMY", 101, 114], ["SARS-CoV antigens", "GENE_OR_GENE_PRODUCT", 60, 77], ["Vero E6 cells", "CELL", 101, 114], ["native SARS-CoV antigens", "PROTEIN", 53, 77], ["Vero E6 cells", "CELL_LINE", 101, 114], ["SARS-CoV", "SPECIES", 60, 68], ["Vero E6", "SPECIES", 101, 108], ["the ELISA plates", "TEST", 15, 31], ["the native SARS-CoV antigens", "PROBLEM", 49, 77], ["Vero E6 cells", "OBSERVATION", 101, 114]]], ["These plates were treated with a disinfecting fixing agent and gamma-irradiated to inactivate infectious virus particles while preserving antigenic structures of SARS-CoV.", [["SARS", "DISEASE", 162, 166], ["SARS-CoV", "ORGANISM", 162, 170], ["SARS-CoV", "SPECIES", 162, 170], ["a disinfecting fixing agent", "TREATMENT", 31, 58], ["gamma-irradiated", "TREATMENT", 63, 79], ["infectious virus particles", "PROBLEM", 94, 120], ["CoV", "PROBLEM", 167, 170]]], ["Lectins were applied at the concentrations specified in the figures.Detection of GNA-or 2G12-Epitopes in the Native Viral Antigen PreparationsThis assay demonstrates that the PHA-L-epitopes were readily detected in the SARS-CoV-coated ELISA plates as we previously observed [14] .", [["PHA", "CHEMICAL", 175, 178], ["GNA", "GENE_OR_GENE_PRODUCT", 81, 84], ["PHA", "SIMPLE_CHEMICAL", 175, 178], ["GNA", "PROTEIN", 81, 84], ["2G12", "PROTEIN", 88, 92], ["PHA-L-epitopes", "PROTEIN", 175, 189], ["SARS-CoV", "SPECIES", 219, 227], ["Lectins", "TREATMENT", 0, 7], ["GNA", "TEST", 81, 84], ["2G12-Epitopes", "TREATMENT", 88, 101], ["the Native Viral Antigen Preparations", "TREATMENT", 105, 142], ["This assay", "TEST", 142, 152], ["the PHA", "TEST", 171, 178], ["the SARS", "TEST", 215, 223], ["CoV-coated ELISA plates", "TREATMENT", 224, 247]]], ["Moreover, it shows that GNA is strongly positive with SARS-CoV.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 54, 62], ["GNA", "PROTEIN", 24, 27], ["SARS-CoV", "SPECIES", 54, 62], ["GNA", "TEST", 24, 27], ["SARS", "PROBLEM", 54, 58]]], ["By contrast, other Gal/GalNAc-reactive lectins, including Helix pomatia (HPA) and Griffonia (Bandeiraea) simplicifolia-I (GS-I), were only marginally reactive with SARS-CoV antigens.", [["GalNAc", "CHEMICAL", 23, 29], ["Gal", "GENE_OR_GENE_PRODUCT", 19, 22], ["GalNAc", "GENE_OR_GENE_PRODUCT", 23, 29], ["Helix pomatia", "ORGANISM", 58, 71], ["Griffonia (Bandeiraea) simplicifolia-I", "GENE_OR_GENE_PRODUCT", 82, 120], ["GS-I", "GENE_OR_GENE_PRODUCT", 122, 126], ["SARS-CoV antigens", "GENE_OR_GENE_PRODUCT", 164, 181], ["Gal/GalNAc-reactive lectins", "PROTEIN", 19, 46], ["SARS-CoV antigens", "PROTEIN", 164, 181], ["Helix pomatia", "SPECIES", 58, 71], ["Griffonia", "SPECIES", 82, 91], ["Bandeiraea) simplicifolia", "SPECIES", 93, 118], ["Helix pomatia", "SPECIES", 58, 71], ["SARS-CoV", "SPECIES", 164, 172], ["other Gal/GalNAc", "TEST", 13, 29], ["reactive lectins", "PROBLEM", 30, 46], ["Helix pomatia", "TEST", 58, 71], ["Griffonia (Bandeiraea) simplicifolia", "TEST", 82, 118], ["marginally reactive", "PROBLEM", 139, 158], ["SARS", "PROBLEM", 164, 168], ["GalNAc", "ANATOMY_MODIFIER", 23, 29], ["reactive lectins", "OBSERVATION", 30, 46], ["Helix pomatia", "ANATOMY", 58, 71]]], ["HPA is specific for GalNAc-and O-GlcNAc-moieties [28] ; GS-I recognizes the \u03b1-Gal-epitope [29, 30] .", [["GalNAc", "CHEMICAL", 20, 26], ["O-GlcNAc", "CHEMICAL", 31, 39], ["GalNAc", "GENE_OR_GENE_PRODUCT", 20, 26], ["O-GlcNAc-moieties [28]", "SIMPLE_CHEMICAL", 31, 53], ["GS-I", "SIMPLE_CHEMICAL", 56, 60], ["\u03b1-Gal-epitope", "SIMPLE_CHEMICAL", 76, 89], ["GalNAc", "TEST", 20, 26], ["GS", "TEST", 56, 58]]], ["The latter is conserved in many microorganisms but is negligible in SARS-CoV as expected.Detection of GNA-or 2G12-Epitopes in the Native Viral Antigen PreparationsIn Figure 1D , we examined whether HCMV expresses oligomannosyl epitopes using GNA and concanavalin A (Con A) in comparison with other lectins of different specificities.", [["concanavalin A", "CHEMICAL", 250, 264], ["Con A", "CHEMICAL", 266, 271], ["SARS-CoV", "ORGANISM", 68, 76], ["GNA", "GENE_OR_GENE_PRODUCT", 102, 105], ["HCMV", "ORGANISM", 198, 202], ["GNA", "SIMPLE_CHEMICAL", 242, 245], ["concanavalin A", "SIMPLE_CHEMICAL", 250, 264], ["Con A", "SIMPLE_CHEMICAL", 266, 271], ["GNA", "PROTEIN", 102, 105], ["2G12", "PROTEIN", 109, 113], ["oligomannosyl epitopes", "PROTEIN", 213, 235], ["GNA", "PROTEIN", 242, 245], ["SARS-CoV", "SPECIES", 68, 76], ["HCMV", "SPECIES", 198, 202], ["SARS", "PROBLEM", 68, 72], ["GNA", "TEST", 102, 105], ["2G12", "TEST", 109, 113], ["Epitopes", "PROBLEM", 114, 122], ["HCMV", "PROBLEM", 198, 202], ["many", "OBSERVATION_MODIFIER", 27, 31], ["microorganisms", "OBSERVATION", 32, 46], ["negligible", "OBSERVATION_MODIFIER", 54, 64], ["SARS", "OBSERVATION", 68, 72], ["CoV", "OBSERVATION_MODIFIER", 73, 76]]], ["In this experiment, ELISA was coated with purified virus (AD169, Creative Diagnostics, New York, NY, USA) at protein concentration approximately 1.0 \u00b5g/mL for lectin-screening.", [["lectin", "GENE_OR_GENE_PRODUCT", 159, 165], ["lectin", "PROTEIN", 159, 165], ["protein concentration", "TREATMENT", 109, 130], ["lectin-screening", "TEST", 159, 175]]], ["The two anti-mannose agents differ in epitope-binding specificities.", [["anti-mannose", "CHEMICAL", 8, 20], ["anti-mannose agents", "SIMPLE_CHEMICAL", 8, 27], ["The two anti-mannose agents", "TREATMENT", 0, 27]]], ["GNA is specific for the Man\u03b11,3Man and Man\u03b11,6Man moieties of oligomannoses; Con A recognizes terminal Man\u03b11\u2192moieties that are more broadly expressed by mannose-containing antigens.", [["mannose", "CHEMICAL", 153, 160], ["GNA", "GENE_OR_GENE_PRODUCT", 0, 3], ["Man\u03b11", "GENE_OR_GENE_PRODUCT", 24, 29], ["3", "GENE_OR_GENE_PRODUCT", 30, 31], ["Man", "GENE_OR_GENE_PRODUCT", 31, 34], ["Man\u03b11", "GENE_OR_GENE_PRODUCT", 39, 44], ["oligomannoses", "SIMPLE_CHEMICAL", 62, 75], ["Con A", "SIMPLE_CHEMICAL", 77, 82], ["Man\u03b11", "GENE_OR_GENE_PRODUCT", 103, 108], ["mannose-containing antigens", "GENE_OR_GENE_PRODUCT", 153, 180], ["Man\u03b11,3Man and Man\u03b11,6Man moieties", "PROTEIN", 24, 58], ["oligomannoses", "PROTEIN", 62, 75], ["Con A", "PROTEIN", 77, 82], ["terminal Man\u03b11\u2192moieties", "PROTEIN", 94, 117], ["mannose-containing antigens", "PROTEIN", 153, 180]]], ["Figure 1E illustrates lectin-binding of a synthetic glycoconjugate, Man9-KLH, which bears both GNA-and Con-A-glyco-epitopes [31] .", [["lectin", "GENE_OR_GENE_PRODUCT", 22, 28], ["Man9-KLH", "GENE_OR_GENE_PRODUCT", 68, 76], ["GNA", "GENE_OR_GENE_PRODUCT", 95, 98], ["lectin", "PROTEIN", 22, 28], ["Man9", "PROTEIN", 68, 72], ["KLH", "PROTEIN", 73, 76], ["GNA", "PROTEIN", 95, 98], ["epitopes", "PROTEIN", 115, 123], ["lectin", "TEST", 22, 28], ["a synthetic glycoconjugate", "TREATMENT", 40, 66], ["GNA", "TEST", 95, 98]]], ["Inspection of Figure 1D readily reveals that the relative binding activity of GNA is markedly higher than the Con-A activity in the HCMV-ELISA assay although the two mannose-specific lectins are similarly reactive with the Man9-KLH standard in the assay.", [["mannose", "CHEMICAL", 166, 173], ["GNA", "SIMPLE_CHEMICAL", 78, 81], ["Con-A", "SIMPLE_CHEMICAL", 110, 115], ["HCMV", "ORGANISM", 132, 136], ["mannose", "SIMPLE_CHEMICAL", 166, 173], ["Con-A", "PROTEIN", 110, 115], ["Man9", "PROTEIN", 223, 227], ["HCMV", "SPECIES", 132, 136], ["the relative binding activity of GNA", "PROBLEM", 45, 81], ["the HCMV", "TEST", 128, 136], ["ELISA assay", "TEST", 137, 148], ["binding activity", "OBSERVATION", 58, 74], ["markedly", "OBSERVATION_MODIFIER", 85, 93], ["higher", "OBSERVATION_MODIFIER", 94, 100], ["HCMV", "OBSERVATION", 132, 136], ["reactive", "OBSERVATION_MODIFIER", 205, 213]]], ["Other lectins of different glycan-binding specificities show certain reactivities with HCMV lysates, which may reflect the glycome complexity of this most intricate human virus [32, 33] , which requires further study.", [["lysates", "ANATOMY", 92, 99], ["HCMV", "ORGANISM", 87, 91], ["human", "ORGANISM", 165, 170], ["human", "SPECIES", 165, 170], ["HCMV", "SPECIES", 87, 91], ["human virus", "SPECIES", 165, 176], ["different glycan-binding specificities", "TEST", 17, 55], ["certain reactivities", "PROBLEM", 61, 81], ["HCMV lysates", "PROBLEM", 87, 99], ["further study", "TEST", 203, 216], ["HCMV lysates", "OBSERVATION", 87, 99], ["may reflect", "UNCERTAINTY", 107, 118]]], ["In summary, we verified expression of the native GNA-epitopes by three phylogenetically distinct viruses, HIV-1, SARS-CoV, and HCMV.", [["HIV-1", "ORGANISM", 106, 111], ["SARS-CoV", "ORGANISM", 113, 121], ["HCMV", "ORGANISM", 127, 131], ["GNA", "PROTEIN", 49, 52], ["epitopes", "PROTEIN", 53, 61], ["HIV-1", "SPECIES", 106, 111], ["HIV-1", "SPECIES", 106, 111], ["SARS-CoV", "SPECIES", 113, 121], ["HCMV", "SPECIES", 127, 131], ["the native GNA", "PROBLEM", 38, 52], ["three phylogenetically distinct viruses", "PROBLEM", 65, 104], ["HIV", "TEST", 106, 109], ["SARS", "PROBLEM", 113, 117], ["HCMV", "PROBLEM", 127, 131], ["viruses", "OBSERVATION", 97, 104], ["HCMV", "OBSERVATION", 127, 131]]], ["In the context of a panel of lectins of different specificities, GNA was identified to have the highest relative binding activities with SARS-CoV and HCMV.Carbohydrate Microarrays to Explore the Potential Glyco-Epitopes of GNAThe ability of GNA to bind and neutralize viruses of distinct phylogenetic origins unavoidably raises questions about its glycan-binding specificity and potential cross-reactivity.", [["Carbohydrate", "CHEMICAL", 155, 167], ["GNA", "GENE_OR_GENE_PRODUCT", 65, 68], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 137, 145], ["HCMV", "ORGANISM", 150, 154], ["GNAThe", "GENE_OR_GENE_PRODUCT", 223, 229], ["GNA", "GENE_OR_GENE_PRODUCT", 241, 244], ["lectins", "PROTEIN", 29, 36], ["GNA", "PROTEIN", 65, 68], ["GNA", "PROTEIN", 241, 244], ["SARS-CoV", "SPECIES", 137, 145], ["HCMV", "SPECIES", 150, 154], ["different specificities", "PROBLEM", 40, 63], ["GNA", "PROBLEM", 65, 68], ["SARS", "PROBLEM", 137, 141], ["HCMV", "PROBLEM", 150, 154], ["Carbohydrate Microarrays", "TREATMENT", 155, 179], ["GNA to bind", "PROBLEM", 241, 252]]], ["One plausible explanation is that these targeted viruses commonly express the defined GNA-epitopes of Man\u03b11,3Man and Man\u03b11,6Man moieties.", [["Man\u03b11", "GENE_OR_GENE_PRODUCT", 102, 107], ["Man", "GENE_OR_GENE_PRODUCT", 109, 112], ["GNA-epitopes", "PROTEIN", 86, 98], ["Man\u03b11", "PROTEIN", 102, 107], ["Man", "PROTEIN", 109, 112], ["Man\u03b11,6Man moieties", "PROTEIN", 117, 136]]], ["However, the selective GNA-positive staining of HCMV without parallel Con A reactivity ( Figure 1D ) suggests an alternative possibility, i.e., presence of other carbohydrate moieties that are negative or weakly reactive with Con A but strongly reactive with GNA.", [["carbohydrate", "CHEMICAL", 162, 174], ["GNA", "GENE_OR_GENE_PRODUCT", 23, 26], ["HCMV", "ORGANISM", 48, 52], ["Con A", "SIMPLE_CHEMICAL", 70, 75], ["Con A", "SIMPLE_CHEMICAL", 226, 231], ["Con A", "PROTEIN", 226, 231], ["GNA", "PROTEIN", 259, 262], ["HCMV", "SPECIES", 48, 52], ["the selective GNA", "TEST", 9, 26], ["positive staining of HCMV", "PROBLEM", 27, 52], ["other carbohydrate moieties", "TEST", 156, 183], ["weakly reactive", "PROBLEM", 205, 220], ["GNA", "PROBLEM", 259, 262], ["selective", "OBSERVATION_MODIFIER", 13, 22], ["positive staining", "OBSERVATION", 27, 44], ["HCMV", "OBSERVATION", 48, 52], ["without", "UNCERTAINTY", 53, 60], ["alternative possibility", "UNCERTAINTY", 113, 136], ["reactive", "OBSERVATION_MODIFIER", 212, 220], ["reactive", "OBSERVATION_MODIFIER", 245, 253]]], ["A carbohydrate antigen with such differential reactivity between GNA and Con A is a yeast-derived phosphomannan polysaccharide (P-Man), which is nevertheless not present in the viral glycome [31, 34] .Carbohydrate Microarrays to Explore the Potential Glyco-Epitopes of GNATo support exploration of the potential GNA glyco-epitopes in this study, we produced a set of comprehensive antigen microarrays, which include a large-panel of carbohydrates, lipids/liposomes, and protein antigens (Supplementary Table S1 ).", [["carbohydrate", "CHEMICAL", 2, 14], ["Carbohydrate", "CHEMICAL", 201, 213], ["carbohydrates", "CHEMICAL", 433, 446], ["carbohydrate antigen", "GENE_OR_GENE_PRODUCT", 2, 22], ["GNA", "GENE_OR_GENE_PRODUCT", 65, 68], ["Con A", "SIMPLE_CHEMICAL", 73, 78], ["phosphomannan polysaccharide", "SIMPLE_CHEMICAL", 98, 126], ["P-Man", "SIMPLE_CHEMICAL", 128, 133], ["GNATo", "GENE_OR_GENE_PRODUCT", 269, 274], ["carbohydrates", "SIMPLE_CHEMICAL", 433, 446], ["lipids", "SIMPLE_CHEMICAL", 448, 454], ["liposomes", "SIMPLE_CHEMICAL", 455, 464], ["carbohydrate antigen", "PROTEIN", 2, 22], ["GNA", "PROTEIN", 65, 68], ["Man", "PROTEIN", 130, 133], ["GNATo", "PROTEIN", 269, 274], ["protein antigens", "PROTEIN", 470, 486], ["S1", "PROTEIN", 508, 510], ["yeast", "SPECIES", 84, 89], ["yeast", "SPECIES", 84, 89], ["A carbohydrate antigen", "TEST", 0, 22], ["GNA", "TEST", 65, 68], ["a yeast", "TEST", 82, 89], ["derived phosphomannan polysaccharide", "TEST", 90, 126], ["the viral glycome", "TEST", 173, 190], ["Carbohydrate Microarrays", "TREATMENT", 201, 225], ["GNATo support exploration", "TREATMENT", 269, 294], ["the potential GNA glyco-epitopes", "PROBLEM", 298, 330], ["this study", "TEST", 334, 344], ["comprehensive antigen microarrays", "TEST", 367, 400], ["carbohydrates", "TEST", 433, 446], ["lipids/liposomes", "TREATMENT", 448, 464]]], ["Key compounds supporting glyco-epitope analysis include the following:Carbohydrate Microarrays to Explore the Potential Glyco-Epitopes of GNA(1) Orosomucoid (OR) (Neu5Ac), ASOR (Tri/m-II), and Agalacto-OR (AGOR) (Tri/m-Gn) (Figure 2A ).", [["Carbohydrate", "CHEMICAL", 70, 82], ["Neu5Ac", "CHEMICAL", 163, 169], ["GNA(1) Orosomucoid", "SIMPLE_CHEMICAL", 138, 156], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 163, 169], ["Tri/m-II", "GENE_OR_GENE_PRODUCT", 178, 186], ["Agalacto-OR", "GENE_OR_GENE_PRODUCT", 193, 204], ["AGOR", "GENE_OR_GENE_PRODUCT", 206, 210], ["OR", "PROTEIN", 158, 160], ["Neu5Ac", "PROTEIN", 163, 169], ["ASOR", "PROTEIN", 172, 176], ["Tri", "PROTEIN", 178, 181], ["II", "PROTEIN", 184, 186], ["Agalacto", "PROTEIN", 193, 201], ["OR", "PROTEIN", 202, 204], ["AGOR", "PROTEIN", 206, 210], ["Tri", "PROTEIN", 213, 216], ["Gn", "PROTEIN", 219, 221], ["Figure 2A", "PROTEIN", 224, 233], ["Carbohydrate Microarrays", "TREATMENT", 70, 94], ["GNA", "PROBLEM", 138, 141], ["Orosomucoid", "TEST", 145, 156], ["ASOR (Tri/m-II)", "TREATMENT", 172, 187], ["Agalacto", "TREATMENT", 193, 201]]], ["These autoantigens display distinct glyco-epitopes with identical protein carriers.", [["autoantigens", "PROTEIN", 6, 18], ["distinct glyco-epitopes", "PROBLEM", 27, 50], ["identical protein carriers", "PROBLEM", 56, 82], ["distinct", "OBSERVATION_MODIFIER", 27, 35], ["glyco-epitopes", "OBSERVATION", 36, 50], ["protein carriers", "OBSERVATION", 66, 82]]], ["ASOR is an asialo-derivative of OR, and AGOR is an agalacto-derivative of ASOR.", [["agalacto", "CHEMICAL", 51, 59], ["AGOR", "SIMPLE_CHEMICAL", 40, 44], ["agalacto", "SIMPLE_CHEMICAL", 51, 59], ["ASOR", "SIMPLE_CHEMICAL", 74, 78], ["ASOR", "PROTEIN", 74, 78]]], ["They are crucial for defining binding-specificities for N-glycan cryptic epitopes, Tri/m-II, and Tri/m-Gn.", [["Tri/m-II", "GENE_OR_GENE_PRODUCT", 83, 91], ["N-glycan cryptic epitopes", "PROTEIN", 56, 81], ["Tri", "PROTEIN", 83, 86], ["II", "PROTEIN", 89, 91], ["Tri", "PROTEIN", 97, 100], ["m", "PROTEIN", 101, 102], ["Gn", "PROTEIN", 103, 105], ["specificities", "TEST", 38, 51], ["N", "TEST", 56, 57], ["glycan cryptic epitopes", "TEST", 58, 81], ["Gn", "OBSERVATION", 103, 105]]], ["(4) Phosphomannan (P-Man), a yeast polysaccharide.", [["Phosphomannan", "CHEMICAL", 4, 17], ["P-Man", "CHEMICAL", 19, 24], ["Phosphomannan", "CHEMICAL", 4, 17], ["P-Man", "CHEMICAL", 19, 24], ["(4) Phosphomannan", "SIMPLE_CHEMICAL", 0, 17], ["P-Man", "SIMPLE_CHEMICAL", 19, 24], ["yeast", "SPECIES", 29, 34], ["yeast", "SPECIES", 29, 34], ["Phosphomannan", "TEST", 4, 17], ["a yeast polysaccharide", "TREATMENT", 27, 49], ["yeast polysaccharide", "OBSERVATION", 29, 49]]], ["Both M5-6-RB and P-Man are known to be positive with GNA; the former but not the latter also binds to Con A. Using these microarrays, we characterized GNA, PHA-L, and 2G12 for their epitope-binding profiles.", [["P-Man", "GENE_OR_GENE_PRODUCT", 17, 22], ["GNA", "GENE_OR_GENE_PRODUCT", 53, 56], ["GNA", "GENE_OR_GENE_PRODUCT", 151, 154], ["PHA-L", "GENE_OR_GENE_PRODUCT", 156, 161], ["2G12", "GENE_OR_GENE_PRODUCT", 167, 171], ["M5", "PROTEIN", 5, 7], ["RB", "PROTEIN", 10, 12], ["P", "PROTEIN", 17, 18], ["Man", "PROTEIN", 19, 22], ["GNA", "PROTEIN", 53, 56], ["GNA", "PROTEIN", 151, 154], ["PHA", "PROTEIN", 156, 159], ["L", "PROTEIN", 160, 161], ["2G12", "PROTEIN", 167, 171], ["M5", "TEST", 5, 7], ["GNA", "PROBLEM", 53, 56], ["these microarrays", "TEST", 115, 132], ["GNA", "TEST", 151, 154], ["PHA", "TEST", 156, 159], ["2G12", "TREATMENT", 167, 171], ["positive", "OBSERVATION", 39, 47]]], ["Figure 2A is a schematic view of structural relationship among autoantigens, OR, ASOR, and AGOR and the glyco-epitopes they display.", [["OR", "GENE_OR_GENE_PRODUCT", 77, 79], ["ASOR", "GENE_OR_GENE_PRODUCT", 81, 85], ["AGOR", "GENE_OR_GENE_PRODUCT", 91, 95], ["autoantigens", "PROTEIN", 63, 75], ["OR", "PROTEIN", 77, 79], ["ASOR", "PROTEIN", 81, 85], ["AGOR", "PROTEIN", 91, 95], ["glyco-epitopes", "PROTEIN", 104, 118]]], ["Figure 2B shows microarray images of PHA-L, GNA, or 2G12 staining against a panel of autoantigens, including OR, ASOR, AGOR, Man9, (M9)4, which stands for [(Man9GlcNAc2Asn)4]n-KLH (M9_2G12) conjugates, and M5-6-RB.", [["PHA-L", "SIMPLE_CHEMICAL", 37, 42], ["GNA", "SIMPLE_CHEMICAL", 44, 47], ["ASOR", "GENE_OR_GENE_PRODUCT", 113, 117], ["AGOR", "GENE_OR_GENE_PRODUCT", 119, 123], ["Man9", "GENE_OR_GENE_PRODUCT", 125, 129], ["Man9GlcNAc2Asn)4]n-KLH", "SIMPLE_CHEMICAL", 157, 179], ["PHA", "PROTEIN", 37, 40], ["GNA", "PROTEIN", 44, 47], ["2G12", "PROTEIN", 52, 56], ["autoantigens", "PROTEIN", 85, 97], ["OR", "PROTEIN", 109, 111], ["ASOR", "PROTEIN", 113, 117], ["AGOR", "PROTEIN", 119, 123], ["Man9", "PROTEIN", 125, 129], ["KLH", "PROTEIN", 176, 179], ["M9_2G12", "PROTEIN", 181, 188], ["M5", "PROTEIN", 206, 208], ["RB", "PROTEIN", 211, 213], ["Figure 2B", "TEST", 0, 9], ["microarray images", "TEST", 16, 33], ["PHA", "TEST", 37, 40], ["GNA", "PROBLEM", 44, 47], ["2G12 staining", "TEST", 52, 65], ["a panel", "TEST", 74, 81], ["autoantigens", "PROBLEM", 85, 97], ["conjugates", "TEST", 190, 200], ["M5", "TEST", 206, 208]]], ["The two control probes spotted are KLH and E. coli K1 polysaccharide.", [["KLH", "GENE_OR_GENE_PRODUCT", 35, 38], ["E. coli", "ORGANISM", 43, 50], ["K1 polysaccharide", "GENE_OR_GENE_PRODUCT", 51, 68], ["E. coli", "SPECIES", 43, 50], ["E. coli", "SPECIES", 43, 50], ["KLH", "PROBLEM", 35, 38], ["E. coli K1 polysaccharide", "PROBLEM", 43, 68], ["coli K1", "OBSERVATION", 46, 53]]], ["Microarray datasets corresponding to Figure 2B are shown in Figure 2C .", [["Microarray datasets", "TEST", 0, 19]]], ["Microarray detections are shown as the mean fluorescent intensities (MFIs) of triplicate microspots for the arrays stained with PHA-L, GNA, and 2G12, respectively.", [["PHA-L", "SIMPLE_CHEMICAL", 128, 133], ["GNA", "SIMPLE_CHEMICAL", 135, 138], ["2G12", "GENE_OR_GENE_PRODUCT", 144, 148], ["PHA", "PROTEIN", 128, 131], ["L", "PROTEIN", 132, 133], ["GNA", "PROTEIN", 135, 138], ["2G12", "PROTEIN", 144, 148], ["Microarray detections", "TEST", 0, 21], ["the arrays", "TEST", 104, 114], ["PHA", "TEST", 128, 131], ["GNA", "TEST", 135, 138]]], ["Results were compared using overlay plots of the MFIs of staining signal (blue bars) versus those of local backgrounds surrounding the antigen microarrays (red bars).", [["antigen", "GENE_OR_GENE_PRODUCT", 135, 142], ["overlay plots", "TEST", 28, 41], ["staining signal", "TEST", 57, 72]]], ["Figure 2B ,E show that PHA-L and 2G12 are specific for ASOR (Tri/m-II) and (M9)4, respectively, which is expected.", [["PHA", "CHEMICAL", 23, 26], ["PHA-L", "GENE_OR_GENE_PRODUCT", 23, 28], ["2G12", "GENE_OR_GENE_PRODUCT", 33, 37], ["PHA", "PROTEIN", 23, 26], ["L", "PROTEIN", 27, 28], ["2G12", "PROTEIN", 33, 37], ["ASOR", "PROTEIN", 55, 59], ["PHA", "TEST", 23, 26], ["ASOR", "TEST", 55, 59]]], ["However, GNA highly and selectively binds to a number of N-glycan cryptic sugar moieties, including Man9, (M9)4, M5-6, and AGOR.", [["sugar", "CHEMICAL", 74, 79], ["sugar moieties", "SIMPLE_CHEMICAL", 74, 88], ["Man9", "SIMPLE_CHEMICAL", 100, 104], ["M5-6", "GENE_OR_GENE_PRODUCT", 113, 117], ["AGOR", "GENE_OR_GENE_PRODUCT", 123, 127], ["GNA", "PROTEIN", 9, 12], ["M5", "PROTEIN", 113, 115], ["AGOR", "PROTEIN", 123, 127], ["GNA", "PROBLEM", 9, 12], ["sugar moieties", "OBSERVATION", 74, 88]]], ["GNA-binding of AGOR is a novel observation.", [["GNA", "SIMPLE_CHEMICAL", 0, 3], ["AGOR", "GENE_OR_GENE_PRODUCT", 15, 19], ["AGOR", "PROTEIN", 15, 19]]], ["Given that GNA had no binding to ASOR (Tri/m-II), which only differs from AGOR (Tri/m-Gn) by having the terminal galactoses.", [["GNA", "SIMPLE_CHEMICAL", 11, 14], ["ASOR", "GENE_OR_GENE_PRODUCT", 33, 37], ["Tri/m-II", "GENE_OR_GENE_PRODUCT", 39, 47], ["GNA", "PROTEIN", 11, 14], ["ASOR", "PROTEIN", 33, 37], ["Tri", "PROTEIN", 39, 42], ["AGOR", "PROTEIN", 74, 78], ["Tri", "PROTEIN", 80, 83], ["Gn", "PROTEIN", 86, 88], ["terminal galactoses", "PROTEIN", 104, 123], ["GNA", "PROBLEM", 11, 14], ["the terminal galactoses", "PROBLEM", 100, 123], ["terminal", "ANATOMY_MODIFIER", 104, 112], ["galactoses", "ANATOMY", 113, 123]]], ["This result demonstrates, therefore, that GNA is most likely specific for the Tri/m-Gn-glyco-epitopes of AGOR with exposed terminal GlcNAc moieties.Carbohydrate Microarrays to Explore the Potential Glyco-Epitopes of GNAIn Figure 3 below, we illustrate the global antigen-binding profiles of GNA and 2G12 against the full panel of antigen preparations.", [["GlcNAc", "CHEMICAL", 132, 138], ["Carbohydrate", "CHEMICAL", 148, 160], ["GNA", "GENE_OR_GENE_PRODUCT", 42, 45], ["AGOR", "SIMPLE_CHEMICAL", 105, 109], ["GlcNAc moieties", "SIMPLE_CHEMICAL", 132, 147], ["GNA", "SIMPLE_CHEMICAL", 291, 294], ["2G12", "GENE_OR_GENE_PRODUCT", 299, 303], ["GNA", "PROTEIN", 42, 45], ["Tri/m-Gn-glyco-epitopes", "PROTEIN", 78, 101], ["AGOR", "PROTEIN", 105, 109], ["exposed terminal GlcNAc moieties", "PROTEIN", 115, 147], ["GNA", "PROTEIN", 291, 294], ["2G12", "PROTEIN", 299, 303], ["GNA", "PROBLEM", 42, 45], ["the Tri/m", "PROBLEM", 74, 83], ["exposed terminal GlcNAc moieties", "TREATMENT", 115, 147], ["Carbohydrate Microarrays", "TREATMENT", 148, 172], ["the global antigen", "TEST", 252, 270], ["GNA", "TEST", 291, 294], ["2G12", "TREATMENT", 299, 303], ["antigen preparations", "TREATMENT", 330, 350], ["most likely", "UNCERTAINTY", 49, 60], ["terminal", "ANATOMY_MODIFIER", 123, 131], ["GlcNAc moieties", "OBSERVATION", 132, 147]]], ["Microarray results were plotted as the ratio of antigen-specific signals over the corresponding spots' background readings, i.e., GNA Ag/Bg, or 2G12 Ag/Bg.", [["Ag", "CHEMICAL", 134, 136], ["Bg", "CHEMICAL", 137, 139], ["Ag", "CHEMICAL", 149, 151], ["Bg", "CHEMICAL", 152, 154], ["antigen", "GENE_OR_GENE_PRODUCT", 48, 55], ["GNA Ag", "PROTEIN", 130, 136], ["Bg", "PROTEIN", 137, 139], ["2G12 Ag", "PROTEIN", 144, 151], ["Bg", "PROTEIN", 152, 154], ["Microarray results", "TEST", 0, 18], ["GNA Ag", "TEST", 130, 136], ["Bg", "TEST", 137, 139], ["2G12 Ag", "TEST", 144, 151], ["Bg", "TEST", 152, 154]]], ["To assist a comparative analysis of binding profiles between GNA and 2G12, datasets were plotted in the same scale in the y-axis.", [["2G12", "GENE_OR_GENE_PRODUCT", 69, 73], ["2G12", "PROTEIN", 69, 73], ["a comparative analysis", "TEST", 10, 32], ["binding profiles", "TEST", 36, 52], ["GNA", "TEST", 61, 64], ["datasets", "TEST", 75, 83]]], ["The positive detections labeled with numbers in the graphs are AGOR (5), Man9 (9), (M9)4 (11), M5-6-RB (15) , and P-Man in two dilutions (17 and 18) .", [["P", "DNA", 114, 115], ["Man", "DNA", 116, 119], ["The positive detections", "TEST", 0, 23]]], ["In this microarray analysis, GNA and 2G12 show minimal or no cross-relativities with irrelevant antigens but illustrate strikingly different glycan-binding profiles.", [["GNA", "GENE_OR_GENE_PRODUCT", 29, 32], ["2G12", "GENE_OR_GENE_PRODUCT", 37, 41], ["GNA", "PROTEIN", 29, 32], ["2G12", "PROTEIN", 37, 41], ["this microarray analysis", "TEST", 3, 27], ["GNA", "TEST", 29, 32], ["2G12", "TEST", 37, 41], ["cross-relativities", "PROBLEM", 61, 79], ["irrelevant antigens", "PROBLEM", 85, 104], ["minimal", "OBSERVATION_MODIFIER", 47, 54]]], ["2G12 is \"mono-specific\" for Man9-clusters (9 and 11) as expected.", [["2G12", "PROTEIN", 0, 4], ["Man9", "PROTEIN", 28, 32]]], ["By contrast, GNA is \"pauci reactive\" with a number of glycan targets.", [["GNA", "TEST", 13, 16], ["pauci reactive", "PROBLEM", 21, 35]]], ["Its binding to the spotted oligomannose antigens (5, 9, 11, and 15 ) and P-Man (17 and 18) can be attributed to the known GNA-specificity for recognition of the shared Man\u03b11,3Man and/or Man\u03b11,6Man moieties.", [["oligomannose", "CHEMICAL", 27, 39], ["oligomannose antigens", "GENE_OR_GENE_PRODUCT", 27, 48], ["Man\u03b11", "GENE_OR_GENE_PRODUCT", 168, 173], ["3", "GENE_OR_GENE_PRODUCT", 174, 175], ["Man", "GENE_OR_GENE_PRODUCT", 175, 178], ["Man\u03b11,6Man moieties", "SIMPLE_CHEMICAL", 186, 205], ["spotted oligomannose antigens", "PROTEIN", 19, 48], ["P", "PROTEIN", 73, 74], ["Man\u03b11,3Man and/or Man\u03b11,6Man moieties", "PROTEIN", 168, 205], ["the spotted oligomannose antigens", "TEST", 15, 48], ["the known GNA", "PROBLEM", 112, 125]]], ["However, GNA-binding to AGOR, but not to ASOR or OR, indicates that GNA also specifically recognize the Tri/m-Gn-glyco-determinants displayed by AGOR.", [["GNA", "GENE_OR_GENE_PRODUCT", 9, 12], ["AGOR", "GENE_OR_GENE_PRODUCT", 24, 28], ["ASOR", "GENE_OR_GENE_PRODUCT", 41, 45], ["GNA", "GENE_OR_GENE_PRODUCT", 68, 71], ["Tri", "GENE_OR_GENE_PRODUCT", 104, 107], ["AGOR", "GENE_OR_GENE_PRODUCT", 145, 149], ["GNA", "PROTEIN", 9, 12], ["AGOR", "PROTEIN", 24, 28], ["ASOR", "PROTEIN", 41, 45], ["OR", "PROTEIN", 49, 51], ["Tri/m-Gn-glyco-determinants", "PROTEIN", 104, 131], ["AGOR", "PROTEIN", 145, 149], ["GNA", "PROBLEM", 9, 12], ["GNA", "PROBLEM", 68, 71]]], ["Supporting to this prediction is the fact that AGOR, ASOR, and OR are negative to other anti-mannose agents, including lectin Con A, mAbs 2G12, TM10, and polyclonal antisera that recognize oligomannosyl moieties of varies cluster configurations [31, 35] .", [["anti-mannose", "CHEMICAL", 88, 100], ["oligomannosyl", "CHEMICAL", 189, 202], ["AGOR", "GENE_OR_GENE_PRODUCT", 47, 51], ["ASOR", "GENE_OR_GENE_PRODUCT", 53, 57], ["anti-mannose agents", "SIMPLE_CHEMICAL", 88, 107], ["lectin Con A", "GENE_OR_GENE_PRODUCT", 119, 131], ["mAbs 2G12", "GENE_OR_GENE_PRODUCT", 133, 142], ["TM10", "GENE_OR_GENE_PRODUCT", 144, 148], ["AGOR", "PROTEIN", 47, 51], ["ASOR", "PROTEIN", 53, 57], ["OR", "PROTEIN", 63, 65], ["lectin Con A", "PROTEIN", 119, 131], ["mAbs 2G12", "PROTEIN", 133, 142], ["TM10", "PROTEIN", 144, 148], ["oligomannosyl moieties", "PROTEIN", 189, 211], ["anti-mannose agents", "TREATMENT", 88, 107], ["lectin Con A, mAbs 2G12", "TEST", 119, 142], ["TM10", "TREATMENT", 144, 148], ["polyclonal antisera", "TREATMENT", 154, 173]]], ["Molecular mechanisms underlying GNA-recognition of the Tri/m-Gn-determinants of AGOR are yet to be explored.Printing Protein, Carbohydrate and Lipid/Liposome MicroarraysA high-precision microarray robot (PIXSYS 5500C, Cartesian Technologies, Irvine, CA, USA) was used to spot antigen preparations onto glass slides pre-coated with nitrocellulose polymer (FAST Slides; Schleicher & Schuell, Keene, NH, USA) as described [36] .", [["Carbohydrate", "CHEMICAL", 126, 138], ["nitrocellulose", "CHEMICAL", 331, 345], ["GNA", "GENE_OR_GENE_PRODUCT", 32, 35], ["Tri", "GENE_OR_GENE_PRODUCT", 55, 58], ["AGOR", "GENE_OR_GENE_PRODUCT", 80, 84], ["Carbohydrate", "SIMPLE_CHEMICAL", 126, 138], ["Lipid", "SIMPLE_CHEMICAL", 143, 148], ["nitrocellulose polymer", "SIMPLE_CHEMICAL", 331, 353], ["Tri/m-Gn-determinants", "PROTEIN", 55, 76], ["AGOR", "PROTEIN", 80, 84], ["Molecular mechanisms underlying GNA", "PROBLEM", 0, 35], ["AGOR", "PROBLEM", 80, 84], ["Carbohydrate", "TEST", 126, 138], ["Lipid/Liposome MicroarraysA", "TREATMENT", 143, 170], ["nitrocellulose polymer (FAST Slides", "TREATMENT", 331, 366]]], ["The antigen preparations applied include carbohydrates, proteins/peptides, and liposomes of various compositions as listed in Supplementary Table S1 .", [["carbohydrates", "CHEMICAL", 41, 54], ["carbohydrates", "SIMPLE_CHEMICAL", 41, 54], ["liposomes", "SIMPLE_CHEMICAL", 79, 88], ["The antigen preparations", "TREATMENT", 0, 24], ["carbohydrates", "TREATMENT", 41, 54], ["proteins/peptides", "TREATMENT", 56, 73], ["liposomes of various compositions", "TREATMENT", 79, 112]]], ["Proteins and carbohydrates were dissolved in phosphate-buffered saline (PBS; pH 7.4) and saline (0.9% NaCl), respectively.", [["phosphate", "CHEMICAL", 45, 54], ["NaCl", "CHEMICAL", 102, 106], ["carbohydrates", "CHEMICAL", 13, 26], ["phosphate", "CHEMICAL", 45, 54], ["NaCl", "CHEMICAL", 102, 106], ["carbohydrates", "SIMPLE_CHEMICAL", 13, 26], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 45, 70], ["saline", "SIMPLE_CHEMICAL", 89, 95], ["Proteins", "TEST", 0, 8], ["carbohydrates", "TEST", 13, 26], ["phosphate", "TEST", 45, 54], ["buffered saline (PBS", "TREATMENT", 55, 75], ["pH", "TEST", 77, 79], ["saline", "TREATMENT", 89, 95]]], ["Liposome preparations were suspended in saline (0.9% NaCl) at the concentrations specified and were printed in triplicate with spot sizes of ~150 \u00b5m and at 375-\u00b5m intervals, center to center.", [["Liposome", "ANATOMY", 0, 8], ["NaCl", "CHEMICAL", 53, 57], ["NaCl", "CHEMICAL", 53, 57], ["saline", "SIMPLE_CHEMICAL", 40, 46], ["Liposome preparations", "TREATMENT", 0, 21], ["saline (0.9% NaCl)", "TREATMENT", 40, 58], ["sizes", "OBSERVATION_MODIFIER", 132, 137]]], ["The printed microarrays were air-dried and stored at room temperature without desiccant before application.Staining and Scanning of MicroarraysImmediately before use, the printed microarrays were rinsed with PBS, pH 7.4, with 0.05% (v/v) Tween 20 and then blocked by incubating the slides in 1% (w/v) bovine serum albumin (BSA) in PBS containing 0.05% (w/v) NaN3 at room temperature (RT) for 30 min.", [["serum", "ANATOMY", 308, 313], ["BSA", "CHEMICAL", 323, 326], ["NaN3", "CHEMICAL", 358, 362], ["Tween 20", "CHEMICAL", 238, 246], ["NaN3", "CHEMICAL", 358, 362], ["Tween 20", "SIMPLE_CHEMICAL", 238, 246], ["bovine", "ORGANISM", 301, 307], ["serum", "ORGANISM_SUBSTANCE", 308, 313], ["albumin", "SIMPLE_CHEMICAL", 314, 321], ["BSA", "SIMPLE_CHEMICAL", 323, 326], ["PBS", "SIMPLE_CHEMICAL", 331, 334], ["NaN3", "SIMPLE_CHEMICAL", 358, 362], ["bovine", "SPECIES", 301, 307], ["Staining", "TEST", 107, 115], ["the printed microarrays", "TREATMENT", 167, 190], ["PBS", "TEST", 208, 211], ["pH", "TEST", 213, 215], ["the slides", "TEST", 278, 288], ["w/v) bovine serum albumin", "TREATMENT", 296, 321], ["BSA", "TEST", 323, 326], ["PBS", "TEST", 331, 334], ["air-dried", "OBSERVATION", 29, 38]]], ["They were then incubated at RT with 2G12 (NIH AIDS Reagent Program, Germantown, MD, USA), biotinylated PHA-L (PHA-L BI ), or GNA BI (EY Laboratories, Inc., San Mateo, CA, USA) at an indicated titration in 1% (w/v) BSA in PBS containing 0.05% (w/v) NaN3 and 0.05% (v/v) Tween 20.", [["AIDS", "DISEASE", 46, 50], ["BSA", "CHEMICAL", 214, 217], ["NaN3", "CHEMICAL", 248, 252], ["NaN3", "CHEMICAL", 248, 252], ["Tween 20", "CHEMICAL", 269, 277], ["PHA-L", "SIMPLE_CHEMICAL", 103, 108], ["PHA-L BI", "SIMPLE_CHEMICAL", 110, 118], ["GNA BI", "SIMPLE_CHEMICAL", 125, 131], ["/v) BSA", "SIMPLE_CHEMICAL", 210, 217], ["NaN3", "SIMPLE_CHEMICAL", 248, 252], ["Tween 20", "SIMPLE_CHEMICAL", 269, 277], ["PHA", "PROTEIN", 103, 106], ["PHA", "PROTEIN", 110, 113], ["biotinylated PHA", "TEST", 90, 106], ["PHA", "TEST", 110, 113], ["GNA BI", "TEST", 125, 131], ["w/v) BSA in PBS", "TREATMENT", 209, 224], ["NaN3", "TREATMENT", 248, 252]]], ["The secondary antibodies or streptavidin conjugates applied for microarray staining are specified in the figure legends.", [["streptavidin conjugates", "SIMPLE_CHEMICAL", 28, 51], ["secondary antibodies", "PROTEIN", 4, 24], ["The secondary antibodies", "TREATMENT", 0, 24], ["streptavidin conjugates", "TREATMENT", 28, 51], ["microarray staining", "TEST", 64, 83]]], ["The stained slides were rinsed five times with PBS with 0.05% (v/v) Tween 20, air-dried at room temperature, and then scanned for fluorescent signals using a ScanArray5000A Microarray Scanner (PerkinElmer Life Science, Boston, MA, USA) following the manufacturer's manual.Microarray Data-Processing and Statistical AnalysisFluorescence intensity values for each array spot and its background were calculated using ScanArray Express software (PerkinElmer Life Science, Boston, MA, USA).", [["Tween 20", "CHEMICAL", 68, 76], ["Tween 20", "SIMPLE_CHEMICAL", 68, 76], ["The stained slides", "TEST", 0, 18], ["PBS", "TREATMENT", 47, 50], ["fluorescent signals", "TEST", 130, 149], ["a ScanArray5000A Microarray Scanner", "TREATMENT", 156, 191], ["Microarray Data", "TEST", 272, 287], ["Statistical Analysis", "TEST", 303, 323], ["Fluorescence intensity values", "TEST", 323, 352], ["each array spot", "TEST", 357, 372]]], ["SAS Institute's JMP-Genomics software package (Cary, NC, USA) was used for further microarray data processing and statistical analysis.", [["SAS", "TEST", 0, 3], ["further microarray data processing", "TEST", 75, 109], ["statistical analysis", "TEST", 114, 134]]], ["In Figure 2 , microarray detections are shown as the mean fluorescent intensities (MFIs) of triplicate detections captured by ScanArray 5000A for the arrays stained with PHA-L, GNA, or 2G12.", [["PHA-L", "SIMPLE_CHEMICAL", 170, 175], ["GNA", "SIMPLE_CHEMICAL", 177, 180], ["2G12", "GENE_OR_GENE_PRODUCT", 185, 189], ["ScanArray 5000A", "DNA", 126, 141], ["PHA", "PROTEIN", 170, 173], ["L", "PROTEIN", 174, 175], ["GNA", "PROTEIN", 177, 180], ["2G12", "PROTEIN", 185, 189], ["microarray detections", "TEST", 14, 35], ["triplicate detections", "TEST", 92, 113], ["ScanArray", "TEST", 126, 135], ["the arrays", "TEST", 146, 156], ["PHA", "TEST", 170, 173], ["GNA", "TEST", 177, 180]]], ["Analysis of such microarray data in association with visual inspection of the microarray image provided an evaluation of reproducibility and variation of this antigen microarray technology.", [["such microarray data", "TEST", 12, 32], ["visual inspection", "TEST", 53, 70], ["the microarray image", "TEST", 74, 94], ["an evaluation", "TEST", 104, 117], ["reproducibility", "TEST", 121, 136]]], ["In Figure 3 , microarray results were plotted as the ratio of antigen-specific signal over corresponding spots' background reading, i.e., GNA Ag/Bg, or 2G12 Ag/Bg.", [["Ag", "CHEMICAL", 142, 144], ["Bg", "CHEMICAL", 145, 147], ["Ag", "CHEMICAL", 157, 159], ["Bg", "CHEMICAL", 160, 162], ["GNA Ag", "PROTEIN", 138, 144], ["Bg", "PROTEIN", 145, 147], ["2G12 Ag", "PROTEIN", 152, 159], ["Bg", "PROTEIN", 160, 162], ["microarray results", "TEST", 14, 32], ["the ratio", "TEST", 49, 58], ["antigen", "TEST", 62, 69], ["GNA Ag", "TEST", 138, 144], ["Bg", "TEST", 145, 147], ["2G12 Ag/Bg", "TEST", 152, 162]]], ["The whole microarray datasets for PHA-L, GNA, and 2G12 were presented in Supplementary Table S2 .Viral Antigen Preparations and Antigen-Specific ELISATwo HIV-1 gp120 preparations, Bal-gp120-Man9 and Bal-gp120, were produced in HEK293 cells as previously described [25, 26] .", [["HEK293 cells", "ANATOMY", 227, 239], ["PHA-L", "GENE_OR_GENE_PRODUCT", 34, 39], ["GNA", "SIMPLE_CHEMICAL", 41, 44], ["Viral", "ORGANISM", 97, 102], ["HIV-1", "ORGANISM", 154, 159], ["gp120", "ORGANISM", 160, 165], ["Bal-gp120", "GENE_OR_GENE_PRODUCT", 180, 189], ["Bal-gp120", "GENE_OR_GENE_PRODUCT", 199, 208], ["HEK293 cells", "CELL", 227, 239], ["PHA", "PROTEIN", 34, 37], ["L", "PROTEIN", 38, 39], ["GNA", "PROTEIN", 41, 44], ["2G12", "PROTEIN", 50, 54], ["gp120", "PROTEIN", 160, 165], ["gp120", "PROTEIN", 184, 189], ["Man9", "PROTEIN", 190, 194], ["Bal", "PROTEIN", 199, 202], ["gp120", "PROTEIN", 203, 208], ["HEK293 cells", "CELL_LINE", 227, 239], ["HIV-1", "SPECIES", 154, 159], ["HIV-1", "SPECIES", 154, 159], ["The whole microarray datasets", "TEST", 0, 29], ["PHA", "TEST", 34, 37], ["GNA", "PROBLEM", 41, 44], ["Viral Antigen Preparations", "TEST", 97, 123], ["Antigen", "TEST", 128, 135], ["Specific ELISATwo HIV", "TEST", 136, 157], ["Bal", "TEST", 180, 183], ["gp120", "TEST", 184, 189], ["Bal", "TEST", 199, 202]]], ["Bal-gp120-Man9 was expressed in the presence of the \u03b1-mannosidase I inhibitor, kifunensine (2 \u00b5g/mL), to enrich high-mannose type glycoforms.", [["Bal-gp120-Man9", "CHEMICAL", 0, 14], ["kifunensine", "CHEMICAL", 79, 90], ["kifunensine", "CHEMICAL", 79, 90], ["mannose", "CHEMICAL", 117, 124], ["Bal-gp120", "GENE_OR_GENE_PRODUCT", 0, 9], ["Man9", "GENE_OR_GENE_PRODUCT", 10, 14], ["\u03b1-mannosidase I", "GENE_OR_GENE_PRODUCT", 52, 67], ["kifunensine", "SIMPLE_CHEMICAL", 79, 90], ["gp120", "PROTEIN", 4, 9], ["Man9", "PROTEIN", 10, 14], ["Bal", "TEST", 0, 3], ["the \u03b1-mannosidase I inhibitor", "TREATMENT", 48, 77], ["kifunensine", "TREATMENT", 79, 90]]], ["A preparation of sucrose density-gradient-purified HCMV (AD169) was obtained from Creative Diagnostics (NY, NY, USA).", [["sucrose", "CHEMICAL", 17, 24], ["sucrose", "CHEMICAL", 17, 24], ["sucrose", "SIMPLE_CHEMICAL", 17, 24], ["HCMV", "ORGANISM", 51, 55], ["HCMV", "SPECIES", 51, 55], ["sucrose density", "TEST", 17, 32], ["sucrose density", "OBSERVATION_MODIFIER", 17, 32]]], ["An ELISA protocol described previously [37] for detection of anti-carbohydrate antibodies was followed with minor modifications.", [["anti-carbohydrate antibodies", "GENE_OR_GENE_PRODUCT", 61, 89], ["anti-carbohydrate antibodies", "PROTEIN", 61, 89], ["An ELISA protocol", "TEST", 0, 17], ["detection of anti-carbohydrate antibodies", "TEST", 48, 89]]], ["In Figure 1A -E, antigen preparations were diluted in 0.1 M sodium bicarbonate buffer solution, pH 9.6, for coating on ELISA microplates (NUNC, MaxiSorp, Thermo Fisher Scientific Inc., Santa Clara, CA, USA) followed by blocking using 1% BSA, PBST.", [["sodium bicarbonate", "CHEMICAL", 60, 78], ["sodium bicarbonate", "CHEMICAL", 60, 78], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 60, 78], ["BSA", "SIMPLE_CHEMICAL", 237, 240], ["antigen preparations", "TREATMENT", 17, 37], ["0.1 M sodium bicarbonate buffer solution", "TREATMENT", 54, 94], ["pH", "TEST", 96, 98], ["ELISA microplates", "TEST", 119, 136]]], ["In Figure 1C , a SARS-CoV-specific ELISA kit (EUROIMMUN AG, L\u00fcbeck, Germany) was used to measure SARS-CoV-expression of lectin-specific glyco-epitopes.", [["lectin", "GENE_OR_GENE_PRODUCT", 120, 126], ["lectin", "PROTEIN", 120, 126], ["glyco-epitopes", "PROTEIN", 136, 150], ["SARS-CoV", "SPECIES", 97, 105], ["a SARS", "TEST", 15, 21], ["CoV", "TEST", 22, 25], ["SARS", "TEST", 97, 101], ["lectin", "TEST", 120, 126]]], ["Anti-glycan antibodies or biotinylated lectins were pre-titrated in 1% BSA, PBST for ELISA.", [["BSA", "SIMPLE_CHEMICAL", 71, 74], ["Anti-glycan antibodies", "PROTEIN", 0, 22], ["Anti-glycan antibodies", "TEST", 0, 22], ["biotinylated lectins", "TEST", 26, 46], ["ELISA", "TEST", 85, 90]]], ["The bound antibodies were revealed by an alkaline phosphatase (AP)-conjugate of goat anti-human IgG-Fc-specific antibody, and the biotinylated lectins captured were quantified by AP-streptavidin-conjugate.ConclusionsIn this pilot study, we examined whether human viruses of distinct phylogenetic origins may express common carbohydrate moieties.", [["carbohydrate", "CHEMICAL", 323, 335], ["AP", "SIMPLE_CHEMICAL", 63, 65], ["goat", "ORGANISM", 80, 84], ["IgG", "GENE_OR_GENE_PRODUCT", 96, 99], ["Fc-", "GENE_OR_GENE_PRODUCT", 100, 103], ["AP", "SIMPLE_CHEMICAL", 179, 181], ["streptavidin", "GENE_OR_GENE_PRODUCT", 182, 194], ["human", "ORGANISM", 257, 262], ["bound antibodies", "PROTEIN", 4, 20], ["alkaline phosphatase (AP)-conjugate", "PROTEIN", 41, 76], ["goat anti-human IgG", "PROTEIN", 80, 99], ["Fc-specific antibody", "PROTEIN", 100, 120], ["biotinylated lectins", "PROTEIN", 130, 150], ["AP", "PROTEIN", 179, 181], ["goat", "SPECIES", 80, 84], ["human", "SPECIES", 257, 262], ["goat", "SPECIES", 80, 84], ["human", "SPECIES", 257, 262], ["The bound antibodies", "TEST", 0, 20], ["an alkaline phosphatase", "TEST", 38, 61], ["AP", "TEST", 63, 65], ["goat anti-human IgG", "TEST", 80, 99], ["Fc-specific antibody", "TEST", 100, 120], ["the biotinylated lectins", "TEST", 126, 150], ["this pilot study", "TEST", 219, 235]]], ["Using carbohydrate microarrays and ELISA-based viral glycan-profiling analysis, we characterized two broadly HIV-neutralizing agents, human monoclonal antibody 2G12 and lectin GNA.", [["carbohydrate", "CHEMICAL", 6, 18], ["HIV", "ORGANISM", 109, 112], ["human", "ORGANISM", 134, 139], ["monoclonal antibody 2G12", "GENE_OR_GENE_PRODUCT", 140, 164], ["lectin GNA", "GENE_OR_GENE_PRODUCT", 169, 179], ["human monoclonal antibody 2G12", "PROTEIN", 134, 164], ["lectin GNA", "PROTEIN", 169, 179], ["human", "SPECIES", 134, 139], ["HIV", "SPECIES", 109, 112], ["human", "SPECIES", 134, 139], ["carbohydrate microarrays", "TREATMENT", 6, 30], ["ELISA", "TEST", 35, 40], ["viral glycan", "TEST", 47, 59], ["profiling analysis", "TEST", 60, 78], ["neutralizing agents", "TREATMENT", 113, 132], ["human monoclonal antibody", "TEST", 134, 159], ["lectin GNA", "PROBLEM", 169, 179]]], ["Although these agents were known to target oligomannosyl antigens, they differ strikingly in the spectrum of viruses they effectively neutralize.", [["oligomannosyl antigens", "GENE_OR_GENE_PRODUCT", 43, 65], ["oligomannosyl antigens", "PROTEIN", 43, 65], ["viruses", "OBSERVATION", 109, 116]]], ["The former is solely HIV-specific; the latter is broadly reactive with human viruses, including HIV-1, SARS-CoV, and HCMV, that are phylogenetically and pathogenically distinct.", [["human", "ORGANISM", 71, 76], ["HIV-1", "ORGANISM", 96, 101], ["SARS-CoV", "ORGANISM", 103, 111], ["HCMV", "ORGANISM", 117, 121], ["human", "SPECIES", 71, 76], ["HIV-1", "SPECIES", 96, 101], ["HIV", "SPECIES", 21, 24], ["human viruses", "SPECIES", 71, 84], ["HIV-1", "SPECIES", 96, 101], ["SARS-CoV", "SPECIES", 103, 111], ["HCMV", "SPECIES", 117, 121], ["human viruses", "PROBLEM", 71, 84], ["HIV", "TEST", 96, 99], ["SARS", "PROBLEM", 103, 107], ["CoV", "PROBLEM", 108, 111], ["HCMV", "PROBLEM", 117, 121], ["reactive", "OBSERVATION", 57, 65], ["human viruses", "OBSERVATION", 71, 84], ["HCMV", "OBSERVATION", 117, 121]]], ["Our carbohydrate microarray analyses demonstrate the two probes differ strikingly in glycan-targeting specificities and the spectrum of glyco-epitopes they recognize.", [["carbohydrate", "CHEMICAL", 4, 16], ["glyco-epitopes", "PROTEIN", 136, 150], ["Our carbohydrate microarray analyses", "TEST", 0, 36], ["glyco-epitopes", "TREATMENT", 136, 150]]], ["Although 2G12 is strictly specific for the high-density Man9 clusters that decorate the HIV envelope spike, GNA recognizes a number of N-glycan cryptic sugar moieties.", [["N", "CHEMICAL", 135, 136], ["sugar", "CHEMICAL", 152, 157], ["2G12", "GENE_OR_GENE_PRODUCT", 9, 13], ["Man9", "GENE_OR_GENE_PRODUCT", 56, 60], ["sugar moieties", "SIMPLE_CHEMICAL", 152, 166], ["2G12", "PROTEIN", 9, 13], ["Man9", "PROTEIN", 56, 60], ["GNA", "PROTEIN", 108, 111], ["N-glycan cryptic sugar moieties", "PROTEIN", 135, 166], ["HIV", "SPECIES", 88, 91], ["HIV", "SPECIES", 88, 91], ["the high-density Man9 clusters", "PROBLEM", 39, 69], ["the HIV envelope spike", "PROBLEM", 84, 106], ["GNA", "PROBLEM", 108, 111], ["sugar moieties", "OBSERVATION", 152, 166]]], ["These include oligomannoses and the previously unrecognized Tri/m-Gn-glyco-determinants.", [["oligomannoses", "SIMPLE_CHEMICAL", 14, 27], ["Tri/m-Gn-glyco-determinants", "PROTEIN", 60, 87], ["oligomannoses", "TEST", 14, 27]]], ["The latter appear to be the potent natural ligands of GNA.", [["GNA", "GENE_OR_GENE_PRODUCT", 54, 57], ["GNA", "PROTEIN", 54, 57], ["GNA", "PROBLEM", 54, 57], ["appear to be", "UNCERTAINTY", 11, 23]]], ["Molecular mechanisms underlying the GNA-model of \"pauci reactive\" glycan-binding and broad virus-neutralization warrant further investigation.", [["pauci reactive", "SIMPLE_CHEMICAL", 50, 64], ["Molecular mechanisms", "PROBLEM", 0, 20], ["the GNA", "TEST", 32, 39], ["\"pauci reactive\" glycan-binding", "PROBLEM", 49, 80], ["broad virus", "PROBLEM", 85, 96], ["further investigation", "TEST", 120, 141]]], ["Owing to the potential immunogenic activity as a plant-derived lectin, GNA is unlikely suitable for anti-virus therapy in vivo.", [["lectin", "GENE_OR_GENE_PRODUCT", 63, 69], ["GNA", "SIMPLE_CHEMICAL", 71, 74], ["anti-virus", "SIMPLE_CHEMICAL", 100, 110], ["lectin", "PROTEIN", 63, 69], ["GNA", "PROBLEM", 71, 74], ["anti-virus therapy", "TREATMENT", 100, 118]]], ["Thus, effort must also be made to establish GNA-like potent and broadly virus-neutralizing antibodies, especially humanized or fully human mAbs that are readily applicable in the front-line biodefense against emerging viral pathogens.Supplementary MaterialsSupplementary materials can be accessed at: http://www.mdpi.com/1420-3049/20/03/4610/s1.", [["viral pathogens", "DISEASE", 218, 233], ["human", "ORGANISM", 133, 138], ["neutralizing antibodies", "PROTEIN", 78, 101], ["humanized or fully human mAbs", "PROTEIN", 114, 143], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["GNA-like potent and broadly virus", "PROBLEM", 44, 77], ["neutralizing antibodies", "TREATMENT", 78, 101], ["fully human mAbs", "TREATMENT", 127, 143], ["emerging viral pathogens", "PROBLEM", 209, 233]]]], "cb81cff4a1c0ab2639ad1d31667d4eac4130b245": [["INTRODUCTIONIn December 2019, the coronavirus disease 2019 (COVID19), caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in Wuhan, China Zhu et al., 2020) .", [["coronavirus disease", "DISEASE", 34, 53], ["coronavirus", "DISEASE", 88, 99], ["acute respiratory syndrome coronavirus", "DISEASE", 113, 151], ["coronavirus", "ORGANISM", 34, 45], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 106, 153], ["SARS-CoV-2", "ORGANISM", 155, 165], ["coronavirus", "SPECIES", 88, 99], ["coronavirus named severe acute respiratory syndrome coronavirus", "SPECIES", 88, 151], ["SARS-CoV-2", "SPECIES", 155, 165], ["the coronavirus disease", "PROBLEM", 30, 53], ["a novel coronavirus", "PROBLEM", 80, 99], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 106, 151], ["coronavirus disease", "OBSERVATION", 34, 53], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["respiratory syndrome", "OBSERVATION", 119, 139]]], ["Since then, COVID19 cases have been increasingly reported in many countries and on March 11, 2020, the World Health Organization (WHO) declared COVID19 as a pandemic.INTRODUCTIONAlthough the symptoms associated with COVID19 are generally mild, approximately 20% of COVID19 patients may develop severe clinical manifestations such as pneumonia, acute respiratory distress syndrome, sepsis and even death (Wu and McGoogan, 2020) .", [["respiratory", "ANATOMY", 350, 361], ["pneumonia", "DISEASE", 333, 342], ["acute respiratory distress syndrome", "DISEASE", 344, 379], ["sepsis", "DISEASE", 381, 387], ["death", "DISEASE", 397, 402], ["COVID19", "GENE_OR_GENE_PRODUCT", 12, 19], ["COVID19", "GENE_OR_GENE_PRODUCT", 216, 223], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 273, 281], ["the symptoms", "PROBLEM", 187, 199], ["COVID19", "TEST", 216, 223], ["severe clinical manifestations", "PROBLEM", 294, 324], ["pneumonia", "PROBLEM", 333, 342], ["acute respiratory distress syndrome", "PROBLEM", 344, 379], ["sepsis", "PROBLEM", 381, 387], ["mild", "OBSERVATION_MODIFIER", 238, 242], ["severe", "OBSERVATION_MODIFIER", 294, 300], ["pneumonia", "OBSERVATION", 333, 342], ["acute", "OBSERVATION_MODIFIER", 344, 349], ["respiratory distress syndrome", "OBSERVATION", 350, 379], ["sepsis", "OBSERVATION", 381, 387]]], ["According to WHO, as of April 30, 2020, there are 3,090,445 confirmed COVID19 cases and 217,769 deaths in total in the world (https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200430-sitr ep-101-covid-19.pdf?sfvrsn=2ba4e093_2).", [["deaths", "DISEASE", 96, 102]]], ["Clearly, COVID19 is a serious public health crisis.", [["COVID19", "CHEMICAL", 9, 16], ["COVID19", "GENE_OR_GENE_PRODUCT", 9, 16], ["COVID19", "PROTEIN", 9, 16], ["a serious public health crisis", "PROBLEM", 20, 50], ["serious", "OBSERVATION_MODIFIER", 22, 29]]], ["However, there is currently no vaccine available for COVID19.", [["COVID19", "SIMPLE_CHEMICAL", 53, 60], ["COVID19", "PROTEIN", 53, 60], ["vaccine", "TREATMENT", 31, 38], ["COVID19", "TREATMENT", 53, 60]]], ["SARS-CoV-2 belongs to the genus Betacoronavirus of the family Coronaviridae (Gorbalenya et al., 2020) .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "SPECIES", 0, 8]]], ["Like other coronaviruses, SARS-CoV-2 is an enveloped virus and possesses a ~30 kb single-stranded positive-sense RNA genome.", [["SARS-CoV-2", "ORGANISM", 26, 36], ["~30 kb single-stranded positive-sense RNA genome", "DNA", 75, 123], ["SARS-CoV-2", "SPECIES", 26, 36], ["other coronaviruses", "PROBLEM", 5, 24], ["an enveloped virus", "PROBLEM", 40, 58], ["coronaviruses", "OBSERVATION", 11, 24], ["virus", "OBSERVATION", 53, 58], ["RNA genome", "OBSERVATION", 113, 123]]], ["This viral genome encodes 4 structural proteins including spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, 16 nonstructural proteins, and a few accessory proteins .", [["membrane", "ANATOMY", 83, 91], ["spike (S)", "GENE_OR_GENE_PRODUCT", 58, 67], ["membrane", "CELLULAR_COMPONENT", 83, 91], ["nucleocapsid (N) proteins", "GENE_OR_GENE_PRODUCT", 101, 126], ["viral genome", "DNA", 5, 17], ["structural proteins", "PROTEIN", 28, 47], ["spike (S), envelope (E), membrane (M)", "PROTEIN", 58, 95], ["nucleocapsid (N) proteins", "PROTEIN", 101, 126], ["16 nonstructural proteins", "PROTEIN", 128, 153], ["accessory proteins", "PROTEIN", 165, 183], ["This viral genome encodes 4 structural proteins", "PROBLEM", 0, 47], ["spike (S", "TEST", 58, 66], ["envelope (E), membrane (M), and nucleocapsid (N) proteins", "TEST", 69, 126], ["nonstructural proteins", "TEST", 131, 153], ["a few accessory proteins", "PROBLEM", 159, 183], ["viral genome", "OBSERVATION", 5, 17]]], ["The S protein consists of an ectodomain, a transmembrane domain, and a short intracellular tail (Walls et al., 2020) .", [["transmembrane", "ANATOMY", 43, 56], ["intracellular", "ANATOMY", 77, 90], ["intracellular tail", "CELLULAR_COMPONENT", 77, 95], ["S protein", "PROTEIN", 4, 13], ["ectodomain", "PROTEIN", 29, 39], ["transmembrane domain", "PROTEIN", 43, 63], ["short intracellular tail", "PROTEIN", 71, 95], ["The S protein", "TEST", 0, 13], ["a transmembrane domain", "TEST", 41, 63], ["ectodomain", "OBSERVATION", 29, 39], ["transmembrane domain", "OBSERVATION", 43, 63]]], ["The ectodomain can be further divided into two functionally distinct subunits, S1 and S2, which are responsible for receptor binding and membrane fusion, respectively.", [["membrane", "ANATOMY", 137, 145], ["S1", "GENE_OR_GENE_PRODUCT", 79, 81], ["S2", "GENE_OR_GENE_PRODUCT", 86, 88], ["membrane", "CELLULAR_COMPONENT", 137, 145], ["ectodomain", "PROTEIN", 4, 14], ["S1", "PROTEIN", 79, 81], ["S2", "PROTEIN", 86, 88], ["The ectodomain", "TREATMENT", 0, 14], ["receptor binding", "PROBLEM", 116, 132], ["membrane fusion", "TREATMENT", 137, 152], ["distinct", "OBSERVATION_MODIFIER", 60, 68], ["subunits", "OBSERVATION_MODIFIER", 69, 77], ["S1", "ANATOMY", 79, 81], ["S2", "ANATOMY", 86, 88], ["responsible for", "UNCERTAINTY", 100, 115], ["receptor binding", "OBSERVATION", 116, 132], ["membrane fusion", "OBSERVATION", 137, 152]]], ["Like the closely related severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2 also uses human angiotensin-converting enzyme 2 (ACE2) as the key receptor to facilitate its entry into host cells .", [["cells", "ANATOMY", 203, 208], ["acute respiratory syndrome coronavirus", "DISEASE", 32, 70], ["SARS", "DISEASE", 72, 76], ["SARS", "DISEASE", 83, 87], ["angiotensin", "CHEMICAL", 110, 121], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 25, 70], ["SARS-CoV", "ORGANISM", 72, 80], ["SARS-CoV-2", "ORGANISM", 83, 93], ["human", "ORGANISM", 104, 109], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 110, 141], ["ACE2", "GENE_OR_GENE_PRODUCT", 143, 147], ["cells", "CELL", 203, 208], ["human angiotensin-converting enzyme 2", "PROTEIN", 104, 141], ["ACE2", "PROTEIN", 143, 147], ["host cells", "CELL_TYPE", 198, 208], ["human", "SPECIES", 104, 109], ["severe acute respiratory syndrome coronavirus", "SPECIES", 25, 70], ["SARS-CoV", "SPECIES", 72, 80], ["SARS-CoV", "SPECIES", 83, 91], ["human", "SPECIES", 104, 109], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 25, 70], ["SARS", "PROBLEM", 83, 87], ["human angiotensin", "TREATMENT", 104, 121], ["converting enzyme 2 (ACE2)", "TREATMENT", 122, 148], ["the key receptor", "TREATMENT", 152, 168], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["respiratory syndrome coronavirus", "OBSERVATION", 38, 70], ["host cells", "OBSERVATION", 198, 208]]], ["The S protein binds human ACE2 protein through its receptor-binding domain (RBD) located within the S1 subunit (Lan et al., 2020; Shang et al., 2020; Wang et al., 2020b; Yan et al., 2020) Many approaches have been tested for rapid development of SARS-CoV-2 vaccines, yielding some exciting results (Amanat and Krammer, 2020; Chen et al., 2020) .", [["human", "ORGANISM", 20, 25], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["SARS-CoV-2", "ORGANISM", 246, 256], ["S protein", "PROTEIN", 4, 13], ["human ACE2 protein", "PROTEIN", 20, 38], ["receptor-binding domain", "PROTEIN", 51, 74], ["RBD", "PROTEIN", 76, 79], ["S1 subunit", "PROTEIN", 100, 110], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["SARS-CoV", "SPECIES", 246, 254], ["The S protein binds human ACE2 protein", "TREATMENT", 0, 38], ["SARS", "PROBLEM", 246, 250], ["CoV-2 vaccines", "TREATMENT", 251, 265], ["S1", "ANATOMY", 100, 102]]], ["For example, Gao et al. recently reported that an inactivated whole-virus vaccine provided protection in macaques against experimental SARS-CoV-2 challenge (Gao et al., 2020) .", [["SARS", "DISEASE", 135, 139], ["whole-virus", "ORGANISM", 62, 73], ["macaques", "ORGANISM", 105, 113], ["CoV-2", "ORGANISM", 140, 145], ["macaques", "SPECIES", 105, 113], ["macaques", "SPECIES", 105, 113], ["SARS-CoV", "SPECIES", 135, 143], ["an inactivated whole-virus vaccine", "TREATMENT", 47, 81], ["experimental SARS", "PROBLEM", 122, 139]]], ["Thus far, a number of SARS-CoV-2 vaccine candidates derived from different vaccine platforms, including DNA vaccine, mRNA vaccine, inactivated whole virus vaccine, and adenovirus-vectored vaccine, have rapidly progressed into clinical trials (Amanat and Krammer, 2020; Callaway, 2020; .INTRODUCTIONOne of the challenges in developing vaccines for coronaviruses is a potential vaccine-induced immune enhancement of disease Huisman et al., 2009) .", [["coronaviruses", "DISEASE", 347, 360], ["SARS-CoV-2", "ORGANISM", 22, 32], ["DNA", "CELLULAR_COMPONENT", 104, 107], ["whole virus", "ORGANISM", 143, 154], ["adenovirus", "ORGANISM", 168, 178], ["coronaviruses", "ORGANISM", 347, 360], ["whole virus vaccine", "SPECIES", 143, 162], ["adenovirus", "SPECIES", 168, 178], ["SARS-CoV-2 vaccine candidates", "TREATMENT", 22, 51], ["different vaccine platforms", "TREATMENT", 65, 92], ["DNA vaccine", "TREATMENT", 104, 115], ["mRNA vaccine", "TREATMENT", 117, 129], ["inactivated whole virus vaccine", "TREATMENT", 131, 162], ["adenovirus-vectored vaccine", "TREATMENT", 168, 195], ["the challenges", "TREATMENT", 305, 319], ["developing vaccines", "TREATMENT", 323, 342], ["coronaviruses", "PROBLEM", 347, 360], ["a potential vaccine", "TREATMENT", 364, 383]]], ["For example, immunization with inactivated whole-virus SARS-CoV vaccine was found to elicit an immune response that exaggerate disease upon viral challenges in animal models (Bolles et al., 2011; Luo et al., 2018; Tseng et al., 2012; Wang et al., 2016) .", [["whole-virus SARS-CoV", "ORGANISM", 43, 63], ["-virus SARS-CoV vaccine", "SPECIES", 48, 71], ["SARS-CoV", "SPECIES", 55, 63], ["immunization", "TREATMENT", 13, 25], ["inactivated whole-virus SARS", "PROBLEM", 31, 59], ["CoV vaccine", "TREATMENT", 60, 71], ["exaggerate disease upon viral challenges", "PROBLEM", 116, 156], ["viral challenges", "OBSERVATION", 140, 156]]], ["Results from some other studies suggest that antibodies targeting the spike protein of coronaviruses play a major role in antibody-dependent enhancement (ADE) likely through increasing the binding/entry of antibody-bound virion to Fc receptor (FcR)-expressing cells Jaume et al., 2011; Liu et al., 2019; Olsen et al., 1992; Wan et al., 2020; Wang et al., 2014; Yip et al., 2014) .", [["cells", "ANATOMY", 260, 265], ["virion", "CELLULAR_COMPONENT", 221, 227], ["Fc receptor", "GENE_OR_GENE_PRODUCT", 231, 242], ["FcR", "GENE_OR_GENE_PRODUCT", 244, 247], ["antibodies", "PROTEIN", 45, 55], ["spike protein", "PROTEIN", 70, 83], ["antibody", "PROTEIN", 206, 214], ["Fc receptor", "PROTEIN", 231, 242], ["FcR", "PROTEIN", 244, 247], ["some other studies", "TEST", 13, 31], ["antibodies", "TEST", 45, 55], ["the spike protein of coronaviruses", "PROBLEM", 66, 100], ["dependent enhancement", "PROBLEM", 131, 152], ["antibody", "TEST", 206, 214], ["dependent enhancement", "OBSERVATION_MODIFIER", 131, 152]]], ["So far, all the SARS-CoV-2 vaccine candidates entering clinical trials contain or express full-length or near full-length S protein and therefore bear the risk of ADE.INTRODUCTIONThus, it is important to continue the search for a safe and effective SARS-CoV-2 vaccine.INTRODUCTIONRecombinantly produced RBD proteins of SARS-CoV and MERS-CoV have been shown to potently induce protective neutralizing antibodies against respective viruses in preclinical studies and are therefore considered promising vaccine candidates (reviewed in (Jiang et al., 2012; Zhou et al., 2018) ).", [["ADE", "DISEASE", 163, 166], ["SARS-CoV-2", "ORGANISM", 16, 26], ["CoV-2", "ORGANISM", 254, 259], ["RBD", "GENE_OR_GENE_PRODUCT", 303, 306], ["SARS-CoV", "ORGANISM", 319, 327], ["MERS-CoV", "ORGANISM", 332, 340], ["S protein", "PROTEIN", 122, 131], ["RBD proteins", "PROTEIN", 303, 315], ["MERS", "PROTEIN", 332, 336], ["neutralizing antibodies", "PROTEIN", 387, 410], ["SARS-CoV", "SPECIES", 16, 24], ["SARS-CoV", "SPECIES", 319, 327], ["MERS-CoV", "SPECIES", 332, 340], ["CoV-2 vaccine", "TREATMENT", 21, 34], ["near full-length S protein", "TREATMENT", 105, 131], ["a safe", "TREATMENT", 228, 234], ["CoV-2 vaccine", "TREATMENT", 254, 267], ["SARS", "PROBLEM", 319, 323], ["CoV", "PROBLEM", 324, 327], ["CoV", "PROBLEM", 337, 340], ["protective neutralizing antibodies", "TREATMENT", 376, 410], ["preclinical studies", "TEST", 441, 460], ["RBD", "OBSERVATION", 303, 306], ["SARS", "OBSERVATION", 319, 323]]], ["In the present study, we investigated the vaccine potential of SARS-CoV-2 RBD (hereafter referred as SARS2-RBD).", [["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 101, 110], ["RBD", "PROTEIN", 74, 77], ["SARS2", "PROTEIN", 101, 106], ["RBD", "PROTEIN", 107, 110], ["SARS-CoV-2 RBD", "SPECIES", 63, 77], ["the present study", "TEST", 3, 20], ["SARS", "PROBLEM", 63, 67], ["CoV-2 RBD", "PROBLEM", 68, 77]]], ["We found that immunization of mice with recombinant SARS2-RBD elicited the production of serum antibodies that efficiently neutralized both SARS-CoV-2 and SARS-CoV but did not promote ADE.Mice immunized with RBD-Fc fusion protein produced SARS-CoV-2 neutralizing antibodiesTo rapidly evaluate the vaccine potential of SARS2-RBD, a pilot mouse immunization study was performed with a recombinant RBD fusion protein containing the Fc region of mouse IgG1 at the C-terminus (RBD-Fc) as the immunogen.", [["serum", "ANATOMY", 89, 94], ["mice", "ORGANISM", 30, 34], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 52, 61], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["SARS-CoV-2", "ORGANISM", 140, 150], ["SARS-CoV", "ORGANISM", 155, 163], ["Mice", "ORGANISM", 188, 192], ["RBD-Fc", "GENE_OR_GENE_PRODUCT", 208, 214], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 239, 249], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 318, 327], ["mouse", "ORGANISM", 337, 342], ["mouse", "ORGANISM", 442, 447], ["IgG1", "GENE_OR_GENE_PRODUCT", 448, 452], ["RBD-Fc", "GENE_OR_GENE_PRODUCT", 472, 478], ["SARS2", "PROTEIN", 52, 57], ["RBD", "PROTEIN", 58, 61], ["serum antibodies", "PROTEIN", 89, 105], ["RBD", "PROTEIN", 208, 211], ["Fc fusion protein", "PROTEIN", 212, 229], ["SARS-CoV-2 neutralizing antibodies", "PROTEIN", 239, 273], ["SARS2", "PROTEIN", 318, 323], ["RBD", "PROTEIN", 324, 327], ["recombinant RBD fusion protein", "PROTEIN", 383, 413], ["Fc region", "PROTEIN", 429, 438], ["mouse IgG1", "PROTEIN", 442, 452], ["C-terminus", "PROTEIN", 460, 470], ["RBD", "PROTEIN", 472, 475], ["Fc", "PROTEIN", 476, 478], ["mice", "SPECIES", 30, 34], ["Mice", "SPECIES", 188, 192], ["mouse", "SPECIES", 337, 342], ["mouse", "SPECIES", 442, 447], ["mice", "SPECIES", 30, 34], ["SARS-CoV", "SPECIES", 140, 148], ["SARS-CoV", "SPECIES", 155, 163], ["mouse", "SPECIES", 337, 342], ["mouse", "SPECIES", 442, 447], ["immunization of mice", "TREATMENT", 14, 34], ["recombinant SARS2", "TEST", 40, 57], ["RBD", "PROBLEM", 58, 61], ["serum antibodies", "TEST", 89, 105], ["CoV", "TEST", 145, 148], ["SARS", "PROBLEM", 155, 159], ["RBD", "TEST", 208, 211], ["Fc fusion protein", "TEST", 212, 229], ["SARS", "TEST", 239, 243], ["CoV", "TEST", 244, 247], ["neutralizing antibodies", "TEST", 250, 273], ["SARS2-RBD", "PROBLEM", 318, 327], ["a pilot mouse immunization study", "TEST", 329, 361], ["a recombinant RBD fusion protein", "TREATMENT", 381, 413], ["the immunogen", "TREATMENT", 483, 496], ["mouse IgG1", "OBSERVATION", 442, 452]]], ["The mice received three vaccine doses at days 0, 8, and 13, respectively.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["three vaccine doses", "TREATMENT", 18, 37]]], ["The first vaccine dose contained 100 \u03bcg of RBD-Fc protein, 500 \u03bcg of aluminum hydroxide and 25 \u03bcg of CpG, the second one contained 50 \u03bcg of RBD-Fc in complete Freund's adjuvant, and the third one contained 50 \u03bcg of RBD-Fc formulated with Titermax adjuvant.", [["aluminum hydroxide", "CHEMICAL", 69, 87], ["CpG", "CHEMICAL", 101, 104], ["Titermax", "CHEMICAL", 238, 246], ["aluminum hydroxide", "CHEMICAL", 69, 87], ["CpG", "CHEMICAL", 101, 104], ["RBD-Fc", "GENE_OR_GENE_PRODUCT", 43, 49], ["aluminum hydroxide", "SIMPLE_CHEMICAL", 69, 87], ["RBD-Fc", "GENE_OR_GENE_PRODUCT", 140, 146], ["Freund", "ORGANISM", 159, 165], ["RBD-Fc", "SIMPLE_CHEMICAL", 215, 221], ["Titermax", "SIMPLE_CHEMICAL", 238, 246], ["RBD", "PROTEIN", 43, 46], ["Fc protein", "PROTEIN", 47, 57], ["RBD", "PROTEIN", 140, 143], ["Fc", "PROTEIN", 144, 146], ["RBD", "PROTEIN", 215, 218], ["Fc", "PROTEIN", 219, 221], ["The first vaccine dose", "TREATMENT", 0, 22], ["RBD-Fc protein", "TREATMENT", 43, 57], ["aluminum hydroxide", "TREATMENT", 69, 87], ["CpG", "TREATMENT", 101, 104], ["RBD", "PROBLEM", 140, 143], ["Fc", "TREATMENT", 144, 146], ["complete Freund's adjuvant", "TREATMENT", 150, 176], ["RBD", "PROBLEM", 215, 218], ["Titermax adjuvant", "TREATMENT", 238, 255]]], ["One week after the last immunization (day 20), serum samples were collected from the three immunized mice for antibody measurement.", [["serum samples", "ANATOMY", 47, 60], ["serum samples", "ORGANISM_SUBSTANCE", 47, 60], ["mice", "ORGANISM", 101, 105], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105], ["the last immunization", "TREATMENT", 15, 36], ["serum samples", "TEST", 47, 60], ["antibody measurement", "TEST", 110, 130]]], ["All three antisera dose-dependently reacted with His-tagged SARS2-RBD in ELISA, whereas the control sera from an age-matching na\u00efve mouse did not show significant reactivity regardless of the sera doses used (Fig. 1A) .", [["sera", "ANATOMY", 100, 104], ["sera", "ANATOMY", 192, 196], ["His-", "SIMPLE_CHEMICAL", 49, 53], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 60, 69], ["sera", "ORGANISM_SUBSTANCE", 100, 104], ["mouse", "ORGANISM", 132, 137], ["sera", "ORGANISM_SUBSTANCE", 192, 196], ["SARS2", "PROTEIN", 60, 65], ["RBD", "PROTEIN", 66, 69], ["mouse", "SPECIES", 132, 137], ["mouse", "SPECIES", 132, 137], ["RBD in ELISA", "PROBLEM", 66, 78], ["the control sera", "TEST", 88, 104], ["significant reactivity", "PROBLEM", 151, 173], ["the sera doses", "TREATMENT", 188, 202]]], ["The anti-RBD-Fc sera #1 that had the highest RBD-binding titer (2\u00d710 5 ) was selected for further functional analyses.", [["anti-RBD", "PROTEIN", 4, 12], ["RBD", "PROTEIN", 45, 48], ["The anti-RBD-Fc sera", "TEST", 0, 20], ["further functional analyses", "TEST", 90, 117]]], ["The anti-RBD-Fc sera #1 could dose-dependently inhibit the binding between recombinant ACE2-Fc fusion protein and His-tagged SARS2-RBD in competition ELISA (Fig. 1B) , indicating that the antisera contain antibodies targeting the ACE2-binding motif within RBD.", [["ACE2-Fc", "GENE_OR_GENE_PRODUCT", 87, 94], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 125, 134], ["ACE2", "GENE_OR_GENE_PRODUCT", 230, 234], ["anti-RBD", "PROTEIN", 4, 12], ["ACE2", "PROTEIN", 87, 91], ["Fc fusion protein", "PROTEIN", 92, 109], ["His-tagged SARS2", "PROTEIN", 114, 130], ["RBD", "PROTEIN", 131, 134], ["antibodies", "PROTEIN", 205, 215], ["ACE2", "PROTEIN", 230, 234], ["RBD", "PROTEIN", 256, 259], ["The anti-RBD-Fc sera", "TREATMENT", 0, 20], ["the binding", "PROBLEM", 55, 66], ["recombinant ACE2", "TEST", 75, 91], ["fusion protein", "TEST", 95, 109], ["His-", "TEST", 114, 118], ["tagged SARS2", "TEST", 118, 130], ["RBD", "PROBLEM", 131, 134], ["competition ELISA", "TEST", 138, 155], ["the antisera", "TEST", 184, 196]]], ["The anti-RBD-Fc sera #1 was then assessed for its ability to neutralize SARS-CoV-2 S protein-pseudotyped retrovirus (hereafter referred as SARS2-PV) and to neutralize live SARS-CoV-2.", [["SARS-CoV-2", "ORGANISM", 72, 82], ["pseudotyped retrovirus", "ORGANISM", 93, 115], ["SARS2-PV", "GENE_OR_GENE_PRODUCT", 139, 147], ["CoV-2", "ORGANISM", 177, 182], ["anti-RBD", "PROTEIN", 4, 12], ["SARS-CoV-2 S protein", "PROTEIN", 72, 92], ["SARS2", "PROTEIN", 139, 144], ["SARS-CoV", "SPECIES", 72, 80], ["SARS-CoV", "SPECIES", 172, 180], ["SARS", "TEST", 72, 76], ["CoV", "TEST", 77, 80], ["S protein", "TEST", 83, 92], ["pseudotyped retrovirus", "PROBLEM", 93, 115]]], ["As shown in Fig. 1C , the antisera dose-dependently neutralized SARS2-PV entry with a calculated NT50 value of 10513.", [["SARS2-PV", "GENE_OR_GENE_PRODUCT", 64, 72], ["SARS2", "PROTEIN", 64, 69], ["the antisera dose", "TEST", 22, 39], ["a calculated NT50 value", "TEST", 84, 107]]], ["Moreover, addition of the anti-RBD-Fc sera #1 prevented the development of cytopathic effect (CPE) in SARS-CoV-2-inoculated VeroE6 cells ( Supplementary Fig. 1) .", [["VeroE6 cells", "ANATOMY", 124, 136], ["SARS-CoV-2", "CELL", 102, 112], ["VeroE6 cells", "CELL", 124, 136], ["anti-RBD", "PROTEIN", 26, 34], ["Fc sera #1", "PROTEIN", 35, 45], ["VeroE6 cells", "CELL_LINE", 124, 136], ["SARS-CoV", "SPECIES", 102, 110], ["the anti-RBD-Fc sera", "TREATMENT", 22, 42], ["cytopathic effect (CPE", "PROBLEM", 75, 97], ["SARS", "PROBLEM", 102, 106], ["CoV", "TEST", 107, 110], ["inoculated VeroE6 cells", "PROBLEM", 113, 136], ["cytopathic", "OBSERVATION_MODIFIER", 75, 85]]], ["Results from qRT-PCR and IFA assays showed that the anti-RBD-Fc sera #1 were highly effective, neutralizing \uff1e50% infection even at the serum dilution of 1:5120 ( Fig. 1D-E) .", [["serum", "ANATOMY", 135, 140], ["infection", "DISEASE", 113, 122], ["serum", "ORGANISM_SUBSTANCE", 135, 140], ["anti-RBD", "PROTEIN", 52, 60], ["qRT", "TEST", 13, 16], ["PCR", "TEST", 17, 20], ["IFA assays", "TEST", 25, 35], ["the anti-RBD-Fc sera", "TEST", 48, 68], ["neutralizing \uff1e50% infection", "PROBLEM", 95, 122], ["the serum dilution", "TEST", 131, 149]]], ["Taken together, the above results demonstrate that RBD-Fc is an immunogen capable of efficiently inducing SARS-CoV-2-neutralizing antibodies.RBD alone potently elicited cross-reactive, ACE2-binding blockade antibodies towards SARS-CoV-2 and SARS-CoVTo verify that the RBD part within the RBD-Fc fusion protein is indeed responsible for the induction of neutralizing antibodies against SARS-CoV-2, we performed a second mouse immunization study with recombinant SARS-CoV-2 RBD fused with a small 6xHis tag as the vaccine antigen.", [["RBD", "DISEASE", 141, 144], ["RBD-Fc", "GENE_OR_GENE_PRODUCT", 51, 57], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 106, 116], ["ACE2", "GENE_OR_GENE_PRODUCT", 185, 189], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 226, 236], ["SARS-CoVTo", "GENE_OR_GENE_PRODUCT", 241, 251], ["RBD-Fc", "GENE_OR_GENE_PRODUCT", 288, 294], ["SARS-CoV-2", "ORGANISM", 385, 395], ["mouse", "ORGANISM", 419, 424], ["SARS-CoV-2", "ORGANISM", 461, 471], ["RBD", "ORGANISM", 472, 475], ["RBD", "PROTEIN", 51, 54], ["Fc", "PROTEIN", 55, 57], ["SARS-CoV-2-neutralizing antibodies", "PROTEIN", 106, 140], ["RBD", "PROTEIN", 141, 144], ["ACE2", "PROTEIN", 185, 189], ["binding blockade antibodies", "PROTEIN", 190, 217], ["RBD", "PROTEIN", 268, 271], ["RBD", "PROTEIN", 288, 291], ["Fc fusion protein", "PROTEIN", 292, 309], ["neutralizing antibodies", "PROTEIN", 353, 376], ["recombinant SARS-CoV-2 RBD", "PROTEIN", 449, 475], ["small 6xHis tag", "PROTEIN", 489, 504], ["vaccine antigen", "PROTEIN", 512, 527], ["mouse", "SPECIES", 419, 424], ["SARS-CoV", "SPECIES", 385, 393], ["mouse", "SPECIES", 419, 424], ["SARS-CoV", "SPECIES", 461, 469], ["RBD", "TEST", 51, 54], ["an immunogen", "TEST", 61, 73], ["SARS", "TEST", 106, 110], ["CoV", "TEST", 111, 114], ["neutralizing antibodies", "PROBLEM", 117, 140], ["cross-reactive", "TEST", 169, 183], ["ACE2", "TEST", 185, 189], ["binding blockade antibodies", "TEST", 190, 217], ["SARS", "TEST", 226, 230], ["CoV", "TEST", 231, 234], ["SARS", "PROBLEM", 241, 245], ["Fc fusion protein", "TREATMENT", 292, 309], ["neutralizing antibodies", "TEST", 353, 376], ["SARS", "PROBLEM", 385, 389], ["a second mouse immunization study", "TREATMENT", 410, 443], ["recombinant SARS", "TEST", 449, 465], ["CoV", "TEST", 466, 469], ["a small 6xHis tag", "TREATMENT", 487, 504], ["the vaccine antigen", "TREATMENT", 508, 527], ["RBD", "OBSERVATION", 51, 54], ["RBD", "OBSERVATION", 268, 271]]], ["A group of six BALB/c mice were immunized by i.p. injection with 5 \u03bcg of recombinant RBD protein formulated with Alum adjuvant at days 1, 10, and 25 ( Fig. 2A) .", [["Alum", "CHEMICAL", 113, 117], ["Alum", "CHEMICAL", 113, 117], ["BALB/c mice", "ORGANISM", 15, 26], ["Alum", "SIMPLE_CHEMICAL", 113, 117], ["recombinant RBD protein", "PROTEIN", 73, 96], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["A group of six BALB/c mice", "TREATMENT", 0, 26], ["recombinant RBD protein", "TREATMENT", 73, 96], ["Alum adjuvant", "TREATMENT", 113, 126]]], ["Another group of mice were injected with an irrelevant protein (HBc) plus Alum adjuvant, serving as the control.", [["Alum", "CHEMICAL", 74, 78], ["Alum", "CHEMICAL", 74, 78], ["mice", "ORGANISM", 17, 21], ["HBc", "GENE_OR_GENE_PRODUCT", 64, 67], ["Alum", "SIMPLE_CHEMICAL", 74, 78], ["HBc", "PROTEIN", 64, 67], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["an irrelevant protein (HBc)", "TREATMENT", 41, 68], ["Alum adjuvant", "TREATMENT", 74, 87]]], ["Serum samples were collected from individual mice at days 20 and 40, and analyzed for RBD-specific antibody by ELISA using SARS2-RBD as the capture antigen.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["mice", "ORGANISM", 45, 49], ["RBD", "GENE_OR_GENE_PRODUCT", 86, 89], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 123, 132], ["RBD", "PROTEIN", 86, 89], ["SARS2", "PROTEIN", 123, 128], ["RBD", "PROTEIN", 129, 132], ["capture antigen", "PROTEIN", 140, 155], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["Serum samples", "TEST", 0, 13], ["RBD", "TEST", 86, 89], ["specific antibody", "TEST", 90, 107], ["ELISA", "TEST", 111, 116], ["SARS2", "TEST", 123, 128], ["the capture antigen", "TEST", 136, 155]]], ["As shown in Fig. 2B , neither the day-20 nor the day-40 sera in the control (HBc) group exhibited any significant binding activity; in contrast, SARS2-RBD-binding activity was readily detectable at day 20 in the sera from RBD-immunized mice and a significant increase in SARS2-RBD-binding was observed for the day-40 anti-RBD sera.", [["sera", "ANATOMY", 56, 60], ["sera", "ANATOMY", 212, 216], ["sera", "ANATOMY", 326, 330], ["sera", "ORGANISM_SUBSTANCE", 56, 60], ["SARS2", "GENE_OR_GENE_PRODUCT", 145, 150], ["sera", "ORGANISM_SUBSTANCE", 212, 216], ["RBD", "GENE_OR_GENE_PRODUCT", 222, 225], ["mice", "ORGANISM", 236, 240], ["SARS2", "GENE_OR_GENE_PRODUCT", 271, 276], ["RBD", "GENE_OR_GENE_PRODUCT", 277, 280], ["sera", "ORGANISM_SUBSTANCE", 326, 330], ["SARS2", "PROTEIN", 145, 150], ["RBD", "PROTEIN", 151, 154], ["RBD", "PROTEIN", 222, 225], ["SARS2", "PROTEIN", 271, 276], ["RBD", "PROTEIN", 277, 280], ["RBD", "PROTEIN", 322, 325], ["mice", "SPECIES", 236, 240], ["mice", "SPECIES", 236, 240], ["any significant binding activity", "PROBLEM", 98, 130], ["SARS2", "TEST", 145, 150], ["a significant increase in SARS2-RBD", "PROBLEM", 245, 280], ["significant", "OBSERVATION_MODIFIER", 247, 258], ["increase", "OBSERVATION_MODIFIER", 259, 267]]], ["Equal amount of individual antisera in the same groups were pooled for antibody titer measurement and subsequent analyses.", [["individual antisera", "TEST", 16, 35], ["antibody titer measurement", "TEST", 71, 97], ["subsequent analyses", "TEST", 102, 121], ["amount", "OBSERVATION_MODIFIER", 6, 12], ["individual", "OBSERVATION_MODIFIER", 16, 26], ["antisera", "OBSERVATION_MODIFIER", 27, 35]]], ["The day-20 and day-40 pooled anti-RBD sera dose-dependently reacted with SARS2-RBD in ELISAs (Fig. 2C ) and their binding antibody titers were determined to be 1.6\u00d710 5 and 3.2\u00d710 6 , respectively.", [["sera", "ANATOMY", 38, 42], ["anti-RBD", "SIMPLE_CHEMICAL", 29, 37], ["sera", "ORGANISM_SUBSTANCE", 38, 42], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 73, 82], ["SARS2", "PROTEIN", 73, 78], ["RBD", "PROTEIN", 79, 82], ["pooled anti-RBD sera dose", "TREATMENT", 22, 47], ["SARS2", "TEST", 73, 78], ["ELISAs", "TEST", 86, 92], ["their binding antibody titers", "TEST", 108, 137]]], ["The SARS2-RBD-binding activity of the anti-RBD sera collected at day 60 (when the mice were euthanized) was comparable to that of the day-40 anti-RBD sera (Supplemental SARS2-RBD shares high homology with the RBD of SARS-CoV (hereafter referred as SARS-RBD) in amino acid sequence, especially the regions outside the receptor-binding motif.", [["sera", "ANATOMY", 47, 51], ["sera", "ANATOMY", 150, 154], ["SARS", "DISEASE", 216, 220], ["SARS-RBD", "DISEASE", 248, 256], ["amino acid", "CHEMICAL", 261, 271], ["amino acid", "CHEMICAL", 261, 271], ["SARS2", "GENE_OR_GENE_PRODUCT", 4, 9], ["anti-RBD", "ORGANISM_SUBSTANCE", 38, 46], ["sera", "ORGANISM_SUBSTANCE", 47, 51], ["mice", "ORGANISM", 82, 86], ["sera", "ORGANISM_SUBSTANCE", 150, 154], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 169, 178], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 216, 224], ["amino acid", "AMINO_ACID", 261, 271], ["SARS2", "PROTEIN", 4, 9], ["RBD", "PROTEIN", 10, 13], ["anti-RBD sera", "PROTEIN", 38, 51], ["RBD sera", "PROTEIN", 146, 154], ["SARS2", "PROTEIN", 169, 174], ["RBD", "PROTEIN", 175, 178], ["RBD", "PROTEIN", 209, 212], ["SARS-CoV", "PROTEIN", 216, 224], ["SARS", "PROTEIN", 248, 252], ["RBD", "PROTEIN", 253, 256], ["amino acid sequence", "PROTEIN", 261, 280], ["receptor-binding motif", "PROTEIN", 317, 339], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 82, 86], ["SARS-CoV", "SPECIES", 216, 224], ["The SARS2", "TEST", 0, 9], ["the anti-RBD sera", "TEST", 34, 51], ["anti-RBD sera", "TEST", 141, 154], ["Supplemental SARS2", "TEST", 156, 174], ["SARS", "PROBLEM", 216, 220], ["CoV", "PROBLEM", 221, 224], ["amino acid sequence", "TEST", 261, 280], ["binding motif", "OBSERVATION", 326, 339]]], ["This prompted us to evaluate the cross-reactivity of our SARS2-RBD-immunized sera towards SARS-RBD.", [["sera", "ANATOMY", 77, 81], ["SARS-RBD", "DISEASE", 90, 98], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 57, 66], ["sera", "ORGANISM_SUBSTANCE", 77, 81], ["SARS2", "PROTEIN", 57, 62], ["RBD", "PROTEIN", 63, 66], ["SARS-RBD", "PROTEIN", 90, 98], ["our SARS2", "TEST", 53, 62], ["SARS", "PROBLEM", 90, 94], ["RBD", "PROBLEM", 95, 98]]], ["As shown in Fig. 2D and 2E, both individual and pooled sera from the SARS2-RBD-immunized mice showed dose-dependent binding activity with SARS-RBD.", [["sera", "ANATOMY", 55, 59], ["SARS-RBD", "DISEASE", 138, 146], ["sera", "ORGANISM_SUBSTANCE", 55, 59], ["SARS2-RBD", "ORGANISM", 69, 78], ["mice", "ORGANISM", 89, 93], ["SARS-RBD", "GENE_OR_GENE_PRODUCT", 138, 146], ["SARS2", "PROTEIN", 69, 74], ["RBD", "PROTEIN", 75, 78], ["RBD", "PROTEIN", 143, 146], ["mice", "SPECIES", 89, 93], ["mice", "SPECIES", 89, 93], ["pooled sera", "TEST", 48, 59], ["the SARS2", "TEST", 65, 74], ["SARS-RBD", "PROBLEM", 138, 146], ["RBD", "OBSERVATION", 143, 146]]], ["The SARS-RBD-binding titers of the pooled day-20 and day-40 anti-RBD sera were determined to be 4\u00d710 3 and 1.6\u00d7 10 5 , respectively.RBD alone potently elicited cross-reactive, ACE2-binding blockade antibodies towards SARS-CoV-2 and SARS-CoVThe pooled day-40 antisera were assessed for their ability to block the interaction between RBDs and ACE2, the entry receptor for both SARS-CoV-2 and SARS-CoV.RBD alone potently elicited cross-reactive, ACE2-binding blockade antibodies towards SARS-CoV-2 and SARS-CoVResults from ACE2-binding blockade ELISA showed that the day-40 anti-RBD sera dose-dependently inhibited hACE2-Fc binding to SARS2-RBD whereas the control sera had no inhibitory effect on the SARS2-RBD/hACE2-Fc interaction regardless of the sera concentration used (Fig. 2F) .", [["sera", "ANATOMY", 69, 73], ["sera", "ANATOMY", 580, 584], ["sera", "ANATOMY", 662, 666], ["sera", "ANATOMY", 748, 752], ["RBD", "DISEASE", 132, 135], ["RBD", "DISEASE", 399, 402], ["sera", "ORGANISM_SUBSTANCE", 69, 73], ["ACE2", "GENE_OR_GENE_PRODUCT", 176, 180], ["SARS-CoV-2", "ORGANISM", 217, 227], ["SARS-CoVThe", "ORGANISM", 232, 243], ["RBDs", "GENE_OR_GENE_PRODUCT", 332, 336], ["ACE2", "GENE_OR_GENE_PRODUCT", 341, 345], ["SARS-CoV-2", "ORGANISM", 375, 385], ["SARS-CoV", "ORGANISM", 390, 398], ["ACE2", "GENE_OR_GENE_PRODUCT", 443, 447], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 484, 494], ["SARS-CoVResults", "SIMPLE_CHEMICAL", 499, 514], ["ACE2", "GENE_OR_GENE_PRODUCT", 520, 524], ["sera", "ORGANISM_SUBSTANCE", 580, 584], ["hACE2-Fc", "GENE_OR_GENE_PRODUCT", 612, 620], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 632, 641], ["sera", "ORGANISM_SUBSTANCE", 662, 666], ["SARS2", "GENE_OR_GENE_PRODUCT", 699, 704], ["RBD", "GENE_OR_GENE_PRODUCT", 705, 708], ["hACE2-Fc", "GENE_OR_GENE_PRODUCT", 709, 717], ["sera", "ORGANISM_SUBSTANCE", 748, 752], ["RBD", "PROTEIN", 9, 12], ["RBD", "PROTEIN", 65, 68], ["RBD", "PROTEIN", 132, 135], ["ACE2", "PROTEIN", 176, 180], ["binding blockade antibodies", "PROTEIN", 181, 208], ["RBDs", "PROTEIN", 332, 336], ["ACE2", "PROTEIN", 341, 345], ["entry receptor", "PROTEIN", 351, 365], ["RBD", "PROTEIN", 399, 402], ["ACE2", "PROTEIN", 443, 447], ["ACE2", "PROTEIN", 520, 524], ["RBD", "PROTEIN", 576, 579], ["hACE2", "PROTEIN", 612, 617], ["SARS2", "PROTEIN", 632, 637], ["RBD", "PROTEIN", 638, 641], ["SARS2", "PROTEIN", 699, 704], ["RBD", "PROTEIN", 705, 708], ["hACE2", "PROTEIN", 709, 714], ["Fc", "PROTEIN", 715, 717], ["SARS-CoV", "SPECIES", 217, 225], ["SARS-CoV", "SPECIES", 375, 383], ["SARS-CoV", "SPECIES", 390, 398], ["The SARS", "TEST", 0, 8], ["binding titers", "TEST", 13, 27], ["anti-RBD sera", "TEST", 60, 73], ["cross-reactive", "TEST", 160, 174], ["ACE2", "TEST", 176, 180], ["binding blockade antibodies", "TEST", 181, 208], ["SARS", "TEST", 217, 221], ["CoV", "TEST", 222, 225], ["SARS", "PROBLEM", 232, 236], ["RBDs", "TREATMENT", 332, 336], ["ACE2", "TREATMENT", 341, 345], ["the entry receptor", "TREATMENT", 347, 365], ["both SARS", "TEST", 370, 379], ["CoV", "TEST", 380, 383], ["SARS", "PROBLEM", 390, 394], ["cross-reactive", "TEST", 427, 441], ["ACE2", "TEST", 443, 447], ["binding blockade antibodies", "TEST", 448, 475], ["SARS", "TEST", 484, 488], ["CoV", "TEST", 489, 492], ["SARS", "PROBLEM", 499, 503], ["CoVResults", "TEST", 504, 514], ["ACE2", "TEST", 520, 524], ["binding blockade ELISA", "TEST", 525, 547], ["anti-RBD sera dose", "TEST", 571, 589], ["dependently inhibited hACE2", "PROBLEM", 590, 617], ["Fc binding", "PROBLEM", 618, 628], ["SARS2", "TEST", 632, 637], ["RBD", "PROBLEM", 638, 641], ["the control sera", "TEST", 650, 666], ["inhibitory effect", "PROBLEM", 674, 691], ["the SARS2", "TEST", 695, 704], ["the sera concentration", "TREATMENT", 744, 766]]], ["The anti-RBD sera also exhibited blockade effect on the SARS-RBD/hACE2-Fc interaction, albeit with a lower efficiency (Fig. 2G ).Anti-RBD sera inhibited SARS-CoV-2 spike-mediated cell-cell fusionThe spike protein of SARS-CoV-2 has been shown to bind cell surface ACE2 and mediate cell-cell fusion, leading to syncytia formation (Wang et al., 2020a) .", [["sera", "ANATOMY", 13, 17], ["sera", "ANATOMY", 138, 142], ["cell", "ANATOMY", 179, 183], ["cell", "ANATOMY", 184, 188], ["cell surface", "ANATOMY", 250, 262], ["cell", "ANATOMY", 280, 284], ["cell", "ANATOMY", 285, 289], ["syncytia", "ANATOMY", 309, 317], ["syncytia", "DISEASE", 309, 317], ["sera", "ORGANISM_SUBSTANCE", 13, 17], ["SARS-RBD", "GENE_OR_GENE_PRODUCT", 56, 64], ["hACE2-Fc", "GENE_OR_GENE_PRODUCT", 65, 73], ["sera", "ORGANISM_SUBSTANCE", 138, 142], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 153, 163], ["cell", "CELL", 179, 183], ["cell", "CELL", 184, 188], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 216, 226], ["cell", "CELL", 250, 254], ["ACE2", "GENE_OR_GENE_PRODUCT", 263, 267], ["cell", "CELL", 280, 284], ["cell", "CELL", 285, 289], ["syncytia", "CELL", 309, 317], ["RBD", "PROTEIN", 61, 64], ["hACE2", "PROTEIN", 65, 70], ["Fc", "PROTEIN", 71, 73], ["spike protein", "PROTEIN", 199, 212], ["SARS-CoV-2", "PROTEIN", 216, 226], ["ACE2", "PROTEIN", 263, 267], ["SARS-CoV", "SPECIES", 216, 224], ["The anti-RBD sera", "TEST", 0, 17], ["blockade effect", "PROBLEM", 33, 48], ["the SARS", "TEST", 52, 60], ["a lower efficiency", "PROBLEM", 99, 117], ["Anti-RBD sera", "TEST", 129, 142], ["SARS", "TEST", 153, 157], ["CoV", "TEST", 158, 161], ["spike", "PROBLEM", 164, 169], ["cell-cell fusion", "TREATMENT", 179, 195], ["The spike protein", "TEST", 195, 212], ["SARS", "PROBLEM", 216, 220], ["CoV", "TEST", 221, 224], ["ACE2", "TEST", 263, 267], ["mediate cell-cell fusion", "TREATMENT", 272, 296], ["syncytia formation", "PROBLEM", 309, 327], ["lower efficiency", "OBSERVATION_MODIFIER", 101, 117], ["cell fusion", "OBSERVATION", 184, 195], ["mediate cell", "OBSERVATION", 272, 284], ["cell fusion", "OBSERVATION", 285, 296], ["syncytia formation", "OBSERVATION", 309, 327]]], ["A cell-cell fusion assay was developed to determine whether the anti-RBD sera could prevent S-mediated syncytia formation.", [["cell", "ANATOMY", 2, 6], ["cell", "ANATOMY", 7, 11], ["sera", "ANATOMY", 73, 77], ["syncytia", "ANATOMY", 103, 111], ["syncytia", "DISEASE", 103, 111], ["cell", "CELL", 2, 6], ["cell", "CELL", 7, 11], ["sera", "ORGANISM_SUBSTANCE", 73, 77], ["syncytia", "CELL", 103, 111], ["A cell-cell fusion assay", "TEST", 0, 24], ["the anti-RBD sera", "TREATMENT", 60, 77], ["S-mediated syncytia formation", "PROBLEM", 92, 121], ["cell-cell fusion", "OBSERVATION", 2, 18], ["syncytia formation", "OBSERVATION", 103, 121]]], ["Co-culture of the 293T cells transiently expressing S:EGFP fusion protein and the ones expressing human ACE2 protein fused with mCherry (hACE2:mCherry) for 24 hours led to the detection of dual-fluorescent cells,Anti-RBD sera inhibited SARS-CoV-2 spike-mediated cell-cell fusionindicating the occurrence of cell-cell fusion (Supplemental Fig. 3 ).", [["293T cells", "ANATOMY", 18, 28], ["cells", "ANATOMY", 206, 211], ["sera", "ANATOMY", 221, 225], ["cell", "ANATOMY", 262, 266], ["cell", "ANATOMY", 267, 271], ["cell", "ANATOMY", 307, 311], ["cell", "ANATOMY", 312, 316], ["293T cells", "CELL", 18, 28], ["EGFP", "GENE_OR_GENE_PRODUCT", 54, 58], ["human", "ORGANISM", 98, 103], ["ACE2", "GENE_OR_GENE_PRODUCT", 104, 108], ["mCherry", "GENE_OR_GENE_PRODUCT", 128, 135], ["cells", "CELL", 206, 211], ["sera", "ORGANISM_SUBSTANCE", 221, 225], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 236, 246], ["cell", "CELL", 262, 266], ["cell", "CELL", 267, 271], ["cell", "CELL", 307, 311], ["cell", "CELL", 312, 316], ["293T cells", "CELL_LINE", 18, 28], ["S:EGFP fusion protein", "PROTEIN", 52, 73], ["human ACE2 protein", "PROTEIN", 98, 116], ["mCherry", "PROTEIN", 128, 135], ["hACE2", "PROTEIN", 137, 142], ["Cherry", "PROTEIN", 144, 150], ["dual-fluorescent cells", "CELL_LINE", 189, 211], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["Co-culture", "TEST", 0, 10], ["EGFP fusion protein", "TREATMENT", 54, 73], ["the detection", "TEST", 172, 185], ["dual-fluorescent cells", "PROBLEM", 189, 211], ["Anti-RBD sera", "TEST", 212, 225], ["SARS", "TEST", 236, 240], ["CoV", "TEST", 241, 244], ["cell-cell fusion", "TREATMENT", 307, 323], ["cell", "OBSERVATION", 307, 311], ["cell fusion", "OBSERVATION", 312, 323]]], ["The cells solely emitting green or red fluorescence and the dual-fluorescent cells were quantified by flow cytometry.", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 77, 82], ["cells", "CELL", 4, 9], ["cells", "CELL", 77, 82], ["dual-fluorescent cells", "CELL_LINE", 60, 82], ["red fluorescence", "TEST", 35, 51], ["the dual-fluorescent cells", "TEST", 56, 82], ["flow cytometry", "TEST", 102, 116], ["red fluorescence", "OBSERVATION", 35, 51], ["fluorescent cells", "OBSERVATION", 65, 82], ["flow cytometry", "OBSERVATION", 102, 116]]], ["It was found that addition of the day-40 anti-RBD antisera to the co-cultures significantly inhibited cell-cell fusion in an antisera dose-dependent manner whereas the control sera did not exhibit significant inhibitory effect regardless of the antisera dose used ( Fig. 2H and Supplemental Fig. 4 ).", [["cell", "ANATOMY", 102, 106], ["cell", "ANATOMY", 107, 111], ["sera", "ANATOMY", 176, 180], ["cell", "CELL", 102, 106], ["cell", "CELL", 107, 111], ["sera", "ORGANISM_SUBSTANCE", 176, 180], ["40 anti-RBD antisera", "TREATMENT", 38, 58], ["the co-cultures", "PROBLEM", 62, 77], ["cell-cell fusion", "TREATMENT", 102, 118], ["significant inhibitory effect", "PROBLEM", 197, 226], ["the antisera dose", "TREATMENT", 241, 258], ["cell fusion", "OBSERVATION", 107, 118]]], ["This data indicate that the anti-RBD sera are able to inhibit SARS2-S-mediated cell-cell fusion.Anti-RBD sera neutralized both SARS-CoV-2 and SARS-CoV pseudovirusesThe neutralization capacity of the mouse antisera was first evaluated using SARS-CoV-2 S-pseudotyped retrovirus (SARS2-PV).", [["sera", "ANATOMY", 37, 41], ["cell", "ANATOMY", 79, 83], ["cell", "ANATOMY", 84, 88], ["sera", "ANATOMY", 105, 109], ["sera", "ORGANISM_SUBSTANCE", 37, 41], ["SARS2-S", "GENE_OR_GENE_PRODUCT", 62, 69], ["cell", "CELL", 79, 83], ["cell", "CELL", 84, 88], ["sera", "ORGANISM_SUBSTANCE", 105, 109], ["SARS-CoV-2", "ORGANISM", 127, 137], ["SARS-CoV", "ORGANISM", 142, 150], ["mouse", "ORGANISM", 199, 204], ["SARS-CoV-2 S-pseudotyped retrovirus", "ORGANISM", 240, 275], ["SARS2-PV", "ORGANISM", 277, 285], ["SARS2", "PROTEIN", 62, 67], ["mouse", "SPECIES", 199, 204], ["SARS-CoV", "SPECIES", 127, 135], ["SARS-CoV", "SPECIES", 142, 150], ["mouse", "SPECIES", 199, 204], ["SARS-CoV", "SPECIES", 240, 248], ["PV", "SPECIES", 283, 285], ["the anti-RBD sera", "TEST", 24, 41], ["SARS2", "TEST", 62, 67], ["mediated cell-cell fusion", "TREATMENT", 70, 95], ["Anti-RBD sera", "TEST", 96, 109], ["SARS", "TEST", 127, 131], ["CoV", "TEST", 132, 135], ["SARS", "PROBLEM", 142, 146], ["CoV pseudoviruses", "PROBLEM", 147, 164], ["the mouse antisera", "TREATMENT", 195, 213], ["SARS", "TEST", 240, 244], ["CoV", "TEST", 245, 248], ["pseudotyped retrovirus", "TREATMENT", 253, 275], ["cell fusion", "OBSERVATION", 84, 95], ["neutralization capacity", "OBSERVATION", 168, 191]]], ["The day-40 anti-RBD sera potently inhibited infection of hACE2-overexpressing VeroE6 cells (VeroE6-hACE2) with SARS2-PV and the calculated NT50 was 12764 (Fig. 3A) , whereas the control sera did not show significant inhibition even at the lowest dilution tested (1:100).", [["sera", "ANATOMY", 20, 24], ["hACE2-overexpressing VeroE6 cells", "ANATOMY", 57, 90], ["sera", "ANATOMY", 186, 190], ["infection", "DISEASE", 44, 53], ["sera", "ORGANISM_SUBSTANCE", 20, 24], ["hACE2", "GENE_OR_GENE_PRODUCT", 57, 62], ["VeroE6 cells", "CELL", 78, 90], ["VeroE6-hACE2", "CELL", 92, 104], ["SARS2-PV", "GENE_OR_GENE_PRODUCT", 111, 119], ["sera", "ORGANISM_SUBSTANCE", 186, 190], ["hACE2-overexpressing VeroE6 cells", "CELL_LINE", 57, 90], ["VeroE6", "PROTEIN", 92, 98], ["hACE2", "CELL_LINE", 99, 104], ["SARS2", "PROTEIN", 111, 116], ["anti-RBD sera", "TEST", 11, 24], ["infection", "PROBLEM", 44, 53], ["hACE2", "TEST", 57, 62], ["overexpressing VeroE6 cells", "PROBLEM", 63, 90], ["VeroE6", "TEST", 92, 98], ["SARS2", "TEST", 111, 116], ["the calculated NT50", "TEST", 124, 143], ["the control sera", "TEST", 174, 190], ["significant inhibition", "PROBLEM", 204, 226], ["VeroE6 cells", "OBSERVATION", 78, 90]]], ["The same anti-RBD sera also inhibited infection of VeroE6-hACE2 cells with the SARS-PV (retrovirus pseudotyped with SARS-CoV S) with NT50 being 834.8 (Fig. 3B ).Anti-RBD sera neutralized authentic SARS-CoV-2 infectionThe antisera were next tested for neutralization of authentic SARS-CoV-2 infection.", [["sera", "ANATOMY", 18, 22], ["VeroE6-hACE2 cells", "ANATOMY", 51, 69], ["sera", "ANATOMY", 170, 174], ["infection", "DISEASE", 38, 47], ["SARS", "DISEASE", 279, 283], ["infection", "DISEASE", 290, 299], ["sera", "ORGANISM_SUBSTANCE", 18, 22], ["VeroE6-hACE2 cells", "CELL", 51, 69], ["SARS-PV", "ORGANISM", 79, 86], ["retrovirus", "ORGANISM", 88, 98], ["pseudotyped", "ORGANISM", 99, 110], ["SARS-CoV", "ORGANISM", 116, 124], ["sera", "ORGANISM_SUBSTANCE", 170, 174], ["SARS-CoV-2", "ORGANISM", 197, 207], ["SARS-CoV-2", "ORGANISM", 279, 289], ["VeroE6-hACE2 cells", "CELL_LINE", 51, 69], ["CoV-2", "SPECIES", 202, 207], ["SARS-PV", "SPECIES", 79, 86], ["SARS-CoV", "SPECIES", 116, 124], ["SARS-CoV-2", "SPECIES", 197, 207], ["SARS-CoV-2", "SPECIES", 279, 289], ["The same anti-RBD sera", "TEST", 0, 22], ["infection of VeroE6-hACE2 cells", "PROBLEM", 38, 69], ["the SARS", "TEST", 75, 83], ["PV (retrovirus pseudotyped", "PROBLEM", 84, 110], ["SARS", "PROBLEM", 116, 120], ["CoV S", "TEST", 121, 126], ["NT50", "TEST", 133, 137], ["Anti-RBD sera", "TEST", 161, 174], ["CoV-2 infection", "PROBLEM", 202, 217], ["The antisera", "TREATMENT", 217, 229], ["authentic SARS", "PROBLEM", 269, 283], ["CoV-2 infection", "PROBLEM", 284, 299], ["infection", "OBSERVATION", 38, 47], ["PV", "ANATOMY", 84, 86], ["SARS", "OBSERVATION", 279, 283], ["infection", "OBSERVATION", 290, 299]]], ["The anti-RBD sera were found to potently inhibite infection of VeroE6 cells with authentic SARS2-CoV-2 based on CPE observation (Supplemental Fig. 5 ), whereas the control sera did not prevent CPE development even when a sera dilution of 1:20 (the lowest dilution tested) was used.", [["sera", "ANATOMY", 13, 17], ["VeroE6 cells", "ANATOMY", 63, 75], ["sera", "ANATOMY", 172, 176], ["sera", "ANATOMY", 221, 225], ["infection", "DISEASE", 50, 59], ["CPE", "CHEMICAL", 193, 196], ["anti-RBD", "ORGANISM_SUBSTANCE", 4, 12], ["sera", "ORGANISM_SUBSTANCE", 13, 17], ["VeroE6 cells", "CELL", 63, 75], ["SARS2-CoV-2", "ORGANISM", 91, 102], ["sera", "ORGANISM_SUBSTANCE", 172, 176], ["sera", "ORGANISM_SUBSTANCE", 221, 225], ["VeroE6 cells", "CELL_LINE", 63, 75], ["SARS2", "PROTEIN", 91, 96], ["The anti-RBD sera", "TEST", 0, 17], ["infection of VeroE6 cells", "PROBLEM", 50, 75], ["CPE observation", "TEST", 112, 127], ["CPE development", "PROBLEM", 193, 208], ["a sera dilution", "TEST", 219, 234], ["infection", "OBSERVATION", 50, 59]]], ["Both qRT-PCR and IFA assays revealed that the anti-RBD sera diluted 1:1280 nearly completely block the viral infection and even the 1:5120 diluted anti-RBD sera could inhibit viral infection by 83% ( Fig. 3C -D).Anti-RBD sera neutralized authentic SARS-CoV-2 infectionThese results demonstrate that the anti-RBD sera possessed very strong neutralization capacity against SARS-CoV-2.Anti-RBD mouse sera did not enhance SARS-CoV-2 infection in Fc receptor-expressing cells.For some viruses such as dengue virus, antibodies targeting the envelope protein may increase viral infection of FcR-expressing cells -a phenomenon called antibody-dependent enhancement (ADE) (Huisman et al., 2009; Thomas et al., 2006) .Anti-RBD mouse sera did not enhance SARS-CoV-2 infection in Fc receptor-expressing cells.Several FcR-bearing cell lines were used as the target cell in infection/neutralization assays to evaluate whether our antisera could mediate ADE in vitro, including mouse A20 cells expressing Fc\u03b3RII (Antoniou and Watts, 2002) , human THP-1 cells expressing both Fc\u03b3RI and Fc\u03b3RII (Chan et al., 2011) , and K562 cells expressing human Fc\u03b3RII (Block et al., 2010) .", [["sera", "ANATOMY", 55, 59], ["sera", "ANATOMY", 156, 160], ["sera", "ANATOMY", 221, 225], ["sera", "ANATOMY", 312, 316], ["sera", "ANATOMY", 397, 401], ["cells", "ANATOMY", 465, 470], ["cells", "ANATOMY", 599, 604], ["sera", "ANATOMY", 723, 727], ["cells", "ANATOMY", 791, 796], ["cell lines", "ANATOMY", 817, 827], ["cell", "ANATOMY", 852, 856], ["A20 cells", "ANATOMY", 969, 978], ["THP-1 cells", "ANATOMY", 1032, 1043], ["K562 cells", "ANATOMY", 1103, 1113], ["viral infection", "DISEASE", 103, 118], ["viral infection", "DISEASE", 175, 190], ["infection", "DISEASE", 429, 438], ["dengue", "DISEASE", 496, 502], ["viral infection", "DISEASE", 565, 580], ["infection", "DISEASE", 755, 764], ["infection", "DISEASE", 860, 869], ["sera", "ORGANISM_SUBSTANCE", 55, 59], ["sera", "ORGANISM_SUBSTANCE", 156, 160], ["sera", "ORGANISM_SUBSTANCE", 221, 225], ["SARS-CoV-2", "ORGANISM", 248, 258], ["anti-RBD", "ORGANISM", 303, 311], ["sera", "ORGANISM_SUBSTANCE", 312, 316], ["SARS-CoV-2", "ORGANISM", 371, 381], ["mouse", "ORGANISM", 391, 396], ["sera", "ORGANISM_SUBSTANCE", 397, 401], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 418, 428], ["Fc receptor", "GENE_OR_GENE_PRODUCT", 442, 453], ["cells", "CELL", 465, 470], ["dengue virus", "ORGANISM", 496, 508], ["FcR", "GENE_OR_GENE_PRODUCT", 584, 587], ["cells", "CELL", 599, 604], ["mouse", "ORGANISM", 717, 722], ["sera", "ORGANISM_SUBSTANCE", 723, 727], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 744, 754], ["Fc receptor", "GENE_OR_GENE_PRODUCT", 768, 779], ["cells", "CELL", 791, 796], ["FcR", "GENE_OR_GENE_PRODUCT", 805, 808], ["cell lines", "CELL", 817, 827], ["cell", "CELL", 852, 856], ["mouse", "ORGANISM", 963, 968], ["A20 cells", "CELL", 969, 978], ["Fc\u03b3RII", "GENE_OR_GENE_PRODUCT", 990, 996], ["human", "ORGANISM", 1026, 1031], ["THP-1 cells", "CELL", 1032, 1043], ["Fc\u03b3RI", "GENE_OR_GENE_PRODUCT", 1060, 1065], ["Fc\u03b3RII", "GENE_OR_GENE_PRODUCT", 1070, 1076], ["K562 cells", "CELL", 1103, 1113], ["human", "ORGANISM", 1125, 1130], ["Fc\u03b3RII", "GENE_OR_GENE_PRODUCT", 1131, 1137], ["RBD", "PROTEIN", 387, 390], ["Fc receptor-expressing cells", "CELL_LINE", 442, 470], ["antibodies", "PROTEIN", 510, 520], ["envelope protein", "PROTEIN", 535, 551], ["FcR", "PROTEIN", 584, 587], ["expressing cells", "CELL_TYPE", 588, 604], ["RBD", "PROTEIN", 713, 716], ["Fc receptor-expressing cells", "CELL_LINE", 768, 796], ["FcR-bearing cell lines", "CELL_LINE", 805, 827], ["mouse A20 cells", "CELL_LINE", 963, 978], ["Fc\u03b3RII", "PROTEIN", 990, 996], ["human THP-1 cells", "CELL_LINE", 1026, 1043], ["Fc\u03b3RI", "PROTEIN", 1060, 1065], ["Fc\u03b3RII", "PROTEIN", 1070, 1076], ["K562 cells", "CELL_LINE", 1103, 1113], ["human Fc\u03b3RII", "PROTEIN", 1125, 1137], ["CoV-2", "SPECIES", 253, 258], ["mouse", "SPECIES", 391, 396], ["mouse", "SPECIES", 717, 722], ["mouse", "SPECIES", 963, 968], ["human", "SPECIES", 1026, 1031], ["human", "SPECIES", 1125, 1130], ["SARS-CoV-2", "SPECIES", 248, 258], ["SARS-CoV", "SPECIES", 371, 379], ["mouse", "SPECIES", 391, 396], ["dengue virus", "SPECIES", 496, 508], ["mouse", "SPECIES", 717, 722], ["mouse", "SPECIES", 963, 968], ["human", "SPECIES", 1026, 1031], ["human", "SPECIES", 1125, 1130], ["Both qRT-PCR", "TEST", 0, 12], ["IFA assays", "TEST", 17, 27], ["the anti-RBD sera", "TEST", 42, 59], ["the viral infection", "PROBLEM", 99, 118], ["diluted anti-RBD sera", "TREATMENT", 139, 160], ["viral infection", "PROBLEM", 175, 190], ["Anti-RBD sera", "TEST", 212, 225], ["CoV-2 infection", "PROBLEM", 253, 268], ["the anti-RBD sera", "TEST", 299, 316], ["SARS", "PROBLEM", 371, 375], ["CoV", "TEST", 376, 379], ["Anti-RBD mouse sera", "TEST", 382, 401], ["SARS", "PROBLEM", 418, 422], ["CoV", "TEST", 423, 426], ["2 infection", "PROBLEM", 427, 438], ["some viruses", "PROBLEM", 475, 487], ["dengue virus", "PROBLEM", 496, 508], ["antibodies", "TEST", 510, 520], ["the envelope protein", "TEST", 531, 551], ["viral infection of FcR-expressing cells", "PROBLEM", 565, 604], ["a phenomenon", "TEST", 606, 618], ["antibody", "TEST", 626, 634], ["dependent enhancement", "PROBLEM", 635, 656], ["Anti-RBD mouse sera", "TEST", 708, 727], ["SARS", "PROBLEM", 744, 748], ["CoV", "TEST", 749, 752], ["2 infection", "PROBLEM", 753, 764], ["Several FcR-bearing cell lines", "TREATMENT", 797, 827], ["the target cell in infection", "PROBLEM", 841, 869], ["neutralization assays", "TEST", 870, 891], ["viral", "OBSERVATION_MODIFIER", 103, 108], ["infection", "OBSERVATION", 109, 118], ["infection", "OBSERVATION", 429, 438], ["expressing cells", "OBSERVATION", 454, 470], ["viruses", "OBSERVATION", 480, 487], ["viral infection", "OBSERVATION", 565, 580], ["dependent enhancement", "OBSERVATION_MODIFIER", 635, 656], ["infection", "OBSERVATION", 755, 764], ["expressing cells", "OBSERVATION", 780, 796], ["bearing cell lines", "OBSERVATION", 809, 827], ["infection", "OBSERVATION", 860, 869]]], ["Both THP-1 and K562 cells have been shown to support mouse antibody-mediated enhancement of dengue virus infection in previous studies (Block et al., 2010; Sun et al., 2017; Zhang et al., 2019) .", [["THP-1", "ANATOMY", 5, 10], ["K562 cells", "ANATOMY", 15, 25], ["dengue virus infection", "DISEASE", 92, 114], ["THP-1", "CELL", 5, 10], ["K562 cells", "CELL", 15, 25], ["mouse", "ORGANISM", 53, 58], ["dengue virus", "ORGANISM", 92, 104], ["THP-1", "CELL_LINE", 5, 10], ["K562 cells", "CELL_LINE", 15, 25], ["mouse antibody", "PROTEIN", 53, 67], ["mouse", "SPECIES", 53, 58], ["mouse", "SPECIES", 53, 58], ["dengue virus", "SPECIES", 92, 104], ["K562 cells", "TEST", 15, 25], ["mouse antibody", "PROBLEM", 53, 67], ["dengue virus infection", "PROBLEM", 92, 114], ["dengue virus infection", "OBSERVATION", 92, 114]]], ["We found that SARS2-PV entry into the three FcR-expressing cell lines was minimal (\uff1c0.02%) whereas the same amount of SARS2-PV yielded an infection rate of ~7% in VeroE6-hACE2 cells.", [["cell lines", "ANATOMY", 59, 69], ["VeroE6-hACE2 cells", "ANATOMY", 163, 181], ["infection", "DISEASE", 138, 147], ["SARS2-PV", "GENE_OR_GENE_PRODUCT", 14, 22], ["FcR", "GENE_OR_GENE_PRODUCT", 44, 47], ["cell lines", "CELL", 59, 69], ["SARS2-PV", "GENE_OR_GENE_PRODUCT", 118, 126], ["VeroE6-hACE2 cells", "CELL", 163, 181], ["SARS2", "PROTEIN", 14, 19], ["FcR-expressing cell lines", "CELL_LINE", 44, 69], ["SARS2", "PROTEIN", 118, 123], ["PV", "PROTEIN", 124, 126], ["VeroE6-hACE2 cells", "CELL_LINE", 163, 181], ["SARS2", "TEST", 14, 19], ["SARS2", "TEST", 118, 123], ["an infection rate", "TEST", 135, 152], ["cell lines", "OBSERVATION", 59, 69], ["minimal", "OBSERVATION_MODIFIER", 74, 81], ["infection", "OBSERVATION", 138, 147], ["hACE2 cells", "OBSERVATION", 170, 181]]], ["Moreover, treatment with serially diluted (ranging from 1:10 2 to 1:10 6 ) control sera or anti-RBD sera did not significantly affect SARS2-PV entry of the three cell lines (Fig. 4A-C) , indicating that the anti-RBD sera do not promote ADE of SARS2-PV.", [["sera", "ANATOMY", 83, 87], ["sera", "ANATOMY", 100, 104], ["cell lines", "ANATOMY", 162, 172], ["sera", "ANATOMY", 216, 220], ["sera", "ORGANISM_SUBSTANCE", 83, 87], ["sera", "ORGANISM_SUBSTANCE", 100, 104], ["SARS2-PV", "GENE_OR_GENE_PRODUCT", 134, 142], ["cell lines", "CELL", 162, 172], ["Fig. 4A-C", "CELL", 174, 183], ["anti-RBD", "ORGANISM", 207, 215], ["sera", "ORGANISM_SUBSTANCE", 216, 220], ["SARS2-PV", "GENE_OR_GENE_PRODUCT", 243, 251], ["SARS2", "PROTEIN", 134, 139], ["cell lines", "CELL_LINE", 162, 172], ["SARS2", "PROTEIN", 243, 248], ["sera or anti-RBD sera", "TEST", 83, 104], ["SARS2", "TEST", 134, 139], ["the anti-RBD sera", "TEST", 203, 220], ["cell lines", "OBSERVATION", 162, 172], ["PV", "ANATOMY", 249, 251]]], ["We selected K562 cells for performing ADE assay with authentic SARS-CoV-2 as the challenge virus.", [["K562 cells", "ANATOMY", 12, 22], ["K562 cells", "CELL", 12, 22], ["CoV-2", "ORGANISM", 68, 73], ["K562 cells", "CELL_LINE", 12, 22], ["K562 cells", "TREATMENT", 12, 22], ["ADE assay", "TEST", 38, 47], ["CoV", "TEST", 68, 71], ["the challenge virus", "TREATMENT", 77, 96], ["K562 cells", "OBSERVATION", 12, 22]]], ["No significant increase in viral RNA level was observed for the antisera-treated samples as compared to the control (cells only infected with the virus) regardless of the antisera dilutions (Fig. 4D) .", [["samples", "ANATOMY", 81, 88], ["cells", "ANATOMY", 117, 122], ["cells", "CELL", 117, 122], ["viral RNA", "RNA", 27, 36], ["significant increase in viral RNA level", "PROBLEM", 3, 42], ["the antisera", "TEST", 60, 72], ["the virus", "PROBLEM", 142, 151], ["the antisera dilutions", "TREATMENT", 167, 189], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["viral RNA", "OBSERVATION", 27, 36]]], ["Collectively, these results demonstrate that, in the assay system we tested, the anti-RBD antibodies do not promote ADE.DISCUSSIONThe present study was aimed to investigate the possibility of developing a RBD-based subunit vaccine for SARS-CoV-2.", [["ADE", "DISEASE", 116, 119], ["RBD", "DISEASE", 205, 208], ["anti-RBD antibodies", "GENE_OR_GENE_PRODUCT", 81, 100], ["SARS-CoV-2", "ORGANISM", 235, 245], ["anti-RBD antibodies", "PROTEIN", 81, 100], ["RBD", "PROTEIN", 205, 208], ["SARS-CoV", "SPECIES", 235, 243], ["the assay system", "TEST", 49, 65], ["the anti-RBD antibodies", "TEST", 77, 100], ["The present study", "TEST", 130, 147], ["developing a RBD", "PROBLEM", 192, 208], ["based subunit vaccine", "TREATMENT", 209, 230], ["SARS", "PROBLEM", 235, 239], ["CoV", "TEST", 240, 243], ["RBD", "OBSERVATION", 205, 208]]], ["It was found that RBD fusion proteins with either Fc or 6 \u00d7 His tag elicited high-titer neutralizing antibody responses, indicating that RBD is the antigen component responsible for the induction of neutralizing antibodies.", [["His", "CHEMICAL", 60, 63], ["RBD", "GENE_OR_GENE_PRODUCT", 18, 21], ["Fc", "GENE_OR_GENE_PRODUCT", 50, 52], ["RBD", "GENE_OR_GENE_PRODUCT", 137, 140], ["RBD fusion proteins", "PROTEIN", 18, 37], ["Fc or 6 \u00d7 His tag", "PROTEIN", 50, 67], ["RBD", "PROTEIN", 137, 140], ["neutralizing antibodies", "PROTEIN", 199, 222], ["RBD fusion proteins", "PROBLEM", 18, 37], ["Fc", "TEST", 50, 52], ["His tag", "TEST", 60, 67], ["RBD", "PROBLEM", 137, 140], ["the antigen component", "PROBLEM", 144, 165], ["neutralizing antibodies", "PROBLEM", 199, 222], ["RBD", "OBSERVATION", 137, 140]]], ["In particular, the anti-RBD sera potently neutralized SARS2-PV entry with an NT50 value of 12764 (Fig. 3A ) and its neutralization efficiency against authentic SARS-CoV-2 was \uff1e75% at the serum dilution of 1:5120 ( Fig. 3C ).", [["sera", "ANATOMY", 28, 32], ["serum", "ANATOMY", 187, 192], ["SARS", "DISEASE", 160, 164], ["anti-RBD", "ORGANISM", 19, 27], ["sera", "ORGANISM_SUBSTANCE", 28, 32], ["SARS2-PV", "GENE_OR_GENE_PRODUCT", 54, 62], ["SARS-CoV-2", "ORGANISM", 160, 170], ["serum", "ORGANISM_SUBSTANCE", 187, 192], ["SARS2", "PROTEIN", 54, 59], ["PV", "SPECIES", 60, 62], ["SARS-CoV", "SPECIES", 160, 168], ["the anti-RBD sera", "TEST", 15, 32], ["an NT50 value", "TEST", 74, 87], ["its neutralization efficiency", "PROBLEM", 112, 141], ["authentic SARS", "TEST", 150, 164], ["CoV", "TEST", 165, 168], ["the serum dilution", "TEST", 183, 201]]], ["According to a recent report (Gao et al., 2020) , macaques immunized with a purified inactivated SARS-CoV-2 virus vaccine candidate (which induced NT50 titers up to 3,000 in mice) produced neutralizing serum antibody titers of around 50 to 61 and were protected from authentic SARS-CoV-2 challenge.", [["serum", "ANATOMY", 202, 207], ["SARS", "DISEASE", 277, 281], ["macaques", "ORGANISM", 50, 58], ["SARS-CoV-2 virus", "ORGANISM", 97, 113], ["mice", "ORGANISM", 174, 178], ["serum", "ORGANISM_SUBSTANCE", 202, 207], ["CoV-2", "ORGANISM", 282, 287], ["macaques", "SPECIES", 50, 58], ["SARS-CoV-2 virus vaccine", "SPECIES", 97, 121], ["mice", "SPECIES", 174, 178], ["SARS-CoV-2 virus", "SPECIES", 97, 113], ["mice", "SPECIES", 174, 178], ["a purified inactivated SARS", "PROBLEM", 74, 101], ["CoV-2 virus vaccine", "TREATMENT", 102, 121], ["NT50 titers", "TEST", 147, 158], ["neutralizing serum antibody titers", "TEST", 189, 223]]], ["Therefore, the seemingly higher neutralizing antibody titers of our anti-RBD mouse antisera compared to that of the mouse antisera against the inactivated whole-virus vaccine (although not directly compared) strongly suggest that the RBD subunit vaccine candidate will likely be protective as well.DISCUSSIONThe anti-RBD sera not only were able to efficiently neutralize SARS-CoV-2 infections but also could inhibit SARS2-S-mediated cell-cell fusion ( Fig. 2H and Supplementary Fig. S3 and S4) , demonstrating a two-layer protective potential of the antisera.", [["sera", "ANATOMY", 321, 325], ["cell", "ANATOMY", 433, 437], ["cell", "ANATOMY", 438, 442], ["SARS", "DISEASE", 371, 375], ["infections", "DISEASE", 382, 392], ["mouse", "ORGANISM", 77, 82], ["mouse", "ORGANISM", 116, 121], ["whole-virus", "ORGANISM", 155, 166], ["sera", "ORGANISM_SUBSTANCE", 321, 325], ["SARS-CoV-2", "ORGANISM", 371, 381], ["SARS2-S", "GENE_OR_GENE_PRODUCT", 416, 423], ["cell", "CELL", 433, 437], ["cell", "CELL", 438, 442], ["S4", "GENE_OR_GENE_PRODUCT", 490, 492], ["RBD subunit", "PROTEIN", 234, 245], ["SARS2", "PROTEIN", 416, 421], ["S4", "PROTEIN", 490, 492], ["mouse", "SPECIES", 77, 82], ["mouse", "SPECIES", 116, 121], ["-virus vaccine", "SPECIES", 160, 174], ["mouse", "SPECIES", 77, 82], ["mouse", "SPECIES", 116, 121], ["SARS-CoV-2", "SPECIES", 371, 381], ["our anti-RBD mouse antisera", "TREATMENT", 64, 91], ["the mouse antisera", "TREATMENT", 112, 130], ["the inactivated whole-virus vaccine", "TREATMENT", 139, 174], ["the RBD subunit vaccine", "TREATMENT", 230, 253], ["CoV-2 infections", "PROBLEM", 376, 392], ["SARS2", "TEST", 416, 421], ["mediated cell-cell fusion", "PROBLEM", 424, 449], ["Supplementary Fig", "TREATMENT", 464, 481], ["the antisera", "TREATMENT", 546, 558], ["cell fusion", "OBSERVATION", 438, 449], ["S4", "ANATOMY", 490, 492]]], ["Host receptor recognition and binding is required for coronavirus entry.DISCUSSIONPrevious work showed that, for SARS-CoV and MERS-CoV, RBD binding to the receptor triggers the spike to undergo conformational changes, allowing subsequent protease cleavage, virus internalization and membrane fusion (Millet and Whittaker, 2018; Pallesen et al., 2017) .", [["membrane", "ANATOMY", 283, 291], ["SARS", "DISEASE", 113, 117], ["coronavirus", "ORGANISM", 54, 65], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 113, 121], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 126, 134], ["RBD", "GENE_OR_GENE_PRODUCT", 136, 139], ["membrane", "CELLULAR_COMPONENT", 283, 291], ["RBD", "PROTEIN", 136, 139], ["protease", "PROTEIN", 238, 246], ["SARS-CoV", "SPECIES", 113, 121], ["MERS-CoV", "SPECIES", 126, 134], ["coronavirus entry", "PROBLEM", 54, 71], ["SARS", "PROBLEM", 113, 117], ["CoV", "PROBLEM", 118, 121], ["MERS", "PROBLEM", 126, 130], ["CoV", "PROBLEM", 131, 134], ["RBD binding", "PROBLEM", 136, 147], ["conformational changes", "PROBLEM", 194, 216], ["subsequent protease cleavage", "TREATMENT", 227, 255], ["virus internalization", "TREATMENT", 257, 278], ["membrane fusion", "TREATMENT", 283, 298]]], ["In this study, the anti-RBD sera were found to dose-dependently reduce the RBD binding to ACE2 in ELISAs ( Fig. 1B and 2F ).DISCUSSIONThese data suggest blocking the interaction between RBD/S and the host receptor ACE2 is the main mechanism underlying the observed neutralization and cell-cell fusion inhibition by the anti-RBD sera.DISCUSSIONInterestingly, we found that the mouse antisera raised against SARS2-RBD cross-reacted with SARS-RBD, inhibited SARS-RBD binding to ACE2, and neutralized SARS-PV entry with an NT50 of 834.8.", [["sera", "ANATOMY", 28, 32], ["cell", "ANATOMY", 284, 288], ["cell", "ANATOMY", 289, 293], ["SARS-RBD", "DISEASE", 435, 443], ["anti-RBD", "ORGANISM", 19, 27], ["sera", "ORGANISM_SUBSTANCE", 28, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 90, 94], ["RBD/S", "GENE_OR_GENE_PRODUCT", 186, 191], ["ACE2", "GENE_OR_GENE_PRODUCT", 214, 218], ["cell", "CELL", 284, 288], ["cell", "CELL", 289, 293], ["anti-RBD", "GENE_OR_GENE_PRODUCT", 319, 327], ["mouse", "ORGANISM", 376, 381], ["SARS2", "GENE_OR_GENE_PRODUCT", 406, 411], ["SARS-RBD", "GENE_OR_GENE_PRODUCT", 435, 443], ["SARS-RBD", "GENE_OR_GENE_PRODUCT", 455, 463], ["ACE2", "GENE_OR_GENE_PRODUCT", 475, 479], ["RBD", "PROTEIN", 75, 78], ["ACE2", "PROTEIN", 90, 94], ["RBD", "PROTEIN", 186, 189], ["S", "PROTEIN", 190, 191], ["ACE2", "PROTEIN", 214, 218], ["anti-RBD", "PROTEIN", 319, 327], ["SARS2", "PROTEIN", 406, 411], ["RBD", "PROTEIN", 412, 415], ["SARS-RBD", "PROTEIN", 435, 443], ["RBD", "PROTEIN", 460, 463], ["ACE2", "PROTEIN", 475, 479], ["mouse", "SPECIES", 376, 381], ["mouse", "SPECIES", 376, 381], ["this study", "TEST", 3, 13], ["the anti-RBD sera", "TEST", 15, 32], ["the RBD binding", "PROBLEM", 71, 86], ["ACE2 in ELISAs", "TEST", 90, 104], ["the interaction between RBD/S", "PROBLEM", 162, 191], ["the host receptor ACE2", "TREATMENT", 196, 218], ["the observed neutralization", "PROBLEM", 252, 279], ["cell-cell fusion inhibition", "TREATMENT", 284, 311], ["the mouse antisera", "TEST", 372, 390], ["SARS2", "TEST", 406, 411], ["SARS", "PROBLEM", 435, 439], ["RBD", "PROBLEM", 440, 443], ["SARS", "PROBLEM", 455, 459], ["RBD binding", "PROBLEM", 460, 471], ["ACE2", "TEST", 475, 479], ["neutralized SARS", "TEST", 485, 501], ["an NT50", "TEST", 516, 523], ["RBD", "OBSERVATION", 75, 78], ["neutralization", "OBSERVATION", 265, 279]]], ["SARS2-RBD can be divided into a core subdomain and a receptor-binding motif (RBM) which directly engages ACE2 (Lan et al., 2020; Shang et al., 2020; Yan et al., 2020) .", [["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 0, 9], ["ACE2", "GENE_OR_GENE_PRODUCT", 105, 109], ["SARS2", "PROTEIN", 0, 5], ["RBD", "PROTEIN", 6, 9], ["receptor-binding motif", "PROTEIN", 53, 75], ["RBM", "PROTEIN", 77, 80], ["ACE2", "PROTEIN", 105, 109], ["a receptor-binding motif (RBM", "TREATMENT", 51, 80]]], ["The core subdomain is highly conserved while the RBM varies significantly (~47% homology in amino acid sequence) between SARS-CoV and SARS-CoV-2.", [["amino acid", "CHEMICAL", 92, 102], ["amino acid", "CHEMICAL", 92, 102], ["amino acid", "AMINO_ACID", 92, 102], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 121, 129], ["SARS-CoV-2", "ORGANISM", 134, 144], ["RBM", "PROTEIN", 49, 52], ["amino acid sequence", "PROTEIN", 92, 111], ["SARS-CoV", "SPECIES", 121, 129], ["SARS-CoV", "SPECIES", 134, 142], ["the RBM varies", "TEST", 45, 59], ["amino acid sequence", "TEST", 92, 111], ["SARS", "TEST", 121, 125], ["CoV", "TEST", 126, 129], ["SARS", "TEST", 134, 138], ["CoV", "TEST", 139, 142], ["highly", "OBSERVATION_MODIFIER", 22, 28], ["conserved", "OBSERVATION", 29, 38], ["RBM", "OBSERVATION", 49, 52]]], ["Therefore, we reason that the observed cross binding and neutralization capacity towards SARS-CoV is contributed by antibodies targeting the conserved core subdomain of SARS2-RBD.", [["SARS", "DISEASE", 89, 93], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 89, 97], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 169, 178], ["antibodies", "PROTEIN", 116, 126], ["SARS2", "PROTEIN", 169, 174], ["RBD", "PROTEIN", 175, 178], ["SARS-CoV", "SPECIES", 89, 97], ["the observed cross binding", "PROBLEM", 26, 52], ["neutralization capacity", "PROBLEM", 57, 80], ["SARS", "PROBLEM", 89, 93], ["CoV", "PROBLEM", 94, 97], ["RBD", "PROBLEM", 175, 178], ["RBD", "OBSERVATION", 175, 178]]], ["That is to say, the core subdomain contains SARS-CoV-2/SARS-CoV cross-neutralization antibody epitopes.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 55, 63], ["SARS-CoV-2/SARS-CoV cross-neutralization antibody epitopes", "PROTEIN", 44, 102], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["SARS", "PROBLEM", 55, 59], ["CoV cross-neutralization antibody epitopes", "TREATMENT", 60, 102], ["SARS", "OBSERVATION", 44, 48]]], ["This information will be useful for future design and development of pan-SARS-CoV vaccines.DISCUSSIONA major concern in developing coronavirus vaccines is the risk of vaccine-induced ADE Huisman et al., 2009) .", [["coronavirus", "DISEASE", 131, 142], ["pan-SARS-CoV", "GENE_OR_GENE_PRODUCT", 69, 81], ["coronavirus", "ORGANISM", 131, 142], ["pan-SARS-CoV", "SPECIES", 69, 81], ["pan-SARS", "TREATMENT", 69, 77], ["CoV vaccines", "TREATMENT", 78, 90], ["coronavirus vaccines", "TREATMENT", 131, 151], ["vaccine", "TREATMENT", 167, 174]]], ["ADE phenomenon has been observed for feline coronavirus (Huisman et al., 1998; Huisman et al., 2009; Weiss and Scott, 1981) and for SARS-CoV (Bolles et al., 2011; Luo et al., 2018; Tseng et al., 2012; Wang et al., 2016) .", [["feline coronavirus", "DISEASE", 37, 55], ["SARS-CoV", "DISEASE", 132, 140], ["feline coronavirus", "ORGANISM", 37, 55], ["SARS-CoV", "ORGANISM", 132, 140], ["feline coronavirus", "SPECIES", 37, 55], ["feline coronavirus", "SPECIES", 37, 55], ["SARS-CoV", "SPECIES", 132, 140], ["SARS", "PROBLEM", 132, 136]]], ["Some cell culture studies suggested that anti-S antibodies mediated ADE in FcR-expressing cells likely through enhancing FcR-mediated internalization/entry of antibody-bound virions Jaume et al., 2011; Liu et al., 2019; Olsen et al., 1992; Wan et al., 2020; Wang et al., 2014; Yip et al., 2014) .", [["cell", "ANATOMY", 5, 9], ["cells", "ANATOMY", 90, 95], ["cell", "CELL", 5, 9], ["anti-S antibodies", "GENE_OR_GENE_PRODUCT", 41, 58], ["FcR", "GENE_OR_GENE_PRODUCT", 75, 78], ["cells", "CELL", 90, 95], ["FcR", "GENE_OR_GENE_PRODUCT", 121, 124], ["anti-S antibodies", "PROTEIN", 41, 58], ["FcR", "PROTEIN", 75, 78], ["expressing cells", "CELL_TYPE", 79, 95], ["FcR", "PROTEIN", 121, 124], ["antibody", "PROTEIN", 159, 167], ["Some cell culture studies", "TEST", 0, 25], ["anti-S antibodies", "TEST", 41, 58], ["expressing cells", "PROBLEM", 79, 95]]], ["In the present study, we showed that the anti-RBD sera did not enhance SARS2-PV entry of the three FcR-expressing cell lines (A20, THP-1, and K562) regardless of the antisera concentration.", [["sera", "ANATOMY", 50, 54], ["cell lines", "ANATOMY", 114, 124], ["K562", "ANATOMY", 142, 146], ["sera", "ORGANISM_SUBSTANCE", 50, 54], ["SARS2-PV", "GENE_OR_GENE_PRODUCT", 71, 79], ["FcR", "GENE_OR_GENE_PRODUCT", 99, 102], ["cell lines", "CELL", 114, 124], ["A20", "CELL", 126, 129], ["THP-1", "CELL", 131, 136], ["K562", "CELL", 142, 146], ["SARS2", "PROTEIN", 71, 76], ["FcR-expressing cell lines", "CELL_LINE", 99, 124], ["A20", "CELL_LINE", 126, 129], ["THP-1", "CELL_LINE", 131, 136], ["K562", "CELL_LINE", 142, 146], ["the present study", "TEST", 3, 20], ["the anti-RBD sera", "TEST", 37, 54], ["SARS2", "TEST", 71, 76], ["A20", "TEST", 126, 129], ["THP", "TEST", 131, 134], ["the antisera concentration", "TREATMENT", 162, 188], ["expressing cell lines", "OBSERVATION", 103, 124]]], ["Moreover, treatment with the anti-RBD sera did not increase authentic SARS-CoV-2 infection of K562 cell, despite the same cell line has been shown to support anti-DENV-E mouse antibody-triggered ADE of Dengue virus (DENV) infection in previous studies (Block et al., 2010; Sun et al., 2017; Zhang et al., 2019) .", [["sera", "ANATOMY", 38, 42], ["K562 cell", "ANATOMY", 94, 103], ["cell line", "ANATOMY", 122, 131], ["SARS", "DISEASE", 70, 74], ["infection", "DISEASE", 81, 90], ["Dengue virus (DENV) infection", "DISEASE", 202, 231], ["sera", "ORGANISM_SUBSTANCE", 38, 42], ["CoV-2", "ORGANISM", 75, 80], ["K562 cell", "CELL", 94, 103], ["cell line", "CELL", 122, 131], ["anti-DENV-E mouse", "ORGANISM", 158, 175], ["Dengue virus", "ORGANISM", 202, 214], ["DENV", "ORGANISM", 216, 220], ["K562 cell", "CELL_LINE", 94, 103], ["anti-DENV-E mouse antibody", "PROTEIN", 158, 184], ["mouse", "SPECIES", 170, 175], ["Dengue virus", "SPECIES", 202, 214], ["mouse", "SPECIES", 170, 175], ["Dengue virus", "SPECIES", 202, 214], ["DENV", "SPECIES", 216, 220], ["the anti-RBD sera", "TEST", 25, 42], ["authentic SARS", "PROBLEM", 60, 74], ["2 infection of K562 cell", "PROBLEM", 79, 103], ["the same cell line", "TREATMENT", 113, 131], ["anti-DENV", "TEST", 158, 167], ["Dengue virus (DENV) infection", "PROBLEM", 202, 231], ["K562 cell", "OBSERVATION", 94, 103]]], ["These data clearly show that anti-RBD antibodies do not promote ADE, at least not in the assay system we used.", [["anti-RBD antibodies", "GENE_OR_GENE_PRODUCT", 29, 48], ["anti-RBD antibodies", "PROTEIN", 29, 48], ["anti-RBD antibodies", "PROBLEM", 29, 48]]], ["It remains to be determined whether antibodies targeting other regions of the S protein (which presumably will be non-neutralizing or poorly neutralizing) could mediate ADE of SARS-CoV-2.", [["SARS", "DISEASE", 176, 180], ["S protein", "GENE_OR_GENE_PRODUCT", 78, 87], ["SARS-CoV-2", "ORGANISM", 176, 186], ["antibodies", "PROTEIN", 36, 46], ["S protein", "PROTEIN", 78, 87], ["SARS-CoV", "SPECIES", 176, 184], ["the S protein", "PROBLEM", 74, 87], ["CoV", "TEST", 181, 184]]], ["Nonetheless, the extraordinary neutralization potency and lack of ADE effect observed for the anti-RBD sera indicate that SARS2-RBD is an elite antigen target for developing subunit vaccines for SARS-CoV-2.DISCUSSIONCollectively, our results show that recombinantly expressed SARS2-RBD proteins potently elicits cross-neutralizing antibodies against both SARS-CoV-2 and SARS-CoV without induction of ADE antibodies, providing important information for further development of RBD-based SARS-CoV-2 or pan-SARS-CoV subunit vaccines.Cells and virusesVeroE6 cells were grown as described previously (Zhao et al., 2018) .", [["sera", "ANATOMY", 103, 107], ["Cells", "ANATOMY", 529, 534], ["VeroE6 cells", "ANATOMY", 546, 558], ["sera", "ORGANISM_SUBSTANCE", 103, 107], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 122, 131], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 276, 285], ["SARS-CoV-2", "ORGANISM", 355, 365], ["SARS-CoV", "ORGANISM", 370, 378], ["ADE antibodies", "GENE_OR_GENE_PRODUCT", 400, 414], ["SARS-CoV-2", "ORGANISM", 485, 495], ["pan-SARS-CoV", "ORGANISM", 499, 511], ["Cells", "CELL", 529, 534], ["VeroE6 cells", "CELL", 546, 558], ["SARS2", "PROTEIN", 122, 127], ["RBD", "PROTEIN", 128, 131], ["SARS2", "PROTEIN", 276, 281], ["RBD proteins", "PROTEIN", 282, 294], ["neutralizing antibodies", "PROTEIN", 318, 341], ["ADE antibodies", "PROTEIN", 400, 414], ["RBD", "PROTEIN", 475, 478], ["VeroE6 cells", "CELL_LINE", 546, 558], ["SARS-CoV", "SPECIES", 355, 363], ["SARS-CoV", "SPECIES", 370, 378], ["the extraordinary neutralization potency", "PROBLEM", 13, 53], ["ADE effect", "PROBLEM", 66, 76], ["the anti-RBD sera", "TEST", 90, 107], ["SARS2", "TEST", 122, 127], ["RBD", "PROBLEM", 128, 131], ["developing subunit vaccines", "TREATMENT", 163, 190], ["SARS2", "TEST", 276, 281], ["neutralizing antibodies", "TEST", 318, 341], ["both SARS", "TEST", 350, 359], ["CoV", "TEST", 360, 363], ["SARS", "PROBLEM", 370, 374], ["ADE antibodies", "TREATMENT", 400, 414], ["RBD", "TEST", 475, 478], ["CoV", "TEST", 490, 493], ["pan-SARS", "PROBLEM", 499, 507], ["CoV subunit vaccines", "TREATMENT", 508, 528], ["virusesVeroE6 cells", "PROBLEM", 539, 558], ["viruses", "OBSERVATION_MODIFIER", 539, 546], ["VeroE6 cells", "OBSERVATION", 546, 558]]], ["HEK 293T, A20, THP-1, and K562 cells were purchased from the Cell Bank of Chinese Academy of Sciences (www.cellbank.org.cn).", [["HEK 293T", "ANATOMY", 0, 8], ["A20", "ANATOMY", 10, 13], ["THP-1", "ANATOMY", 15, 20], ["K562 cells", "ANATOMY", 26, 36], ["Cell", "ANATOMY", 61, 65], ["HEK 293T", "CELL", 0, 8], ["A20", "CELL", 10, 13], ["THP-1", "CELL", 15, 20], ["K562 cells", "CELL", 26, 36], ["Cell", "CELL", 61, 65], ["HEK 293T", "CELL_LINE", 0, 8], ["A20", "CELL_LINE", 10, 13], ["THP-1", "CELL_LINE", 15, 20], ["K562 cells", "CELL_LINE", 26, 36], ["HEK", "TEST", 0, 3], ["A20", "TEST", 10, 13], ["THP", "TEST", 15, 18], ["K562 cells", "PROBLEM", 26, 36], ["K562", "ANATOMY", 26, 30]]], ["A clinical isolate of SARS-CoV-2, nCoV-SH01 (GenBank: MT121215.1) (Rong et al., 2020) , was propagated in VeroE6 cells and viral titer was determined as plaque forming units (PFU) per milliliter (mL) by CPE quantification.", [["VeroE6 cells", "ANATOMY", 106, 118], ["plaque", "ANATOMY", 153, 159], ["SARS", "DISEASE", 22, 26], ["SARS-CoV-2", "ORGANISM", 22, 32], ["nCoV", "ORGANISM", 34, 38], ["VeroE6 cells", "CELL", 106, 118], ["VeroE6 cells", "CELL_LINE", 106, 118], ["SARS-CoV", "SPECIES", 22, 30], ["SARS", "TEST", 22, 26], ["CoV", "TEST", 27, 30], ["nCoV", "TEST", 34, 38], ["viral titer", "TEST", 123, 134], ["viral titer", "OBSERVATION", 123, 134]]], ["Live virus infection experiments were performed in the biosafety level-3 (BSL-3) laboratory of Fudan University.Recombinant proteinsFor mouse immunization, recombinant SARS-CoV-2 RBD fusion protein with the Fc region of mouse IgG1 at the C-terminus (RBD-Fc) was purchased from Sino Biological (Beijing, China), recombinant SARS-CoV-2 RBD with a C-terminal His-tag was purchased from Kactus Biosystems (Shanghai, China), and recombinant hepatitis B core antigen (HBc) was produced in house in E.coli as described previously (Ye et al., 2014) .", [["hepatitis B core antigen", "CHEMICAL", 436, 460], ["C", "CHEMICAL", 345, 346], ["Live virus", "ORGANISM", 0, 10], ["mouse", "ORGANISM", 136, 141], ["SARS-CoV-2", "ORGANISM", 168, 178], ["mouse", "ORGANISM", 220, 225], ["IgG1", "GENE_OR_GENE_PRODUCT", 226, 230], ["RBD-Fc", "GENE_OR_GENE_PRODUCT", 250, 256], ["SARS-CoV-2", "ORGANISM", 323, 333], ["RBD", "ORGANISM", 334, 337], ["hepatitis B core antigen", "GENE_OR_GENE_PRODUCT", 436, 460], ["HBc", "GENE_OR_GENE_PRODUCT", 462, 465], ["Recombinant proteins", "PROTEIN", 112, 132], ["recombinant SARS-CoV-2 RBD fusion protein", "PROTEIN", 156, 197], ["Fc region", "PROTEIN", 207, 216], ["mouse IgG1", "PROTEIN", 220, 230], ["C-terminus", "PROTEIN", 238, 248], ["RBD", "PROTEIN", 250, 253], ["Fc", "PROTEIN", 254, 256], ["recombinant SARS-CoV-2 RBD", "PROTEIN", 311, 337], ["C-terminal His-tag", "DNA", 345, 363], ["recombinant hepatitis B core antigen", "PROTEIN", 424, 460], ["HBc", "PROTEIN", 462, 465], ["mouse", "SPECIES", 136, 141], ["mouse", "SPECIES", 220, 225], ["mouse", "SPECIES", 136, 141], ["mouse", "SPECIES", 220, 225], ["E.coli", "SPECIES", 492, 498], ["Live virus infection experiments", "PROBLEM", 0, 32], ["the biosafety level", "TEST", 51, 70], ["Recombinant proteins", "TREATMENT", 112, 132], ["mouse immunization", "TREATMENT", 136, 154], ["recombinant SARS", "TEST", 156, 172], ["CoV", "TEST", 173, 176], ["RBD fusion protein", "TEST", 179, 197], ["recombinant SARS", "TEST", 311, 327], ["CoV", "TEST", 328, 331], ["RBD", "PROBLEM", 334, 337], ["a C-terminal His-tag", "PROBLEM", 343, 363], ["recombinant hepatitis B core antigen", "TEST", 424, 460], ["E.coli", "PROBLEM", 492, 498], ["infection", "OBSERVATION", 11, 20], ["mouse IgG1", "OBSERVATION", 220, 230], ["E.coli", "OBSERVATION", 492, 498]]], ["For biochemical and immunological assays, several mammalian cell-produced recombinant proteins were generated in house, including SARS-CoV-2 RBD (amino acids 320 to 550) fused with an N-terminal Strep-tag and a C-terminal His-tag, SARS-CoV RBD (amino acids 306-520) fused with a C-terminal His-tag, and human ACE2 ecotodomain fused with human IgG1 Fc at the C-terminus (hACE2-Fc).Recombinant proteinsBiotinylated hACE2-Fc was prepared using EZ-Link\u2122Recombinant proteinsSulfo-NHS-LC-LC-Biotin kit (Thermo Fisher Scientific).Mouse immunizationAll the animal experiments in this study were approved by the Institutional AnimalSerum antibody measurementFor antibody measurement, wells of 96-well microtiter plates were coated with the indicated amounts of the SARS2-RBD or SARS-RBD recombinant protein for 2 hrs at 37\u00b0C or overnight at 4\u00b0C. Then the wells were blocked with PBST containing 5% non-fat dry milk for 1 hr at 37\u2103, incubated with 50\u03bcl serially diluted mouse antisera for 2 hrs at 37\u00b0C and then with 50 \u03bcl of horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody for 1 hr 37\u00b0C. After color development, the absorbance at 450 nm was measured in a 96-well plate reader.", [["cell", "ANATOMY", 60, 64], ["milk", "ANATOMY", 901, 905], ["amino acids", "CHEMICAL", 146, 157], ["amino acids 306-520", "CHEMICAL", 245, 264], ["EZ", "CHEMICAL", 441, 443], ["amino acids", "CHEMICAL", 146, 157], ["N-", "CHEMICAL", 184, 186], ["C", "CHEMICAL", 211, 212], ["amino acids", "CHEMICAL", 245, 256], ["C", "CHEMICAL", 279, 280], ["cell", "CELL", 60, 64], ["SARS-CoV-2", "ORGANISM", 130, 140], ["amino acids", "AMINO_ACID", 146, 157], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 231, 239], ["amino acids", "AMINO_ACID", 245, 256], ["306-520", "AMINO_ACID", 257, 264], ["human", "ORGANISM", 303, 308], ["ACE2", "GENE_OR_GENE_PRODUCT", 309, 313], ["human", "ORGANISM", 337, 342], ["IgG1 Fc", "GENE_OR_GENE_PRODUCT", 343, 350], ["hACE2-Fc", "GENE_OR_GENE_PRODUCT", 370, 378], ["hACE2-Fc", "GENE_OR_GENE_PRODUCT", 413, 421], ["EZ", "SIMPLE_CHEMICAL", 441, 443], ["Mouse", "ORGANISM", 523, 528], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 756, 765], ["milk", "ORGANISM_SUBSTANCE", 901, 905], ["mouse", "ORGANISM", 960, 965], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 1016, 1038], ["HRP", "SIMPLE_CHEMICAL", 1040, 1043], ["goat", "ORGANISM", 1056, 1060], ["mammalian cell-produced recombinant proteins", "PROTEIN", 50, 94], ["SARS-CoV-2 RBD", "PROTEIN", 130, 144], ["amino acids 320 to 550", "PROTEIN", 146, 168], ["N-terminal Strep-tag", "PROTEIN", 184, 204], ["C-terminal His-tag", "PROTEIN", 211, 229], ["SARS-CoV RBD", "PROTEIN", 231, 243], ["amino acids 306-520", "PROTEIN", 245, 264], ["C-terminal His-tag", "PROTEIN", 279, 297], ["human ACE2 ecotodomain", "PROTEIN", 303, 325], ["human IgG1 Fc", "PROTEIN", 337, 350], ["C-terminus", "PROTEIN", 358, 368], ["hACE2", "PROTEIN", 370, 375], ["Fc", "PROTEIN", 376, 378], ["Recombinant proteins", "PROTEIN", 380, 400], ["hACE2", "PROTEIN", 413, 418], ["Fc", "PROTEIN", 419, 421], ["Institutional AnimalSerum antibody", "PROTEIN", 603, 637], ["SARS2", "PROTEIN", 756, 761], ["RBD", "PROTEIN", 762, 765], ["SARS-RBD recombinant protein", "PROTEIN", 769, 797], ["horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody", "PROTEIN", 1016, 1084], ["human", "SPECIES", 303, 308], ["human", "SPECIES", 337, 342], ["Mouse", "SPECIES", 523, 528], ["mouse", "SPECIES", 960, 965], ["horseradish", "SPECIES", 1016, 1027], ["goat", "SPECIES", 1056, 1060], ["anti-mouse", "SPECIES", 1061, 1071], ["SARS-CoV", "SPECIES", 130, 138], ["SARS-CoV", "SPECIES", 231, 239], ["human", "SPECIES", 303, 308], ["human", "SPECIES", 337, 342], ["Mouse", "SPECIES", 523, 528], ["mouse", "SPECIES", 960, 965], ["goat", "SPECIES", 1056, 1060], ["biochemical and immunological assays", "TEST", 4, 40], ["several mammalian cell", "PROBLEM", 42, 64], ["recombinant proteins", "PROBLEM", 74, 94], ["SARS", "TEST", 130, 134], ["CoV", "TEST", 135, 138], ["amino acids", "TEST", 146, 157], ["an N-terminal Strep", "TEST", 181, 200], ["a C", "TEST", 209, 212], ["SARS", "PROBLEM", 231, 235], ["amino acids", "TEST", 245, 256], ["a C-terminal His-tag", "TREATMENT", 277, 297], ["human ACE2 ecotodomain", "TREATMENT", 303, 325], ["human IgG1 Fc", "TREATMENT", 337, 350], ["Recombinant proteinsBiotinylated hACE2", "TREATMENT", 380, 418], ["Recombinant proteins", "TEST", 449, 469], ["Sulfo-NHS", "TEST", 469, 478], ["LC", "TEST", 479, 481], ["LC", "TEST", 482, 484], ["Mouse immunization", "TREATMENT", 523, 541], ["this study", "TEST", 571, 581], ["antibody measurement", "TEST", 653, 673], ["well microtiter plates", "TREATMENT", 687, 709], ["RBD", "PROBLEM", 762, 765], ["SARS", "PROBLEM", 769, 773], ["PBST", "TREATMENT", 870, 874], ["50\u03bcl serially diluted mouse antisera", "TREATMENT", 938, 974], ["horseradish peroxidase", "TREATMENT", 1016, 1038], ["conjugated goat anti-mouse IgG antibody", "TEST", 1045, 1084], ["the absorbance", "TEST", 1125, 1139], ["LC", "ANATOMY", 482, 484]]], ["For a given serum sample, its endpoint titer was reported as the reciprocal of the highest serum dilution that had an absorbance \u22650.1 OD unit above the blank.ACE2 competition ELISAWells of 96-well microtiter plates were coated with 25 ng/well of the SARS2-RBD or SARS-RBD recombinant protein overnight at 4\u00b0C, followed by blocking with PBST containing 5% non-fat dry milk for 1 hr at 37\u2103.", [["serum sample", "ANATOMY", 12, 24], ["serum", "ANATOMY", 91, 96], ["milk", "ANATOMY", 367, 371], ["serum", "ORGANISM_SUBSTANCE", 12, 17], ["serum", "ORGANISM_SUBSTANCE", 91, 96], ["ACE2", "GENE_OR_GENE_PRODUCT", 158, 162], ["SARS2-RBD", "GENE_OR_GENE_PRODUCT", 250, 259], ["milk", "ORGANISM_SUBSTANCE", 367, 371], ["ACE2", "PROTEIN", 158, 162], ["SARS2", "PROTEIN", 250, 255], ["RBD", "PROTEIN", 256, 259], ["SARS-RBD recombinant protein", "PROTEIN", 263, 291], ["a given serum sample", "TEST", 4, 24], ["its endpoint titer", "TEST", 26, 44], ["the highest serum dilution", "TEST", 79, 105], ["an absorbance \u2265", "TREATMENT", 115, 130], ["ACE2 competition ELISAWells", "TEST", 158, 185], ["well microtiter plates", "TREATMENT", 192, 214], ["RBD", "PROBLEM", 256, 259], ["SARS", "PROBLEM", 263, 267], ["RBD recombinant protein", "PROBLEM", 268, 291], ["PBST", "TREATMENT", 336, 340], ["blank", "ANATOMY", 152, 157]]], ["Serially diluted mouse antisera were mixed with 20 ng of biotinylated hACE2-Fc in a final volume of 50\u03bcl and the mixtures were added to the wells, followed by incubation for 2 hrs at 37\u00b0C. Then, 50 \u03bcl of horseradish peroxidase (HRP)-conjugated streptavidin (Life Technologies, USA) was added to wells, followed by incubation for 1 hr at 37\u00b0C. After washing, TMB substrate (Life Technologies) was added into wells for color development.", [["TMB", "CHEMICAL", 358, 361], ["mouse", "ORGANISM", 17, 22], ["hACE2-Fc", "GENE_OR_GENE_PRODUCT", 70, 78], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 204, 226], ["HRP", "SIMPLE_CHEMICAL", 228, 231], ["conjugated streptavidin", "SIMPLE_CHEMICAL", 233, 256], ["TMB", "SIMPLE_CHEMICAL", 358, 361], ["hACE2", "PROTEIN", 70, 75], ["Fc", "PROTEIN", 76, 78], ["horseradish peroxidase", "PROTEIN", 204, 226], ["HRP", "PROTEIN", 228, 231], ["mouse", "SPECIES", 17, 22], ["horseradish", "SPECIES", 204, 215], ["mouse", "SPECIES", 17, 22], ["Serially diluted mouse antisera", "TREATMENT", 0, 31], ["biotinylated hACE2", "TREATMENT", 57, 75], ["the mixtures", "TREATMENT", 109, 121], ["horseradish peroxidase (HRP", "TREATMENT", 204, 231], ["conjugated streptavidin (Life Technologies", "TREATMENT", 233, 275], ["TMB substrate (Life Technologies", "TREATMENT", 358, 390]]], ["The plates were read for absorbance at 450 nm in a 96-well plate reader.ADE assayFcR-expressing cell lines, including A20, THP-1, and K562, were used to perform ADE assays.", [["cell lines", "ANATOMY", 96, 106], ["K562", "ANATOMY", 134, 138], ["assayFcR", "GENE_OR_GENE_PRODUCT", 76, 84], ["cell lines", "CELL", 96, 106], ["A20", "CELL", 118, 121], ["THP-1", "GENE_OR_GENE_PRODUCT", 123, 128], ["K562", "CELL", 134, 138], ["ADE assayFcR-expressing cell lines", "CELL_LINE", 72, 106], ["A20", "CELL_LINE", 118, 121], ["THP-1", "CELL_LINE", 123, 128], ["K562", "CELL_LINE", 134, 138], ["The plates", "TEST", 0, 10], ["absorbance", "TEST", 25, 35], ["ADE assayFcR", "TEST", 72, 84], ["expressing cell lines", "TREATMENT", 85, 106], ["A20", "TEST", 118, 121], ["THP", "TEST", 123, 126], ["K562", "TEST", 134, 138], ["ADE assays", "TEST", 161, 171], ["cell lines", "OBSERVATION", 96, 106]]], ["Briefly, the antisera were serially diluted, mixed with either SARS2-PV or authentic SARS-CoV-2 (6,000 PFU), and incubated at 37\u2103 for 1 hr.", [["SARS-CoV-2", "CHEMICAL", 85, 95], ["the antisera", "TREATMENT", 9, 21], ["CoV", "TEST", 90, 93]]], ["Then, the mixtures were added to the target cells.", [["cells", "ANATOMY", 44, 49], ["cells", "CELL", 44, 49], ["target cells", "CELL_TYPE", 37, 49], ["the mixtures", "TREATMENT", 6, 18]]], ["The following infection and culturing steps were carried out as described above in the pseudovirus neutralization and live virus neutralization assays.", [["infection", "DISEASE", 14, 23], ["pseudovirus", "ORGANISM", 87, 98], ["The following infection", "PROBLEM", 0, 23], ["culturing steps", "TEST", 28, 43], ["the pseudovirus neutralization", "TREATMENT", 83, 113], ["infection", "OBSERVATION", 14, 23]]], ["Mock-infected cells and cells only infected with SARS2-PV or authentic SARS-CoV-2 were set as the negative and positive controls, respectively.ADE assayInfection rates of the samples were determined as described above.Statistics analysisAll statistical analyses were performed using GraphPad Prism software v5.0.Statistics analysisKaplan-Meier survival curves were compared using log-rank test.", [["cells", "ANATOMY", 14, 19], ["cells", "ANATOMY", 24, 29], ["samples", "ANATOMY", 175, 182], ["cells", "CELL", 14, 19], ["cells", "CELL", 24, 29], ["SARS2-PV", "ORGANISM", 49, 57], ["SARS-CoV-2", "ORGANISM", 71, 81], ["Mock-infected cells", "CELL_LINE", 0, 19], ["SARS2", "PROTEIN", 49, 54], ["PV", "SPECIES", 55, 57], ["SARS-CoV", "SPECIES", 71, 79], ["infected cells", "PROBLEM", 5, 19], ["cells", "PROBLEM", 24, 29], ["SARS2", "TEST", 49, 54], ["authentic SARS", "PROBLEM", 61, 75], ["CoV", "TEST", 76, 79], ["ADE assayInfection rates", "TEST", 143, 167], ["the samples", "TEST", 171, 182], ["Statistics analysis", "TEST", 218, 237], ["All statistical analyses", "TEST", 237, 261], ["GraphPad Prism software", "TEST", 283, 306], ["Statistics analysisKaplan", "TEST", 312, 337], ["Meier survival curves", "TEST", 338, 359], ["log-rank test", "TEST", 380, 393], ["infected cells", "OBSERVATION", 5, 19], ["infected", "OBSERVATION_MODIFIER", 35, 43]]], ["Statistical significance between treatments was analyzed using Student's 2-tailed t-test and indicated as follows: ns, not significant (P \u2265 0.05); , P < 0.001.", [["tailed t-test", "TEST", 75, 88], ["ns", "TEST", 115, 117]]], ["VeroE6-hACE2 A20 cell SARS2 PV Ctrl sera Anti-RBD seraStatistics analysis10 -2 10 -3 10 -4 10 -5 10 -6 --------10 -2 10 -3 10 -4 10 -5 10 -6 VeroE6-hACE2 THP-1 cell SARS2 PV Ctrl sera Anti-RBD sera", [["cell", "ANATOMY", 17, 21], ["sera", "ANATOMY", 36, 40], ["cell", "ANATOMY", 160, 164], ["sera", "ANATOMY", 179, 183], ["sera", "ANATOMY", 193, 197], ["THP-1 cell", "CELL", 154, 164], ["sera", "ORGANISM_SUBSTANCE", 179, 183], ["sera", "ORGANISM_SUBSTANCE", 193, 197], ["VeroE6", "PROTEIN", 0, 6], ["hACE2", "PROTEIN", 7, 12], ["Anti-RBD seraStatistics analysis10 -2 10 -3 10 -4 10 -5 10 -6 --------10 -2 10 -3 10 -4 10", "DNA", 41, 131], ["PV", "SPECIES", 28, 30], ["PV", "SPECIES", 171, 173], ["VeroE6", "TEST", 0, 6], ["SARS2", "TEST", 22, 27], ["PV", "TEST", 28, 30], ["Ctrl", "TEST", 31, 35], ["sera", "TEST", 36, 40], ["Anti-RBD", "TEST", 41, 49], ["seraStatistics", "TEST", 50, 64], ["analysis10", "TEST", 65, 75], ["THP", "TEST", 154, 157], ["SARS2", "TEST", 165, 170], ["PV", "TEST", 171, 173], ["sera", "TEST", 179, 183], ["sera", "TEST", 193, 197], ["A20 cell", "OBSERVATION", 13, 21]]]], "PMC7498885": [["The Significance of Early Prognostic Prediction for AECHBHepatitis B virus (HBV) infection is a serious global health problem and is particularly highly endemic in China.", [["AECHBHepatitis B virus (HBV) infection", "DISEASE", 52, 90], ["AECHBHepatitis B virus", "ORGANISM", 52, 74], ["HBV", "ORGANISM", 76, 79], ["B virus", "SPECIES", 67, 74], ["AECHBHepatitis B virus", "SPECIES", 52, 74], ["HBV", "SPECIES", 76, 79], ["Early Prognostic Prediction", "PROBLEM", 20, 47], ["AECHBHepatitis B virus (HBV) infection", "PROBLEM", 52, 90], ["a serious global health problem", "PROBLEM", 94, 125], ["highly", "OBSERVATION_MODIFIER", 146, 152], ["endemic", "OBSERVATION_MODIFIER", 153, 160]]], ["Data obtained from the most recent national HBV survey in China revealed that the prevalence of HBsAg in the general Chinese population was 7.18% in 2006.", [["HBsAg", "CHEMICAL", 96, 101], ["HBsAg", "GENE_OR_GENE_PRODUCT", 96, 101], ["HBsAg", "PROTEIN", 96, 101], ["HBV", "SPECIES", 44, 47], ["HBsAg", "PROBLEM", 96, 101]]], ["The total number of HBV carriers is estimated to be more than 93 million, in which 30 million are patients with chronic HBV infection.", [["HBV infection", "DISEASE", 120, 133], ["HBV", "ORGANISM", 20, 23], ["patients", "ORGANISM", 98, 106], ["HBV", "ORGANISM", 120, 123], ["patients", "SPECIES", 98, 106], ["HBV", "SPECIES", 20, 23], ["HBV", "SPECIES", 120, 123], ["HBV carriers", "PROBLEM", 20, 32], ["chronic HBV infection", "PROBLEM", 112, 133], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["HBV", "OBSERVATION", 20, 23], ["chronic", "OBSERVATION_MODIFIER", 112, 119], ["HBV", "OBSERVATION", 120, 123], ["infection", "OBSERVATION", 124, 133]]], ["Chronic hepatitis B (CHB) exhibits a prolonged course and poor prognosis.", [["Chronic hepatitis B", "DISEASE", 0, 19], ["CHB", "DISEASE", 21, 24], ["Chronic hepatitis B", "ORGANISM", 0, 19], ["CHB", "CANCER", 21, 24], ["Chronic hepatitis B (CHB)", "PROBLEM", 0, 25], ["poor prognosis", "PROBLEM", 58, 72], ["hepatitis", "OBSERVATION", 8, 17]]], ["Liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC) are common long-term pathological consequences of CHB.", [["Liver", "ANATOMY", 0, 5], ["hepatocellular carcinoma", "ANATOMY", 30, 54], ["HCC", "ANATOMY", 56, 59], ["Liver fibrosis", "DISEASE", 0, 14], ["cirrhosis", "DISEASE", 16, 25], ["hepatocellular carcinoma", "DISEASE", 30, 54], ["HCC", "DISEASE", 56, 59], ["CHB", "DISEASE", 111, 114], ["Liver", "ORGAN", 0, 5], ["hepatocellular carcinoma", "CANCER", 30, 54], ["HCC", "CANCER", 56, 59], ["Liver fibrosis", "PROBLEM", 0, 14], ["cirrhosis", "PROBLEM", 16, 25], ["hepatocellular carcinoma", "PROBLEM", 30, 54], ["HCC", "PROBLEM", 56, 59], ["CHB", "PROBLEM", 111, 114], ["fibrosis", "OBSERVATION", 6, 14], ["cirrhosis", "OBSERVATION", 16, 25], ["hepatocellular", "ANATOMY", 30, 44], ["carcinoma", "OBSERVATION", 45, 54], ["HCC", "OBSERVATION", 56, 59], ["common long-term pathological", "OBSERVATION_MODIFIER", 65, 94], ["CHB", "OBSERVATION", 111, 114]]], ["A proportion of HBV carriers and CHB patients can develop into acute, subacute or chronic severe hepatitis in case of rapid deterioration of disease condition.", [["CHB", "DISEASE", 33, 36], ["hepatitis", "DISEASE", 97, 106], ["HBV", "ORGANISM", 16, 19], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["HBV", "SPECIES", 16, 19], ["HBV carriers", "PROBLEM", 16, 28], ["CHB", "PROBLEM", 33, 36], ["chronic severe hepatitis", "PROBLEM", 82, 106], ["rapid deterioration of disease condition", "PROBLEM", 118, 158], ["HBV", "OBSERVATION", 16, 19], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["subacute", "OBSERVATION_MODIFIER", 70, 78], ["chronic", "OBSERVATION_MODIFIER", 82, 89], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["hepatitis", "OBSERVATION", 97, 106], ["rapid", "OBSERVATION_MODIFIER", 118, 123], ["deterioration", "OBSERVATION_MODIFIER", 124, 137], ["disease", "OBSERVATION", 141, 148]]], ["Severe hepatitis caused by HBV infection accounts for approximately 70% of the total severe hepatitis cases in China.", [["hepatitis", "DISEASE", 7, 16], ["HBV infection", "DISEASE", 27, 40], ["hepatitis", "DISEASE", 92, 101], ["HBV", "ORGANISM", 27, 30], ["HBV", "SPECIES", 27, 30], ["Severe hepatitis", "PROBLEM", 0, 16], ["HBV infection", "PROBLEM", 27, 40], ["the total severe hepatitis cases in China", "PROBLEM", 75, 116], ["hepatitis", "OBSERVATION", 7, 16], ["HBV", "OBSERVATION_MODIFIER", 27, 30], ["infection", "OBSERVATION", 31, 40], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["hepatitis", "OBSERVATION", 92, 101]]], ["The low treatment efficacy, poor prognosis and high mortality of patients with severe hepatitis cause a serious threat to people\u2019s health, greatly increasing the economic burden of families and society, as well as affecting social stability.The Significance of Early Prognostic Prediction for AECHBTo date, antiviral treatment for HBV has achieved remarkable progress.", [["hepatitis", "DISEASE", 86, 95], ["patients", "ORGANISM", 65, 73], ["people", "ORGANISM", 122, 128], ["HBV", "ORGANISM", 331, 334], ["patients", "SPECIES", 65, 73], ["people", "SPECIES", 122, 128], ["HBV", "SPECIES", 331, 334], ["The low treatment efficacy", "TREATMENT", 0, 26], ["severe hepatitis", "PROBLEM", 79, 95], ["AECHBTo date", "TREATMENT", 293, 305], ["antiviral treatment", "TREATMENT", 307, 326], ["HBV", "PROBLEM", 331, 334], ["low treatment", "OBSERVATION_MODIFIER", 4, 17], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["hepatitis", "OBSERVATION", 86, 95]]], ["However, the incidence of acute exacerbation of CHB (AECHB) remains high.", [["CHB", "DISEASE", 48, 51], ["AECHB", "DISEASE", 53, 58], ["acute exacerbation", "PROBLEM", 26, 44], ["CHB", "PROBLEM", 48, 51], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["exacerbation", "OBSERVATION", 32, 44], ["CHB", "OBSERVATION", 48, 51], ["high", "OBSERVATION_MODIFIER", 68, 72]]], ["AECHB is characterized by acute onset, complicated condition, poor prognosis and high mortality.", [["AECHB", "DISEASE", 0, 5], ["complicated condition", "PROBLEM", 39, 60], ["high mortality", "PROBLEM", 81, 95], ["acute", "OBSERVATION_MODIFIER", 26, 31]]], ["There is a lack of specific and effective warning and treatment for severe hepatitis.", [["hepatitis", "DISEASE", 75, 84], ["treatment", "TREATMENT", 54, 63], ["severe hepatitis", "PROBLEM", 68, 84], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["hepatitis", "OBSERVATION", 75, 84]]], ["Thus, prognostic prediction is challenging and death rate associated with severe hepatitis is high.", [["death", "DISEASE", 47, 52], ["hepatitis", "DISEASE", 81, 90], ["death rate", "PROBLEM", 47, 57], ["severe hepatitis", "PROBLEM", 74, 90], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["hepatitis", "OBSERVATION", 81, 90], ["high", "OBSERVATION_MODIFIER", 94, 98]]], ["A comprehensive and accurate understanding of the natural outcome and mechanism of AECHB remains critical.", [["AECHB", "DISEASE", 83, 88], ["AECHB", "CANCER", 83, 88]]], ["In China, techniques and methods on the prognostic prediction and early diagnosis of severe hepatitis have not been established.", [["hepatitis", "DISEASE", 92, 101], ["the prognostic prediction", "TEST", 36, 61], ["severe hepatitis", "PROBLEM", 85, 101], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["hepatitis", "OBSERVATION", 92, 101]]], ["The implementation of early intervention of AECHB is limited by the lack of reliable, systematical, sensitive and specific indicators, and a feasible grading system to early predict AECHB and monitor disease progression.", [["AECHB", "DISEASE", 44, 49], ["AECHB", "CANCER", 182, 187], ["early intervention of AECHB", "TREATMENT", 22, 49], ["disease progression", "PROBLEM", 200, 219]]], ["As a consequence, some patients may develop to a worse condition and miss the optimal treatment opportunity.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["a worse condition", "PROBLEM", 47, 64]]], ["At end-stage liver disease or severe hepatitis, treatment efficacy is greatly reduced and death rate significantly increases.", [["liver", "ANATOMY", 13, 18], ["end-stage liver disease", "DISEASE", 3, 26], ["hepatitis", "DISEASE", 37, 46], ["death", "DISEASE", 90, 95], ["liver", "ORGAN", 13, 18], ["end-stage liver disease", "PROBLEM", 3, 26], ["severe hepatitis", "PROBLEM", 30, 46], ["treatment efficacy", "TREATMENT", 48, 66], ["death rate", "TEST", 90, 100], ["stage", "OBSERVATION_MODIFIER", 7, 12], ["liver", "ANATOMY", 13, 18], ["disease", "OBSERVATION", 19, 26], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["hepatitis", "OBSERVATION", 37, 46], ["reduced", "OBSERVATION_MODIFIER", 78, 85]]], ["Therefore, there is an urgent need to unveil the pathogenesis of AECHB and its clinical manifestations, and establish an early prediction assessment system for AECHB.", [["AECHB", "DISEASE", 65, 70], ["AECHB", "DISEASE", 160, 165], ["AECHB", "CANCER", 65, 70], ["an early prediction assessment system", "TEST", 118, 155]]], ["The establishment of a more specific early detection, intervention, treatment and effective prevention system would increase the cure rate and decrease the morbidity and mortality of AECHB.Polymerase Chain Reaction (PCR) ::: Gene Diagnosis Techniques ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBPCR is a technique based on the natural process of DNA replication.", [["AECHB", "DISEASE", 183, 188], ["AECHB", "CANCER", 183, 188], ["DNA", "CELLULAR_COMPONENT", 373, 376], ["intervention", "TREATMENT", 54, 66], ["treatment", "TREATMENT", 68, 77], ["effective prevention system", "TREATMENT", 82, 109], ["the cure rate", "TEST", 125, 138], ["the morbidity", "PROBLEM", 152, 165], ["a technique", "TREATMENT", 329, 340], ["DNA replication", "TREATMENT", 373, 388]]], ["PCR in vitro synthesizes DNA fragments determined by a pair of synthetic oligonucleotides that specifically bind to the two polynucleotide chains, and this reaction is catalyzed by DNA polymerase.", [["DNA", "CELLULAR_COMPONENT", 25, 28], ["DNA", "CELLULAR_COMPONENT", 181, 184], ["DNA fragments", "DNA", 25, 38], ["polynucleotide chains", "PROTEIN", 124, 145], ["DNA polymerase", "PROTEIN", 181, 195], ["PCR", "TEST", 0, 3], ["DNA fragments", "PROBLEM", 25, 38], ["a pair of synthetic oligonucleotides", "TREATMENT", 53, 89], ["this reaction", "PROBLEM", 151, 164], ["DNA fragments", "OBSERVATION", 25, 38], ["polynucleotide chains", "OBSERVATION", 124, 145]]], ["PCR involves three processes: denaturation, annealing and extension.", [["PCR", "TEST", 0, 3], ["denaturation", "PROBLEM", 30, 42], ["annealing and extension", "PROBLEM", 44, 67], ["denaturation", "OBSERVATION", 30, 42], ["annealing", "OBSERVATION_MODIFIER", 44, 53]]], ["PCR is characterized by its simple operation, time and effort saving, high sensitivity, strong specificity, high productivity, and good repeatability.", [["PCR", "TEST", 0, 3], ["high sensitivity", "PROBLEM", 70, 86], ["simple", "OBSERVATION_MODIFIER", 28, 34], ["operation", "OBSERVATION", 35, 44], ["high productivity", "OBSERVATION_MODIFIER", 108, 125]]], ["The discovery of PCR was so revolutionary in genetic technology and is now the most widely used technique in molecular biology research and diagnostics.Polymerase Chain Reaction (PCR) ::: Gene Diagnosis Techniques ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBFor the examination of HBV, the HBV infection state, viral replication level, and prognosis evaluation of the disease can be reflected by accurately quantifying serum HBV DNA using fluorescent quantitative real-time PCR (RT-qPCR).", [["serum", "ANATOMY", 446, 451], ["HBV infection", "DISEASE", 317, 330], ["HBV", "ORGANISM", 308, 311], ["HBV", "ORGANISM", 317, 320], ["serum", "ORGANISM_SUBSTANCE", 446, 451], ["HBV", "ORGANISM", 452, 455], ["DNA", "CELLULAR_COMPONENT", 456, 459], ["serum HBV DNA", "DNA", 446, 459], ["HBV", "SPECIES", 308, 311], ["HBV", "SPECIES", 317, 320], ["HBV", "SPECIES", 452, 455], ["PCR", "TEST", 17, 20], ["the examination", "TEST", 289, 304], ["HBV", "PROBLEM", 308, 311], ["the HBV infection state", "PROBLEM", 313, 336], ["viral replication level", "TEST", 338, 361], ["prognosis evaluation", "TEST", 367, 387], ["the disease", "PROBLEM", 391, 402], ["serum HBV DNA", "PROBLEM", 446, 459], ["HBV", "OBSERVATION_MODIFIER", 317, 320], ["infection", "OBSERVATION", 321, 330]]], ["Additionally, with the aid of specific TaqMan probe, it can simultaneously quantify HBV levels, detect HBV genotyping and locus mutation, study the relationship between HBV DNA content and other serum indices, and analyze the correlation between HBV DNA levels and degrees of liver injury.Polymerase Chain Reaction (PCR) ::: Gene Diagnosis Techniques ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBPCR is not a complicated technique.", [["serum", "ANATOMY", 195, 200], ["liver", "ANATOMY", 276, 281], ["liver injury", "DISEASE", 276, 288], ["HBV", "ORGANISM", 84, 87], ["HBV", "ORGANISM", 169, 172], ["DNA", "CELLULAR_COMPONENT", 173, 176], ["serum", "ORGANISM_SUBSTANCE", 195, 200], ["HBV", "ORGANISM", 246, 249], ["DNA", "CELLULAR_COMPONENT", 250, 253], ["liver", "ORGAN", 276, 281], ["TaqMan probe", "DNA", 39, 51], ["HBV", "SPECIES", 84, 87], ["HBV", "SPECIES", 103, 106], ["HBV", "SPECIES", 169, 172], ["HBV", "SPECIES", 246, 249], ["specific TaqMan probe", "TREATMENT", 30, 51], ["HBV levels", "TEST", 84, 94], ["HBV genotyping", "PROBLEM", 103, 117], ["locus mutation", "PROBLEM", 122, 136], ["HBV DNA content", "TEST", 169, 184], ["other serum indices", "TEST", 189, 208], ["the correlation", "TEST", 222, 237], ["HBV DNA levels", "TEST", 246, 260], ["liver injury", "PROBLEM", 276, 288], ["liver", "ANATOMY", 276, 281], ["injury", "OBSERVATION", 282, 288]]], ["However, as a sensitive technique for detecting a slight abundance of templates, PCR amplification techniques raise considerable concerns regarding contamination.", [["a sensitive technique", "TEST", 12, 33], ["a slight abundance of templates", "PROBLEM", 48, 79], ["PCR amplification techniques", "TREATMENT", 81, 109], ["contamination", "PROBLEM", 148, 161], ["slight", "OBSERVATION_MODIFIER", 50, 56], ["abundance", "OBSERVATION", 57, 66]]], ["Experimental contamination would generate false positive results and consequences would be serious in some cases.", [["Experimental contamination", "PROBLEM", 0, 26], ["false positive results", "PROBLEM", 42, 64]]], ["PCR operations should be performed carefully and accurately to avoid any contamination from outside and/or be suitably controlled with an appropriate negative control to get reliable results.Gene Sequence Analysis ::: Gene Diagnosis Techniques ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBGene sequencing is the process of determining the precise order of nucleotides within a DNA molecule.", [["nucleotides", "CHEMICAL", 382, 393], ["DNA", "CELLULAR_COMPONENT", 403, 406], ["DNA molecule", "PROTEIN", 403, 415], ["PCR operations", "TEST", 0, 14], ["any contamination", "PROBLEM", 69, 86], ["Gene Sequence Analysis", "TEST", 191, 213], ["a DNA molecule", "PROBLEM", 401, 415]]], ["Due to the rich genetic information contained in DNA sequences, the measurement and analysis of the gene sequence plays a key role in uncovering its genetic nature and encoding.", [["DNA", "CELLULAR_COMPONENT", 49, 52], ["DNA sequences", "DNA", 49, 62], ["DNA sequences", "TEST", 49, 62], ["the measurement", "TEST", 64, 79]]], ["The advantage of rapid DNA sequencing methods has greatly accelerated biological and medical research and discovery.", [["DNA", "CELLULAR_COMPONENT", 23, 26], ["rapid DNA sequencing methods", "TREATMENT", 17, 45]]], ["Currently, main gene sequence analyses include: direct sequencing method (DNA double deoxidizing terminal end method, chemical pyrolysis method, pyrophosphate sequencing method, etc.), DNA fingerprint analysis, PCR single-strand conformation polymorphism, PCR sandwich method and the technology of nucleic acid specific structure analysis, etc.Gene Sequence Analysis ::: Gene Diagnosis Techniques ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBResearchers are now able to identify the HBV virus genotype, mutation and mutation type through the whole base sequencing of specific gene fragments of the HBV genome, as well as the subsequent RT-PCR validation of large amounts of clinical samples.", [["samples", "ANATOMY", 709, 716], ["pyrophosphate", "CHEMICAL", 145, 158], ["nucleic acid", "CHEMICAL", 298, 310], ["pyrophosphate", "CHEMICAL", 145, 158], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["pyrophosphate", "SIMPLE_CHEMICAL", 145, 158], ["DNA", "CELLULAR_COMPONENT", 185, 188], ["HBV virus", "ORGANISM", 509, 518], ["HBV", "ORGANISM", 624, 627], ["specific gene fragments", "DNA", 593, 616], ["HBV genome", "DNA", 624, 634], ["HBV virus", "SPECIES", 509, 518], ["HBV", "SPECIES", 624, 627], ["main gene sequence analyses", "TEST", 11, 38], ["direct sequencing method", "TEST", 48, 72], ["DNA double deoxidizing terminal end method", "TREATMENT", 74, 116], ["chemical pyrolysis method", "TREATMENT", 118, 143], ["pyrophosphate sequencing method", "TREATMENT", 145, 176], ["DNA fingerprint analysis", "TEST", 185, 209], ["PCR", "TEST", 211, 214], ["nucleic acid specific structure analysis", "TEST", 298, 338], ["Gene Sequence Analysis", "TEST", 344, 366], ["the HBV virus genotype", "PROBLEM", 505, 527], ["mutation and mutation type", "PROBLEM", 529, 555], ["the HBV genome", "PROBLEM", 620, 634], ["the subsequent RT-PCR validation", "TEST", 647, 679], ["gene fragments", "OBSERVATION", 602, 616], ["HBV genome", "OBSERVATION", 624, 634], ["large", "OBSERVATION_MODIFIER", 683, 688], ["amounts", "OBSERVATION_MODIFIER", 689, 696]]], ["With the screen out of a group of mutation sites that are closely related to the development of AECHB, it generates the possibility to replace the key amino acid of the viral protein to alter the immunogenicity or to affect the replication or transcription of the virus; thus, affecting the development of severe hepatitis.", [["AECHB", "DISEASE", 96, 101], ["amino acid", "CHEMICAL", 151, 161], ["hepatitis", "DISEASE", 313, 322], ["amino acid", "CHEMICAL", 151, 161], ["AECHB", "CANCER", 96, 101], ["amino acid", "AMINO_ACID", 151, 161], ["viral protein", "PROTEIN", 169, 182], ["the screen", "TEST", 5, 15], ["mutation sites", "PROBLEM", 34, 48], ["AECHB", "PROBLEM", 96, 101], ["the viral protein", "TREATMENT", 165, 182], ["the replication", "PROBLEM", 224, 239], ["the virus", "PROBLEM", 260, 269], ["severe hepatitis", "PROBLEM", 306, 322], ["severe", "OBSERVATION_MODIFIER", 306, 312], ["hepatitis", "OBSERVATION", 313, 322]]], ["Further studies to confirm the relationship between these mutations and AECHB, as well as for monitoring these mutations, warrant valuable information for the early warning, prediction and diagnosis of AECHB.", [["AECHB", "DISEASE", 202, 207], ["AECHB", "CANCER", 202, 207], ["Further studies", "TEST", 0, 15], ["monitoring these mutations", "TEST", 94, 120], ["AECHB", "PROBLEM", 202, 207]]], ["These studies would also provide additional treatment strategies and prognosis evaluation of hepatitis B; thus, helping to reduce the morbidity and mortality of AECHB.Gene Chip ::: Gene Diagnosis Techniques ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBGene chip is also known as DNA microarray or DNA chips.", [["hepatitis B", "DISEASE", 93, 104], ["AECHB", "DISEASE", 161, 166], ["hepatitis B", "ORGANISM", 93, 104], ["AECHB", "CANCER", 161, 166], ["DNA", "CELLULAR_COMPONENT", 305, 308], ["DNA", "CELLULAR_COMPONENT", 323, 326], ["AECHBGene chip", "DNA", 273, 287], ["hepatitis B", "SPECIES", 93, 104], ["These studies", "TEST", 0, 13], ["additional treatment strategies", "TREATMENT", 33, 64], ["prognosis evaluation", "TEST", 69, 89], ["hepatitis B", "PROBLEM", 93, 104], ["the morbidity", "PROBLEM", 130, 143], ["AECHBGene chip", "TREATMENT", 273, 287], ["DNA chips", "TREATMENT", 323, 332], ["hepatitis", "OBSERVATION", 93, 102]]], ["Gene chip is a kind of DNA sequencing technique that can provide the rapid, parallel and efficient screening and analysis of biological samples.", [["samples", "ANATOMY", 136, 143], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["DNA sequencing technique", "TREATMENT", 23, 47], ["biological samples", "TEST", 125, 143]]], ["The operation process of gene chip is as follows.", [["The operation process of gene chip", "TREATMENT", 0, 34], ["gene chip", "OBSERVATION", 25, 34]]], ["First, DNA probes are covalently attached to the surface of a solid support by micro-applicator technique or in situ synthesizing technology to generate a 2D DNA probe microarray.", [["surface", "ANATOMY", 49, 56], ["DNA", "CELLULAR_COMPONENT", 7, 10], ["surface", "CELLULAR_COMPONENT", 49, 56], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["DNA probes", "DNA", 7, 17], ["DNA probes", "TREATMENT", 7, 17], ["a solid support", "TREATMENT", 60, 75], ["micro-applicator technique", "TREATMENT", 79, 105], ["a 2D DNA probe microarray", "TREATMENT", 153, 178]]], ["Next, it is hybridized with labeled samples, and hybridized signals are detected by a fluorescence scanner and subjected to computer analysis.", [["samples", "ANATOMY", 36, 43], ["labeled samples", "TEST", 28, 43], ["hybridized signals", "TEST", 49, 67], ["a fluorescence scanner", "TEST", 84, 106], ["computer analysis", "TEST", 124, 141]]], ["The working principle of gene chip is similar to that of classical nucleic acid molecule hybridization methods such as northern and southern blots; in which the probe (the known nucleic acid sequence) is hybridized with a complementary target nucleotide sequence in samples, and then qualitative and quantitative analyses are conducted through signal detection.", [["samples", "ANATOMY", 266, 273], ["nucleic acid", "CHEMICAL", 67, 79], ["nucleic acid", "CHEMICAL", 178, 190], ["nucleotide", "CHEMICAL", 243, 253], ["nucleotide", "CHEMICAL", 243, 253], ["complementary target nucleotide sequence", "DNA", 222, 262], ["gene chip", "TREATMENT", 25, 34], ["classical nucleic acid molecule hybridization methods", "TREATMENT", 57, 110], ["southern blots", "PROBLEM", 132, 146], ["the known nucleic acid sequence", "PROBLEM", 168, 199], ["quantitative analyses", "TEST", 300, 321], ["signal detection", "TEST", 344, 360]]], ["Furthermore, gene chip is featured with high throughput, integration, miniaturization and automation.", [["gene chip", "TEST", 13, 22], ["automation", "TEST", 90, 100], ["chip", "OBSERVATION", 18, 22], ["high", "OBSERVATION_MODIFIER", 40, 44]]], ["It is another major technological revolution in life sciences after PCR.", [["PCR", "TEST", 68, 71]]], ["Researchers have screened out a number of key molecules and signal pathways involved in severe hepatitis via the analysis of the gene expression profile in a mice model of ConA-induced severe hepatitis by using the gene chip technique and bioinformatics method.", [["hepatitis", "DISEASE", 95, 104], ["ConA", "CHEMICAL", 172, 176], ["hepatitis", "DISEASE", 192, 201], ["mice", "ORGANISM", 158, 162], ["ConA", "GENE_OR_GENE_PRODUCT", 172, 176], ["mice", "SPECIES", 158, 162], ["mice", "SPECIES", 158, 162], ["severe hepatitis", "PROBLEM", 88, 104], ["the analysis", "TEST", 109, 121], ["severe hepatitis", "PROBLEM", 185, 201], ["the gene chip technique", "TREATMENT", 211, 234], ["bioinformatics method", "TEST", 239, 260], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["hepatitis", "OBSERVATION", 95, 104], ["severe", "OBSERVATION_MODIFIER", 185, 191], ["hepatitis", "OBSERVATION", 192, 201]]], ["These data were further validated on a large number of clinical samples.", [["samples", "ANATOMY", 64, 71], ["samples", "CANCER", 64, 71]]], ["It is expected that the exploration of gene expression in early severe hepatitis could be used for the early prediction of AECHB and monitoring of the development of this disease.Genome-Wide Association Studies (GWAS) ::: Gene Diagnosis Techniques ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBGWAS, also known as whole-genome association studies (WGAS), is an examination of many common genetic variants in different individuals to determine if any variant is associated with a trait.", [["hepatitis", "DISEASE", 71, 80], ["AECHB", "CANCER", 123, 128], ["AECHBGWAS", "DNA", 314, 323], ["the exploration", "TEST", 20, 35], ["gene expression", "PROBLEM", 39, 54], ["early severe hepatitis", "PROBLEM", 58, 80], ["AECHB", "TREATMENT", 123, 128], ["this disease", "PROBLEM", 166, 178], ["an examination", "TEST", 383, 397], ["early", "OBSERVATION_MODIFIER", 58, 63], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["hepatitis", "OBSERVATION", 71, 80]]], ["GWAS typically focus on associations between single nucleotide polymorphisms (SNPs) and traits such as major diseases.", [["single nucleotide polymorphisms (SNPs)", "PROBLEM", 45, 83], ["major diseases", "PROBLEM", 103, 117]]], ["For a certain disease, this method can perform an overall correlation analysis of SNPs on the whole population within the scope of the whole genome, in order to determine the relationship between some SNPs and disease phenotype, and fully reveal genetic markers associated to disease occurrence, development, treatment and prognosis.", [["a certain disease", "PROBLEM", 4, 21], ["some SNPs and disease phenotype", "PROBLEM", 196, 227], ["genetic markers", "PROBLEM", 246, 261], ["disease occurrence", "PROBLEM", 276, 294], ["treatment", "TREATMENT", 309, 318], ["disease", "OBSERVATION", 14, 21]]], ["Recently, three independent large-sample GWAS from the United States, Europe and Japan reported that a racial difference in the rs1297980 site near gene IL-28B exists.", [["rs1297980", "GENE_OR_GENE_PRODUCT", 128, 137], ["IL-28B", "GENE_OR_GENE_PRODUCT", 153, 159], ["rs1297980 site", "DNA", 128, 142], ["gene IL-28B", "DNA", 148, 159], ["a racial difference", "PROBLEM", 101, 120], ["gene IL", "TEST", 148, 155], ["large", "OBSERVATION_MODIFIER", 28, 33]]], ["These sites were related to the host\u2019s ability of HCV spontaneous clearance and response to interferon treatment.", [["interferon", "CHEMICAL", 92, 102], ["HCV", "ORGANISM", 50, 53], ["interferon", "GENE_OR_GENE_PRODUCT", 92, 102], ["interferon", "PROTEIN", 92, 102], ["HCV", "SPECIES", 50, 53], ["HCV spontaneous clearance", "PROBLEM", 50, 75], ["interferon treatment", "TREATMENT", 92, 112]]], ["Predictably, the application of this method could help determine genetic targets associated with AECHB susceptibility, carry out risk assessments on patients with susceptibility gene, set individualized treatment strategies, and eventually prevent the development of AECHB in hepatitis B patients.Metagenome ::: Gene Diagnosis Techniques ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBMetagenome are the sum of all genetic materials in the microbial community, which consists of the genomes of many individual organisms.", [["community", "ANATOMY", 474, 483], ["AECHB", "DISEASE", 267, 272], ["hepatitis B", "DISEASE", 276, 287], ["AECHB", "CANCER", 97, 102], ["patients", "ORGANISM", 149, 157], ["AECHB", "CANCER", 267, 272], ["hepatitis B patients", "ORGANISM", 276, 296], ["susceptibility gene", "DNA", 163, 182], ["patients", "SPECIES", 149, 157], ["patients", "SPECIES", 288, 296], ["hepatitis B", "SPECIES", 276, 287], ["this method", "TREATMENT", 32, 43], ["AECHB susceptibility", "PROBLEM", 97, 117], ["risk assessments", "TEST", 129, 145], ["susceptibility gene", "TREATMENT", 163, 182], ["individualized treatment strategies", "TREATMENT", 188, 223], ["AECHB", "PROBLEM", 267, 272], ["hepatitis B patients", "TREATMENT", 276, 296], ["hepatitis", "OBSERVATION", 276, 285]]], ["Humans have evolved intimate symbiotic relationships with a consortium of microbes (microbiome).", [["Humans", "ORGANISM", 0, 6]]], ["For example, the gut of humans is verily a microbial ecosystem, whereas the immune system\u2019s primary home is in the gut.", [["gut", "ANATOMY", 17, 20], ["gut", "ANATOMY", 115, 118], ["gut", "ORGANISM_SUBDIVISION", 17, 20], ["humans", "ORGANISM", 24, 30], ["gut", "ORGANISM_SUBDIVISION", 115, 118], ["humans", "SPECIES", 24, 30], ["humans", "SPECIES", 24, 30], ["microbial ecosystem", "OBSERVATION", 43, 62], ["gut", "ANATOMY", 115, 118]]], ["Hence, gastrointestinal microbiota has a direct effect on the body\u2019s immune response, and the composition of symbiotic microbes can reflect human health conditions.", [["gastrointestinal", "ANATOMY", 7, 23], ["body", "ANATOMY", 62, 66], ["gastrointestinal microbiota", "PATHOLOGICAL_FORMATION", 7, 34], ["body", "ORGANISM_SUBDIVISION", 62, 66], ["human", "ORGANISM", 140, 145], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["gastrointestinal", "ANATOMY", 7, 23]]], ["Therefore, in addition to the control by the genes of the human itself, the growth, development, immunity, metabolism and disease process of the human body are also regulated by genetic information and flora structure of the symbiotic bacteria.Metagenome ::: Gene Diagnosis Techniques ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBMetagenomics has emerged as a powerful tool that can be used to analyze microbial communities regardless of the ability of member organisms to be cultured in the laboratory.", [["body", "ANATOMY", 151, 155], ["communities", "ANATOMY", 438, 449], ["human", "ORGANISM", 58, 63], ["human", "ORGANISM", 145, 150], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 145, 150], ["immunity, metabolism and disease process of the human body", "PROBLEM", 97, 155], ["the symbiotic bacteria", "PROBLEM", 221, 243], ["human body", "ANATOMY", 145, 155], ["symbiotic bacteria", "OBSERVATION", 225, 243]]], ["Metagenomics is based on the genomic analysis of microbial DNA extracted directly from communities in environmental samples.", [["communities", "ANATOMY", 87, 98], ["samples", "ANATOMY", 116, 123], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["microbial DNA", "DNA", 49, 62], ["the genomic analysis", "TEST", 25, 45], ["microbial DNA", "PROBLEM", 49, 62], ["microbial DNA", "OBSERVATION", 49, 62]]], ["Except intestinal diseases, a number of systemic metabolic diseases and even oncogenesis are related to the microbiota.", [["intestinal", "ANATOMY", 7, 17], ["intestinal diseases", "DISEASE", 7, 26], ["metabolic diseases", "DISEASE", 49, 67], ["intestinal", "ORGAN", 7, 17], ["intestinal diseases", "PROBLEM", 7, 26], ["systemic metabolic diseases", "PROBLEM", 40, 67], ["intestinal", "ANATOMY", 7, 17], ["diseases", "OBSERVATION", 18, 26], ["number", "OBSERVATION_MODIFIER", 30, 36], ["systemic", "OBSERVATION_MODIFIER", 40, 48], ["metabolic diseases", "OBSERVATION", 49, 67]]], ["CHB patients are vulnerable to microecological imbalance, impaired immune barrier function, and declined colonization capacity; which lead to bacterial translocation and endotoxemia, promoting the development of AECHB.", [["immune barrier", "ANATOMY", 67, 81], ["CHB", "DISEASE", 0, 3], ["endotoxemia", "DISEASE", 170, 181], ["AECHB", "DISEASE", 212, 217], ["patients", "ORGANISM", 4, 12], ["immune barrier", "TISSUE", 67, 81], ["AECHB", "CANCER", 212, 217], ["patients", "SPECIES", 4, 12], ["CHB", "PROBLEM", 0, 3], ["microecological imbalance", "PROBLEM", 31, 56], ["impaired immune barrier function", "PROBLEM", 58, 90], ["colonization capacity", "PROBLEM", 105, 126], ["bacterial translocation", "PROBLEM", 142, 165], ["endotoxemia", "PROBLEM", 170, 181], ["AECHB", "PROBLEM", 212, 217], ["impaired", "OBSERVATION_MODIFIER", 58, 66], ["immune barrier", "OBSERVATION", 67, 81], ["bacterial translocation", "OBSERVATION", 142, 165], ["endotoxemia", "OBSERVATION", 170, 181]]], ["In the past few years, Chinese scientists have analyzed the composition of gut microbiota and the metabolic characteristics of patients with CHB and liver cirrhosis.", [["gut microbiota", "ANATOMY", 75, 89], ["liver cirrhosis", "ANATOMY", 149, 164], ["CHB", "DISEASE", 141, 144], ["liver cirrhosis", "DISEASE", 149, 164], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 75, 89], ["patients", "ORGANISM", 127, 135], ["liver", "ORGAN", 149, 154], ["patients", "SPECIES", 127, 135], ["CHB", "PROBLEM", 141, 144], ["liver cirrhosis", "PROBLEM", 149, 164], ["CHB", "OBSERVATION", 141, 144], ["liver", "ANATOMY", 149, 154], ["cirrhosis", "OBSERVATION", 155, 164]]], ["They demonstrated the existence of specific intestinal microflora in liver pathological state and initially proposed that there is intestinal microecological imbalance in patients with AECHB or liver cirrhosis.", [["intestinal microflora", "ANATOMY", 44, 65], ["liver", "ANATOMY", 69, 74], ["intestinal", "ANATOMY", 131, 141], ["liver cirrhosis", "ANATOMY", 194, 209], ["AECHB", "DISEASE", 185, 190], ["liver cirrhosis", "DISEASE", 194, 209], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 44, 65], ["liver", "ORGAN", 69, 74], ["intestinal", "ORGAN", 131, 141], ["patients", "ORGANISM", 171, 179], ["liver", "ORGAN", 194, 199], ["patients", "SPECIES", 171, 179], ["specific intestinal microflora in liver pathological state", "PROBLEM", 35, 93], ["intestinal microecological imbalance", "PROBLEM", 131, 167], ["AECHB", "PROBLEM", 185, 190], ["liver cirrhosis", "PROBLEM", 194, 209], ["intestinal", "ANATOMY", 44, 54], ["microflora", "OBSERVATION", 55, 65], ["liver", "ANATOMY", 69, 74], ["intestinal", "ANATOMY", 131, 141], ["microecological imbalance", "OBSERVATION", 142, 167], ["liver", "ANATOMY", 194, 199], ["cirrhosis", "OBSERVATION", 200, 209]]], ["The proportion of beneficial intestinal bacteria such as bifidobacteria significantly decreases, while the proportion of pathogenic bacteria such as intestinal bacillus, streptococcus and Pasteur bacteria significantly increase.", [["intestinal", "ANATOMY", 29, 39], ["bifidobacteria", "CHEMICAL", 57, 71], ["intestinal", "ORGAN", 29, 39], ["bifidobacteria", "SIMPLE_CHEMICAL", 57, 71], ["intestinal bacillus", "ORGANISM", 149, 168], ["Pasteur bacteria", "ORGANISM", 188, 204], ["beneficial intestinal bacteria", "PROBLEM", 18, 48], ["bifidobacteria", "PROBLEM", 57, 71], ["pathogenic bacteria", "PROBLEM", 121, 140], ["intestinal bacillus", "PROBLEM", 149, 168], ["streptococcus", "PROBLEM", 170, 183], ["Pasteur bacteria", "PROBLEM", 188, 204], ["beneficial", "OBSERVATION_MODIFIER", 18, 28], ["intestinal", "ANATOMY", 29, 39], ["bacteria", "OBSERVATION", 40, 48], ["pathogenic", "OBSERVATION_MODIFIER", 121, 131], ["bacteria", "OBSERVATION", 132, 140], ["intestinal bacillus", "ANATOMY", 149, 168]]], ["It was revealed that the degree of intestinal microecological imbalance is associated with the severity of liver disease, and correlates with the increase of blood endotoxin level and liver damage.", [["intestinal", "ANATOMY", 35, 45], ["liver", "ANATOMY", 107, 112], ["blood", "ANATOMY", 158, 163], ["liver", "ANATOMY", 184, 189], ["liver disease", "DISEASE", 107, 120], ["endotoxin", "CHEMICAL", 164, 173], ["liver damage", "DISEASE", 184, 196], ["intestinal", "ORGAN", 35, 45], ["liver", "ORGAN", 107, 112], ["blood", "ORGANISM_SUBSTANCE", 158, 163], ["endotoxin", "SIMPLE_CHEMICAL", 164, 173], ["liver", "ORGAN", 184, 189], ["intestinal microecological imbalance", "PROBLEM", 35, 71], ["liver disease", "PROBLEM", 107, 120], ["the increase of blood endotoxin level", "PROBLEM", 142, 179], ["liver damage", "PROBLEM", 184, 196], ["degree", "OBSERVATION_MODIFIER", 25, 31], ["intestinal", "ANATOMY", 35, 45], ["microecological imbalance", "OBSERVATION", 46, 71], ["liver", "ANATOMY", 107, 112], ["disease", "OBSERVATION", 113, 120], ["increase", "OBSERVATION_MODIFIER", 146, 154], ["liver", "ANATOMY", 184, 189], ["damage", "OBSERVATION", 190, 196]]], ["They identified the specific mode of intestinal flora as flora \u201cbiomarkers\u201d of liver disease state and progression.", [["intestinal flora", "ANATOMY", 37, 53], ["liver", "ANATOMY", 79, 84], ["liver disease", "DISEASE", 79, 92], ["intestinal flora", "PATHOLOGICAL_FORMATION", 37, 53], ["liver", "ORGAN", 79, 84], ["intestinal flora", "PROBLEM", 37, 53], ["liver disease state", "PROBLEM", 79, 98], ["intestinal", "ANATOMY", 37, 47], ["flora", "OBSERVATION", 48, 53], ["liver", "ANATOMY", 79, 84], ["disease", "OBSERVATION", 85, 92], ["progression", "OBSERVATION_MODIFIER", 103, 114]]], ["The above studies illustrate the possible mechanism of the impact of intestinal flora changes on the intestinal immune barrier function, and consequently on liver disease prognosis.", [["intestinal flora", "ANATOMY", 69, 85], ["intestinal", "ANATOMY", 101, 111], ["liver", "ANATOMY", 157, 162], ["liver disease", "DISEASE", 157, 170], ["intestinal flora", "MULTI-TISSUE_STRUCTURE", 69, 85], ["intestinal immune barrier", "TISSUE", 101, 126], ["liver", "ORGAN", 157, 162], ["The above studies", "TEST", 0, 17], ["intestinal flora changes", "PROBLEM", 69, 93], ["liver disease prognosis", "PROBLEM", 157, 180], ["intestinal", "ANATOMY", 69, 79], ["flora", "OBSERVATION", 80, 85], ["intestinal", "ANATOMY", 101, 111], ["liver", "ANATOMY", 157, 162], ["disease", "OBSERVATION", 163, 170]]], ["These studies provide theoretical basis for the development of etiologic agents of gut microbiota for the clinical treatment of CHB.", [["gut", "ANATOMY", 83, 86], ["CHB", "DISEASE", 128, 131], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 83, 97], ["These studies", "TEST", 0, 13], ["gut microbiota", "TREATMENT", 83, 97], ["the clinical treatment", "TREATMENT", 102, 124], ["CHB", "PROBLEM", 128, 131], ["CHB", "OBSERVATION", 128, 131]]], ["Thus, metagenomics study of the intestinal flora plays an important role in the comprehensive management of CHB and prevention of AECHB.Two-Dimensional Gel Electrophoresis ::: Protein Diagnostic Techniques ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBTwo-dimensional Gel Electrophoresis, abbreviated as 2-DE or 2-D electrophoresis, is a form of gel electrophoresis commonly used to analyze proteins.", [["intestinal flora", "ANATOMY", 32, 48], ["CHB", "DISEASE", 108, 111], ["AECHB", "DISEASE", 130, 135], ["intestinal flora", "MULTI-TISSUE_STRUCTURE", 32, 48], ["AECHB", "CANCER", 130, 135], ["metagenomics study", "TEST", 6, 24], ["the intestinal flora", "PROBLEM", 28, 48], ["the comprehensive management", "TREATMENT", 76, 104], ["CHB", "PROBLEM", 108, 111], ["AECHB", "PROBLEM", 130, 135], ["Dimensional Gel Electrophoresis", "TEST", 140, 171], ["dimensional Gel Electrophoresis", "TEST", 281, 312], ["D electrophoresis", "TEST", 339, 356], ["gel electrophoresis", "TREATMENT", 371, 390], ["intestinal", "ANATOMY", 32, 42], ["flora", "OBSERVATION", 43, 48], ["CHB", "OBSERVATION", 108, 111]]], ["2-DE is the core technique for proteome research.", [["2-DE", "CHEMICAL", 0, 4]]], ["Mixtures of proteins are separated by two properties in two dimensions on 2D gels.", [["2D gels", "TREATMENT", 74, 81], ["proteins", "OBSERVATION", 12, 20], ["two", "OBSERVATION_MODIFIER", 56, 59], ["dimensions", "OBSERVATION_MODIFIER", 60, 70]]], ["The principle is to utilize the differential charge and molecular weight of proteins.", [["the differential charge", "TEST", 28, 51]]], ["First, proteins are horizontally separated along the pH gradient based on the isoelectric points; and second, proteins would be isolated effectively according to molecular weight along the vertical direction.", [["the pH gradient", "TEST", 49, 64], ["the isoelectric points", "TEST", 74, 96], ["horizontally", "OBSERVATION_MODIFIER", 20, 32], ["pH gradient", "OBSERVATION", 53, 64], ["vertical", "OBSERVATION_MODIFIER", 189, 197]]], ["Currently, the combined use of 2-DE with mass spectrometry can realize the accurate and large-scale identification of proteins.Mass Spectrometry (MS) ::: Protein Diagnostic Techniques ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBMS is another rapidly developed and commonly used quantitative strategy in proteomic studies.", [["mass spectrometry", "PROBLEM", 41, 58], ["proteomic studies", "TEST", 330, 347]]], ["It is an analytical chemistry technique that helps identify the amount and type of chemicals present in a sample by measuring the mass-to-charge ratio and abundance of gas-phase ions.", [["sample", "ANATOMY", 106, 112], ["an analytical chemistry technique", "TEST", 6, 39], ["the mass", "TEST", 126, 134], ["amount", "OBSERVATION_MODIFIER", 64, 70], ["chemicals", "OBSERVATION", 83, 92], ["mass", "OBSERVATION", 130, 134], ["gas", "OBSERVATION", 168, 171]]], ["MS separates moving ions (charged atoms, molecules or molecular fragments) in the electric field and magnetic field according to their different mass-to-charge ratio, then measures the accurate mass of ions, and finally determines the ionic compounds.", [["MS", "DISEASE", 0, 2], ["molecular fragments", "PROBLEM", 54, 73], ["fragments", "OBSERVATION", 64, 73], ["mass", "OBSERVATION", 145, 149], ["mass", "OBSERVATION", 194, 198]]], ["A mass spectrum (plural spectra) is a plot of the ion signal as a function of the mass-to-charge ratio.Mass Spectrometry (MS) ::: Protein Diagnostic Techniques ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBSerum protein specimens from patients with moderate or AECHB, acute hepatitis B (AHB) in the recovery stage, and HCC associated with hepatitis B have been analyzed by 2-DE.", [["specimens", "ANATOMY", 245, 254], ["HCC", "ANATOMY", 344, 347], ["AECHB", "DISEASE", 286, 291], ["acute hepatitis B", "DISEASE", 293, 310], ["AHB", "DISEASE", 312, 315], ["HCC", "DISEASE", 344, 347], ["hepatitis B", "DISEASE", 364, 375], ["patients", "ORGANISM", 260, 268], ["AHB", "CANCER", 312, 315], ["HCC", "CANCER", 344, 347], ["patients", "SPECIES", 260, 268], ["A mass spectrum (plural spectra", "PROBLEM", 0, 31], ["the mass", "PROBLEM", 78, 86], ["AECHBSerum protein specimens", "TEST", 226, 254], ["moderate or AECHB", "PROBLEM", 274, 291], ["acute hepatitis B (AHB)", "PROBLEM", 293, 316], ["HCC", "PROBLEM", 344, 347], ["hepatitis B", "PROBLEM", 364, 375], ["mass", "OBSERVATION", 2, 6], ["mass", "OBSERVATION", 82, 86], ["moderate", "OBSERVATION_MODIFIER", 274, 282], ["acute", "OBSERVATION_MODIFIER", 293, 298], ["hepatitis", "OBSERVATION", 299, 308], ["HCC", "OBSERVATION", 344, 347]]], ["A comprehensive analysis of spot diagrams is expected to determine key proteins in HBV pathogenesis and identify some serological markers that can be used in the early diagnosis of AECHB.", [["AECHB", "DISEASE", 181, 186], ["HBV", "ORGANISM", 83, 86], ["AECHB", "CANCER", 181, 186], ["HBV", "SPECIES", 83, 86], ["A comprehensive analysis", "TEST", 0, 24], ["spot diagrams", "TEST", 28, 41], ["HBV pathogenesis", "PROBLEM", 83, 99], ["some serological markers", "PROBLEM", 113, 137], ["HBV", "OBSERVATION", 83, 86]]], ["There are proteins with obvious changes in serum in the AECHB group, compared with those in other groups.", [["serum", "ANATOMY", 43, 48], ["AECHB", "ANATOMY", 56, 61], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["AECHB", "CANCER", 56, 61], ["obvious changes in serum in the AECHB group", "PROBLEM", 24, 67], ["proteins", "OBSERVATION", 10, 18], ["obvious", "OBSERVATION_MODIFIER", 24, 31], ["changes", "OBSERVATION", 32, 39], ["serum", "OBSERVATION_MODIFIER", 43, 48]]], ["The combined MS analysis identified that \u03b1-antitrypsin expression increased significantly in the AECHB group, suggesting that \u03b1-antitrypsin might be used as a serological marker for developing AECHB, which provides an important implication for the early prediction and diagnosis of CHB exacerbation.Epigenetics ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBThe genetic information of the human genome contains two parts: the information stored by the DNA sequence itself and the genetic regulation of gene expression in a certain time and space.", [["AECHB", "ANATOMY", 97, 102], ["\u03b1-antitrypsin", "CHEMICAL", 126, 139], ["AECHB", "DISEASE", 193, 198], ["CHB", "DISEASE", 282, 285], ["\u03b1-antitrypsin", "GENE_OR_GENE_PRODUCT", 41, 54], ["AECHB", "CANCER", 97, 102], ["\u03b1-antitrypsin", "GENE_OR_GENE_PRODUCT", 126, 139], ["AECHB", "CANCER", 193, 198], ["human", "ORGANISM", 413, 418], ["DNA", "CELLULAR_COMPONENT", 476, 479], ["\u03b1-antitrypsin", "PROTEIN", 41, 54], ["\u03b1-antitrypsin", "PROTEIN", 126, 139], ["human genome", "DNA", 413, 425], ["DNA sequence", "DNA", 476, 488], ["human", "SPECIES", 413, 418], ["human", "SPECIES", 413, 418], ["The combined MS analysis", "TEST", 0, 24], ["\u03b1-antitrypsin expression", "PROBLEM", 41, 65], ["a serological marker", "TEST", 157, 177], ["CHB exacerbation", "PROBLEM", 282, 298], ["the DNA sequence", "TEST", 472, 488], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["significantly", "OBSERVATION_MODIFIER", 76, 89], ["CHB", "OBSERVATION", 282, 285]]], ["Epigenetics is the study of cellular and physiological phenotypic trait variations that are caused by external or environmental factors, which switch genes on and off and affect how cells read genes instead of being caused by changes in the DNA sequence.", [["cellular", "ANATOMY", 28, 36], ["cells", "ANATOMY", 182, 187], ["cellular", "CELL", 28, 36], ["cells", "CELL", 182, 187], ["DNA", "CELLULAR_COMPONENT", 241, 244], ["DNA sequence", "DNA", 241, 253], ["the study", "TEST", 15, 24], ["cellular and physiological phenotypic trait variations", "PROBLEM", 28, 82], ["external or environmental factors", "PROBLEM", 102, 135], ["the DNA sequence", "TEST", 237, 253], ["phenotypic trait", "OBSERVATION", 55, 71]]], ["Epigenetic modifications mainly include DNA methylation, histone modification, RNA related silence, chromatin remodeling and genomic imprinting; among which, DNA methylation modification is the most common epigenetic change.Epigenetics ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBAt present, epigenetics has become a hot spot in the study of hepatitis B. Research have mostly focused on two aspects: the relationship between HBV associated genome-wide hypomethylation or site specificity hypermethylation and the development of hepatitis B associated HCC.", [["chromatin", "ANATOMY", 100, 109], ["HCC", "ANATOMY", 578, 581], ["hepatitis B.", "DISEASE", 369, 381], ["hepatitis B", "DISEASE", 555, 566], ["HCC", "DISEASE", 578, 581], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["histone", "GENE_OR_GENE_PRODUCT", 57, 64], ["chromatin", "CELLULAR_COMPONENT", 100, 109], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["HBV", "ORGANISM", 452, 455], ["hepatitis B", "ORGANISM", 555, 566], ["HCC", "CANCER", 578, 581], ["chromatin", "DNA", 100, 109], ["hepatitis B.", "SPECIES", 369, 381], ["HBV", "SPECIES", 452, 455], ["hepatitis B", "SPECIES", 555, 566], ["Epigenetic modifications", "TREATMENT", 0, 24], ["DNA methylation, histone modification", "TREATMENT", 40, 77], ["RNA related silence", "PROBLEM", 79, 98], ["chromatin remodeling", "PROBLEM", 100, 120], ["genomic imprinting", "PROBLEM", 125, 143], ["DNA methylation modification", "TREATMENT", 158, 186], ["a hot spot", "PROBLEM", 342, 352], ["the study", "TEST", 356, 365], ["hepatitis B.", "PROBLEM", 369, 381], ["HBV associated genome", "PROBLEM", 452, 473], ["wide hypomethylation", "PROBLEM", 474, 494], ["site specificity hypermethylation", "PROBLEM", 498, 531], ["hepatitis B associated HCC", "PROBLEM", 555, 581], ["chromatin remodeling", "OBSERVATION", 100, 120], ["genomic imprinting", "OBSERVATION", 125, 143], ["most common", "OBSERVATION_MODIFIER", 194, 205], ["hepatitis", "OBSERVATION", 369, 378], ["hepatitis", "OBSERVATION", 555, 564], ["HCC", "OBSERVATION", 578, 581]]], ["However, research on hepatitis B-related epigenetic susceptibility remains limited.", [["hepatitis B", "DISEASE", 21, 32], ["hepatitis B", "ORGANISM", 21, 32], ["hepatitis B", "TEST", 21, 32], ["epigenetic susceptibility", "PROBLEM", 41, 66], ["hepatitis", "OBSERVATION", 21, 30]]], ["In recent years, researchers have qualitatively and quantitatively analyzed genomic methylation status using gene chip technique combined with epigenetics in a high-throughput manner.", [["gene chip technique", "TREATMENT", 109, 128]]], ["By comparing methylome from liver tissues with normal and severe hepatitis, they found global methylation loci on the whole genome of hepatitis B patients; and revealed that methylation loci on promoter can regulate the expression of a gene.", [["liver tissues", "ANATOMY", 28, 41], ["hepatitis", "DISEASE", 65, 74], ["hepatitis B", "DISEASE", 134, 145], ["liver tissues", "TISSUE", 28, 41], ["hepatitis B patients", "ORGANISM", 134, 154], ["methylation loci", "DNA", 174, 190], ["patients", "SPECIES", 146, 154], ["hepatitis B", "SPECIES", 134, 145], ["severe hepatitis", "PROBLEM", 58, 74], ["global methylation loci", "PROBLEM", 87, 110], ["methylation loci", "PROBLEM", 174, 190], ["liver", "ANATOMY", 28, 33], ["normal", "OBSERVATION", 47, 53], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["hepatitis", "OBSERVATION", 65, 74], ["global", "OBSERVATION_MODIFIER", 87, 93], ["methylation loci", "OBSERVATION", 94, 110], ["hepatitis", "OBSERVATION", 134, 143]]], ["With functional screening on cell and animal models, several key methylation loci were identified; and were suggested to be closely associated with the severity and prognosis of hepatitis B. Given the advantage of the rich resources of hepatitis B in China, GWAS and genome-wide methylation differential spectrum studies on AECHB are needed in the future to improve the identification of the methylation specific loci and distribution frequency map at different disease states, and to systematically explore the methylation regulating mechanism.", [["cell", "ANATOMY", 29, 33], ["hepatitis", "DISEASE", 178, 187], ["hepatitis B", "DISEASE", 236, 247], ["cell", "CELL", 29, 33], ["hepatitis B", "ORGANISM", 236, 247], ["AECHB", "CANCER", 324, 329], ["methylation loci", "DNA", 65, 81], ["hepatitis B.", "SPECIES", 178, 190], ["functional screening", "TEST", 5, 25], ["several key methylation loci", "PROBLEM", 53, 81], ["hepatitis B.", "PROBLEM", 178, 190], ["hepatitis B", "PROBLEM", 236, 247], ["GWAS", "TEST", 258, 262], ["AECHB", "TREATMENT", 324, 329], ["the methylation specific loci", "PROBLEM", 388, 417], ["different disease states", "PROBLEM", 452, 476]]], ["These may play a positive role for the prediction, prevention and treatment of AECHB, together with traditional strategies.Bioinformatics ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBThe close combinational analyses of gene information and protein structures by computer science, statistics, mathematics and engineering form an interdisciplinary field, bioinformatics.", [["AECHB", "DISEASE", 79, 84], ["treatment", "TREATMENT", 66, 75], ["AECHB", "TREATMENT", 79, 84], ["traditional strategies", "TREATMENT", 100, 122]]], ["It integrates and analyzes large amounts of biological information in experiments with the aid of computer and bioelectronic equipment.", [["bioelectronic equipment", "TREATMENT", 111, 134], ["large", "OBSERVATION_MODIFIER", 27, 32], ["amounts", "OBSERVATION_MODIFIER", 33, 40]]], ["Bioinformatics uses mathematical interpretation and the integration of biological experimental data based on information theory and technology to illuminate the significance of biological macromolecules and its implications in health.Bioinformatics ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBInformation analyzed by bioinformatics are mainly in three fields: genomic information, protein structure modeling and drug design.", [["mathematical interpretation", "TEST", 20, 47]]], ["These include sequence comparison and analysis, gene identification and function prediction, prediction of protein structure, etc. In China, bioinformatics research has started relatively late, and research on hepatitis B by bioinformatics remains in the early stage.", [["hepatitis B", "DISEASE", 210, 221], ["hepatitis B", "ORGANISM", 210, 221], ["hepatitis B", "SPECIES", 210, 221], ["sequence comparison", "TEST", 14, 33], ["analysis", "TEST", 38, 46], ["gene identification", "TEST", 48, 67], ["function prediction", "TEST", 72, 91], ["protein structure", "PROBLEM", 107, 124], ["hepatitis B", "PROBLEM", 210, 221]]], ["Prediction based on high-throughput chip analysis remains preliminary, which needs further verification.", [["Prediction", "TEST", 0, 10], ["chip analysis", "TEST", 36, 49], ["further verification", "TEST", 83, 103]]], ["In the future, the combination of molecular biology and bioinformatics techniques would be the mainstream in the pathogenesis research of major diseases such as hepatitis B. The integration of these techniques would bring hope to the exploration of the early prediction, diagnosis and treatment of AECHB.Systems Biology ::: Techniques and Methods for the\u00a0Early Prognostic Prediction of AECHBSystems biology is a biology-based interdisciplinary field that focuses on complex interactions within biological systems using a holistic approach to biological and biomedical researches.", [["hepatitis B.", "DISEASE", 161, 173], ["AECHB", "DISEASE", 298, 303], ["AECHB", "CANCER", 298, 303], ["bioinformatics techniques", "TREATMENT", 56, 81], ["major diseases", "PROBLEM", 138, 152], ["hepatitis B.", "PROBLEM", 161, 173], ["these techniques", "TREATMENT", 193, 209], ["the exploration", "TEST", 230, 245], ["treatment of AECHB", "TREATMENT", 285, 303], ["a holistic approach", "TREATMENT", 519, 538]]], ["Systems biology integrates the interaction network of cell signal transduction regulation, protein expression regulation, metabolism of tissues and organs, and so on.", [["cell", "ANATOMY", 54, 58], ["tissues", "ANATOMY", 136, 143], ["organs", "ANATOMY", 148, 154], ["cell", "CELL", 54, 58], ["tissues", "TISSUE", 136, 143], ["organs", "ORGAN", 148, 154], ["cell signal transduction regulation", "TREATMENT", 54, 89], ["protein expression regulation", "TEST", 91, 120], ["organs", "ANATOMY", 148, 154]]], ["It explores the occurrence and progression of activities and diseases of the whole biological system from different perspectives by applying bioinformatics and other techniques, and establishing the biological model.", [["progression of activities and diseases of the whole biological system", "PROBLEM", 31, 100], ["other techniques", "TEST", 160, 176], ["progression", "OBSERVATION_MODIFIER", 31, 42]]], ["Through the dynamic analysis of gene and protein expression characteristics in different courses of hepatitis B, and through its correlation with clinical manifestations, laboratory examinations and overall metabolism conditions, system biology would help screen biological markers for the early diagnosis and predication of AECHB.", [["hepatitis B", "DISEASE", 100, 111], ["AECHB", "DISEASE", 325, 330], ["hepatitis B", "ORGANISM", 100, 111], ["AECHB", "CANCER", 325, 330], ["hepatitis B", "SPECIES", 100, 111], ["the dynamic analysis", "TEST", 8, 28], ["hepatitis B", "PROBLEM", 100, 111], ["laboratory examinations", "TEST", 171, 194], ["overall metabolism conditions", "PROBLEM", 199, 228], ["biological markers", "TEST", 263, 281], ["AECHB", "TREATMENT", 325, 330], ["hepatitis", "OBSERVATION", 100, 109]]], ["In the future, systems biology is expected to be a powerful weapon in studying the early diagnosis and prevention of AECHB.Liver Function and Laboratory Examinations ::: Clinical Significance of Early Prognostic Predictive Indicators of AECHBThe liver is the body\u2019s second largest organ and the largest metabolic organ.", [["Liver", "ANATOMY", 123, 128], ["liver", "ANATOMY", 246, 251], ["body", "ANATOMY", 259, 263], ["organ", "ANATOMY", 281, 286], ["organ", "ANATOMY", 313, 318], ["AECHB", "DISEASE", 117, 122], ["AECHB", "CANCER", 117, 122], ["Liver", "ORGAN", 123, 128], ["liver", "ORGAN", 246, 251], ["body", "ORGANISM_SUBDIVISION", 259, 263], ["organ", "ORGAN", 281, 286], ["organ", "ORGAN", 313, 318], ["AECHB", "PROBLEM", 117, 122], ["Liver Function", "TEST", 123, 137], ["Laboratory Examinations", "TEST", 142, 165], ["Early", "OBSERVATION_MODIFIER", 195, 200], ["liver", "ANATOMY", 246, 251], ["body", "ANATOMY_MODIFIER", 259, 263], ["largest", "OBSERVATION_MODIFIER", 273, 280], ["largest", "OBSERVATION_MODIFIER", 295, 302], ["metabolic organ", "OBSERVATION", 303, 318]]], ["The liver performs many essential functions related to digestion, metabolism, immunity and the storage of nutrients within the body.", [["liver", "ANATOMY", 4, 9], ["body", "ANATOMY", 127, 131], ["liver", "ORGAN", 4, 9], ["body", "ORGANISM_SUBDIVISION", 127, 131], ["digestion", "PROBLEM", 55, 64], ["liver", "ANATOMY", 4, 9], ["body", "ANATOMY", 127, 131]]], ["These functions make the liver a vital organ, and liver dysfunction can lead to abnormalities in metabolism, synthesis and expression signal transduction molecules, and various chemical substances; and subsequently result in corresponding changes in various serum biochemical parameters.", [["liver", "ANATOMY", 25, 30], ["organ", "ANATOMY", 39, 44], ["liver", "ANATOMY", 50, 55], ["serum", "ANATOMY", 258, 263], ["liver dysfunction", "DISEASE", 50, 67], ["liver", "ORGAN", 25, 30], ["organ", "ORGAN", 39, 44], ["liver", "ORGAN", 50, 55], ["serum", "ORGANISM_SUBSTANCE", 258, 263], ["liver dysfunction", "PROBLEM", 50, 67], ["abnormalities in metabolism", "PROBLEM", 80, 107], ["synthesis and expression signal transduction molecules", "PROBLEM", 109, 163], ["corresponding changes in various serum biochemical parameters", "PROBLEM", 225, 286], ["liver", "ANATOMY", 25, 30], ["liver", "ANATOMY", 50, 55], ["dysfunction", "OBSERVATION", 56, 67]]], ["Many early warning indicators have been used in clinical laboratories for liver dysfunction including alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin, prothrombin time (PT) and prothrombin activity (PTA), serum albumin and pre-albumin, serum cholinesterase and blood ammonia.", [["liver", "ANATOMY", 74, 79], ["serum", "ANATOMY", 168, 173], ["serum", "ANATOMY", 245, 250], ["serum", "ANATOMY", 276, 281], ["blood", "ANATOMY", 301, 306], ["liver dysfunction", "DISEASE", 74, 91], ["alanine", "CHEMICAL", 102, 109], ["aspartate", "CHEMICAL", 134, 143], ["bilirubin", "CHEMICAL", 180, 189], ["ammonia", "CHEMICAL", 307, 314], ["alanine", "CHEMICAL", 102, 109], ["aspartate", "CHEMICAL", 134, 143], ["bilirubin", "CHEMICAL", 180, 189], ["ammonia", "CHEMICAL", 307, 314], ["liver", "ORGAN", 74, 79], ["alanine", "AMINO_ACID", 102, 109], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 110, 126], ["ALT", "SIMPLE_CHEMICAL", 128, 131], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 134, 160], ["AST", "SIMPLE_CHEMICAL", 162, 165], ["serum", "ORGANISM_SUBSTANCE", 168, 173], ["bilirubin", "SIMPLE_CHEMICAL", 180, 189], ["prothrombin", "GENE_OR_GENE_PRODUCT", 191, 202], ["prothrombin", "GENE_OR_GENE_PRODUCT", 217, 228], ["PTA", "SIMPLE_CHEMICAL", 239, 242], ["serum", "ORGANISM_SUBSTANCE", 245, 250], ["albumin", "GENE_OR_GENE_PRODUCT", 251, 258], ["pre-albumin", "SIMPLE_CHEMICAL", 263, 274], ["serum", "ORGANISM_SUBSTANCE", 276, 281], ["cholinesterase", "SIMPLE_CHEMICAL", 282, 296], ["blood", "ORGANISM_SUBSTANCE", 301, 306], ["ammonia", "SIMPLE_CHEMICAL", 307, 314], ["alanine aminotransferase", "PROTEIN", 102, 126], ["ALT", "PROTEIN", 128, 131], ["aspartate aminotransferase", "PROTEIN", 134, 160], ["AST", "PROTEIN", 162, 165], ["serum total bilirubin", "PROTEIN", 168, 189], ["prothrombin", "PROTEIN", 191, 202], ["prothrombin", "PROTEIN", 217, 228], ["serum albumin", "PROTEIN", 245, 258], ["serum cholinesterase", "PROTEIN", 276, 296], ["clinical laboratories", "TEST", 48, 69], ["liver dysfunction", "PROBLEM", 74, 91], ["alanine aminotransferase", "TEST", 102, 126], ["ALT", "TEST", 128, 131], ["aspartate aminotransferase", "TEST", 134, 160], ["AST", "TEST", 162, 165], ["serum total bilirubin", "TEST", 168, 189], ["prothrombin time", "TEST", 191, 207], ["PT", "TEST", 209, 211], ["prothrombin activity", "TEST", 217, 237], ["PTA", "TEST", 239, 242], ["serum albumin", "TEST", 245, 258], ["pre-albumin", "TEST", 263, 274], ["serum cholinesterase", "TEST", 276, 296], ["blood ammonia", "TEST", 301, 314], ["liver", "ANATOMY", 74, 79], ["dysfunction", "OBSERVATION", 80, 91]]], ["The above indicators also play important roles in the early warning of AECHB.", [["AECHB", "DISEASE", 71, 76], ["AECHB", "CANCER", 71, 76]]], ["However, none of them are perfect in predicting the severity of liver disease, and a single indicator alone is not enough to accurately predict or diagnose the complicated and rapid changes of liver diseases.", [["liver", "ANATOMY", 64, 69], ["liver", "ANATOMY", 193, 198], ["liver disease", "DISEASE", 64, 77], ["liver diseases", "DISEASE", 193, 207], ["liver", "ORGAN", 64, 69], ["liver", "ORGAN", 193, 198], ["liver disease", "PROBLEM", 64, 77], ["liver diseases", "PROBLEM", 193, 207], ["liver", "ANATOMY", 64, 69], ["disease", "OBSERVATION", 70, 77], ["complicated", "OBSERVATION", 160, 171], ["rapid", "OBSERVATION_MODIFIER", 176, 181], ["liver", "ANATOMY", 193, 198], ["diseases", "OBSERVATION", 199, 207]]], ["In order to accurately determine a condition and make a diagnosis, clinicians must dynamically monitor key serum biochemical parameters and comprehensively analyze clinical manifestations and complications.", [["serum", "ANATOMY", 107, 112], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["serum biochemical parameters", "TEST", 107, 135], ["complications", "PROBLEM", 192, 205]]], ["Thus, to exactly predict the risk of AECHB, it is necessary to weight and score clinical manifestations and laboratory indicators based on established techniques and methods; and to establish hepatitis aggravation-related mathematical model equations and scoring systems using multiple regression analysis.", [["AECHB", "DISEASE", 37, 42], ["hepatitis", "DISEASE", 192, 201], ["AECHB", "CANCER", 37, 42], ["AECHB", "TREATMENT", 37, 42], ["laboratory indicators", "TEST", 108, 129], ["methods", "TEST", 166, 173], ["hepatitis aggravation", "PROBLEM", 192, 213], ["multiple regression analysis", "TEST", 277, 305]]], ["The establishment of these systems would greatly assist the progress and new breakthroughs in the early warning and diagnosis of AECHB.Viral Factors ::: Exploration of Potential Clinical Indicators for Early Warning of AECHB ::: Clinical Significance of Early Prognostic Predictive Indicators of AECHB", [["AECHB", "DISEASE", 129, 134], ["AECHB", "CANCER", 129, 134], ["AECHB", "PROBLEM", 129, 134]]]], "c63e2bbb0915e7d4d40813d58286d51e80453507": [["BackgroundInfluenza viruses belong to the Orthomyxoviridae family, which are characterized by segmented negative sense RNA genomes.", [["Influenza viruses", "ORGANISM", 10, 27], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 42, 58], ["Orthomyxoviridae family", "PROTEIN", 42, 65], ["segmented negative sense RNA genomes", "RNA", 94, 130], ["BackgroundInfluenza viruses", "PROBLEM", 0, 27], ["Influenza", "OBSERVATION", 10, 19], ["sense RNA genomes", "OBSERVATION", 113, 130]]], ["The viral RNAs (vRNAs) are bound by nucleoprotein (NP) and three viral polymerase subunits (PB1, PB2, and PA) to form a ribonucleoprotein (RNP) complex, the minimal replication unit [1] [2] [3] .", [["vRNAs", "GENE_OR_GENE_PRODUCT", 16, 21], ["NP", "GENE_OR_GENE_PRODUCT", 51, 53], ["PB1", "GENE_OR_GENE_PRODUCT", 92, 95], ["PB2", "GENE_OR_GENE_PRODUCT", 97, 100], ["PA", "GENE_OR_GENE_PRODUCT", 106, 108], ["RNP", "CELLULAR_COMPONENT", 139, 142], ["viral RNAs", "RNA", 4, 14], ["vRNAs", "PROTEIN", 16, 21], ["nucleoprotein", "PROTEIN", 36, 49], ["NP", "PROTEIN", 51, 53], ["viral polymerase subunits", "PROTEIN", 65, 90], ["PB1", "PROTEIN", 92, 95], ["PB2", "PROTEIN", 97, 100], ["PA", "PROTEIN", 106, 108], ["ribonucleoprotein (RNP) complex", "PROTEIN", 120, 151], ["The viral RNAs", "TEST", 0, 14], ["three viral polymerase subunits", "TREATMENT", 59, 90], ["PB1", "TEST", 92, 95], ["PB2", "TEST", 97, 100], ["a ribonucleoprotein (RNP) complex", "TREATMENT", 118, 151], ["viral RNAs", "OBSERVATION", 4, 14]]], ["Influenza vRNAs have conserved 5\u2032 and 3\u2032 terminals that contain all the signals necessary for transcription, replication, and packaging [4, 5] . vRNAs with precise 5\u2032 and 3\u2032 ends are generally obtained using the RNA polymerase I (PolI) promoter [6, 7] .", [["vRNAs", "GENE_OR_GENE_PRODUCT", 10, 15], ["3", "GENE_OR_GENE_PRODUCT", 38, 39], ["vRNAs", "GENE_OR_GENE_PRODUCT", 145, 150], ["5\u2032", "GENE_OR_GENE_PRODUCT", 164, 166], ["RNA polymerase I", "GENE_OR_GENE_PRODUCT", 212, 228], ["PolI", "GENE_OR_GENE_PRODUCT", 230, 234], ["Influenza vRNAs", "PROTEIN", 0, 15], ["5\u2032 and 3\u2032 terminals", "DNA", 31, 50], ["vRNAs", "PROTEIN", 145, 150], ["5\u2032 and 3\u2032 ends", "DNA", 164, 178], ["RNA polymerase I (PolI) promoter", "DNA", 212, 244], ["Influenza vRNAs", "TEST", 0, 15], ["vRNAs", "TEST", 145, 150], ["the RNA polymerase I (PolI) promoter", "TREATMENT", 208, 244]]], ["Viral polymerase subunits and nucleoprotein are synthesized under the regulation of the RNA polymerase II (PolII) promoter [8] .", [["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 88, 105], ["PolII", "GENE_OR_GENE_PRODUCT", 107, 112], ["Viral polymerase subunits", "PROTEIN", 0, 25], ["RNA polymerase II (PolII) promoter", "DNA", 88, 122], ["Viral polymerase subunits", "TREATMENT", 0, 25], ["nucleoprotein", "TREATMENT", 30, 43], ["the RNA polymerase II (PolII) promoter", "TREATMENT", 84, 122]]], ["To generate influenza virus, pure plasmid-based reverse genetics systems are developed using 12-17 plasmids [9, 10] .", [["influenza virus", "DISEASE", 12, 27], ["influenza virus", "ORGANISM", 12, 27], ["pure plasmid", "DNA", 29, 41], ["influenza virus", "SPECIES", 12, 27], ["influenza virus", "PROBLEM", 12, 27], ["pure plasmid", "TREATMENT", 29, 41], ["influenza virus", "OBSERVATION", 12, 27]]], ["Invention of the PolI-PolII bidirectional transcription vector results in a more robust 8-plasmid system [11, 12] .", [["PolI", "GENE_OR_GENE_PRODUCT", 17, 21], ["PolII", "GENE_OR_GENE_PRODUCT", 22, 27], ["PolI-PolII bidirectional transcription vector", "DNA", 17, 62], ["the PolI", "TEST", 13, 21]]], ["Due to the fact that PolI promoters are species-specific [13] , different reverse genetics systems are developed for primate, avian, and canine cells [9, [14] [15] [16] .", [["cells", "ANATOMY", 144, 149], ["PolI", "GENE_OR_GENE_PRODUCT", 21, 25], ["canine cells", "CELL", 137, 149], ["[14] [15] [16]", "SIMPLE_CHEMICAL", 154, 168], ["PolI promoters", "DNA", 21, 35], ["primate, avian, and canine cells", "CELL_TYPE", 117, 149], ["canine", "SPECIES", 137, 143], ["canine", "SPECIES", 137, 143], ["PolI promoters", "TREATMENT", 21, 35]]], ["A universal T7 promoterbased system has been built, but shows less efficiency than the PolI-based bidirectional transcription system [17] .", [["PolI", "GENE_OR_GENE_PRODUCT", 87, 91], ["T7", "DNA", 12, 14], ["PolI", "PROTEIN", 87, 91], ["A universal T7 promoterbased system", "PROBLEM", 0, 35], ["T7", "ANATOMY", 12, 14], ["less", "OBSERVATION_MODIFIER", 62, 66], ["efficiency", "OBSERVATION_MODIFIER", 67, 77]]], ["Through tandem ligation of multiple viral gene cassettes, influenza virus is reconstituted using a 3-plasmid system [18] , and a single DNA construct [19, 20] .BackgroundAn important application of reverse genetics is the generation of influenza vaccine seed viruses [21] [22] [23] .", [["influenza virus", "ORGANISM", 58, 73], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["multiple viral gene cassettes", "DNA", 27, 56], ["single DNA construct", "DNA", 129, 149], ["influenza virus", "SPECIES", 58, 73], ["influenza virus", "SPECIES", 58, 73], ["tandem ligation", "TREATMENT", 8, 23], ["multiple viral gene cassettes", "TREATMENT", 27, 56], ["influenza virus", "PROBLEM", 58, 73], ["a 3-plasmid system", "TREATMENT", 97, 115], ["a single DNA construct", "TREATMENT", 127, 149], ["influenza vaccine seed viruses", "TREATMENT", 236, 266], ["multiple", "OBSERVATION_MODIFIER", 27, 35], ["viral", "OBSERVATION", 36, 41]]], ["Usually, seasonal influenza vaccine is composed of two influenza A viruses and one influenza B virus.", [["influenza", "DISEASE", 18, 27], ["influenza A viruses", "DISEASE", 55, 74], ["influenza B", "DISEASE", 83, 94], ["influenza A viruses", "ORGANISM", 55, 74], ["influenza B virus", "ORGANISM", 83, 100], ["influenza A viruses", "SPECIES", 55, 74], ["influenza B virus", "SPECIES", 83, 100], ["influenza A viruses", "SPECIES", 55, 74], ["influenza B virus", "SPECIES", 83, 100], ["seasonal influenza vaccine", "TREATMENT", 9, 35], ["two influenza A viruses", "PROBLEM", 51, 74], ["one influenza B virus", "PROBLEM", 79, 100]]], ["Using the reverse genetics method, each seed virus is generated with HA and NA from a circulating strain, and the remaining six segments from a high-yield strain or an attenuated strain [24] [25] [26] .", [["NA", "CHEMICAL", 76, 78], ["the reverse genetics method", "TREATMENT", 6, 33], ["each seed virus", "PROBLEM", 35, 50], ["HA", "PROBLEM", 69, 71], ["a circulating strain", "PROBLEM", 84, 104], ["a high-yield strain", "PROBLEM", 142, 161], ["an attenuated strain", "PROBLEM", 165, 185], ["high", "OBSERVATION_MODIFIER", 144, 148], ["attenuated", "OBSERVATION_MODIFIER", 168, 178]]], ["Nonetheless, manufacture of the vaccines still heavily relies on embryonated hens' eggs or cell culture to grow the viruses [27] , two time-consuming processes which are unlikely to provide adequate vaccines for a sudden influenza pandemic.", [["eggs", "ANATOMY", 83, 87], ["cell", "ANATOMY", 91, 95], ["influenza pandemic", "DISEASE", 221, 239], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 83, 87], ["cell culture", "CELL", 91, 103], ["the vaccines", "TREATMENT", 28, 40], ["cell culture", "TEST", 91, 103], ["the viruses", "PROBLEM", 112, 123], ["adequate vaccines", "TREATMENT", 190, 207], ["a sudden influenza pandemic", "PROBLEM", 212, 239]]], ["The majority of vaccines are administered through intramuscular injection or by individually nasal spray, two labor-intensive ways which further increase the cost of current vaccines in vaccinating huge flocks of birds.", [["intramuscular", "ANATOMY", 50, 63], ["nasal", "ANATOMY", 93, 98], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 63], ["birds", "ORGANISM", 213, 218], ["vaccines", "TREATMENT", 16, 24], ["intramuscular injection", "TREATMENT", 50, 73], ["individually nasal spray", "TREATMENT", 80, 104], ["current vaccines", "TREATMENT", 166, 182]]], ["To develop a quick-manufacturable and low-cost influenza vaccine, we proposed that an influenza viral genome-encoding plasmid could be delivered in vivo by a bacterial carrier, resulting in production of attenuated influenza viruses to induce protective immunity against influenza [19] .", [["plasmid", "ANATOMY", 118, 125], ["influenza viruses", "DISEASE", 215, 232], ["influenza", "DISEASE", 271, 280], ["influenza viruses", "ORGANISM", 215, 232], ["influenza viral genome", "DNA", 86, 108], ["a quick-manufacturable", "PROBLEM", 11, 33], ["low-cost influenza vaccine", "TREATMENT", 38, 64], ["an influenza viral genome", "PROBLEM", 83, 108], ["encoding plasmid", "TREATMENT", 109, 125], ["a bacterial carrier", "PROBLEM", 156, 175], ["attenuated influenza viruses", "PROBLEM", 204, 232], ["influenza", "PROBLEM", 271, 280]]], ["In a feasibility study, we constructed a chicken PolI-driven plasmid expressing all vRNAs, NP and polymerase from a influenza A virus (A/WSN/33) [19] .", [["plasmid", "ANATOMY", 61, 68], ["chicken", "ORGANISM", 41, 48], ["PolI", "GENE_OR_GENE_PRODUCT", 49, 53], ["vRNAs", "GENE_OR_GENE_PRODUCT", 84, 89], ["influenza A virus", "ORGANISM", 116, 133], ["chicken PolI-driven plasmid", "DNA", 41, 68], ["vRNAs", "PROTEIN", 84, 89], ["NP and polymerase", "PROTEIN", 91, 108], ["chicken", "SPECIES", 41, 48], ["influenza A virus", "SPECIES", 116, 133], ["chicken", "SPECIES", 41, 48], ["influenza A virus (A/WSN/33", "SPECIES", 116, 143], ["a feasibility study", "TEST", 3, 22], ["a chicken PolI", "TREATMENT", 39, 53], ["a influenza A virus", "PROBLEM", 114, 133]]], ["Generation of influenza virus was found in cultured avian cells infected by auxotrophic Salmonella strains carrying the plasmid or its derivatives, but not in chickens inoculated with the recombinant Salmonella [28] .", [["cells", "ANATOMY", 58, 63], ["plasmid", "ANATOMY", 120, 127], ["influenza virus", "DISEASE", 14, 29], ["influenza virus", "ORGANISM", 14, 29], ["avian", "ORGANISM", 52, 57], ["cells", "CELL", 58, 63], ["Salmonella strains", "ORGANISM", 88, 106], ["chickens", "ORGANISM", 159, 167], ["cultured avian cells", "CELL_LINE", 43, 63], ["influenza virus", "SPECIES", 14, 29], ["chickens", "SPECIES", 159, 167], ["influenza virus", "SPECIES", 14, 29], ["Salmonella", "SPECIES", 88, 98], ["chickens", "SPECIES", 159, 167], ["influenza virus", "PROBLEM", 14, 29], ["cultured avian cells", "PROBLEM", 43, 63], ["auxotrophic Salmonella strains", "PROBLEM", 76, 106], ["the plasmid", "TREATMENT", 116, 127], ["influenza virus", "OBSERVATION", 14, 29]]], ["The study proved that a single plasmid could be constructed to reconstitute influenza virus and stably maintained in engineered Salmonella strains.", [["plasmid", "ANATOMY", 31, 38], ["influenza virus", "ORGANISM", 76, 91], ["Salmonella strains", "ORGANISM", 128, 146], ["influenza virus", "SPECIES", 76, 91], ["influenza virus", "SPECIES", 76, 91], ["The study", "TEST", 0, 9], ["a single plasmid", "TREATMENT", 22, 38], ["influenza virus", "PROBLEM", 76, 91], ["engineered Salmonella strains", "PROBLEM", 117, 146], ["influenza virus", "OBSERVATION", 76, 91], ["Salmonella strains", "OBSERVATION", 128, 146]]], ["The engineered Salmonella could deliver the plasmid into host cells resulting in generation of live influenza virus.", [["plasmid", "ANATOMY", 44, 51], ["cells", "ANATOMY", 62, 67], ["influenza virus", "DISEASE", 100, 115], ["host cells", "CELL", 57, 67], ["live influenza virus", "ORGANISM", 95, 115], ["plasmid", "DNA", 44, 51], ["host cells", "CELL_TYPE", 57, 67], ["influenza virus", "SPECIES", 100, 115], ["Salmonella", "SPECIES", 15, 25], ["The engineered Salmonella", "TREATMENT", 0, 25], ["the plasmid into host cells", "TREATMENT", 40, 67], ["live influenza virus", "PROBLEM", 95, 115], ["Salmonella", "OBSERVATION", 15, 25], ["host cells", "OBSERVATION", 57, 67]]], ["Nonetheless, to make the hypothesized influenza vaccine, the one-plasmid reverse genetics system still needs to be improved in virus generation efficiency, and the Salmonella carrier has to be engineered to deliver plasmid efficiently, especially in vivo.BackgroundThe mouse represents an easily handling animal and is widely used in studies of influenza virus, Salmonella and vaccine development.", [["plasmid", "ANATOMY", 215, 222], ["influenza", "DISEASE", 38, 47], ["influenza virus", "DISEASE", 345, 360], ["mouse", "ORGANISM", 269, 274], ["influenza virus", "ORGANISM", 345, 360], ["mouse", "SPECIES", 269, 274], ["influenza virus", "SPECIES", 345, 360], ["Salmonella", "SPECIES", 164, 174], ["mouse", "SPECIES", 269, 274], ["influenza virus", "SPECIES", 345, 360], ["Salmonella", "SPECIES", 362, 372], ["the hypothesized influenza vaccine", "TREATMENT", 21, 55], ["virus generation efficiency", "PROBLEM", 127, 154], ["the Salmonella carrier", "PROBLEM", 160, 182], ["influenza virus", "PROBLEM", 345, 360], ["Salmonella", "PROBLEM", 362, 372], ["vaccine development", "TREATMENT", 377, 396], ["influenza virus", "OBSERVATION", 345, 360]]], ["A large number of wellcharacterized rodent cell lines provide another advantage for in vitro study.", [["cell lines", "ANATOMY", 43, 53], ["rodent", "ORGANISM", 36, 42], ["cell lines", "CELL", 43, 53], ["wellcharacterized rodent cell lines", "CELL_LINE", 18, 53], ["rodent", "SPECIES", 36, 42], ["wellcharacterized rodent cell lines", "TREATMENT", 18, 53], ["vitro study", "TEST", 87, 98], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["rodent cell lines", "OBSERVATION", 36, 53]]], ["Therefore, a mouse PolI-driven oneplasmid system is very useful to determine the factors limiting virus generation and Salmonella-mediated plasmid delivery.", [["plasmid", "ANATOMY", 139, 146], ["mouse", "ORGANISM", 13, 18], ["PolI", "GENE_OR_GENE_PRODUCT", 19, 23], ["PolI", "PROTEIN", 19, 23], ["mouse", "SPECIES", 13, 18], ["mouse", "SPECIES", 13, 18], ["Salmonella", "SPECIES", 119, 129], ["a mouse PolI", "TEST", 11, 23], ["virus generation", "PROBLEM", 98, 114], ["Salmonella-mediated plasmid delivery", "TREATMENT", 119, 155]]], ["Some rodent cell lines, such as Chinese hamster ovary (CHO) cells and baby hamster kidney (BHK-21) cells, are widely used for research and vaccine development [29] [30] [31] .", [["cell lines", "ANATOMY", 12, 22], ["hamster ovary (CHO) cells", "ANATOMY", 40, 65], ["kidney", "ANATOMY", 83, 89], ["BHK-21) cells", "ANATOMY", 91, 104], ["cell lines", "CELL", 12, 22], ["hamster ovary (CHO) cells", "CELL", 40, 65], ["baby hamster kidney", "CELL", 70, 89], ["BHK-21) cells", "CELL", 91, 104], ["rodent cell lines", "CELL_LINE", 5, 22], ["Chinese hamster ovary (CHO) cells", "CELL_LINE", 32, 65], ["baby hamster kidney (BHK-21) cells", "CELL_LINE", 70, 104], ["hamster", "SPECIES", 75, 82], ["Chinese hamster", "SPECIES", 32, 47], ["hamster", "SPECIES", 75, 82], ["Some rodent cell lines", "PROBLEM", 0, 22], ["Chinese hamster ovary (CHO) cells", "TREATMENT", 32, 65], ["BHK", "TEST", 91, 94], ["research and vaccine development", "TREATMENT", 126, 158], ["rodent cell lines", "OBSERVATION", 5, 22], ["hamster ovary", "ANATOMY", 40, 53], ["kidney", "ANATOMY", 83, 89]]], ["BHK-21 cells synthesize \u03b1-2, 3 and \u03b1-2, 6 sialic acid (SA) linked receptors [32] , and support the growth of influenza A and B viruses [32, 33] .", [["BHK-21 cells", "ANATOMY", 0, 12], ["sialic acid", "CHEMICAL", 42, 53], ["influenza A", "DISEASE", 109, 120], ["sialic acid", "CHEMICAL", 42, 53], ["BHK-21 cells", "CELL", 0, 12], ["\u03b1-2", "GENE_OR_GENE_PRODUCT", 24, 27], ["3", "GENE_OR_GENE_PRODUCT", 29, 30], ["\u03b1-2", "GENE_OR_GENE_PRODUCT", 35, 38], ["6 sialic acid", "SIMPLE_CHEMICAL", 40, 53], ["SA", "SIMPLE_CHEMICAL", 55, 57], ["influenza A", "ORGANISM", 109, 120], ["B viruses", "ORGANISM", 125, 134], ["BHK-21 cells", "CELL_LINE", 0, 12], ["\u03b1-2, 3 and \u03b1-2, 6 sialic acid (SA) linked receptors", "PROTEIN", 24, 75], ["B viruses", "SPECIES", 125, 134], ["BHK", "TEST", 0, 3], ["cells synthesize", "TEST", 7, 23], ["\u03b1", "TEST", 24, 25], ["\u03b1", "TEST", 35, 36], ["sialic acid", "TEST", 42, 53], ["influenza A and B viruses", "PROBLEM", 109, 134], ["21 cells", "OBSERVATION_MODIFIER", 4, 12], ["influenza", "OBSERVATION", 109, 118]]], ["BHK-21 cells are also highly transfectable, even with 30-kb plasmids [34] , and therefore are an appropriate cell substrate for rodent PolI-based reverse genetics systems.BackgroundIn this study, we constructed a mouse PolI-driven all-in-one plasmid to reconstitute influenza virus.", [["BHK-21 cells", "ANATOMY", 0, 12], ["cell", "ANATOMY", 109, 113], ["plasmid", "ANATOMY", 242, 249], ["influenza virus", "DISEASE", 266, 281], ["BHK-21 cells", "CELL", 0, 12], ["cell", "CELL", 109, 113], ["PolI", "GENE_OR_GENE_PRODUCT", 135, 139], ["mouse", "ORGANISM", 213, 218], ["PolI", "GENE_OR_GENE_PRODUCT", 219, 223], ["influenza virus", "ORGANISM", 266, 281], ["BHK-21 cells", "CELL_LINE", 0, 12], ["PolI", "PROTEIN", 135, 139], ["mouse PolI-driven all-in-one plasmid", "DNA", 213, 249], ["mouse", "SPECIES", 213, 218], ["influenza virus", "SPECIES", 266, 281], ["mouse", "SPECIES", 213, 218], ["influenza virus", "SPECIES", 266, 281], ["BHK", "TEST", 0, 3], ["an appropriate cell substrate", "TREATMENT", 94, 123], ["rodent PolI", "TEST", 128, 139], ["this study", "TEST", 184, 194], ["a mouse PolI", "TREATMENT", 211, 223], ["influenza virus", "PROBLEM", 266, 281], ["21 cells", "OBSERVATION_MODIFIER", 4, 12], ["influenza virus", "OBSERVATION", 266, 281]]], ["A \"1 + 2\" plasmid strategy was also tested to simplify the yearly generation of influenza vaccine seeds.Plasmid constructionUsing the truncated mouse PolI promoter (MPI, 250 bp), plasmid pYA4924 was constructed to transcribe negative sense EGFP RNA flanked by the 5\u2032 and 3\u2032 non-translating regions of influenza virus M segment (vRNA-like).", [["influenza", "DISEASE", 80, 89], ["mouse", "ORGANISM", 144, 149], ["PolI", "GENE_OR_GENE_PRODUCT", 150, 154], ["pYA4924", "GENE_OR_GENE_PRODUCT", 187, 194], ["EGFP", "GENE_OR_GENE_PRODUCT", 240, 244], ["\u2032", "GENE_OR_GENE_PRODUCT", 265, 266], ["influenza virus", "ORGANISM", 301, 316], ["truncated mouse PolI promoter", "DNA", 134, 163], ["MPI", "DNA", 165, 168], ["250 bp", "DNA", 170, 176], ["plasmid pYA4924", "DNA", 179, 194], ["EGFP RNA", "RNA", 240, 248], ["5\u2032 and 3\u2032 non-translating regions", "DNA", 264, 297], ["influenza virus M segment", "DNA", 301, 326], ["vRNA", "DNA", 328, 332], ["mouse", "SPECIES", 144, 149], ["influenza virus M", "SPECIES", 301, 318], ["mouse", "SPECIES", 144, 149], ["2\" plasmid strategy", "TREATMENT", 7, 26], ["influenza vaccine seeds", "TREATMENT", 80, 103], ["Plasmid constructionUsing the truncated mouse PolI promoter", "TREATMENT", 104, 163], ["MPI", "TEST", 165, 168], ["plasmid pYA4924", "TREATMENT", 179, 194], ["influenza virus M segment (vRNA", "PROBLEM", 301, 332], ["influenza virus", "OBSERVATION", 301, 316]]], ["EGFP expression was observed in BHK-21 cells only when pYA4924 has been cotransfected with plasmids encoding influenza polymerase and NP (Data not shown), suggesting that the cloned MPI is functional in hamster cells.", [["BHK-21 cells", "ANATOMY", 32, 44], ["plasmids", "ANATOMY", 91, 99], ["hamster cells", "ANATOMY", 203, 216], ["pYA4924", "CHEMICAL", 55, 62], ["EGFP", "GENE_OR_GENE_PRODUCT", 0, 4], ["BHK-21 cells", "CELL", 32, 44], ["pYA4924", "GENE_OR_GENE_PRODUCT", 55, 62], ["influenza polymerase", "GENE_OR_GENE_PRODUCT", 109, 129], ["hamster cells", "CELL", 203, 216], ["EGFP", "PROTEIN", 0, 4], ["BHK-21 cells", "CELL_LINE", 32, 44], ["pYA4924", "PROTEIN", 55, 62], ["plasmids", "DNA", 91, 99], ["influenza polymerase", "PROTEIN", 109, 129], ["NP", "PROTEIN", 134, 136], ["MPI", "PROTEIN", 182, 185], ["hamster cells", "CELL_TYPE", 203, 216], ["hamster", "SPECIES", 203, 210], ["BHK-21", "SPECIES", 32, 38], ["hamster", "SPECIES", 203, 210], ["BHK", "TEST", 32, 35], ["plasmids encoding influenza polymerase", "PROBLEM", 91, 129], ["NP (Data", "TEST", 134, 142], ["the cloned MPI", "PROBLEM", 171, 185], ["hamster cells", "OBSERVATION", 203, 216]]], ["By combining MPI with the SV40 polyadenylation sequence (SV40 pA, 131 bp), truncated mouse PolI terminator (MTI, 41 bp), and functional truncated CMV promoter (188 bp), a bidirectional CMV/MPI-driven transcription vector, pYA4963, was constructed.", [["SV40", "ORGANISM", 26, 30], ["SV40", "ORGANISM", 57, 61], ["mouse", "ORGANISM", 85, 90], ["PolI", "GENE_OR_GENE_PRODUCT", 91, 95], ["CMV", "ORGANISM", 146, 149], ["CMV", "ORGANISM", 185, 188], ["MPI", "GENE_OR_GENE_PRODUCT", 189, 192], ["pYA4963", "GENE_OR_GENE_PRODUCT", 222, 229], ["MPI", "DNA", 13, 16], ["SV40 polyadenylation sequence", "DNA", 26, 55], ["truncated mouse PolI terminator", "DNA", 75, 106], ["MTI", "DNA", 108, 111], ["CMV promoter", "DNA", 146, 158], ["188 bp", "DNA", 160, 166], ["bidirectional CMV/MPI-driven transcription vector", "DNA", 171, 220], ["pYA4963", "DNA", 222, 229], ["mouse", "SPECIES", 85, 90], ["mouse", "SPECIES", 85, 90], ["the SV40 polyadenylation sequence", "TREATMENT", 22, 55], ["SV40 pA", "TEST", 57, 64], ["bp", "TEST", 70, 72], ["MTI", "TEST", 108, 111], ["bp", "TEST", 116, 118], ["functional truncated CMV promoter", "TREATMENT", 125, 158], ["bp", "TEST", 164, 166], ["a bidirectional CMV/MPI", "TEST", 169, 192]]], ["Two BsmBI sites were designed between MPI and MTI to allow precise insertion of influenza cDNA.", [["BsmBI", "GENE_OR_GENE_PRODUCT", 4, 9], ["BsmBI sites", "DNA", 4, 15], ["MPI", "DNA", 38, 41], ["MTI", "DNA", 46, 49], ["influenza cDNA", "DNA", 80, 94], ["Two BsmBI sites", "PROBLEM", 0, 15], ["MPI", "TEST", 38, 41], ["MTI", "TREATMENT", 46, 49], ["precise insertion of influenza cDNA", "TREATMENT", 59, 94]]], ["A BamHI site was designed between the two BsmBI sites.", [["BamHI", "GENE_OR_GENE_PRODUCT", 2, 7], ["BamHI site", "DNA", 2, 12], ["BsmBI sites", "DNA", 42, 53], ["A BamHI site", "TREATMENT", 0, 12]]], ["By inserting a prokaryotic GFPexpression cassette at the BamHI site, an easy-to-use bidirectional vector pYA4964 was constructed (Fig. 1) .", [["GFPexpression", "GENE_OR_GENE_PRODUCT", 27, 40], ["BamHI", "GENE_OR_GENE_PRODUCT", 57, 62], ["pYA4964", "GENE_OR_GENE_PRODUCT", 105, 112], ["prokaryotic GFPexpression cassette", "DNA", 15, 49], ["BamHI site", "DNA", 57, 67], ["pYA4964", "DNA", 105, 112], ["a prokaryotic GFPexpression cassette", "TREATMENT", 13, 49], ["bidirectional vector pYA4964", "TREATMENT", 84, 112]]], ["Substitution of the GFP cassette with influenza cDNA resulted in loss of green fluorescence in bacterial host cells.", [["cells", "ANATOMY", 110, 115], ["GFP", "GENE_OR_GENE_PRODUCT", 20, 23], ["bacterial host cells", "CELL", 95, 115], ["GFP cassette", "DNA", 20, 32], ["influenza cDNA", "DNA", 38, 52], ["bacterial host cells", "CELL_TYPE", 95, 115], ["the GFP cassette", "TREATMENT", 16, 32], ["influenza cDNA", "PROBLEM", 38, 52], ["loss of green fluorescence in bacterial host cells", "PROBLEM", 65, 115], ["green fluorescence", "OBSERVATION", 73, 91], ["bacterial host cells", "OBSERVATION", 95, 115]]], ["The GFP-based selection method facilitated construction of the mouse PolI-driven 8-plasmid system that included plasmids pYA4965 (PB1), pYA4966 (PB2), pYA4967 (PA), pYA4968 (NP), pYA4969 (HA), pYA4970 (NA), pYA4971 (M), and pYA4972 (NS) ( Table 1) .Plasmid constructionTo combine all CMV/MPI-driven influenza gene cassettes on one plasmid, four influenza cassettes were first cloned into a linearized vector which has single 3\u2032-T overhangs on both ends (T-vector) (Fig. 2) .", [["plasmids", "ANATOMY", 112, 120], ["plasmid", "ANATOMY", 331, 338], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["mouse", "ORGANISM", 63, 68], ["PolI", "GENE_OR_GENE_PRODUCT", 69, 73], ["pYA4965", "GENE_OR_GENE_PRODUCT", 121, 128], ["pYA4966", "GENE_OR_GENE_PRODUCT", 136, 143], ["pYA4967 (PA)", "GENE_OR_GENE_PRODUCT", 151, 163], ["CMV", "ORGANISM", 284, 287], ["mouse PolI-driven 8-plasmid system", "DNA", 63, 97], ["plasmids", "DNA", 112, 120], ["PB1", "DNA", 130, 133], ["PB2", "DNA", 145, 148], ["CMV/MPI-driven influenza gene cassettes", "DNA", 284, 323], ["plasmid", "DNA", 331, 338], ["influenza cassettes", "DNA", 345, 364], ["3\u2032-T overhangs", "DNA", 425, 439], ["mouse", "SPECIES", 63, 68], ["mouse", "SPECIES", 63, 68], ["The GFP", "TEST", 0, 7], ["the mouse PolI", "TREATMENT", 59, 73], ["plasmids", "TEST", 112, 120], ["PB2", "TEST", 145, 148], ["PA", "TEST", 160, 162], ["NP", "TEST", 174, 176], ["HA", "TEST", 188, 190], ["NA", "TEST", 202, 204], ["Plasmid constructionTo", "TREATMENT", 249, 271], ["MPI", "TREATMENT", 288, 291], ["influenza gene cassettes", "TREATMENT", 299, 323], ["one plasmid", "TREATMENT", 327, 338], ["four influenza cassettes", "TREATMENT", 340, 364], ["a linearized vector", "TREATMENT", 388, 407], ["single 3\u2032-T overhangs", "TREATMENT", 418, 439]]], ["Unique restriction enzyme cleavage sites were designed at each end of the cassette to allow insertion of the other cassette.", [["restriction enzyme cleavage sites", "DNA", 7, 40], ["Unique restriction enzyme cleavage sites", "PROBLEM", 0, 40], ["insertion of the other cassette", "TREATMENT", 92, 123], ["enzyme", "OBSERVATION_MODIFIER", 19, 25], ["cleavage sites", "OBSERVATION", 26, 40]]], ["A prokaryotic GFP cassette was first inserted between two adjacent enzyme sites, followed by selection of green colonies under excitation with 488 nm light.", [["GFP", "GENE_OR_GENE_PRODUCT", 14, 17], ["prokaryotic GFP cassette", "DNA", 2, 26], ["adjacent enzyme sites", "DNA", 58, 79], ["green colonies", "CELL_LINE", 106, 120], ["A prokaryotic GFP cassette", "TREATMENT", 0, 26], ["two adjacent enzyme sites", "PROBLEM", 54, 79], ["prokaryotic", "OBSERVATION", 2, 13], ["GFP cassette", "OBSERVATION", 14, 26], ["green colonies", "OBSERVATION", 106, 120]]], ["The GFP cassettes were then substituted with influenza cassettes by selecting non-fluorescent colonies.", [["colonies", "ANATOMY", 94, 102], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["GFP cassettes", "DNA", 4, 17], ["influenza cassettes", "DNA", 45, 64], ["non-fluorescent colonies", "CELL_LINE", 78, 102], ["The GFP cassettes", "TREATMENT", 0, 17], ["influenza cassettes", "TREATMENT", 45, 64], ["non-fluorescent colonies", "OBSERVATION", 78, 102]]], ["These steps resulted in four 2unit plasmids, with each unit representing a bidirectional influenza cassette.", [["plasmids", "ANATOMY", 35, 43], ["2unit plasmids", "DNA", 29, 43], ["bidirectional influenza cassette", "DNA", 75, 107], ["four 2unit plasmids", "TREATMENT", 24, 43], ["a bidirectional influenza cassette", "TREATMENT", 73, 107]]], ["The GFP cassettes were again inserted into three of the 2-unit plasmids.", [["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["GFP cassettes", "DNA", 4, 17], ["2-unit plasmids", "DNA", 56, 71], ["The GFP cassettes", "TREATMENT", 0, 17], ["the 2-unit plasmids", "TREATMENT", 52, 71]]], ["Each of the two 2-unit plasmids were combined to obtain two 4-unit plasmids, pYA4988 and pYA4989.", [["pYA4988", "GENE_OR_GENE_PRODUCT", 77, 84], ["2-unit plasmids", "DNA", 16, 31], ["4-unit plasmids", "DNA", 60, 75], ["pYA4988", "DNA", 77, 84], ["pYA4989", "DNA", 89, 96], ["the two 2-unit plasmids", "TREATMENT", 8, 31], ["two 4-unit plasmids", "TREATMENT", 56, 75]]], ["Combination of the 4-unit plasmids resulted in the all-in-one plasmid pYA4990 which was further confirmed by sequencing.", [["pYA4990", "GENE_OR_GENE_PRODUCT", 70, 77], ["4-unit plasmids", "DNA", 19, 34], ["plasmid pYA4990", "DNA", 62, 77], ["the 4-unit plasmids", "TREATMENT", 15, 34]]], ["The all-in-one plasmid was designed to transcribe all eight vRNAs and eight mRNAs (10 mRNAs after spliced) in rodent cells.", [["plasmid", "ANATOMY", 15, 22], ["cells", "ANATOMY", 117, 122], ["cells", "CELL", 117, 122], ["vRNAs", "RNA", 60, 65], ["mRNAs", "RNA", 76, 81], ["10 mRNAs", "RNA", 83, 91], ["rodent cells", "CELL_TYPE", 110, 122], ["rodent", "SPECIES", 110, 116], ["rodent cells", "OBSERVATION", 110, 122]]], ["The HA and NA cassettes in pYA4990 were deleted to form a 6-unit plasmid that composes a \"1 + 2\" plasmid system with the HA and NA plasmids (pYA4969 and pYA4970).Plasmid stability in E. coliThe all-in-one plasmid contains repetitive sequences in the promoter and terminator elements flanking each of the viral genes (Fig. 2) .", [["plasmid", "ANATOMY", 205, 212], ["NA", "CHEMICAL", 11, 13], ["pYA4990", "CHEMICAL", 27, 34], ["HA", "GENE_OR_GENE_PRODUCT", 4, 6], ["pYA4990", "GENE_OR_GENE_PRODUCT", 27, 34], ["E. coli", "ORGANISM", 183, 190], ["HA and NA cassettes", "DNA", 4, 23], ["pYA4990", "DNA", 27, 34], ["6-unit plasmid", "DNA", 58, 72], ["HA and NA plasmids", "DNA", 121, 139], ["pYA4969", "DNA", 141, 148], ["pYA4970", "DNA", 153, 160], ["plasmid", "DNA", 205, 212], ["repetitive sequences", "DNA", 222, 242], ["promoter", "DNA", 250, 258], ["terminator elements", "DNA", 263, 282], ["viral genes", "DNA", 304, 315], ["E. coli", "SPECIES", 183, 190], ["E. coli", "SPECIES", 183, 190], ["The HA", "PROBLEM", 0, 6], ["NA cassettes", "TREATMENT", 11, 23], ["a 6-unit plasmid", "TREATMENT", 56, 72], ["the HA", "TREATMENT", 117, 123], ["NA plasmids", "TREATMENT", 128, 139], ["Plasmid stability in E. coli", "PROBLEM", 162, 190], ["stability", "OBSERVATION_MODIFIER", 170, 179], ["E. coli", "OBSERVATION", 183, 190], ["viral genes", "OBSERVATION", 304, 315]]], ["Homologous DNA recombination among these repetitive sequences impairs plasmid stability.", [["plasmid", "ANATOMY", 70, 77], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["repetitive sequences", "DNA", 41, 61], ["Homologous DNA recombination", "TREATMENT", 0, 28], ["these repetitive sequences", "TEST", 35, 61], ["plasmid stability", "OBSERVATION", 70, 87]]], ["To stably maintain and amplify the plasmid, an E. coli strain with a recA mutation was used.", [["plasmid", "ANATOMY", 35, 42], ["E. coli", "ORGANISM", 47, 54], ["recA", "GENE_OR_GENE_PRODUCT", 69, 73], ["plasmid", "DNA", 35, 42], ["recA mutation", "DNA", 69, 82], ["E. coli", "SPECIES", 47, 54], ["E. coli", "SPECIES", 47, 54], ["the plasmid", "TREATMENT", 31, 42], ["an E. coli strain", "PROBLEM", 44, 61], ["a recA mutation", "TREATMENT", 67, 82]]], ["As shown in Fig. 3 , plasmid pYA4990 was electroporated into E. coli strain EPI300 (RecA \u2212 ).", [["plasmid", "ANATOMY", 21, 28], ["pYA4990", "CHEMICAL", 29, 36], ["pYA4990", "GENE_OR_GENE_PRODUCT", 29, 36], ["E. coli", "ORGANISM", 61, 68], ["EPI300", "GENE_OR_GENE_PRODUCT", 76, 82], ["RecA", "GENE_OR_GENE_PRODUCT", 84, 88], ["plasmid pYA4990", "DNA", 21, 36], ["RecA", "PROTEIN", 84, 88], ["E. coli", "SPECIES", 61, 68], ["E. coli", "SPECIES", 61, 68], ["coli strain", "OBSERVATION", 64, 75]]], ["A single colony was first inoculated in 3 ml of growth media, and passaged at dilution ratio of 1:1000.", [["colony", "ANATOMY", 9, 15], ["A single colony", "PROBLEM", 0, 15], ["growth media", "TREATMENT", 48, 60], ["single", "OBSERVATION_MODIFIER", 2, 8], ["colony", "OBSERVATION", 9, 15]]], ["DNA recombination was monitored by restriction enzyme digestion of plasmid DNA isolated from different passages.", [["plasmid", "ANATOMY", 67, 74], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["plasmid DNA", "DNA", 67, 78], ["DNA recombination", "PROBLEM", 0, 17], ["plasmid DNA", "PROBLEM", 67, 78]]], ["At the fourth passage, there was apparent change in the restriction map of pYA4990, indicating significantly impaired plasmid structure.", [["plasmid", "ANATOMY", 118, 125], ["pYA4990", "GENE_OR_GENE_PRODUCT", 75, 82], ["pYA4990", "DNA", 75, 82], ["apparent change", "PROBLEM", 33, 48], ["significantly impaired plasmid structure", "PROBLEM", 95, 135], ["fourth", "OBSERVATION_MODIFIER", 7, 13], ["passage", "OBSERVATION_MODIFIER", 14, 21], ["change", "OBSERVATION_MODIFIER", 42, 48], ["significantly", "OBSERVATION_MODIFIER", 95, 108], ["impaired", "OBSERVATION_MODIFIER", 109, 117], ["plasmid structure", "OBSERVATION", 118, 135]]], ["Qualitative evaluation of the DNA bands on agarose gels suggested that the plasmid structure was stable for the first 3 passages in E. coli strain EPI300.", [["plasmid", "ANATOMY", 75, 82], ["DNA", "CELLULAR_COMPONENT", 30, 33], ["agarose", "SIMPLE_CHEMICAL", 43, 50], ["E. coli", "ORGANISM", 132, 139], ["strain", "ORGANISM", 140, 146], ["EPI300", "ORGANISM", 147, 153], ["E. coli", "SPECIES", 132, 139], ["E. coli", "SPECIES", 132, 139], ["Qualitative evaluation", "TEST", 0, 22], ["the DNA bands", "PROBLEM", 26, 39], ["agarose gels", "TEST", 43, 55], ["the plasmid structure", "PROBLEM", 71, 92], ["E. coli strain EPI300", "TREATMENT", 132, 153], ["stable", "OBSERVATION_MODIFIER", 97, 103], ["coli strain", "OBSERVATION", 135, 146]]], ["We also tested pYA4490 recombination in another E. coli strain Stbl3 (RecA \u2212 ) and got similar result (data not shown).", [["pYA4490", "CHEMICAL", 15, 22], ["pYA4490", "GENE_OR_GENE_PRODUCT", 15, 22], ["E. coli", "ORGANISM", 48, 55], ["Stbl3", "GENE_OR_GENE_PRODUCT", 63, 68], ["RecA", "GENE_OR_GENE_PRODUCT", 70, 74], ["pYA4490", "DNA", 15, 22], ["RecA", "PROTEIN", 70, 74], ["E. coli", "SPECIES", 48, 55], ["E. coli", "SPECIES", 48, 55], ["another E. coli strain", "PROBLEM", 40, 62]]], ["In theory, three passages could result in 3 \u00d7 10 9 ml of bacterial culture for plasmid preparation.", [["plasmid", "ANATOMY", 79, 86], ["bacterial culture", "TEST", 57, 74], ["plasmid preparation", "TREATMENT", 79, 98]]], ["Therefore, DNA recombination does not represent a big problem with the all-in-one plasmid when an E. coli strain with a recA mutation is used during cloning and plasmid amplification processes.Virus generationTo test virus generation, 4 \u03bcg of the all-in-one plasmid pYA4990 was used to transfect BHK-21, CHO, or MDCK cells.", [["plasmid", "ANATOMY", 161, 168], ["plasmid", "ANATOMY", 258, 265], ["BHK-21", "ANATOMY", 296, 302], ["CHO", "ANATOMY", 304, 307], ["MDCK cells", "ANATOMY", 312, 322], ["pYA4990", "CHEMICAL", 266, 273], ["pYA4990", "CHEMICAL", 266, 273], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["E. coli", "ORGANISM", 98, 105], ["strain", "ORGANISM", 106, 112], ["recA", "GENE_OR_GENE_PRODUCT", 120, 124], ["Virus", "ORGANISM", 193, 198], ["plasmid", "ORGANISM", 258, 265], ["pYA4990", "SIMPLE_CHEMICAL", 266, 273], ["BHK-21", "CELL", 296, 302], ["CHO", "CELL", 304, 307], ["MDCK cells", "CELL", 312, 322], ["recA mutation", "DNA", 120, 133], ["plasmid pYA4990", "DNA", 258, 273], ["BHK-21", "CELL_LINE", 296, 302], ["CHO", "CELL_LINE", 304, 307], ["MDCK cells", "CELL_LINE", 312, 322], ["E. coli", "SPECIES", 98, 105], ["E. coli", "SPECIES", 98, 105], ["BHK-21", "SPECIES", 296, 302], ["DNA recombination", "PROBLEM", 11, 28], ["a big problem", "PROBLEM", 48, 61], ["an E. coli strain", "PROBLEM", 95, 112], ["a recA mutation", "TREATMENT", 118, 133], ["cloning and plasmid amplification processes", "TREATMENT", 149, 192], ["Virus generation", "TREATMENT", 193, 209], ["BHK", "TEST", 296, 299], ["CHO", "TEST", 304, 307], ["coli strain", "OBSERVATION", 101, 112]]], ["For BHK-21 cells, the virus titers ranged from 1 to 3 \u00d7 10 5 median tissue culture infective dose (TCID 50 ) per mL on the third day post-transfection (Experiments 1-3; Table 2 ).", [["BHK-21 cells", "ANATOMY", 4, 16], ["tissue", "ANATOMY", 68, 74], ["BHK-21 cells", "CELL", 4, 16], ["tissue", "TISSUE", 68, 74], ["BHK-21 cells", "CELL_LINE", 4, 16], ["BHK", "TEST", 4, 7], ["the virus titers", "TEST", 18, 34], ["21 cells", "OBSERVATION_MODIFIER", 8, 16]]], ["When less confluent BHK-21 cells were used in transfection, the virus titers went up to 3-6 \u00d7 10 6 TCID 50 /mL (Experiments 4-6).", [["BHK-21 cells", "ANATOMY", 20, 32], ["BHK-21 cells", "CELL", 20, 32], ["BHK-21 cells", "CELL_LINE", 20, 32], ["less confluent BHK-21 cells", "PROBLEM", 5, 32], ["the virus titers", "TEST", 60, 76], ["confluent", "OBSERVATION_MODIFIER", 10, 19], ["21 cells", "OBSERVATION_MODIFIER", 24, 32]]], ["In contrast, the CHO cells showed very poor virus generation (0-10 TCID 50 /mL) on the third day post-transfection.", [["CHO cells", "ANATOMY", 17, 26], ["CHO cells", "CELL", 17, 26], ["CHO cells", "CELL_LINE", 17, 26], ["the CHO cells", "TEST", 13, 26], ["very poor virus generation", "PROBLEM", 34, 60]]], ["The MDCK cells showed inconsistent virus generation ranged from 0 to 1 \u00d7 10 6 TCID 50 /mL on the third day post-transfection.", [["MDCK cells", "ANATOMY", 4, 14], ["MDCK cells", "CELL", 4, 14], ["MDCK cells", "CELL_LINE", 4, 14], ["The MDCK cells", "TEST", 0, 14], ["inconsistent virus generation", "PROBLEM", 22, 51], ["virus", "OBSERVATION", 35, 40]]], ["In Experiments 4-6, the virus titers went up to 1-3 \u00d7 10 7 TCID 50 /mL on the fifth day (not shown in Table 2 ).", [["the virus titers", "TEST", 20, 36]]], ["As control, 4 \u03bcg of the 6-unit plasmid pYA5000 was transfected into each type of cells.", [["cells", "ANATOMY", 81, 86], ["pYA5000", "GENE_OR_GENE_PRODUCT", 39, 46], ["cells", "CELL", 81, 86], ["6-unit plasmid pYA5000", "DNA", 24, 46], ["the 6-unit plasmid pYA5000", "TREATMENT", 20, 46]]], ["No virus generation was observed.", [["virus generation", "PROBLEM", 3, 19], ["virus generation", "OBSERVATION", 3, 19]]], ["To test the \"1 + 2\" plasmid system, 4 \u03bcg of the 6-unit plasmid pYA5000 was cotransfected into either BHK-21 or MDCK cells with 2 \u03bcg of the HA plasmid pYA4969 and 2 \u03bcg of the NA plasmid pYA4970.", [["BHK-21", "ANATOMY", 101, 107], ["MDCK cells", "ANATOMY", 111, 121], ["plasmid", "ANATOMY", 142, 149], ["plasmid", "ANATOMY", 177, 184], ["pYA4969", "CHEMICAL", 150, 157], ["pYA4970", "CHEMICAL", 185, 192], ["pYA5000", "GENE_OR_GENE_PRODUCT", 63, 70], ["BHK-21", "CELL", 101, 107], ["MDCK cells", "CELL", 111, 121], ["1 + 2\" plasmid", "DNA", 13, 27], ["6-unit plasmid pYA5000", "DNA", 48, 70], ["BHK-21", "CELL_LINE", 101, 107], ["MDCK cells", "CELL_LINE", 111, 121], ["HA plasmid pYA4969", "DNA", 139, 157], ["NA plasmid pYA4970", "DNA", 174, 192], ["BHK-21", "SPECIES", 101, 107], ["the 6-unit plasmid pYA5000", "TREATMENT", 44, 70], ["BHK", "TEST", 101, 104], ["MDCK cells", "TEST", 111, 121], ["the HA plasmid", "TREATMENT", 135, 149], ["the NA plasmid pYA4970", "TREATMENT", 170, 192]]], ["Although, no virus generation was observed in MDCK cells, the \"1 + 2\" approach resulted in similar titers of influenza virus in BHK-21 cells as the all-in-one plasmid pYA4990 in the parallel experiments ( Table 2) .Virus generationWe found that the transfected BHK-21 cells detached but remained viable in media containing 2 \u03bcg/ml TPCK-trypsin, the virus yield was around 10 5 TCID50/ ml (data not shown).", [["MDCK cells", "ANATOMY", 46, 56], ["BHK-21 cells", "ANATOMY", 128, 140], ["plasmid", "ANATOMY", 159, 166], ["BHK-21 cells", "ANATOMY", 261, 273], ["influenza", "DISEASE", 109, 118], ["TPCK", "CHEMICAL", 331, 335], ["MDCK cells", "CELL", 46, 56], ["influenza virus", "ORGANISM", 109, 124], ["BHK-21 cells", "CELL", 128, 140], ["Virus", "ORGANISM", 215, 220], ["BHK-21 cells", "CELL", 261, 273], ["TPCK-trypsin", "SIMPLE_CHEMICAL", 331, 343], ["MDCK cells", "CELL_LINE", 46, 56], ["BHK-21 cells", "CELL_LINE", 128, 140], ["plasmid pYA4990", "DNA", 159, 174], ["transfected BHK-21 cells", "CELL_LINE", 249, 273], ["trypsin", "PROTEIN", 336, 343], ["influenza virus", "SPECIES", 109, 124], ["influenza virus", "SPECIES", 109, 124], ["BHK-21", "SPECIES", 128, 134], ["virus generation", "PROBLEM", 13, 29], ["MDCK cells", "TEST", 46, 56], ["influenza virus in BHK", "PROBLEM", 109, 131], ["the transfected BHK", "PROBLEM", 245, 264], ["TPCK", "TEST", 331, 335], ["trypsin", "TREATMENT", 336, 343], ["no", "UNCERTAINTY", 10, 12], ["virus generation", "OBSERVATION", 13, 29], ["influenza virus", "OBSERVATION", 109, 124], ["21 cells", "OBSERVATION_MODIFIER", 265, 273]]], ["TPCK-trypsin at a concentration of 0.2 \u03bcg/ml did not apparently affect cell attachment but provided as consistent virus yields as the trypsinfree condition.", [["cell", "ANATOMY", 71, 75], ["TPCK-trypsin", "CHEMICAL", 0, 12], ["TPCK-trypsin", "GENE_OR_GENE_PRODUCT", 0, 12], ["cell", "CELL", 71, 75], ["trypsin", "PROTEIN", 5, 12], ["TPCK-trypsin", "TREATMENT", 0, 12]]], ["The generated viruses were confirmed to be influenza A virus by western blot analysis with antibodies specific to the NP and M2 proteins (data not shown).", [["influenza A virus", "ORGANISM", 43, 60], ["M2", "GENE_OR_GENE_PRODUCT", 125, 127], ["antibodies", "PROTEIN", 91, 101], ["NP and M2 proteins", "PROTEIN", 118, 136], ["influenza A virus", "SPECIES", 43, 60], ["influenza A virus", "SPECIES", 43, 60], ["The generated viruses", "PROBLEM", 0, 21], ["influenza A virus", "PROBLEM", 43, 60], ["blot analysis", "TEST", 72, 85], ["antibodies", "TEST", 91, 101], ["viruses", "OBSERVATION", 14, 21]]], ["We also extracted vRNA from influenza virus generated in BHK-21 cells.", [["BHK-21 cells", "ANATOMY", 57, 69], ["influenza virus", "ORGANISM", 28, 43], ["BHK-21 cells", "CELL", 57, 69], ["BHK-21 cells", "CELL_LINE", 57, 69], ["influenza virus", "SPECIES", 28, 43], ["BHK-21", "SPECIES", 57, 63], ["vRNA", "PROBLEM", 18, 22], ["influenza virus", "PROBLEM", 28, 43], ["vRNA", "OBSERVATION", 18, 22], ["influenza virus", "OBSERVATION", 28, 43]]], ["The HA and NA segments were reverse transcribed and amplified by PCR.", [["HA and NA segments", "DNA", 4, 22], ["NA segments", "ANATOMY", 11, 22]]], ["Sequencing results showed that influenza virus from threeTransfection efficiencyThe BHK-21, CHO, and MDCK cells in 80-90 % confluence were transfected with a 6.1-kb plasmid pYA4731 (CMV-mCherry) or a 25.3-kb plasmid pYA4732 (CMV-mCherry) [19] .", [["BHK-21", "ANATOMY", 84, 90], ["CHO", "ANATOMY", 92, 95], ["MDCK cells", "ANATOMY", 101, 111], ["influenza virus", "DISEASE", 31, 46], ["influenza virus", "ORGANISM", 31, 46], ["BHK-21", "CELL", 84, 90], ["CHO", "CELL", 92, 95], ["MDCK cells", "CELL", 101, 111], ["pYA4731", "GENE_OR_GENE_PRODUCT", 173, 180], ["CMV-mCherry", "GENE_OR_GENE_PRODUCT", 182, 193], ["CMV", "ORGANISM", 225, 228], ["BHK-21", "CELL_LINE", 84, 90], ["CHO", "CELL_LINE", 92, 95], ["MDCK cells", "CELL_LINE", 101, 111], ["6.1-kb plasmid", "DNA", 158, 172], ["pYA4731", "DNA", 173, 180], ["CMV-mCherry", "DNA", 182, 193], ["25.3-kb plasmid", "DNA", 200, 215], ["pYA4732", "DNA", 216, 223], ["influenza virus", "SPECIES", 31, 46], ["influenza virus", "SPECIES", 31, 46], ["BHK-21", "SPECIES", 84, 90], ["Sequencing results", "TEST", 0, 18], ["influenza virus", "PROBLEM", 31, 46], ["The BHK", "TEST", 80, 87], ["CHO", "TEST", 92, 95], ["MDCK cells", "TEST", 101, 111], ["kb plasmid", "TEST", 162, 172], ["CMV", "TEST", 182, 185], ["kb plasmid", "TEST", 205, 215], ["CMV", "TEST", 225, 228]]], ["Both plasmids resulted in similar levels of mCherry expression in BHK-21 and in MDCK cells (Fig. 4) .", [["plasmids", "ANATOMY", 5, 13], ["BHK-21", "ANATOMY", 66, 72], ["MDCK cells", "ANATOMY", 80, 90], ["mCherry", "GENE_OR_GENE_PRODUCT", 44, 51], ["BHK-21", "CELL", 66, 72], ["MDCK cells", "CELL", 80, 90], ["plasmids", "DNA", 5, 13], ["mCherry", "PROTEIN", 44, 51], ["BHK-21", "CELL_LINE", 66, 72], ["MDCK cells", "CELL_LINE", 80, 90], ["BHK-21", "SPECIES", 66, 72], ["Both plasmids", "TREATMENT", 0, 13], ["BHK", "TEST", 66, 69], ["plasmids", "OBSERVATION", 5, 13], ["mCherry expression", "OBSERVATION", 44, 62]]], ["The CHO cells showed preferential uptake of the smaller plasmid.", [["CHO cells", "ANATOMY", 4, 13], ["plasmid", "ANATOMY", 56, 63], ["CHO cells", "CELL", 4, 13], ["CHO cells", "CELL_LINE", 4, 13], ["plasmid", "DNA", 56, 63], ["The CHO cells", "TEST", 0, 13], ["preferential uptake of the smaller plasmid", "PROBLEM", 21, 63], ["preferential", "OBSERVATION_MODIFIER", 21, 33], ["uptake", "OBSERVATION_MODIFIER", 34, 40], ["smaller", "OBSERVATION_MODIFIER", 48, 55], ["plasmid", "OBSERVATION", 56, 63]]], ["The three types of cells were cotransfected with pYA4924 and pYA4732 which encodes influenza viral polymerase and NP.", [["cells", "ANATOMY", 19, 24], ["cells", "CELL", 19, 24], ["pYA4924", "GENE_OR_GENE_PRODUCT", 49, 56], ["pYA4732", "GENE_OR_GENE_PRODUCT", 61, 68], ["pYA4924", "PROTEIN", 49, 56], ["pYA4732", "PROTEIN", 61, 68], ["influenza viral polymerase", "PROTEIN", 83, 109], ["influenza viral polymerase", "PROBLEM", 83, 109], ["influenza viral polymerase", "OBSERVATION", 83, 109]]], ["The BHK-21 and CHO cells showed efficient EGFP expression, indicating that the vRNA-like molecules were converted into mRNA.", [["BHK-21", "ANATOMY", 4, 10], ["CHO cells", "ANATOMY", 15, 24], ["BHK-21", "CELL", 4, 10], ["CHO cells", "CELL", 15, 24], ["EGFP", "GENE_OR_GENE_PRODUCT", 42, 46], ["BHK-21", "CELL_LINE", 4, 10], ["CHO cells", "CELL_LINE", 15, 24], ["EGFP", "PROTEIN", 42, 46], ["vRNA-like molecules", "PROTEIN", 79, 98], ["mRNA", "RNA", 119, 123], ["The BHK", "TEST", 0, 7], ["CHO cells", "TEST", 15, 24], ["efficient EGFP expression", "PROBLEM", 32, 57], ["the vRNA-like molecules", "PROBLEM", 75, 98], ["EGFP expression", "OBSERVATION", 42, 57]]], ["In contrast, only numerous MDCK cells expressed EGFP, which suggests that the mouse PolI promoter is poorly active in canine cells.DiscussionTo combat influenza virus infections, the inactivated and attenuated vaccines remain the most effective tools [35] .", [["MDCK cells", "ANATOMY", 27, 37], ["cells", "ANATOMY", 125, 130], ["influenza virus infections", "DISEASE", 151, 177], ["MDCK cells", "CELL", 27, 37], ["EGFP", "GENE_OR_GENE_PRODUCT", 48, 52], ["mouse", "ORGANISM", 78, 83], ["PolI", "GENE_OR_GENE_PRODUCT", 84, 88], ["canine", "ORGANISM", 118, 124], ["cells", "CELL", 125, 130], ["influenza virus", "ORGANISM", 151, 166], ["MDCK cells", "CELL_LINE", 27, 37], ["EGFP", "PROTEIN", 48, 52], ["mouse PolI promoter", "DNA", 78, 97], ["canine cells", "CELL_TYPE", 118, 130], ["mouse", "SPECIES", 78, 83], ["influenza virus", "SPECIES", 151, 166], ["mouse", "SPECIES", 78, 83], ["canine", "SPECIES", 118, 124], ["influenza virus", "SPECIES", 151, 166], ["numerous MDCK cells expressed EGFP", "PROBLEM", 18, 52], ["the mouse PolI promoter", "TREATMENT", 74, 97], ["poorly active in canine cells", "PROBLEM", 101, 130], ["influenza virus infections", "PROBLEM", 151, 177], ["attenuated vaccines", "TREATMENT", 199, 218], ["numerous", "OBSERVATION_MODIFIER", 18, 26], ["MDCK cells", "OBSERVATION", 27, 37], ["active", "OBSERVATION_MODIFIER", 108, 114], ["canine cells", "OBSERVATION", 118, 130]]], ["The time-consuming manufacture process and labor-intensive immunization methods of current vaccines render them suboptimal for an influenza pandemic or huge flocks of birds.", [["influenza pandemic", "DISEASE", 130, 148], ["birds", "ORGANISM", 167, 172], ["labor", "PROBLEM", 43, 48], ["intensive immunization methods", "TREATMENT", 49, 79], ["current vaccines", "TREATMENT", 83, 99], ["an influenza pandemic", "PROBLEM", 127, 148]]], ["Recently, we proposed a novel influenza vaccine which composes a bacterial carrier harboring an influenza plasmid [19, 28] .", [["a novel influenza vaccine", "TREATMENT", 22, 47], ["a bacterial carrier harboring an influenza plasmid", "PROBLEM", 63, 113]]], ["The vaccine can be quickly propagated in simple media in large scale, and potentially be orally administered.", [["The vaccine", "TREATMENT", 0, 11], ["simple media in large scale", "TREATMENT", 41, 68]]], ["In vivo delivery of the influenza plasmid results in generation of attenuated influenza virus which in turn induces protective immunity.", [["influenza virus", "DISEASE", 78, 93], ["influenza virus", "ORGANISM", 78, 93], ["influenza plasmid", "DNA", 24, 41], ["influenza virus", "SPECIES", 78, 93], ["influenza virus", "SPECIES", 78, 93], ["the influenza plasmid", "TREATMENT", 20, 41], ["attenuated influenza virus", "PROBLEM", 67, 93], ["influenza virus", "OBSERVATION", 78, 93]]], ["The feasibility study showed that such a form of recombinant bacteria could be constructed and used to mediate generation of influenza virus [28] .", [["influenza virus", "DISEASE", 125, 140], ["influenza virus", "ORGANISM", 125, 140], ["influenza virus", "SPECIES", 125, 140], ["The feasibility study", "TEST", 0, 21], ["recombinant bacteria", "PROBLEM", 49, 69], ["influenza virus", "PROBLEM", 125, 140]]], ["As expected, there are limiting factors still needing to be overcome, such as inefficient virus generation from the influenza plasmid.", [["influenza plasmid", "DNA", 116, 133], ["limiting factors", "PROBLEM", 23, 39], ["inefficient virus generation", "PROBLEM", 78, 106], ["the influenza plasmid", "TREATMENT", 112, 133]]], ["In this study we aimed to construct a mouse PolI-driven plasmid for reconstitution of influenza virus, so that we can determine the factors limiting virus generation in the future using well-characterized rodent cell lines.DiscussionThe whole set of vRNA, neucleoprotein and three polymerase subunits are the minimal components required to initiate influenza virus replication and packaging [3, 9] .", [["plasmid", "ANATOMY", 56, 63], ["cell lines", "ANATOMY", 212, 222], ["influenza virus", "DISEASE", 86, 101], ["mouse", "ORGANISM", 38, 43], ["PolI", "GENE_OR_GENE_PRODUCT", 44, 48], ["influenza virus", "ORGANISM", 86, 101], ["rodent", "ORGANISM", 205, 211], ["cell lines", "CELL", 212, 222], ["vRNA", "GENE_OR_GENE_PRODUCT", 250, 254], ["neucleoprotein", "GENE_OR_GENE_PRODUCT", 256, 270], ["influenza virus", "ORGANISM", 349, 364], ["mouse PolI-driven plasmid", "DNA", 38, 63], ["rodent cell lines", "CELL_LINE", 205, 222], ["vRNA", "PROTEIN", 250, 254], ["neucleoprotein", "PROTEIN", 256, 270], ["polymerase subunits", "PROTEIN", 281, 300], ["mouse", "SPECIES", 38, 43], ["influenza virus", "SPECIES", 86, 101], ["mouse", "SPECIES", 38, 43], ["influenza virus", "SPECIES", 86, 101], ["this study", "TEST", 3, 13], ["a mouse PolI", "TREATMENT", 36, 48], ["plasmid", "TREATMENT", 56, 63], ["influenza virus", "PROBLEM", 86, 101], ["virus generation", "PROBLEM", 149, 165], ["vRNA, neucleoprotein", "TREATMENT", 250, 270], ["three polymerase subunits", "TREATMENT", 275, 300], ["the minimal components", "PROBLEM", 305, 327], ["influenza virus replication", "TREATMENT", 349, 376], ["influenza virus", "OBSERVATION", 86, 101], ["rodent cell lines", "OBSERVATION", 205, 222]]], ["The virus production efficiency may be improved by coexpression of proteins from M, MS, HA and NA segments [9] .", [["The virus production efficiency", "PROBLEM", 0, 31], ["MS, HA and NA segments", "PROBLEM", 84, 106], ["virus", "OBSERVATION", 4, 9], ["production efficiency", "OBSERVATION", 10, 31], ["may be", "UNCERTAINTY", 32, 38], ["improved", "OBSERVATION_MODIFIER", 39, 47], ["NA segments", "ANATOMY", 95, 106]]], ["Synthesis of these proteins requires four more copies of PolII promoter and terminator sequence.", [["PolII", "GENE_OR_GENE_PRODUCT", 57, 62], ["PolII promoter", "DNA", 57, 71], ["terminator sequence", "DNA", 76, 95], ["PolII promoter", "TREATMENT", 57, 71]]], ["This increase in plasmid size, however, has a negative effect on the nuclear import of plasmid DNA and virus production [19, 36] .", [["plasmid", "ANATOMY", 17, 24], ["nuclear", "ANATOMY", 69, 76], ["plasmid", "ANATOMY", 87, 94], ["nuclear", "CELLULAR_COMPONENT", 69, 76], ["plasmid", "CELLULAR_COMPONENT", 87, 94], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["plasmid DNA", "DNA", 87, 98], ["This increase in plasmid size", "PROBLEM", 0, 29], ["plasmid DNA", "PROBLEM", 87, 98], ["increase", "OBSERVATION_MODIFIER", 5, 13], ["plasmid", "OBSERVATION_MODIFIER", 17, 24], ["size", "OBSERVATION_MODIFIER", 25, 29], ["negative effect", "OBSERVATION_MODIFIER", 46, 61]]], ["To solve this problem, we used a short PolII terminator (SV40 pA) and a truncated less-active CMV promoter (data not shown).", [["PolII", "GENE_OR_GENE_PRODUCT", 39, 44], ["SV40", "ORGANISM", 57, 61], ["CMV", "ORGANISM", 94, 97], ["PolII terminator", "DNA", 39, 55], ["CMV promoter", "DNA", 94, 106], ["a short PolII terminator (SV40 pA", "TREATMENT", 31, 64], ["active CMV promoter", "TREATMENT", 87, 106], ["active", "OBSERVATION_MODIFIER", 87, 93], ["CMV promoter", "OBSERVATION", 94, 106]]], ["With these changes, we made the 21-kb all-in-one plasmid, which is 2.6 kb less in size than the 8-cassette influenza plasmid described previously [19] .", [["plasmid", "ANATOMY", 49, 56], ["21-kb all-in-one plasmid", "DNA", 32, 56], ["8-cassette influenza plasmid", "DNA", 96, 124], ["cassette influenza plasmid", "TREATMENT", 98, 124], ["2.6 kb", "OBSERVATION_MODIFIER", 67, 73], ["size", "OBSERVATION_MODIFIER", 82, 86]]], ["We did not consider to use the T7 promoter-based system, as it is less efficient than the PolI-PolII bidirectional transcription system [17] , and requires coexpression of T7 RNA polymerase.DiscussionTransfection of BHK-21 cells with plasmid pYA4990 resulted in high titers of influenza virus, most likely because the cells synthesize \u03b1-2, 6 SA-linked influenza receptor [32] and can be efficiently transfected by large size plasmids [34] .", [["BHK-21 cells", "ANATOMY", 216, 228], ["plasmid", "ANATOMY", 234, 241], ["cells", "ANATOMY", 318, 323], ["pYA4990", "CHEMICAL", 242, 249], ["influenza virus", "DISEASE", 277, 292], ["PolI-PolII", "GENE_OR_GENE_PRODUCT", 90, 100], ["T7", "GENE_OR_GENE_PRODUCT", 172, 174], ["BHK-21 cells", "CELL", 216, 228], ["influenza virus", "ORGANISM", 277, 292], ["cells", "CELL", 318, 323], ["\u03b1-2", "GENE_OR_GENE_PRODUCT", 335, 338], ["SA", "GENE_OR_GENE_PRODUCT", 342, 344], ["T7 promoter", "DNA", 31, 42], ["PolI", "DNA", 90, 94], ["PolII", "PROTEIN", 95, 100], ["T7 RNA polymerase", "PROTEIN", 172, 189], ["BHK-21 cells", "CELL_LINE", 216, 228], ["plasmid pYA4990", "DNA", 234, 249], ["\u03b1", "PROTEIN", 335, 336], ["SA", "PROTEIN", 342, 344], ["influenza receptor", "PROTEIN", 352, 370], ["influenza virus", "SPECIES", 277, 292], ["influenza virus", "SPECIES", 277, 292], ["the T7 promoter", "TREATMENT", 27, 42], ["coexpression of T7 RNA polymerase", "PROBLEM", 156, 189], ["BHK", "TEST", 216, 219], ["plasmid pYA4990", "TEST", 234, 249], ["high titers of influenza virus", "PROBLEM", 262, 292], ["the cells synthesize", "TEST", 314, 334], ["large size plasmids", "PROBLEM", 414, 433], ["T7", "ANATOMY", 172, 174], ["high titers", "OBSERVATION_MODIFIER", 262, 273], ["influenza virus", "OBSERVATION", 277, 292], ["most likely", "UNCERTAINTY", 294, 305], ["large", "OBSERVATION_MODIFIER", 414, 419], ["size", "OBSERVATION_MODIFIER", 420, 424]]], ["The CHO cells, another hamster cell line, only yielded merely detectable influenza virus.", [["CHO cells", "ANATOMY", 4, 13], ["hamster cell line", "ANATOMY", 23, 40], ["influenza virus", "DISEASE", 73, 88], ["CHO cells", "CELL", 4, 13], ["hamster cell line", "CELL", 23, 40], ["influenza virus", "ORGANISM", 73, 88], ["CHO cells", "CELL_LINE", 4, 13], ["hamster cell line", "CELL_LINE", 23, 40], ["hamster", "SPECIES", 23, 30], ["The CHO cells", "TEST", 0, 13], ["another hamster cell line", "TEST", 15, 40], ["merely detectable influenza virus", "PROBLEM", 55, 88], ["CHO cells", "OBSERVATION", 4, 13], ["hamster cell line", "OBSERVATION", 23, 40], ["detectable", "OBSERVATION_MODIFIER", 62, 72], ["influenza virus", "OBSERVATION", 73, 88]]], ["One reason is that CHO cells do not have \u03b1-2, 6 SAlinked receptor to support influenza virus propagation [37, 38] .", [["CHO cells", "ANATOMY", 19, 28], ["influenza virus propagation", "DISEASE", 77, 104], ["CHO cells", "CELL", 19, 28], ["\u03b1-2", "GENE_OR_GENE_PRODUCT", 41, 44], ["influenza virus", "ORGANISM", 77, 92], ["CHO cells", "CELL_LINE", 19, 28], ["\u03b1-2, 6 SAlinked receptor", "PROTEIN", 41, 65], ["CHO cells", "TEST", 19, 28], ["SAlinked receptor", "TREATMENT", 48, 65], ["influenza virus propagation", "PROBLEM", 77, 104]]], ["These two hamster cell lines may help determine the mechanism limiting nuclear import of the large size plasmid and the factors inhibiting virus generation.", [["hamster cell lines", "ANATOMY", 10, 28], ["nuclear", "ANATOMY", 71, 78], ["plasmid", "ANATOMY", 104, 111], ["hamster cell lines", "CELL", 10, 28], ["nuclear", "CELLULAR_COMPONENT", 71, 78], ["hamster cell lines", "CELL_LINE", 10, 28], ["large size plasmid", "DNA", 93, 111], ["hamster", "SPECIES", 10, 17], ["These two hamster cell lines", "TREATMENT", 0, 28], ["the large size plasmid", "TREATMENT", 89, 111], ["the factors inhibiting virus generation", "PROBLEM", 116, 155], ["hamster cell lines", "OBSERVATION", 10, 28], ["large", "OBSERVATION_MODIFIER", 93, 98], ["size", "OBSERVATION_MODIFIER", 99, 103]]], ["A plasmid enable to overcome the barriers Each seed virus of influenza vaccines is generated yearly with HA and NA genes from a circulating influenza virus, and the remaining backbone segments (PB1, PB2, PA, NP, M and NS) from a high-yield or cold- Fig. 2 Construction of the all-in-one plasmid. a Using primers engineered with unique restriction enzyme cleavage sites, the NP, PB1, NS, and NA cassettes from pYA4968 (NP), pYA4965 (PB1), pYA4972 (NS), and pYA4970 (NA) were amplified and cloned into the pYA4518-derived T-vector to obtain four 1-unit plasmids pYA4974 (NP), pYA4973 (PB1), pYA4976(NS), and pYA4975 (NA). b The GFP cassettes were amplified from pYA4964 and inserted into the four 1-unit plasmids between SmaI, and the adjacent enzyme site downstream each influenza gene cassette.", [["plasmid", "ANATOMY", 2, 9], ["influenza", "DISEASE", 61, 70], ["influenza virus", "DISEASE", 140, 155], ["influenza virus", "ORGANISM", 140, 155], ["PA", "GENE_OR_GENE_PRODUCT", 204, 206], ["pYA4968 (NP)", "GENE_OR_GENE_PRODUCT", 409, 421], ["pYA4965 (PB1)", "GENE_OR_GENE_PRODUCT", 423, 436], ["pYA4972 (NS)", "GENE_OR_GENE_PRODUCT", 438, 450], ["pYA4970 (NA)", "GENE_OR_GENE_PRODUCT", 456, 468], ["pYA4518", "GENE_OR_GENE_PRODUCT", 504, 511], ["pYA4974", "GENE_OR_GENE_PRODUCT", 560, 567], ["GFP", "GENE_OR_GENE_PRODUCT", 626, 629], ["pYA4964", "GENE_OR_GENE_PRODUCT", 660, 667], ["SmaI", "GENE_OR_GENE_PRODUCT", 719, 723], ["HA and NA genes", "DNA", 105, 120], ["restriction enzyme cleavage sites", "DNA", 335, 368], ["NP, PB1, NS, and NA cassettes", "DNA", 374, 403], ["PB1", "DNA", 432, 435], ["pYA4972", "DNA", 438, 445], ["pYA4970", "DNA", 456, 463], ["NA", "DNA", 465, 467], ["pYA4518", "DNA", 504, 511], ["1-unit plasmids", "DNA", 544, 559], ["NP", "DNA", 569, 571], ["PB1", "DNA", 583, 586], ["pYA4975", "DNA", 606, 613], ["NA", "DNA", 615, 617], ["GFP cassettes", "DNA", 626, 639], ["pYA4964", "DNA", 660, 667], ["1-unit plasmids", "DNA", 695, 710], ["SmaI", "DNA", 719, 723], ["adjacent enzyme site", "DNA", 733, 753], ["influenza gene cassette", "DNA", 770, 793], ["influenza virus", "SPECIES", 140, 155], ["A plasmid", "TREATMENT", 0, 9], ["the barriers", "TREATMENT", 29, 41], ["influenza vaccines", "TREATMENT", 61, 79], ["HA", "PROBLEM", 105, 107], ["NA genes", "PROBLEM", 112, 120], ["a circulating influenza virus", "PROBLEM", 126, 155], ["PB1", "TEST", 194, 197], ["PB2", "TEST", 199, 202], ["PA", "TEST", 204, 206], ["NP", "TEST", 208, 210], ["NS", "TREATMENT", 218, 220], ["a Using primers engineered", "TREATMENT", 296, 322], ["unique restriction enzyme cleavage sites", "TREATMENT", 328, 368], ["NS", "TREATMENT", 383, 385], ["NA cassettes", "TREATMENT", 391, 403], ["NS", "TEST", 447, 449], ["The GFP cassettes", "TEST", 622, 639], ["1-unit plasmids", "TREATMENT", 695, 710], ["SmaI", "TREATMENT", 719, 723], ["the adjacent enzyme site", "TREATMENT", 729, 753], ["influenza gene cassette", "TREATMENT", 770, 793], ["influenza virus", "OBSERVATION", 140, 155], ["backbone", "ANATOMY_MODIFIER", 175, 183], ["segments", "ANATOMY_MODIFIER", 184, 192]]], ["The resulting plasmids were pYA4978 (NP, GFP), pYA4977 (PB1, GFP), pYA4980 (NS, GFP), and pYA4979 (NA, GFP). c The PA, PB2, M, and HA cassettes were amplified from pYA4967 (PA), pYA4966 (PB2), pYA4971 (M), and pYA4969 (HA) to replace the GFP cassettes in the 1-unit plasmids from step b.", [["plasmids", "ANATOMY", 14, 22], ["pYA4978", "GENE_OR_GENE_PRODUCT", 28, 35], ["GFP", "GENE_OR_GENE_PRODUCT", 41, 44], ["pYA4977", "GENE_OR_GENE_PRODUCT", 47, 54], ["GFP", "GENE_OR_GENE_PRODUCT", 61, 64], ["pYA4980", "GENE_OR_GENE_PRODUCT", 67, 74], ["GFP", "GENE_OR_GENE_PRODUCT", 80, 83], ["pYA4979", "GENE_OR_GENE_PRODUCT", 90, 97], ["GFP", "GENE_OR_GENE_PRODUCT", 103, 106], ["c", "GENE_OR_GENE_PRODUCT", 109, 110], ["PA", "GENE_OR_GENE_PRODUCT", 115, 117], ["PB2", "GENE_OR_GENE_PRODUCT", 119, 122], ["M", "GENE_OR_GENE_PRODUCT", 124, 125], ["HA", "GENE_OR_GENE_PRODUCT", 131, 133], ["pYA4967", "GENE_OR_GENE_PRODUCT", 164, 171], ["PA", "GENE_OR_GENE_PRODUCT", 173, 175], ["pYA4969 (HA)", "GENE_OR_GENE_PRODUCT", 210, 222], ["GFP", "GENE_OR_GENE_PRODUCT", 238, 241], ["plasmids", "DNA", 14, 22], ["pYA4978", "DNA", 28, 35], ["NP", "DNA", 37, 39], ["GFP", "DNA", 41, 44], ["pYA4977", "DNA", 47, 54], ["PB1", "DNA", 56, 59], ["GFP", "DNA", 61, 64], ["pYA4980", "DNA", 67, 74], ["NS", "DNA", 76, 78], ["GFP", "DNA", 80, 83], ["pYA4979", "DNA", 90, 97], ["NA", "DNA", 99, 101], ["GFP", "DNA", 103, 106], ["PA, PB2, M, and HA cassettes", "DNA", 115, 143], ["GFP cassettes", "DNA", 238, 251], ["1-unit plasmids", "DNA", 259, 274], ["The resulting plasmids", "TEST", 0, 22], ["NP", "TEST", 37, 39], ["GFP", "TEST", 41, 44], ["PB1", "TEST", 56, 59], ["GFP", "TEST", 61, 64], ["NS", "TEST", 76, 78], ["GFP", "TEST", 80, 83], ["pYA4979", "TEST", 90, 97], ["NA", "TEST", 99, 101], ["GFP", "TEST", 103, 106], ["The PA", "TEST", 111, 117], ["HA cassettes", "TREATMENT", 131, 143], ["PB2", "TEST", 187, 190], ["the GFP cassettes", "TREATMENT", 234, 251], ["the 1-unit plasmids", "TREATMENT", 255, 274]]], ["The resulting 2-unit plasmids were pYA4982 (NP, PA), pYA4981 (PB1, PB2), pYA4984 (NS, M), and pYA4983 (NA, HA). d The GFP cassettes were amplified from pYA4964 and inserted into three of the 2-unit plasmids.", [["pYA4983", "SIMPLE_CHEMICAL", 94, 101], ["GFP", "GENE_OR_GENE_PRODUCT", 118, 121], ["pYA4964", "GENE_OR_GENE_PRODUCT", 152, 159], ["2-unit plasmids", "DNA", 14, 29], ["GFP cassettes", "DNA", 118, 131], ["pYA4964", "DNA", 152, 159], ["2-unit plasmids", "DNA", 191, 206], ["The resulting 2-unit plasmids", "TREATMENT", 0, 29], ["PB1", "TEST", 62, 65], ["PB2", "TEST", 67, 70], ["NS", "TEST", 82, 84], ["The GFP cassettes", "TEST", 114, 131], ["the 2-unit plasmids", "TREATMENT", 187, 206]]], ["The resulting plasmids were pYA4986 (NP, PA, GFP), pYA4985 (PB1, PB2, GFP), and pYA4987 (NS, M, GFP). e The AsiSI-XmaI fragments from plasmids pYA4986 (NP, PA, GFP) and pYA4985 (PB1, PB2, GFP) were combined to obtain a 4-unit plasmid pYA4988 (NP, PA, PB1, PB2, GFP).", [["plasmids", "ANATOMY", 14, 22], ["plasmids", "ANATOMY", 134, 142], ["pYA4986", "GENE_OR_GENE_PRODUCT", 28, 35], ["PA", "GENE_OR_GENE_PRODUCT", 41, 43], ["GFP", "GENE_OR_GENE_PRODUCT", 45, 48], ["pYA4985", "GENE_OR_GENE_PRODUCT", 51, 58], ["GFP", "GENE_OR_GENE_PRODUCT", 70, 73], ["pYA4987", "GENE_OR_GENE_PRODUCT", 80, 87], ["GFP", "GENE_OR_GENE_PRODUCT", 96, 99], ["AsiSI", "GENE_OR_GENE_PRODUCT", 108, 113], ["XmaI", "GENE_OR_GENE_PRODUCT", 114, 118], ["pYA4986", "GENE_OR_GENE_PRODUCT", 143, 150], ["PA", "GENE_OR_GENE_PRODUCT", 156, 158], ["GFP", "GENE_OR_GENE_PRODUCT", 160, 163], ["pYA4985", "GENE_OR_GENE_PRODUCT", 169, 176], ["PB2", "GENE_OR_GENE_PRODUCT", 183, 186], ["GFP", "GENE_OR_GENE_PRODUCT", 188, 191], ["pYA4988", "GENE_OR_GENE_PRODUCT", 234, 241], ["PA", "GENE_OR_GENE_PRODUCT", 247, 249], ["PB2", "GENE_OR_GENE_PRODUCT", 256, 259], ["GFP", "GENE_OR_GENE_PRODUCT", 261, 264], ["plasmids", "DNA", 14, 22], ["pYA4986", "DNA", 28, 35], ["NP", "DNA", 37, 39], ["GFP", "DNA", 45, 48], ["pYA4985", "DNA", 51, 58], ["PB1", "DNA", 60, 63], ["PB2", "DNA", 65, 68], ["GFP", "DNA", 70, 73], ["pYA4987", "DNA", 80, 87], ["GFP", "DNA", 96, 99], ["AsiSI-XmaI fragments", "DNA", 108, 128], ["pYA4986", "DNA", 143, 150], ["NP", "DNA", 152, 154], ["PA", "DNA", 156, 158], ["GFP", "DNA", 160, 163], ["pYA4985", "DNA", 169, 176], ["PB1", "DNA", 178, 181], ["PB2", "DNA", 183, 186], ["GFP", "DNA", 188, 191], ["4-unit plasmid", "DNA", 219, 233], ["pYA4988", "DNA", 234, 241], ["NP", "DNA", 243, 245], ["PA", "DNA", 247, 249], ["PB1", "DNA", 251, 254], ["PB2", "DNA", 256, 259], ["GFP", "DNA", 261, 264], ["The resulting plasmids", "TEST", 0, 22], ["NP", "TEST", 37, 39], ["PA", "TEST", 41, 43], ["GFP", "TEST", 45, 48], ["PB1", "TEST", 60, 63], ["PB2", "TEST", 65, 68], ["GFP", "TEST", 70, 73], ["NS", "TEST", 89, 91], ["GFP", "TEST", 96, 99], ["XmaI fragments", "PROBLEM", 114, 128], ["plasmids", "TEST", 134, 142], ["NP", "TEST", 152, 154], ["GFP", "TEST", 160, 163], ["PB1", "TEST", 178, 181], ["PB2", "TEST", 183, 186], ["GFP", "TEST", 188, 191], ["a 4-unit plasmid", "TREATMENT", 217, 233], ["NP", "TEST", 243, 245], ["PA", "TEST", 247, 249], ["PB1", "TEST", 251, 254], ["PB2", "TEST", 256, 259], ["GFP", "TEST", 261, 264]]], ["The AsiSI-XmaI fragments from plasmids pYA4987 (NS, M, GFP) and pYA4983 (NA, HA) were combined to obtain another 4-unit plasmid pYA4989 (NS, M, NA, HA). f The two 4-unit plasmids were digested with BssHII and XmaI.", [["plasmids", "ANATOMY", 30, 38], ["NA", "CHEMICAL", 73, 75], ["AsiSI", "GENE_OR_GENE_PRODUCT", 4, 9], ["GFP", "GENE_OR_GENE_PRODUCT", 55, 58], ["BssHII", "GENE_OR_GENE_PRODUCT", 198, 204], ["XmaI", "GENE_OR_GENE_PRODUCT", 209, 213], ["AsiSI-XmaI fragments", "DNA", 4, 24], ["pYA4983", "DNA", 64, 71], ["HA", "DNA", 77, 79], ["4-unit plasmids", "DNA", 163, 178], ["BssHII", "PROTEIN", 198, 204], ["XmaI", "DNA", 209, 213], ["The AsiSI", "TEST", 0, 9], ["plasmids", "TEST", 30, 38], ["NS", "TEST", 48, 50], ["GFP", "TEST", 55, 58], ["pYA4983", "TEST", 64, 71], ["NA", "TEST", 73, 75], ["HA", "TEST", 77, 79], ["The two 4-unit plasmids", "TREATMENT", 155, 178], ["BssHII", "TREATMENT", 198, 204], ["XmaI", "TREATMENT", 209, 213]]], ["Combination of the fragments containing influenza cassettes resulted in the all-in-one plasmid pYA4990.", [["influenza cassettes", "DNA", 40, 59], ["plasmid pYA4990", "DNA", 87, 102], ["the fragments", "PROBLEM", 15, 28], ["influenza cassettes", "TREATMENT", 40, 59], ["fragments", "OBSERVATION", 19, 28], ["influenza cassettes", "OBSERVATION", 40, 59]]], ["The PA, PB2, M, HA, and GFP cassettes had triple C (CCC) at their 3\u2032-end for connecting to the SmaI-generated blunt end (as shown by primer sequence in Table 3 ).", [["PA", "GENE_OR_GENE_PRODUCT", 4, 6], ["PB2", "GENE_OR_GENE_PRODUCT", 8, 11], ["M", "GENE_OR_GENE_PRODUCT", 13, 14], ["HA", "GENE_OR_GENE_PRODUCT", 16, 18], ["GFP", "GENE_OR_GENE_PRODUCT", 24, 27], ["SmaI", "GENE_OR_GENE_PRODUCT", 95, 99], ["PA, PB2, M, HA, and GFP cassettes", "DNA", 4, 37], ["3\u2032-end", "DNA", 66, 72], ["SmaI-generated blunt end", "DNA", 95, 119], ["primer sequence", "DNA", 133, 148], ["The PA", "TEST", 0, 6], ["PB2", "TEST", 8, 11]]], ["The SmaI and XmaI endonucleases were isoschizomers.", [["SmaI", "GENE_OR_GENE_PRODUCT", 4, 8], ["XmaI", "GENE_OR_GENE_PRODUCT", 13, 17], ["SmaI and XmaI endonucleases", "DNA", 4, 31], ["The SmaI and XmaI endonucleases", "TREATMENT", 0, 31], ["isoschizomers", "PROBLEM", 37, 50]]], ["Since the backbone encoding segments remain the same every year, they can be used to make a 6-cassete plasmid.", [["6-cassete plasmid", "DNA", 92, 109], ["a 6-cassete plasmid", "TREATMENT", 90, 109], ["backbone", "ANATOMY_MODIFIER", 10, 18], ["segments", "OBSERVATION_MODIFIER", 28, 36]]], ["The 6-cassete plasmid forms a 3-plasmid reverse genetics system with the two plasmids encoding HA and NA genes.", [["plasmids", "ANATOMY", 77, 85], ["HA", "GENE_OR_GENE_PRODUCT", 95, 97], ["NA", "GENE_OR_GENE_PRODUCT", 102, 104], ["6-cassete plasmid", "DNA", 4, 21], ["plasmids", "DNA", 77, 85], ["HA and NA genes", "DNA", 95, 110], ["The 6-cassete plasmid", "TREATMENT", 0, 21], ["the two plasmids", "TREATMENT", 69, 85]]], ["This \"1 + 2\" approach was proven successful in the BHK-21 cells (Table 2) .", [["BHK-21 cells", "ANATOMY", 51, 63], ["BHK-21 cells", "CELL", 51, 63], ["BHK-21 cells", "CELL_LINE", 51, 63]]], ["We then tested virus generation in CHO cells which have been used to produce human vaccines and other therapeutics for many years [31] .", [["CHO cells", "ANATOMY", 35, 44], ["CHO cells", "CELL", 35, 44], ["human", "ORGANISM", 77, 82], ["CHO cells", "CELL_LINE", 35, 44], ["human", "SPECIES", 77, 82], ["CHO", "SPECIES", 35, 38], ["human", "SPECIES", 77, 82], ["virus generation in CHO cells", "TREATMENT", 15, 44], ["human vaccines", "TREATMENT", 77, 91]]], ["The all-in-one plasmid could reconstitute low titers of influenza virus in CHO cells, but the \"1 + 2\" strategy was not successful.", [["plasmid", "ANATOMY", 15, 22], ["CHO cells", "ANATOMY", 75, 84], ["influenza", "DISEASE", 56, 65], ["influenza virus", "ORGANISM", 56, 71], ["CHO cells", "CELL", 75, 84], ["CHO cells", "CELL_LINE", 75, 84], ["influenza virus", "SPECIES", 56, 71], ["influenza virus", "SPECIES", 56, 71], ["CHO", "SPECIES", 75, 78], ["influenza virus in CHO cells", "PROBLEM", 56, 84], ["low titers", "OBSERVATION_MODIFIER", 42, 52], ["influenza virus", "OBSERVATION", 56, 71]]], ["This may be overcome by using CHO cells expressing influenza receptor [41] [42] [43] , or coculture of CHO and MDCK cells.", [["CHO cells", "ANATOMY", 30, 39], ["CHO", "ANATOMY", 103, 106], ["MDCK cells", "ANATOMY", 111, 121], ["CHO cells", "CELL", 30, 39], ["CHO", "CELL", 103, 106], ["MDCK cells", "CELL", 111, 121], ["CHO cells", "CELL_LINE", 30, 39], ["CHO", "CELL_LINE", 103, 106], ["MDCK cells", "CELL_LINE", 111, 121], ["influenza receptor", "TEST", 51, 69], ["CHO", "TEST", 103, 106], ["MDCK cells", "OBSERVATION", 111, 121]]], ["On the other hand, it also suggests that a more comprehensive system yields higher titers of virus [18] .", [["higher titers of virus", "PROBLEM", 76, 98]]], ["The 3-plasmid system should reconstituteseed virus more efficiently than an 8-plasmid system in CEF, Vero cells and MDCK cells [44] .", [["CEF", "ANATOMY", 96, 99], ["Vero cells", "ANATOMY", 101, 111], ["MDCK cells", "ANATOMY", 116, 126], ["CEF", "CELL", 96, 99], ["Vero cells", "CELL", 101, 111], ["MDCK cells", "CELL", 116, 126], ["CEF", "CELL_LINE", 96, 99], ["Vero cells", "CELL_LINE", 101, 111], ["MDCK cells", "CELL_LINE", 116, 126], ["The 3-plasmid system", "TREATMENT", 0, 20], ["virus", "PROBLEM", 45, 50], ["MDCK cells", "TEST", 116, 126], ["Vero cells", "OBSERVATION", 101, 111]]], ["In other circumstance, if one needs to generate a large number of influenza viruses merely different in one gene, such as NP, a 7-cassette plasmid may be constructed to compose a 2-plasmid system with the NP plasmid.", [["influenza", "DISEASE", 66, 75], ["influenza viruses", "ORGANISM", 66, 83], ["NP", "DNA", 122, 124], ["7-cassette plasmid", "DNA", 128, 146], ["NP plasmid", "DNA", 205, 215], ["influenza viruses", "PROBLEM", 66, 83], ["a 7-cassette plasmid", "TREATMENT", 126, 146], ["a 2-plasmid system", "TREATMENT", 177, 195], ["the NP plasmid", "TREATMENT", 201, 215], ["large", "OBSERVATION_MODIFIER", 50, 55]]], ["If just numerous influenza viruses need to be generated, it is not worth the time to construct a complicated plasmid, and an 8-plasmid system should be used.DiscussionGiven the well-known fact that the PolI promoter is species-specific, the human PolI promoter is, however, highly active in MDCK cells [45] .", [["plasmid", "ANATOMY", 109, 116], ["MDCK cells", "ANATOMY", 291, 301], ["influenza viruses", "DISEASE", 17, 34], ["PolI", "GENE_OR_GENE_PRODUCT", 202, 206], ["human", "ORGANISM", 241, 246], ["PolI", "GENE_OR_GENE_PRODUCT", 247, 251], ["MDCK cells", "CELL", 291, 301], ["PolI promoter", "DNA", 202, 215], ["human PolI promoter", "DNA", 241, 260], ["MDCK cells", "CELL_LINE", 291, 301], ["human", "SPECIES", 241, 246], ["human", "SPECIES", 241, 246], ["numerous influenza viruses", "PROBLEM", 8, 34], ["a complicated plasmid", "TREATMENT", 95, 116], ["an 8-plasmid system", "TREATMENT", 122, 141], ["the human PolI promoter", "TREATMENT", 237, 260], ["numerous", "OBSERVATION_MODIFIER", 8, 16], ["influenza", "OBSERVATION", 17, 26]]], ["The mouse PolI promoter was found to be active in hamster cell lines, but showed very poor or no activity in MDCK cells.", [["hamster cell lines", "ANATOMY", 50, 68], ["MDCK cells", "ANATOMY", 109, 119], ["mouse", "ORGANISM", 4, 9], ["PolI", "GENE_OR_GENE_PRODUCT", 10, 14], ["hamster cell lines", "CELL", 50, 68], ["MDCK cells", "CELL", 109, 119], ["mouse PolI promoter", "DNA", 4, 23], ["hamster cell lines", "CELL_LINE", 50, 68], ["MDCK cells", "CELL_LINE", 109, 119], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 4, 9], ["hamster", "SPECIES", 50, 57], ["The mouse PolI promoter", "TREATMENT", 0, 23], ["activity in MDCK cells", "PROBLEM", 97, 119], ["active", "OBSERVATION_MODIFIER", 40, 46], ["hamster cell lines", "OBSERVATION", 50, 68], ["MDCK cells", "OBSERVATION", 109, 119]]], ["The results suggest that it is an inefficient process to produce the first viral particle in MDCK cells transfected by the all-in-one plasmid as a result of poor vRNA transcription.", [["MDCK cells", "ANATOMY", 93, 103], ["plasmid", "ANATOMY", 134, 141], ["MDCK cells", "CELL", 93, 103], ["MDCK cells", "CELL_LINE", 93, 103], ["an inefficient process", "PROBLEM", 31, 53], ["the first viral particle in MDCK cells", "PROBLEM", 65, 103], ["poor vRNA transcription", "PROBLEM", 157, 180], ["MDCK cells", "OBSERVATION", 93, 103], ["poor vRNA transcription", "OBSERVATION", 157, 180]]], ["However, once a live influenza viral particle is generated, it can replicate rapidly in MDCK cells.", [["MDCK cells", "ANATOMY", 88, 98], ["MDCK cells", "CELL", 88, 98], ["MDCK cells", "CELL_LINE", 88, 98], ["a live influenza viral particle", "TEST", 14, 45], ["MDCK cells", "OBSERVATION", 88, 98]]], ["Like the finding with CHO cells, the 3-plasmid system did not reconstitute influenza virus in MDCK cells.", [["CHO cells", "ANATOMY", 22, 31], ["MDCK cells", "ANATOMY", 94, 104], ["CHO cells", "CELL", 22, 31], ["influenza virus", "ORGANISM", 75, 90], ["MDCK cells", "CELL", 94, 104], ["CHO cells", "CELL_LINE", 22, 31], ["MDCK cells", "CELL_LINE", 94, 104], ["CHO cells", "PROBLEM", 22, 31], ["the 3-plasmid system", "TREATMENT", 33, 53], ["influenza virus in MDCK cells", "PROBLEM", 75, 104], ["CHO cells", "OBSERVATION", 22, 31], ["influenza virus", "OBSERVATION", 75, 90], ["MDCK cells", "OBSERVATION", 94, 104]]], ["This is because cotransfection of three plasmids into MDCK cells is less efficient than a plasmid, and leads to even less vRNA production in canine cells.DiscussionConstruction of a plasmid containing all influenza genes driven by different promoters could be laborious and time consuming.", [["plasmids", "ANATOMY", 40, 48], ["MDCK cells", "ANATOMY", 54, 64], ["plasmid", "ANATOMY", 90, 97], ["cells", "ANATOMY", 148, 153], ["MDCK cells", "CELL", 54, 64], ["canine cells", "CELL", 141, 153], ["plasmids", "DNA", 40, 48], ["MDCK cells", "CELL_LINE", 54, 64], ["canine cells", "CELL_TYPE", 141, 153], ["plasmid", "DNA", 182, 189], ["influenza genes", "DNA", 205, 220], ["promoters", "DNA", 241, 250], ["canine", "SPECIES", 141, 147], ["canine", "SPECIES", 141, 147], ["cotransfection of three plasmids into MDCK cells", "PROBLEM", 16, 64], ["a plasmid", "TREATMENT", 88, 97], ["less vRNA production in canine cells", "PROBLEM", 117, 153], ["a plasmid", "TREATMENT", 180, 189], ["all influenza genes", "TREATMENT", 201, 220], ["MDCK cells", "OBSERVATION", 54, 64], ["less", "OBSERVATION_MODIFIER", 68, 72], ["less", "OBSERVATION_MODIFIER", 117, 121], ["vRNA", "OBSERVATION", 122, 126], ["canine cells", "OBSERVATION", 141, 153]]], ["As shown in Fig. 2 , we simplified and speeded up the process with multiple strategies including parallel construction of multiple plasmids, GFP-based selection, use of a low copy plasmid vector [19] , and use of E. coli strains with a recA1 mutation [46, 47] .", [["plasmids", "ANATOMY", 131, 139], ["GFP", "GENE_OR_GENE_PRODUCT", 141, 144], ["E. coli", "ORGANISM", 213, 220], ["strains", "ORGANISM", 221, 228], ["recA1", "GENE_OR_GENE_PRODUCT", 236, 241], ["multiple plasmids", "DNA", 122, 139], ["GFP", "DNA", 141, 144], ["E. coli", "SPECIES", 213, 220], ["E. coli", "SPECIES", 213, 220], ["multiple strategies", "TREATMENT", 67, 86], ["multiple plasmids", "TREATMENT", 122, 139], ["a low copy plasmid vector", "TREATMENT", 169, 194], ["E. coli strains", "PROBLEM", 213, 228], ["a recA1 mutation", "TEST", 234, 250]]], ["During gel purification of vector and fragment DNA, UV transillumination causes cross-linking of nucleosides and profoundly reduces transformation frequencies of ligation product, especially for large DNA constructs [48] .", [["nucleosides", "CHEMICAL", 97, 108], ["nucleosides", "CHEMICAL", 97, 108], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["DNA", "CELLULAR_COMPONENT", 201, 204], ["vector and fragment DNA", "DNA", 27, 50], ["gel purification of vector", "TREATMENT", 7, 33], ["fragment DNA", "PROBLEM", 38, 50], ["UV transillumination", "TREATMENT", 52, 72], ["cross-linking of nucleosides", "PROBLEM", 80, 108], ["ligation product", "TREATMENT", 162, 178], ["large DNA constructs", "PROBLEM", 195, 215], ["ligation", "OBSERVATION", 162, 170]]], ["During construction of the 4-unit and the all-in-one plasmids, the DNA fragments were therefore prepared by staining the agarose gel with crystal violet [49] and detected under white light illumination.ConclusionsWe developed mouse PolI-driven reverse genetics systems of influenza virus.", [["plasmids", "ANATOMY", 53, 61], ["fragments", "ANATOMY", 71, 80], ["crystal violet", "CHEMICAL", 138, 152], ["influenza virus", "DISEASE", 272, 287], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["agarose", "SIMPLE_CHEMICAL", 121, 128], ["mouse", "ORGANISM", 226, 231], ["PolI", "GENE_OR_GENE_PRODUCT", 232, 236], ["influenza virus", "ORGANISM", 272, 287], ["4-unit and the all-in-one plasmids", "DNA", 27, 61], ["DNA fragments", "DNA", 67, 80], ["mouse PolI", "PROTEIN", 226, 236], ["mouse", "SPECIES", 226, 231], ["influenza virus", "SPECIES", 272, 287], ["mouse", "SPECIES", 226, 231], ["influenza virus", "SPECIES", 272, 287], ["the all-in-one plasmids", "TREATMENT", 38, 61], ["the DNA fragments", "PROBLEM", 63, 80], ["crystal violet", "TEST", 138, 152], ["mouse PolI", "PROBLEM", 226, 236], ["influenza virus", "PROBLEM", 272, 287], ["DNA fragments", "OBSERVATION", 67, 80], ["influenza virus", "OBSERVATION", 272, 287]]], ["Both the all-in-one plasmid and \"1 + 2\" plasmid system were efficient in generation of influenza virus in BHK-21 cells, but not in CHO cells used in the study.", [["plasmid", "ANATOMY", 20, 27], ["BHK-21 cells", "ANATOMY", 106, 118], ["CHO cells", "ANATOMY", 131, 140], ["influenza", "DISEASE", 87, 96], ["influenza virus", "ORGANISM", 87, 102], ["BHK-21 cells", "CELL", 106, 118], ["CHO cells", "CELL", 131, 140], ["plasmid", "DNA", 20, 27], ["BHK-21 cells", "CELL_LINE", 106, 118], ["CHO cells", "CELL_LINE", 131, 140], ["influenza virus", "SPECIES", 87, 102], ["influenza virus", "SPECIES", 87, 102], ["BHK-21", "SPECIES", 106, 112], ["influenza virus in BHK", "PROBLEM", 87, 109], ["the study", "TEST", 149, 158], ["all", "OBSERVATION_MODIFIER", 9, 12], ["influenza virus", "OBSERVATION", 87, 102]]], ["The all-in-one plasmid is an ideal tool to determine the mechanism limiting nuclear import of the large size plasmid and the factors inhibiting virus generation using well-characterized rodent cell lines.", [["nuclear", "ANATOMY", 76, 83], ["plasmid", "ANATOMY", 109, 116], ["cell lines", "ANATOMY", 193, 203], ["nuclear", "CELLULAR_COMPONENT", 76, 83], ["rodent", "ORGANISM", 186, 192], ["cell lines", "CELL", 193, 203], ["large size plasmid", "DNA", 98, 116], ["rodent cell lines", "CELL_LINE", 186, 203], ["the large size plasmid", "TREATMENT", 94, 116], ["large", "OBSERVATION_MODIFIER", 98, 103], ["size", "OBSERVATION_MODIFIER", 104, 108], ["rodent cell lines", "OBSERVATION", 186, 203]]], ["In addition, we recommend a more simple and efficient \"1 + 2\" plasmid system to generate seed virus of influenza vaccine where one plasmid encodes backbone segments (PB1, PB2, PA, NP, M, NS) from a high-yield or cold-adapted strain, and remains the same every year.", [["plasmid", "ANATOMY", 131, 138], ["seed virus", "ORGANISM", 89, 99], ["PA", "GENE_OR_GENE_PRODUCT", 176, 178], ["plasmid", "DNA", 131, 138], ["backbone segments", "PROTEIN", 147, 164], ["PB2", "PROTEIN", 171, 174], ["2\" plasmid system", "TREATMENT", 59, 76], ["influenza vaccine", "TREATMENT", 103, 120], ["PB1", "TEST", 166, 169], ["PB2", "TEST", 171, 174], ["PA", "TEST", 176, 178], ["NP", "TEST", 180, 182], ["NS", "TEST", 187, 189], ["a high-yield", "PROBLEM", 196, 208], ["cold-adapted strain", "PROBLEM", 212, 231]]], ["The other two plasmids are constructed yearly by cloning the HA and NA genes from a circulating strain of influenza virus.Bacterial strain and cell linesThe Escherichia coli recA1 mutant strain EPI300 (Epicentre) was used for all DNA cloning.", [["plasmids", "ANATOMY", 14, 22], ["cell lines", "ANATOMY", 143, 153], ["influenza virus", "DISEASE", 106, 121], ["HA", "GENE_OR_GENE_PRODUCT", 61, 63], ["influenza virus", "ORGANISM", 106, 121], ["cell lines", "CELL", 143, 153], ["Escherichia coli", "ORGANISM", 157, 173], ["recA1", "GENE_OR_GENE_PRODUCT", 174, 179], ["DNA", "CELLULAR_COMPONENT", 230, 233], ["plasmids", "DNA", 14, 22], ["HA and NA genes", "DNA", 61, 76], ["cell lines", "CELL_LINE", 143, 153], ["influenza virus", "SPECIES", 106, 121], ["Escherichia coli", "SPECIES", 157, 173], ["influenza virus", "SPECIES", 106, 121], ["Escherichia coli", "SPECIES", 157, 173], ["the HA", "PROBLEM", 57, 63], ["NA genes", "PROBLEM", 68, 76], ["a circulating strain of influenza virus", "PROBLEM", 82, 121], ["Bacterial strain", "PROBLEM", 122, 138], ["cell lines", "TREATMENT", 143, 153], ["The Escherichia coli recA1 mutant strain EPI300 (Epicentre)", "TREATMENT", 153, 212], ["all DNA cloning", "TREATMENT", 226, 241], ["plasmids", "OBSERVATION", 14, 22], ["influenza virus", "OBSERVATION", 106, 121], ["cell lines", "OBSERVATION", 143, 153], ["Escherichia coli", "OBSERVATION", 157, 173]]], ["Baby hamster kidney (BHK-21) cells, Chinese hamster ovary (CHO) cells, and Madin-Darby canine kidney (MDCK) cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % fetal bovine serum (FBS), 100 U/ mL penicillin, and 100 \u03bcg/mL streptomycin.Plasmid constructionThe PfuUltra High-Fidelity DNA polymerase (Stratagene) was used to amplify the influenza genes and cassettes in the current study.", [["kidney", "ANATOMY", 13, 19], ["BHK-21) cells", "ANATOMY", 21, 34], ["hamster ovary (CHO) cells", "ANATOMY", 44, 69], ["Madin-Darby canine kidney (MDCK) cells", "ANATOMY", 75, 113], ["fetal bovine serum", "ANATOMY", 198, 216], ["FBS", "ANATOMY", 218, 221], ["penicillin", "CHEMICAL", 234, 244], ["streptomycin", "CHEMICAL", 260, 272], ["penicillin", "CHEMICAL", 234, 244], ["streptomycin", "CHEMICAL", 260, 272], ["Baby hamster kidney", "CELL", 0, 19], ["BHK-21) cells", "CELL", 21, 34], ["Chinese hamster ovary (CHO) cells", "CELL", 36, 69], ["Madin-Darby canine kidney (MDCK) cells", "CELL", 75, 113], ["bovine", "ORGANISM", 204, 210], ["serum", "ORGANISM_SUBSTANCE", 211, 216], ["FBS", "ORGANISM_SUBSTANCE", 218, 221], ["penicillin", "SIMPLE_CHEMICAL", 234, 244], ["streptomycin", "SIMPLE_CHEMICAL", 260, 272], ["DNA", "CELLULAR_COMPONENT", 320, 323], ["Baby hamster kidney (BHK-21) cells", "CELL_LINE", 0, 34], ["Chinese hamster ovary (CHO) cells", "CELL_LINE", 36, 69], ["Madin-Darby canine kidney (MDCK) cells", "CELL_LINE", 75, 113], ["PfuUltra High-Fidelity DNA polymerase", "PROTEIN", 297, 334], ["influenza genes", "DNA", 372, 387], ["hamster", "SPECIES", 5, 12], ["bovine", "SPECIES", 204, 210], ["Baby hamster", "SPECIES", 0, 12], ["Chinese hamster", "SPECIES", 36, 51], ["BHK", "TEST", 21, 24], ["Chinese hamster ovary (CHO) cells", "TREATMENT", 36, 69], ["Madin", "TREATMENT", 75, 80], ["Darby canine kidney (MDCK) cells", "TREATMENT", 81, 113], ["10 % fetal bovine serum (FBS", "TREATMENT", 193, 221], ["penicillin", "TREATMENT", 234, 244], ["streptomycin", "TREATMENT", 260, 272], ["Plasmid construction", "TREATMENT", 273, 293], ["The PfuUltra High-Fidelity DNA polymerase (Stratagene)", "TREATMENT", 293, 347], ["the current study", "TEST", 405, 422], ["kidney", "ANATOMY", 13, 19], ["hamster ovary", "ANATOMY", 44, 57], ["kidney", "ANATOMY", 94, 100]]], ["Agarose gel containing 10 \u03bcg/mL of crystal violet was used to isolate large DNA fragments.Plasmid constructionThe plasmids and primers used in the study are presented in Tables 1 and 3 .", [["fragments", "ANATOMY", 80, 89], ["plasmids", "ANATOMY", 114, 122], ["Agarose", "SIMPLE_CHEMICAL", 0, 7], ["DNA", "CELLULAR_COMPONENT", 76, 79], ["DNA fragments", "DNA", 76, 89], ["plasmids", "DNA", 114, 122], ["Agarose gel", "TREATMENT", 0, 11], ["crystal violet", "TREATMENT", 35, 49], ["large DNA fragments", "PROBLEM", 70, 89], ["Plasmid construction", "TREATMENT", 90, 110], ["The plasmids and primers", "TREATMENT", 110, 134], ["the study", "TEST", 143, 152], ["large", "OBSERVATION_MODIFIER", 70, 75], ["DNA fragments", "OBSERVATION", 76, 89], ["plasmids", "OBSERVATION", 114, 122]]], ["From plasmid pYA4392 [19] , the DNA fragment containing truncated mouse PolI terminator (MTI, 41 bp) and EGFP gene was amplified with primers P1 and P2.", [["DNA", "CELLULAR_COMPONENT", 32, 35], ["mouse", "ORGANISM", 66, 71], ["PolI", "GENE_OR_GENE_PRODUCT", 72, 76], ["EGFP", "GENE_OR_GENE_PRODUCT", 105, 109], ["DNA fragment", "DNA", 32, 44], ["truncated mouse PolI terminator", "DNA", 56, 87], ["MTI", "DNA", 89, 92], ["EGFP gene", "DNA", 105, 114], ["P1", "DNA", 142, 144], ["P2", "DNA", 149, 151], ["mouse", "SPECIES", 66, 71], ["mouse", "SPECIES", 66, 71], ["the DNA fragment", "PROBLEM", 28, 44], ["truncated mouse PolI terminator", "TREATMENT", 56, 87], ["bp", "TEST", 97, 99], ["EGFP gene", "TREATMENT", 105, 114], ["primers P1 and P2", "TREATMENT", 134, 151]]], ["The 250 bp truncated mouse RNA PolI promoter (MPI) was amplified from BALB/c mouse genomic DNA with primers P3 and P4.", [["mouse", "ORGANISM", 21, 26], ["PolI", "GENE_OR_GENE_PRODUCT", 31, 35], ["BALB/c mouse", "ORGANISM", 70, 82], ["DNA", "CELLULAR_COMPONENT", 91, 94], ["250 bp truncated mouse RNA PolI promoter", "DNA", 4, 44], ["MPI", "DNA", 46, 49], ["BALB/c mouse genomic DNA", "DNA", 70, 94], ["primers P3 and P4", "DNA", 100, 117], ["mouse", "SPECIES", 21, 26], ["mouse", "SPECIES", 77, 82], ["mouse", "SPECIES", 21, 26], ["mouse", "SPECIES", 77, 82], ["The 250 bp truncated mouse RNA PolI promoter (MPI", "TREATMENT", 0, 49], ["BALB/c mouse genomic DNA", "TREATMENT", 70, 94], ["primers P3 and P4", "TREATMENT", 100, 117]]], ["The two amplified fragments were fused by PCR using primers P1 and P4.", [["fragments", "ANATOMY", 18, 27], ["amplified fragments", "DNA", 8, 27], ["P1", "DNA", 60, 62], ["P4", "DNA", 67, 69], ["The two amplified fragments", "TREATMENT", 0, 27], ["primers P1 and P4", "TREATMENT", 52, 69], ["two", "OBSERVATION_MODIFIER", 4, 7], ["amplified", "OBSERVATION_MODIFIER", 8, 17], ["fragments", "OBSERVATION", 18, 27]]], ["Purified PCR products were treated with dATP and Taq DNA polymerase to add 3\u2032A at each end.", [["dATP", "CHEMICAL", 40, 44], ["dATP", "CHEMICAL", 40, 44], ["dATP", "SIMPLE_CHEMICAL", 40, 44], ["Taq", "GENE_OR_GENE_PRODUCT", 49, 52], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["Taq DNA polymerase", "PROTEIN", 49, 67], ["Purified PCR products", "TREATMENT", 0, 21], ["dATP", "TREATMENT", 40, 44], ["Taq DNA polymerase", "TREATMENT", 49, 67]]], ["Plasmid pYA4924 was constructed by cloning the treated PCR product into a lab-made T-vector derived from pYA4518 [50] .", [["pYA4924", "DNA", 8, 15], ["lab-made T-vector", "DNA", 74, 91]]], ["Plasmid pYA4518 had a p15A ori, a chloramphenicol-resistance marker (Cm R ), and a prokaryotic green fluorescent protein (GFP) gene cassette flanked by two AhdI sites.", [["pYA4518", "CHEMICAL", 8, 15], ["chloramphenicol", "CHEMICAL", 34, 49], ["chloramphenicol", "CHEMICAL", 34, 49], ["chloramphenicol", "SIMPLE_CHEMICAL", 34, 49], ["Cm R", "GENE_OR_GENE_PRODUCT", 69, 73], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 95, 120], ["GFP", "GENE_OR_GENE_PRODUCT", 122, 125], ["AhdI", "GENE_OR_GENE_PRODUCT", 156, 160], ["pYA4518", "DNA", 8, 15], ["p15A ori", "DNA", 22, 30], ["chloramphenicol-resistance marker", "DNA", 34, 67], ["Cm R", "DNA", 69, 73], ["prokaryotic green fluorescent protein (GFP) gene cassette", "DNA", 83, 140], ["AhdI sites", "DNA", 156, 166], ["a chloramphenicol", "TEST", 32, 49], ["a prokaryotic green fluorescent protein (GFP) gene cassette", "TREATMENT", 81, 140]]], ["Removal of the GFP cassette from plasmid pYA4518 through AhdI digestion resulted in a T-vector for cloning PCR products.Plasmid constructionFrom plasmid pcDNA3.1(\u2212) (Invitrogen), the SV40 polyadenylation sequence (SV40 pA, 131 bp) was amplified with primers P5 and P6, and the truncated CMV promoter (188 bp) was amplified with primers P7 and P8.", [["plasmid", "ANATOMY", 33, 40], ["GFP", "GENE_OR_GENE_PRODUCT", 15, 18], ["pYA4518", "GENE_OR_GENE_PRODUCT", 41, 48], ["AhdI", "GENE_OR_GENE_PRODUCT", 57, 61], ["pcDNA3.1(\u2212)", "GENE_OR_GENE_PRODUCT", 153, 164], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 166, 176], ["SV40", "ORGANISM", 183, 187], ["SV40", "ORGANISM", 214, 218], ["CMV", "ORGANISM", 287, 290], ["GFP cassette", "DNA", 15, 27], ["plasmid pYA4518", "DNA", 33, 48], ["AhdI", "DNA", 57, 61], ["cloning PCR products", "PROTEIN", 99, 119], ["Plasmid constructionFrom plasmid pcDNA3.1(\u2212)", "DNA", 120, 164], ["Invitrogen", "DNA", 166, 176], ["SV40 polyadenylation sequence", "DNA", 183, 212], ["SV40 pA", "DNA", 214, 221], ["P5", "DNA", 258, 260], ["P6", "DNA", 265, 267], ["truncated CMV promoter", "DNA", 277, 299], ["188 bp", "DNA", 301, 307], ["primers P7 and P8", "DNA", 328, 345], ["Removal", "TREATMENT", 0, 7], ["the GFP cassette", "TREATMENT", 11, 27], ["AhdI digestion", "PROBLEM", 57, 71], ["a T-vector", "TREATMENT", 84, 94], ["cloning PCR products", "TREATMENT", 99, 119], ["Plasmid constructionFrom plasmid pcDNA3", "TEST", 120, 159], ["Invitrogen", "TEST", 166, 176], ["the SV40 polyadenylation sequence", "TEST", 179, 212], ["SV40 pA", "TEST", 214, 221], ["bp", "TEST", 227, 229], ["primers P5", "TEST", 250, 260], ["the truncated CMV promoter", "TEST", 273, 299], ["bp", "TEST", 305, 307], ["primers P7", "TEST", 328, 338], ["CMV promoter", "OBSERVATION", 287, 299]]], ["The MPI was amplified from pYA4924 with primers P9 and P10.", [["pYA4924", "GENE_OR_GENE_PRODUCT", 27, 34], ["MPI", "DNA", 4, 7], ["pYA4924", "DNA", 27, 34], ["primers P9 and P10", "DNA", 40, 58], ["The MPI", "TREATMENT", 0, 7], ["primers P9", "TREATMENT", 40, 50]]], ["The 41-bp MTI was introduced by primers P7 and P10.", [["41-bp MTI", "DNA", 4, 13], ["primers P7 and P10", "DNA", 32, 50], ["The 41-bp MTI", "TREATMENT", 0, 13]]], ["A DNA fragment containing BglII-CMV-MTI-BsmBI-BamHI-BsmBI-MPI-SV40pA was obtained by fusing the three PCR products with primers P5 and P8.", [["DNA", "CELLULAR_COMPONENT", 2, 5], ["BglII-CMV", "GENE_OR_GENE_PRODUCT", 26, 35], ["BamHI", "GENE_OR_GENE_PRODUCT", 46, 51], ["DNA fragment", "DNA", 2, 14], ["BglII-CMV-MTI-BsmBI-BamHI", "DNA", 26, 51], ["BsmBI", "DNA", 52, 57], ["MPI", "DNA", 58, 61], ["SV40pA", "DNA", 62, 68], ["PCR products", "DNA", 102, 114], ["primers P5 and P8", "DNA", 120, 137], ["A DNA fragment", "PROBLEM", 0, 14], ["BglII-CMV", "TEST", 26, 35], ["MTI", "TEST", 36, 39], ["BsmBI", "TEST", 40, 45], ["BamHI", "TEST", 46, 51], ["BsmBI", "TEST", 52, 57], ["MPI", "TEST", 58, 61], ["primers P5", "TREATMENT", 120, 130], ["fragment", "OBSERVATION_MODIFIER", 6, 14]]], ["The purified PCR product was digested with BglII and ligated into pcDNA3.1(\u2212) digested with BstZ17I and BglII to replace the DNA fragment containing the CMV promoter, the bovine growth hormone (BGH) pA, and the neo cassette.", [["BglII", "GENE_OR_GENE_PRODUCT", 43, 48], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 66, 72], ["BstZ17I", "GENE_OR_GENE_PRODUCT", 92, 99], ["BglII", "GENE_OR_GENE_PRODUCT", 104, 109], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["CMV", "ORGANISM", 153, 156], ["bovine growth hormone", "GENE_OR_GENE_PRODUCT", 171, 192], ["BGH", "GENE_OR_GENE_PRODUCT", 194, 197], ["neo", "GENE_OR_GENE_PRODUCT", 211, 214], ["BglII", "DNA", 43, 48], ["pcDNA3.1(\u2212)", "DNA", 66, 77], ["BstZ17I", "DNA", 92, 99], ["BglII", "DNA", 104, 109], ["DNA fragment", "DNA", 125, 137], ["CMV promoter", "DNA", 153, 165], ["bovine growth hormone (BGH) pA", "DNA", 171, 201], ["neo cassette", "DNA", 211, 223], ["bovine", "SPECIES", 171, 177], ["The purified PCR product", "TREATMENT", 0, 24], ["BglII", "TREATMENT", 43, 48], ["BstZ17I", "TREATMENT", 92, 99], ["BglII", "TREATMENT", 104, 109], ["the DNA fragment", "PROBLEM", 121, 137], ["the CMV promoter", "TREATMENT", 149, 165], ["the bovine growth hormone", "TEST", 167, 192], ["the neo cassette", "TREATMENT", 207, 223], ["DNA fragment", "OBSERVATION", 125, 137], ["CMV promoter", "OBSERVATION", 153, 165]]], ["The resulting bidirectional vector was designated as pYA4963.", [["pYA4963", "CHEMICAL", 53, 60], ["pYA4963", "GENE_OR_GENE_PRODUCT", 53, 60], ["pYA4963", "DNA", 53, 60]]], ["To make an easy-to-use vector, Fig. 4 Analysis of gene expression in BHK-21, CHO, and MDCK cells.", [["BHK-21", "ANATOMY", 69, 75], ["CHO", "ANATOMY", 77, 80], ["MDCK cells", "ANATOMY", 86, 96], ["BHK-21", "CELL", 69, 75], ["CHO", "CELL", 77, 80], ["MDCK cells", "CELL", 86, 96], ["BHK-21", "CELL_LINE", 69, 75], ["CHO", "CELL_LINE", 77, 80], ["MDCK cells", "CELL_LINE", 86, 96], ["BHK-21", "SPECIES", 69, 75], ["gene expression", "TEST", 50, 65], ["BHK", "TEST", 69, 72], ["CHO", "TEST", 77, 80]]], ["The cells were transfected with reporter plasmids carrying a CMV-driven mCherry cassette.", [["cells", "ANATOMY", 4, 9], ["plasmids", "ANATOMY", 41, 49], ["cells", "CELL", 4, 9], ["CMV", "ORGANISM", 61, 64], ["mCherry", "GENE_OR_GENE_PRODUCT", 72, 79], ["reporter plasmids", "DNA", 32, 49], ["CMV-driven mCherry cassette", "DNA", 61, 88], ["reporter plasmids", "TREATMENT", 32, 49], ["a CMV", "TREATMENT", 59, 64]]], ["The large pYA4732 plasmid showed significantly lower mCherry expression in CHO cells than the small pYA4731 plasmid.", [["CHO cells", "ANATOMY", 75, 84], ["plasmid", "ANATOMY", 108, 115], ["pYA4732", "GENE_OR_GENE_PRODUCT", 10, 17], ["mCherry", "GENE_OR_GENE_PRODUCT", 53, 60], ["CHO cells", "CELL", 75, 84], ["pYA4731", "GENE_OR_GENE_PRODUCT", 100, 107], ["pYA4732 plasmid", "DNA", 10, 25], ["CHO cells", "CELL_LINE", 75, 84], ["pYA4731 plasmid", "DNA", 100, 115], ["The large pYA4732 plasmid", "TEST", 0, 25], ["significantly lower mCherry expression in CHO cells", "PROBLEM", 33, 84], ["the small pYA4731 plasmid", "TREATMENT", 90, 115], ["large", "OBSERVATION_MODIFIER", 4, 9], ["significantly", "OBSERVATION_MODIFIER", 33, 46], ["lower", "OBSERVATION_MODIFIER", 47, 52], ["mCherry expression", "OBSERVATION", 53, 71], ["CHO cells", "OBSERVATION", 75, 84], ["small", "OBSERVATION_MODIFIER", 94, 99]]], ["Cells were also cotransfected with pYA4732 and pYA4924.", [["Cells", "ANATOMY", 0, 5], ["pYA4732", "CHEMICAL", 35, 42], ["pYA4924", "CHEMICAL", 47, 54], ["Cells", "CELL", 0, 5], ["pYA4732", "GENE_OR_GENE_PRODUCT", 35, 42], ["pYA4924", "GENE_OR_GENE_PRODUCT", 47, 54]]], ["The EGFP expression indicated that vRNA-like EGFP RNA was generated from pYA4924 and converted into mRNA for EGFP synthesis in the presence of the influenza NP and polymerase provided by pYA4732.", [["pYA4732", "CHEMICAL", 187, 194], ["EGFP", "GENE_OR_GENE_PRODUCT", 4, 8], ["vRNA", "GENE_OR_GENE_PRODUCT", 35, 39], ["EGFP", "GENE_OR_GENE_PRODUCT", 45, 49], ["pYA4924", "GENE_OR_GENE_PRODUCT", 73, 80], ["EGFP", "GENE_OR_GENE_PRODUCT", 109, 113], ["pYA4732", "GENE_OR_GENE_PRODUCT", 187, 194], ["vRNA-like EGFP RNA", "RNA", 35, 53], ["pYA4924", "PROTEIN", 73, 80], ["mRNA", "RNA", 100, 104], ["EGFP", "PROTEIN", 109, 113], ["influenza NP and polymerase", "PROTEIN", 147, 174], ["pYA4732", "PROTEIN", 187, 194], ["The EGFP expression", "TEST", 0, 19], ["vRNA-like EGFP RNA", "PROBLEM", 35, 53], ["EGFP synthesis", "PROBLEM", 109, 123], ["the influenza NP", "TREATMENT", 143, 159], ["influenza", "OBSERVATION", 147, 156]]], ["Compared with BHK-21 and CHO cells, very few MDCK cells expressed EGFP.", [["BHK-21", "ANATOMY", 14, 20], ["CHO cells", "ANATOMY", 25, 34], ["MDCK cells", "ANATOMY", 45, 55], ["BHK-21", "CELL", 14, 20], ["CHO cells", "CELL", 25, 34], ["MDCK cells", "CELL", 45, 55], ["EGFP", "GENE_OR_GENE_PRODUCT", 66, 70], ["BHK-21", "CELL_LINE", 14, 20], ["CHO cells", "CELL_LINE", 25, 34], ["MDCK cells", "CELL_LINE", 45, 55], ["EGFP", "PROTEIN", 66, 70], ["BHK-21", "SPECIES", 14, 20], ["BHK", "TEST", 14, 17], ["CHO cells", "TEST", 25, 34]]], ["Expression of EGFP and mCherry were recorded from the same field the prokaryotic expression GFP cassette was amplified from pYA4332 with primers BglII-lpp and BglII-5ST1T2.", [["EGFP", "GENE_OR_GENE_PRODUCT", 14, 18], ["mCherry", "GENE_OR_GENE_PRODUCT", 23, 30], ["GFP", "GENE_OR_GENE_PRODUCT", 92, 95], ["pYA4332", "GENE_OR_GENE_PRODUCT", 124, 131], ["BglII-lpp", "GENE_OR_GENE_PRODUCT", 145, 154], ["BglII-5ST1T2", "GENE_OR_GENE_PRODUCT", 159, 171], ["EGFP", "DNA", 14, 18], ["mCherry", "DNA", 23, 30], ["prokaryotic expression GFP cassette", "DNA", 69, 104], ["pYA4332", "DNA", 124, 131], ["primers BglII", "DNA", 137, 150], ["lpp", "DNA", 151, 154], ["BglII", "DNA", 159, 164], ["5ST1T2", "DNA", 165, 171], ["Expression of EGFP and mCherry", "PROBLEM", 0, 30], ["primers BglII", "TEST", 137, 150], ["BglII", "TEST", 159, 164]]], ["The GFP cassette was digested with BglII and ligated into the pYA4963 vector that was digested with BamHI and treated with calf intestinal alkaline phosphatase (CIAP); the resulting plasmid was pYA4964 (Fig. 1) .", [["plasmid", "ANATOMY", 182, 189], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["BglII", "GENE_OR_GENE_PRODUCT", 35, 40], ["pYA4963", "GENE_OR_GENE_PRODUCT", 62, 69], ["BamHI", "GENE_OR_GENE_PRODUCT", 100, 105], ["calf intestinal alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 123, 159], ["CIAP", "GENE_OR_GENE_PRODUCT", 161, 165], ["GFP cassette", "DNA", 4, 16], ["BglII", "DNA", 35, 40], ["pYA4963 vector", "DNA", 62, 76], ["BamHI", "DNA", 100, 105], ["calf intestinal alkaline phosphatase", "PROTEIN", 123, 159], ["CIAP", "PROTEIN", 161, 165], ["calf", "SPECIES", 123, 127], ["The GFP cassette", "TREATMENT", 0, 16], ["BglII", "TREATMENT", 35, 40], ["BamHI", "TREATMENT", 100, 105], ["calf intestinal alkaline phosphatase", "TEST", 123, 159], ["calf intestinal", "ANATOMY", 123, 138], ["alkaline phosphatase", "ANATOMY", 139, 159]]], ["The linearized and ready-to-use pYA4964 was prepared by removing the GFP cassette with BsmBI.", [["pYA4964", "CHEMICAL", 32, 39], ["pYA4964", "CHEMICAL", 32, 39], ["pYA4964", "SIMPLE_CHEMICAL", 32, 39], ["GFP", "GENE_OR_GENE_PRODUCT", 69, 72], ["BsmBI", "GENE_OR_GENE_PRODUCT", 87, 92], ["pYA4964", "DNA", 32, 39], ["GFP cassette", "DNA", 69, 81], ["BsmBI", "PROTEIN", 87, 92], ["the GFP cassette", "TREATMENT", 65, 81], ["BsmBI", "TEST", 87, 92]]], ["From the chicken PolI promoter based 8-plasmid system pYA4383 (PB2), pYA4384 (PB1), pYA4385 (PA), pYA4386 (NP), pYA4388 (HA), pYA4389 (NA), pYA4390 (M), and pYA4391 (NS) [19] , the influenza A virus (A/WSN/ 33(H1N1)) genes were amplified by PCR and digested with BsmBI or AarI.", [["chicken", "ORGANISM", 9, 16], ["PolI", "GENE_OR_GENE_PRODUCT", 17, 21], ["pYA4384", "GENE_OR_GENE_PRODUCT", 69, 76], ["pYA4385 (PA)", "GENE_OR_GENE_PRODUCT", 84, 96], ["pYA4386 (NP)", "GENE_OR_GENE_PRODUCT", 98, 110], ["pYA4388 (HA)", "GENE_OR_GENE_PRODUCT", 112, 124], ["pYA4389 (NA)", "GENE_OR_GENE_PRODUCT", 126, 138], ["pYA4390 (M)", "GENE_OR_GENE_PRODUCT", 140, 151], ["influenza A virus", "ORGANISM", 181, 198], ["A/WSN/ 33(H1N1)", "ORGANISM", 200, 215], ["BsmBI", "GENE_OR_GENE_PRODUCT", 263, 268], ["AarI", "GENE_OR_GENE_PRODUCT", 272, 276], ["chicken PolI promoter", "DNA", 9, 30], ["PB2", "DNA", 63, 66], ["PB1", "DNA", 78, 81], ["BsmBI", "PROTEIN", 263, 268], ["AarI", "DNA", 272, 276], ["chicken", "SPECIES", 9, 16], ["influenza A virus", "SPECIES", 181, 198], ["chicken", "SPECIES", 9, 16], ["influenza A virus", "SPECIES", 181, 198], ["A/WSN/ 33(H1N1)", "SPECIES", 200, 215], ["PB2", "TEST", 63, 66], ["PB1", "TEST", 78, 81], ["PA", "TEST", 93, 95], ["NP", "TEST", 107, 109], ["HA", "TEST", 121, 123], ["NA", "TEST", 135, 137], ["NS", "TEST", 166, 168], ["the influenza A virus", "PROBLEM", 177, 198], ["A/WSN", "TEST", 200, 205], ["BsmBI", "PROBLEM", 263, 268], ["AarI", "PROBLEM", 272, 276]]], ["Each treated gene was cloned individually into the linearized pYA4964.", [["pYA4964", "GENE_OR_GENE_PRODUCT", 62, 69], ["treated gene", "DNA", 5, 17], ["pYA4964", "DNA", 62, 69]]], ["Only colonies that did not show green fluorescence under excitation of 488 nm were selected and verified by restriction digestion of the plasmid DNA.", [["colonies", "ANATOMY", 5, 13], ["plasmid", "ANATOMY", 137, 144], ["DNA", "CELLULAR_COMPONENT", 145, 148], ["plasmid DNA", "DNA", 137, 148], ["the plasmid DNA", "PROBLEM", 133, 148], ["colonies", "OBSERVATION", 5, 13], ["plasmid DNA", "OBSERVATION", 137, 148]]], ["The resulting mouse RNA PolIdriven 8-plasmid system included plasmids pYA4965 (PB1), pYA4966 (PB2), pYA4967 (PA), pYA4968 (NP), pYA4969 (HA), pYA4970 (NA), pYA4971 (M), and pYA4972 (NS).", [["plasmids", "ANATOMY", 61, 69], ["mouse", "ORGANISM", 14, 19], ["pYA4965", "GENE_OR_GENE_PRODUCT", 70, 77], ["pYA4967 (PA)", "GENE_OR_GENE_PRODUCT", 100, 112], ["pYA4970 (NA)", "GENE_OR_GENE_PRODUCT", 142, 154], ["mouse RNA PolIdriven 8-plasmid system", "DNA", 14, 51], ["PB1", "DNA", 79, 82], ["PB2", "DNA", 94, 97], ["mouse", "SPECIES", 14, 19], ["mouse", "SPECIES", 14, 19], ["The resulting mouse RNA PolIdriven", "TREATMENT", 0, 34], ["plasmids", "TEST", 61, 69], ["PB2", "TEST", 94, 97], ["PA", "TEST", 109, 111], ["NP", "TEST", 123, 125], ["HA", "TEST", 137, 139], ["NA", "TEST", 151, 153]]], ["Using primers engineered with unique restriction enzyme cleavage sites, the influenza gene cassettes were amplified from the mouse PolI-driven plasmids.", [["plasmids", "ANATOMY", 143, 151], ["mouse", "ORGANISM", 125, 130], ["PolI", "GENE_OR_GENE_PRODUCT", 131, 135], ["restriction enzyme cleavage sites", "DNA", 37, 70], ["influenza gene cassettes", "DNA", 76, 100], ["mouse PolI-driven plasmids", "DNA", 125, 151], ["mouse", "SPECIES", 125, 130], ["mouse", "SPECIES", 125, 130], ["primers engineered", "TREATMENT", 6, 24], ["unique restriction enzyme cleavage sites", "TREATMENT", 30, 70], ["the influenza gene cassettes", "TREATMENT", 72, 100], ["the mouse PolI", "TREATMENT", 121, 135], ["driven plasmids", "TREATMENT", 136, 151]]], ["An allin-one plasmid pYA4990 was constructed by combining all of the cassettes (Fig. 2) .", [["allin-one plasmid pYA4990", "DNA", 3, 28], ["cassettes", "DNA", 69, 78], ["An allin-one plasmid pYA4990", "TREATMENT", 0, 28]]], ["The pYA4990 was sequenced with 54 primers that target influenza genes (not shown).", [["pYA4990", "GENE_OR_GENE_PRODUCT", 4, 11], ["pYA4990", "DNA", 4, 11], ["influenza genes", "DNA", 54, 69], ["target influenza genes", "PROBLEM", 47, 69]]], ["To construct a 6-unit plasmid without HA and NA cassettes, the pYA4990 was digested by PacI and SmaI.", [["pYA4990", "GENE_OR_GENE_PRODUCT", 63, 70], ["PacI", "GENE_OR_GENE_PRODUCT", 87, 91], ["SmaI", "GENE_OR_GENE_PRODUCT", 96, 100], ["6-unit plasmid", "DNA", 15, 29], ["HA and NA cassettes", "DNA", 38, 57], ["pYA4990", "DNA", 63, 70], ["PacI", "DNA", 87, 91], ["SmaI", "DNA", 96, 100], ["a 6-unit plasmid", "TREATMENT", 13, 29], ["HA", "PROBLEM", 38, 40], ["NA cassettes", "TREATMENT", 45, 57], ["SmaI", "TEST", 96, 100]]], ["The large linearized fragment was treated with Klenow large fragment to form blunt ends, and self-ligated.", [["fragment", "CELLULAR_COMPONENT", 21, 29], ["The large linearized fragment", "PROBLEM", 0, 29], ["Klenow large fragment", "TREATMENT", 47, 68], ["blunt ends", "PROBLEM", 77, 87], ["large", "OBSERVATION_MODIFIER", 4, 9], ["linearized", "OBSERVATION_MODIFIER", 10, 20], ["fragment", "OBSERVATION", 21, 29], ["Klenow", "OBSERVATION_MODIFIER", 47, 53], ["large", "OBSERVATION_MODIFIER", 54, 59], ["fragment", "OBSERVATION", 60, 68], ["blunt", "OBSERVATION_MODIFIER", 77, 82], ["ends", "OBSERVATION_MODIFIER", 83, 87]]], ["The resulting plasmid was pYA5000, which served as the control or constituted the \"1 + 2\" plasmids system for generating influenza virus with plasmids pYA4969 (HA) and pYA4970 (NA).DNA recombination assayDNA recombination of the all-in-one plasmid in E. coli was evaluated as described previously [28] .DNA recombination assayTransfection BHK-21, CHO, and MDCK cells grown in 6-well plates were transfected according to the manufacturer's instructions.", [["plasmid", "ANATOMY", 14, 21], ["BHK-21", "ANATOMY", 339, 345], ["CHO", "ANATOMY", 347, 350], ["MDCK cells", "ANATOMY", 356, 366], ["pYA5000", "CHEMICAL", 26, 33], ["influenza virus", "DISEASE", 121, 136], ["pYA5000", "SIMPLE_CHEMICAL", 26, 33], ["influenza virus", "ORGANISM", 121, 136], ["pYA4969", "GENE_OR_GENE_PRODUCT", 151, 158], ["DNA", "CELLULAR_COMPONENT", 181, 184], ["E. coli", "ORGANISM", 251, 258], ["BHK-21", "CELL", 339, 345], ["CHO", "CELL", 347, 350], ["MDCK cells", "CELL", 356, 366], ["pYA5000", "DNA", 26, 33], ["plasmid", "DNA", 240, 247], ["BHK-21", "CELL_LINE", 339, 345], ["CHO", "CELL_LINE", 347, 350], ["MDCK cells", "CELL_LINE", 356, 366], ["influenza virus", "SPECIES", 121, 136], ["E. coli", "SPECIES", 251, 258], ["influenza virus", "SPECIES", 121, 136], ["E. coli", "SPECIES", 251, 258], ["BHK-21", "SPECIES", 339, 345], ["2\" plasmids system", "TREATMENT", 87, 105], ["generating influenza virus", "PROBLEM", 110, 136], ["DNA recombination", "TREATMENT", 181, 198], ["E. coli", "PROBLEM", 251, 258], ["Transfection BHK", "TEST", 326, 342], ["CHO", "TEST", 347, 350], ["MDCK cells", "TEST", 356, 366], ["influenza virus", "OBSERVATION", 121, 136], ["E. coli", "OBSERVATION", 251, 258]]], ["Briefly, 2 \u03bcL of Lipofectamine 2000 (Invitrogen) per \u03bcg plasmid DNA were individually diluted in 100 \u03bcL of Opti-MEM.", [["Lipofectamine", "CHEMICAL", 17, 30], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["plasmid DNA", "DNA", 56, 67], ["Lipofectamine", "TREATMENT", 17, 30], ["Invitrogen", "TREATMENT", 37, 47], ["\u03bcg plasmid DNA", "TREATMENT", 53, 67]]], ["After 5 min incubation at room temperature, the diluted transfection reagent was mixed with the DNA.", [["DNA", "CELLULAR_COMPONENT", 96, 99], ["the diluted transfection reagent", "TREATMENT", 44, 76], ["the DNA", "PROBLEM", 92, 99]]], ["After 40 min incubation at room temperature, the transfection mix was added to prewashed cells.", [["cells", "ANATOMY", 89, 94], ["cells", "CELL", 89, 94], ["prewashed cells", "CELL_LINE", 79, 94], ["the transfection mix", "TREATMENT", 45, 65]]], ["After 5 h, the transfection medium was replaced with DMEM supplemented with 10 % FBS.", [["FBS", "ANATOMY", 81, 84], ["FBS", "ORGANISM_SUBSTANCE", 81, 84], ["the transfection medium", "TREATMENT", 11, 34], ["DMEM", "TREATMENT", 53, 57], ["10 % FBS", "TREATMENT", 76, 84]]], ["At 24 h post-transfection, images were acquired using a Zeiss Axio Cam Mrc-5 mounted onto a Zeiss Axioskop 40-fluorescent microscope.Virus generationFor influenza virus generation, BHK-21, CHO, or MDCK cells grown in 6-well plates were transfected with plasmid DNA as described above.", [["BHK-21", "ANATOMY", 181, 187], ["CHO", "ANATOMY", 189, 192], ["MDCK cells", "ANATOMY", 197, 207], ["plasmid", "ANATOMY", 253, 260], ["Virus", "ORGANISM", 133, 138], ["influenza virus", "ORGANISM", 153, 168], ["BHK-21", "CELL", 181, 187], ["CHO", "CELL", 189, 192], ["MDCK cells", "CELL", 197, 207], ["DNA", "CELLULAR_COMPONENT", 261, 264], ["Zeiss Axio Cam Mrc-5", "DNA", 56, 76], ["Zeiss Axioskop 40-fluorescent microscope", "DNA", 92, 132], ["BHK-21", "CELL_LINE", 181, 187], ["CHO", "CELL_LINE", 189, 192], ["MDCK cells", "CELL_LINE", 197, 207], ["plasmid DNA", "DNA", 253, 264], ["influenza virus", "SPECIES", 153, 168], ["BHK-21", "SPECIES", 181, 187], ["images", "TEST", 27, 33], ["a Zeiss Axio Cam Mrc", "TREATMENT", 54, 74], ["a Zeiss Axioskop", "TREATMENT", 90, 106], ["Virus generation", "PROBLEM", 133, 149], ["influenza virus generation", "PROBLEM", 153, 179], ["BHK", "TEST", 181, 184], ["CHO", "TEST", 189, 192], ["MDCK cells", "TEST", 197, 207], ["plasmid DNA", "PROBLEM", 253, 264], ["plasmid DNA", "OBSERVATION", 253, 264]]], ["After 5 h of incubation, the transfection medium was replaced with 2.5 mL of Opti-MEM containing penicillin and streptomycin.", [["Opti-MEM", "CHEMICAL", 77, 85], ["penicillin", "CHEMICAL", 97, 107], ["streptomycin", "CHEMICAL", 112, 124], ["penicillin", "CHEMICAL", 97, 107], ["streptomycin", "CHEMICAL", 112, 124], ["penicillin", "SIMPLE_CHEMICAL", 97, 107], ["streptomycin", "SIMPLE_CHEMICAL", 112, 124], ["incubation", "TREATMENT", 13, 23], ["the transfection medium", "TREATMENT", 25, 48], ["Opti-MEM", "TREATMENT", 77, 85], ["penicillin", "TREATMENT", 97, 107], ["streptomycin", "TREATMENT", 112, 124]]], ["At 24 h post-transfection, the medium was replaced with 3 mL of Opti-MEM containing 0.2 \u03bcg/mL TPCK-trypsin, 0.3 % BSA, penicillin, and streptomycin.", [["MEM", "CHEMICAL", 69, 72], ["TPCK-trypsin", "CHEMICAL", 94, 106], ["BSA", "CHEMICAL", 114, 117], ["penicillin", "CHEMICAL", 119, 129], ["streptomycin", "CHEMICAL", 135, 147], ["TPCK", "CHEMICAL", 94, 98], ["penicillin", "CHEMICAL", 119, 129], ["streptomycin", "CHEMICAL", 135, 147], ["TPCK-trypsin", "SIMPLE_CHEMICAL", 94, 106], ["BSA", "SIMPLE_CHEMICAL", 114, 117], ["penicillin", "SIMPLE_CHEMICAL", 119, 129], ["streptomycin", "SIMPLE_CHEMICAL", 135, 147], ["Opti-MEM", "TREATMENT", 64, 72], ["TPCK-trypsin", "TREATMENT", 94, 106], ["penicillin", "TREATMENT", 119, 129], ["streptomycin", "TREATMENT", 135, 147]]], ["At three to six days post-transfection, cell supernates were titrated on MDCK cell monolayers to estimate influenza virus titers.", [["cell", "ANATOMY", 40, 44], ["MDCK cell monolayers", "ANATOMY", 73, 93], ["cell", "CELL", 40, 44], ["MDCK cell monolayers", "CELL", 73, 93], ["influenza virus", "ORGANISM", 106, 121], ["MDCK cell monolayers", "CELL_LINE", 73, 93], ["cell supernates", "TREATMENT", 40, 55], ["MDCK cell monolayers", "TREATMENT", 73, 93], ["influenza virus titers", "PROBLEM", 106, 128], ["influenza virus titers", "OBSERVATION", 106, 128]]], ["The restriction enzyme sites or the GGG (corresponding to 3\u2032-triple C of the PA, PB2, M, HA, and GFP cassettes in Fig. 2) were underlined b Primer GGG-5ST1T2 was paired with each of the other 7 primers for amplifying GFP cassette from pYA4964", [["GGG", "SIMPLE_CHEMICAL", 36, 39], ["PA", "GENE_OR_GENE_PRODUCT", 77, 79], ["HA", "GENE_OR_GENE_PRODUCT", 89, 91], ["GFP", "GENE_OR_GENE_PRODUCT", 97, 100], ["GFP", "GENE_OR_GENE_PRODUCT", 217, 220], ["pYA4964", "GENE_OR_GENE_PRODUCT", 235, 242], ["restriction enzyme sites", "DNA", 4, 28], ["3\u2032-triple C of the PA, PB2, M, HA, and GFP cassettes", "DNA", 58, 110], ["5ST1T2", "DNA", 151, 157], ["GFP cassette", "DNA", 217, 229], ["pYA4964", "DNA", 235, 242], ["The restriction enzyme sites", "PROBLEM", 0, 28], ["the GGG", "TEST", 32, 39], ["the PA", "TEST", 73, 79], ["PB2", "TEST", 81, 84], ["HA", "TEST", 89, 91], ["GFP cassettes", "TREATMENT", 97, 110], ["b Primer GGG", "TREATMENT", 138, 150]]]], "PMC7354819": [["IntroductionIn a seminal paper published in 2002, Passino showed how bacterial individuals and groups find nutrients and how to model it as a distributed optimization process, which he named the Bacterial Foraging Optimization (BFO)[1].", [["a distributed optimization process", "PROBLEM", 140, 174], ["seminal", "ANATOMY", 17, 24]]], ["The algorithm is designed to simulate foraging behavior of animals in nature, which has excellent capability to search optimal value of functions with steep function images[2].", [["steep function images", "TEST", 151, 172]]], ["Moreover, in the standard BFO, bacteria can avoid falling into the local optimum to some extent and also cooperating[3].", [["BFO", "SIMPLE_CHEMICAL", 26, 29], ["bacteria", "PROBLEM", 31, 39]]], ["In recent decades, many researchers have optimized BFO to enhance the performance.", [["BFO", "SIMPLE_CHEMICAL", 51, 54]]], ["In the improvement of BFO scholars focus on two aspects: BFO\u2019s operational strategy and algorithm combination.IntroductionIn terms of algorithm strategy improvement, Mishra et al. combined the fuzzy rule system of Takagi-Sugeno (TS) in the BFO and then put forward a Fuzzy Bacterial Foraging (FBF) algorithm[4].", [["operational strategy", "TREATMENT", 63, 83], ["algorithm combination", "TREATMENT", 88, 109], ["improvement", "OBSERVATION_MODIFIER", 7, 18], ["BFO scholars", "OBSERVATION", 22, 34], ["Bacterial Foraging", "OBSERVATION", 273, 291]]], ["Besides, compared with classical algorithms, adaptive chemotactic operators have better performance.", [["adaptive chemotactic operators", "TREATMENT", 45, 75]]], ["Ben Niu proposed an improved BFO with adaptive chemotaixs step and a non-linearly decreasing exponential modulation model[5].", [["BFO", "SIMPLE_CHEMICAL", 29, 32], ["adaptive chemotaixs step", "TREATMENT", 38, 62], ["a non-linearly decreasing exponential modulation model", "TREATMENT", 67, 121]]], ["The BFO of automatic chemoattractant step size is brought up by Majhi[6].IntroductionIn regards to algorithm combination, Tang suggested a multi-level threshold method using the modified Bacterial Foraging Optimization (MBFO)[7] so as to enhance the practicability of the optimal threshold technology.", [["a multi-level threshold method", "TREATMENT", 137, 167], ["the modified Bacterial Foraging Optimization (MBFO)", "TREATMENT", 174, 225], ["size", "OBSERVATION_MODIFIER", 42, 46]]], ["Researchers found that bacteria could learn from the best position in the population by integrating Particle Swarm Optimization (PSO) into each chemotactic step, which enhanced the global search capability of the algorithm[8].", [["bacteria", "PROBLEM", 23, 31], ["integrating Particle Swarm Optimization (PSO)", "TREATMENT", 88, 133], ["bacteria", "OBSERVATION", 23, 31]]], ["Luh considered biological evolution and came up with Bacterial Evolutionary Algorithm (BEA)[10].", [["Luh", "CHEMICAL", 0, 3]]], ["Combining the Bacterial Foraging and Particle Swarm Optimization, Biswas proposed the hybrid optimization algorithm and applied it to solve the optimization of multi-modal functions[11].IntroductionDespite the great efforts of the researchers, the problems of premature convergence and slow convergence speed remain tricky.", [["the Bacterial Foraging", "TREATMENT", 10, 32], ["Particle Swarm Optimization", "TREATMENT", 37, 64], ["the hybrid optimization algorithm", "TREATMENT", 82, 115], ["premature convergence", "PROBLEM", 260, 281], ["slow convergence speed", "PROBLEM", 286, 308], ["Bacterial Foraging", "OBSERVATION", 14, 32], ["great", "OBSERVATION_MODIFIER", 210, 215]]], ["In order to promote the development of BFO algorithm, this paper proposes an improved BFO with Differential and Poisson Distribution strategies (PDBFO) to shed some light on the problems.", [["BFO algorithm", "TREATMENT", 39, 52], ["Poisson Distribution strategies (PDBFO)", "TREATMENT", 112, 151]]], ["To begin with, differential operators are incorporated into standard BFO to increase the convergence accuracy.", [["BFO", "CELL_LINE", 69, 72]]], ["Meanwhile, the segmentation step size change strategy is adopted.", [["the segmentation step size change strategy", "PROBLEM", 11, 53], ["step", "OBSERVATION_MODIFIER", 28, 32], ["size", "OBSERVATION_MODIFIER", 33, 37], ["change", "OBSERVATION", 38, 44]]], ["Finally, the Poisson Distribution strategy is used to disperse the bacteria.IntroductionOptimization algorithms are widely used to solve practical problems with high complexity.", [["the Poisson Distribution strategy", "TREATMENT", 9, 42], ["the bacteria", "PROBLEM", 63, 75], ["IntroductionOptimization algorithms", "TREATMENT", 76, 111], ["bacteria", "OBSERVATION", 67, 75], ["high complexity", "OBSERVATION_MODIFIER", 161, 176]]], ["Alireza Goli applied the Accelerated Cuckoo Algorithm to the vehicle routing problem[12].", [["Alireza Goli", "TREATMENT", 0, 12], ["the Accelerated Cuckoo Algorithm", "TREATMENT", 21, 53]]], ["Precup, R.E. suggests the use of Grey Wolf Optimizer algorithms to optimize the parameters of Takagi-Sugeno proportional-integral-fuzzy controllers[13].", [["Takagi", "PROTEIN", 94, 100], ["Grey Wolf Optimizer algorithms", "TREATMENT", 33, 63], ["Takagi", "TREATMENT", 94, 100]]], ["To further demonstrate the effectiveness of PDBFO in solving the real-world problem, a real Nurse Scheduling Problem (NSP) which improves the working efficiency and quality of nurses is employed[14].IntroductionThis paper is organized as follows.", [["PDBFO", "CHEMICAL", 44, 49], ["PDBFO", "SIMPLE_CHEMICAL", 44, 49]]], ["Section 4 presents the model of NSP.", [["NSP", "GENE_OR_GENE_PRODUCT", 32, 35]]], ["6.Chemotaxis ::: Bacterial Foraging OptimizationChemotaxis is the most important process of BFO, in which bacteria gradually approach the optimal value through rotation and swimming.", [["BFO", "SIMPLE_CHEMICAL", 92, 95], ["Bacterial Foraging OptimizationChemotaxis", "PROBLEM", 17, 58], ["bacteria", "PROBLEM", 106, 114], ["Foraging Optimization", "OBSERVATION", 27, 48]]]], "b2cc35b4f97bffb860416d9b453a0b268aa69a3c": [["J o u r n a l P r e -p r o o f 4 statistics shows that most of the cases were imported (Gilbert et al., 2020) from European countries (for example, the statistics data from February 25 to March 18: 190 input cases, 76 local cases) (https://www.afro.who.int/).", [["a l P r e -p r o o f 4 statistics", "TEST", 10, 43]]]], "PMC7152868": [["Painful bone metastasisThis metastatic population is extremely frail and should be kept away from the risk of COVID-19 infection.", [["bone", "ANATOMY", 8, 12], ["infection", "DISEASE", 119, 128], ["bone", "TISSUE", 8, 12], ["COVID-19", "ORGANISM", 110, 118], ["Painful bone metastasis", "PROBLEM", 0, 23], ["This metastatic population", "PROBLEM", 23, 49], ["extremely frail", "PROBLEM", 53, 68], ["COVID-19 infection", "PROBLEM", 110, 128], ["bone", "ANATOMY", 8, 12], ["metastasis", "OBSERVATION", 13, 23], ["metastatic", "OBSERVATION", 28, 38], ["infection", "OBSERVATION", 119, 128]]], ["It is essential to adapt the medical treatment as much as possible and to avoid palliative radiotherapy in patients controlled by level 1 to 3 oral analgesics.-Statement 1: Palliative radiotherapy remains an important option for patients experiencing significant pain, diminished quality of life and reduced autonomy as a result of bone metastases.", [["oral", "ANATOMY", 143, 147], ["bone metastases", "ANATOMY", 332, 347], ["pain", "DISEASE", 263, 267], ["bone metastases", "DISEASE", 332, 347], ["patients", "ORGANISM", 107, 115], ["oral", "ORGANISM_SUBDIVISION", 143, 147], ["patients", "ORGANISM", 229, 237], ["bone", "TISSUE", 332, 336], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 229, 237], ["the medical treatment", "TREATMENT", 25, 46], ["palliative radiotherapy", "TREATMENT", 80, 103], ["3 oral analgesics", "TREATMENT", 141, 158], ["Palliative radiotherapy", "TREATMENT", 173, 196], ["significant pain", "PROBLEM", 251, 267], ["diminished quality of life", "PROBLEM", 269, 295], ["reduced autonomy", "PROBLEM", 300, 316], ["bone metastases", "PROBLEM", 332, 347], ["bone", "ANATOMY", 332, 336], ["metastases", "OBSERVATION", 337, 347]]], ["This is especially so if it enables a reduction in the need for daily nursing care (patients at home with intravenous pain medication), in opioid-resistant pain or in case of poor tolerance of opioids.-Statement 2: We recommend the use of monofractionated radiotherapy (8Gy in 1 fraction).", [["intravenous", "ANATOMY", 106, 117], ["pain", "DISEASE", 118, 122], ["pain", "DISEASE", 156, 160], ["patients", "ORGANISM", 84, 92], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 106, 117], ["patients", "SPECIES", 84, 92], ["a reduction", "TREATMENT", 36, 47], ["daily nursing care", "TREATMENT", 64, 82], ["intravenous pain medication", "TREATMENT", 106, 133], ["resistant pain", "PROBLEM", 146, 160], ["opioids", "TREATMENT", 193, 200], ["monofractionated radiotherapy", "TREATMENT", 239, 268]]], ["Fractionated treatment should be avoided (eg., 30Gy / 10 fractions, 20Gy / 4 or 5 fractions).-Statement 3: The simplest conformal radiation therapy techniques should be used.", [["Fractionated treatment", "TREATMENT", 0, 22], ["The simplest conformal radiation therapy techniques", "TREATMENT", 107, 158]]]], "7c0f3b30925853e11b26c4794dfe39a1c8269b7b": [["But their impact on education is likely to be most devastating in countries with already low learning outcomes, high dropout rates, and low resilience to shocks.", [["high dropout rates", "PROBLEM", 112, 130]]]]}